<SEC-DOCUMENT>0001558370-21-015862.txt : 20211115
<SEC-HEADER>0001558370-21-015862.hdr.sgml : 20211115
<ACCEPTANCE-DATETIME>20211115071953
ACCESSION NUMBER:		0001558370-21-015862
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		48
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211115
DATE AS OF CHANGE:		20211115

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		211406300

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20210930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7908.23199 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/15/2021 12:11:02 PM -->
      <!-- iXBRL Library version: 1.0.7908.23207 -->
      <!-- iXBRL Service Job ID: cb26ddcc-3c5f-4868-92c5-244e5fd8e4ca -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:plx="http://www.protalix.com/20210930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" sign="-" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Ls2p4Irw_0ar4AaG-VN61g">0.48</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" sign="-" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_-udCUrhU1EmoptK9Td-q7w">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_JnoPwAklSU-IzZCNO9kgXA">0.09</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" sign="-" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_fpFZQPuAz02xrz-nrMCWPA">0.14</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_sKnaYkqH5kO4ygWQnm54lA">43761769</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_slnbF_-hAE60gHfCBySPxA">27758104</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_MKbFHQ2t90uvUpUJfZ7rHg">45556647</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_y11AAqeeiE2a1D_XWn11kQ">32863788</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityCentralIndexKey" id="Tc_KOn-ZQMu7kW60vByH792og_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:CurrentFiscalYearEndDate" id="Tc_0cXmEXaqRUKdKdh_SMVONA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:DocumentFiscalYearFocus" id="Tc_086CLQxT102WTksWDCO4Sg_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:DocumentFiscalPeriodFocus" id="Tc_2DwqG3W0RE6F99_lbd2S7g_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:AmendmentFlag" id="Narr_Er6M5e4E6kWKSfnMtCM1sA">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cfPZTTulqkernD2EnEhf1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K112MyLGIEyF188YEMII6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SzExwvidwEKr4i4UBC0FeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ObypWAjZfkumwrue2SoofQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_6e4TEe_8H0S9ZKRRnpwe0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ajr0YlG7z0mN2jc2ptdz3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QDIZWika_k258jbF39gQfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XqPOXgGBqUa1Fz3o4j1BTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_67iC4kJN5EWDKR82GNj9iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q-w46iXNMEC75S22Wy4_XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vALHgTVTI0qpDI5OS2no8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_nF71pgQNK0Sm4dLM4r805Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SshBsuzbEE-H-tzxnt_IRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DzXzpFAVKUa090qZyz2PWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_osEJghx1vkyNcPXIkVFTwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FhAO6ZCXfUeU1PtZmtoW6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TNv1Z6zXV0WmttZRhAIl4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gAacYeLtwE-Mj1yvi-z7VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2021_P7ERVIdUQUOUY7klvL64CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_-Ye7tysNN0uIamEerOPohA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_C4rvOPWVQUO7NyuzPVG_vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_CvN_3Qdilkmih_xyi8l8VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_toBWVVxhOE2Xyr7X8eD-wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yeoKiF-YDUOrT3vhZw5yGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_iAnH6udRs0WIM3yRgdqIUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_OyqOeTcPvEeZzice06IGyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:KirinHoldingsCompanyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_mydcMxM_oU2kJNHEONj5Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_QCMjIXNGnE6keq97DV1Ceg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_JjbHSiTd-EinvS16jCvSmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iAbMMUv_L06GXvemRzxxLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_fCAhfegnYkmYa8xJ3eOd-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Xo2XYmDaCUSxewIa-WYycw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_xXLYsWN7vUSK8B4I4_cOqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_lb46u3iL-Eq_NMiIYmE5Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_pjmKKZep_k-eRCW8jmhsEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember__RK7HZ3EbEuarJ7s2oVtsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z2g_D1kyFE6aa-f9W-PAug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_d2w1x6Wq0UWIzS1bPmcmPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_lWJ_c72CZk-SxD9FOrYgfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_YONib1KiMUiXNGrGvXI9NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_osPvD8x1U0Wr7PmiN4rWyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_DsIEE72dY0ijxi72whl2Xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_XpT7MCVwU0eKoVnFArW5NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2021_To_2_17_2021_1i-AeCXmUEuYJ6FKsF7Dqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-17</xbrli:startDate><xbrli:endDate>2021-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3H5BKgTVfEanIQa3JfzDpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ahmxUbUVBkm9EcsPC2dvdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MGJAPFogqkW3PHmVyWwQXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VQUwy6ZsqUWKoDwiSQgUCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_c9iBJVgvmE6XPL7XnYJeDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_I0Grm-B4g0GE3UCgk-DBhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_wgnkkX_RZkCtKFWS55dCIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_VDBEZhK3uke05lvqCgGCcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ey6qGfWfJki49fNChKl-sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2HD1crqgP0We3_b66UftRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_wKRANVGWK0CGjF_78kn1Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_fjePpaWSpkeew6EE71xYVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_VfiXjGij6E2FnqQWtpJIoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_fyankMlPgUSx83FT7iCVmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_zGLIgBqMs0SokSMlmYxJWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_U-JzHzcc2UOd4vdE3TN_9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U9xEZDL-PEmh5wLjZtn6JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_hrtLH0ARGkuJLrKOpEM2VQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_86dWT-PfXUCCzWKVSULmMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_VD26SZ1y0ESvFdYomEg95Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_N3NNBZmbcUSZicNMNONsbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_1972KmuibUyJZ-gIneryuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_uKHcMPfNtE6lZclLW6H1BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_wPu82-n0Ck6cnwIfWVVgng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WxYGSDFoFk2A-2JGt6XSSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_E62ftnuUYUSTpfSddSfQnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Ggzgc2uf3EKFGBDEr8E4Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u4SuBfYydEm3isvsquTltA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9_wMuN2NN0i7qwtMQCbLVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Z6NWekiCLE6G-qLdOHDf5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_PIoT_NoejU-L2QS4flELFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_rmjAbtU_mE681EqPesN7RA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ET9P1_n8jEmWQhl6pxUUhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Krs4XcDTxE-mc88POrcQMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_R6xvGSBAO0OzR-4qkTKWaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_nRNi-j4GhEuD86VBNDouHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JKiMKIkB9UmEZUv66KEFDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_VID5cVVn_U-ANCDy0jyJ5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_nPLZoO1ae0abxvTvACXCXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WiaTr_50-EC2jyC_GsZuBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7FO9jabvyEuwVCPMPOvyvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0o9tvW5BwkWKJJJLxMSbvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_SZUr4ebLNES5P_WEJfhHrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_UgRSQaaG60edGgxVl9FI7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-87NC5EOIESzFcXTIBQgjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-25</xbrli:startDate><xbrli:endDate>2021-07-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_S2ZvjQoxA0KSIEjlJS6ciQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_hAKdSmKW7U6VWH6p5lybLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_L2L59hXyMEOR7OKOotcc8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_4rTi-nl39kOEXFLSWbJdzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_R3eVdAJPmU-INbiD0ErvuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2021_To_10_15_2021_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_5jcweHS-wUeCpJ8p1sBaGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-15</xbrli:startDate><xbrli:endDate>2021-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_14_2021_To_10_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_h9tz6gqia0KnVd70vTBKjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-14</xbrli:startDate><xbrli:endDate>2021-10-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_m9nl_SJDHUWIRCUsIOV1yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_-_pc4KjjIESt-NNMJSZPIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_t77xAm2kAU-zv8pYeCND3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3hEtaSNNrE-fNBLdsevplg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Ubpzjp7z0kmMySSYJsgF6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cHP7im6RgECQAwEEf3hC_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_vfhkQ56Ww0a1Pq5YaRlmwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-25</xbrli:startDate><xbrli:endDate>2021-08-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_mxIiF-Oq6kSHobdbWU0lig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Vkt7LBou5EOkM2AjnrrdNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_LfY0cj9P4U6EKioM2_MD0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5917jrg-_kWEb92bxu9mtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fO3KmyeTREaqgOM51FScaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_9xptzgs0gkyakgmyzK1ZtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_eXGUnuCXhEyws-3Rm25qEA"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_torZYRpNtkSE8e779rh00g"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA"><xbrli:measure>plx:Y</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_bv08SIutWEiAUmKkUOwRvA_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_LC5aYmq5CEm0nrSnW315LA_10_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_KVz_6BTRVUilpbpsqmJrNg_29_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_FnsMO4D770WjajQaqxOl2w_17_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_nFt_VGt_Zk-MAJJ9PTINCQ_11_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_KAsebpcFckK4WP4du54Beg_30_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gwNvOAk-mUub1bCcc4W3gg_20_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_2CkcVuVuQEG7KItaDjm3Lw_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ZkyIUdI8cEy4nBlfEeOeWw_25_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_gYxgWB6MAE-BH4tEtEVhfQ_32_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_J7-Sq9OR3kSfIYfoKZU3Tg_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_NIZffxgW_ke3Yy9mBpWl-Q_14_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Oi7uyOMTvEOr2dNaywPhVQ_33_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Lz4nTLvqp0O3NIGXqO4b8Q_40_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_c3mVXk-AU0S4yi7qfsOOrQ_24_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_me7GFoP0YkmFe4qvGxo_OA_16_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ujAhtiQEI0G_PvbYtR0RBA_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_a0AO9iNjFUmJDJ0swtW58Q_6_12" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_UXaW6tCThEueJFWWrehxkg_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_VWDEdav1l0KVbiG3czgXMA_6_9" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_EwA9jMSbrkmqVUjiaygazg_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_lLCWNuJnyEmJP5GZvzI68Q_7_12" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_PM8BG-8MtUqH8347xY2PYg_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5UmuXfk5SEu1oghPX8bF0Q_7_9" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_vzSLRiq810m1mK3Itk834A_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_S8ItGGynjEerZ_i8JDgscg_8_12" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_EnHdNIHt8kGZKEO1M8w9Ag_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_hUWovraG7EG9Kf7dUYzRnQ_8_9" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;">fFFAS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_93340c33_7625_4d4c_8f6f_e18378327f0a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:DocumentType" id="Narr_FgiDAbqpmUu_NDx_lVCLWg"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:DocumentQuarterlyReport" id="Narr_2CGCfk7askiK66PJzgn3mw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:DocumentPeriodEndDate" id="Narr_Hq5TjgHiqEKS5tC2BQT6aw"><b style="font-size:8pt;font-weight:bold;">September&#160;30, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:DocumentTransitionReport" id="Narr_i9j5WZ-Gs0aets-Qj8AspA"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityFileNumber" id="Narr_pQLzAs-R-UOjfFNZQHrEjA"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityRegistrantName" id="Narr_jAWUb8v0wEW4GldOgkOR3Q"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_XPyN7Tt0VE-91qGntyOZ6g_1_1"></a><a id="Tc_GSm3bHreiECubemW44H2Qw_2_0"></a><a id="Tc_aKm-MbCp7Umwl9eQlbTkSQ_2_1"></a><a id="Tc_EKZZ8Dr750uhBszwyEwY0w_4_0"></a><a id="Tc_mFSThxExfUyHjLfqub3QfQ_5_0"></a><a id="Tc_QSv5rU6j8kK1VEw-GY_vWg_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityIncorporationStateCountryCode" id="Tc_EFU8yG-gW0CFTox7Tdfx6g_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityTaxIdentificationNumber" id="Narr_jaBvosEd1kGY0gM5gBEvQQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityAddressAddressLine1" id="Narr_gDHhrsfxOUC1f8Gvv9HDBA"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityAddressAddressLine2" id="Narr_VLxr2ay1CkWCmaRBgPbulA"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityAddressCityOrTown" id="Narr_HNk1aTGjGE-jGx5R8DurRg"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityAddressStateOrProvince" id="Narr_7r2hY1g9Wk-GBB4ySIRJlA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityAddressPostalZipCode" id="Tc_QOpGhBgsFESIWXExFoWHSQ_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:CityAreaCode" id="Narr_wDyFlQpEiE6q0B0ZZVqRUg"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:LocalPhoneNumber" id="Narr_B6_OwKRBiU-K_Zvw6FXKZA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_N2ej_WkFtEOb86d8CmF1Uw_1_0"></a><a id="Tc_cbzP8l0rkUC1DUFi1NArFw_1_2"></a><a id="Tc_sjvAS13U1k28QwuHHb_e2g_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:Security12bTitle" id="Tc_ceBD3WK8WkGKMiRC7eOdQA_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:TradingSymbol" id="Tc_nd-TOs1jHEWaCglmd0yo4A_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:SecurityExchangeName" id="Tc_du4rd0ACX0WjD8QFYpugWg_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityCurrentReportingStatus" id="Narr_Z1Jpxfk4MkSRg_vOd3nUyw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityInteractiveDataCurrent" id="Narr_0NRBQTe6akOr1Lf_nTQj3w"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_0P-Vd50EyUCfd4dbnPlt6A_1_0"></a><a id="Tc_IJ0cvRl-30q4HrAEWlepIw_1_1"></a><a id="Tc_Xtsd9R9KrUi_2hPPNo2B0A_1_2"></a><a id="Tc_0QJmPeOCt0e9fQLoexaRUg_1_3"></a><a id="Tc_yZ-G6JOjlECHDFnCbSuIZg_2_1"></a><a id="Tc_2i4zcTj-m06evJct1UegWg_2_2"></a><a id="Tc_EQBdVzrZ5ESVxnxiPVMoxg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityFilerCategory" id="Tc_zyJYdxKew0i3oxg_JM3cFQ_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntitySmallBusiness" id="Tc_IIeMvq7uu0qvkITkwtJcew_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityEmergingGrowthCompany" id="Tc_XE8PIXiAHEeDygvZGz_iZQ_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="dei:EntityShellCompany" id="Narr_wtFATSL6o0uEFx_s5U5ePw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On November&#160;1, 2021, approximately <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_1_2021_9xptzgs0gkyakgmyzK1ZtA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_xvSTJez38EyB6j5fQtn63Q">45,556,647</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9944cb5a_dfb1_4dbb_bd8e_22e46e05caf4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495">Condensed Consolidated Balance</a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"> Sheets (Unaudited) &#8211; As of September&#160;30, 2021 and December&#160;31, 2020</a></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Changes in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Stockholders&#8217; equity (</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Capital Deficiency) (Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2021 and 2020</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Nine Months ended September&#160;30, 2021 and 2020</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f275c393_200f_4cab_af06_1e5a9312cf62"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_i4CaHZxHDkynVsUueH1csA_1_2"></a><a id="Tc_aq54vq5sLEyuFrXzOr3FPw_1_5"></a><a id="Tc_lcwUjMj2z0q8jA6UsA2FJQ_3_0"></a><a id="Tc_u2ybXLR6bUmNBN_CJmp6jg_5_0"></a><a id="Tc_7_F5MMW39kCaukvh7fwZxg_6_0"></a><a id="Tc_apTM4NORAE-2-_EZ_QqIiQ_6_2"></a><a id="Tc_oZTSvWoyAUyTdUI0YqsuDA_6_5"></a><a id="Tc_QuAZsCjOyEqYPqAefI_d3w_7_0"></a><a id="Tc_pT5L2Ufyxk-XU1wNzCbrmA_8_0"></a><a id="Tc_Hfq-Rv7JzkSlqTFUxl7aWg_9_0"></a><a id="Tc_OfC8X6mAFk6HaiI3eD_6JA_10_0"></a><a id="Tc_0xwbRU_MAECZ0UBpjwSvDA_11_0"></a><a id="Tc_y9nAibQisESmDYZLXCuxZw_11_2"></a><a id="Tc_Rt1PPcphpk6fwE9g7l2gbQ_11_5"></a><a id="Tc_OffuLrwKH0KQQc6auFBv6w_13_0"></a><a id="Tc_sf67OYf_GkOGu4yCvF4xaw_14_0"></a><a id="Tc_pT4Iblm2D0ujkKc2BunxKw_14_5"></a><a id="Tc_RscBnvIin0yVNJwsEu3fDg_15_0"></a><a id="Tc_6G1RLlslY0Cs4QVQGsfGow_16_0"></a><a id="Tc_dNKHLhsj2U2Ut6fgegskxQ_17_0"></a><a id="Tc_9azs_UzziUiQzRC4bubJCw_17_2"></a><a id="Tc_O2Rewm_TvkCExLlOqg7NPg_17_5"></a><a id="Tc_p8npo9LyH06npYJdkBX6Pw_19_0"></a><a id="Tc_ZRo-b8pOOUqGpKmEns-oPQ_21_0"></a><a id="Tc___5mXIbIvkioXJerO_xcyQ_22_0"></a><a id="Tc_sDzLg9NnvkGTji4RqpOWSQ_23_0"></a><a id="Tc_andDhigdtEiovRsf_Pj-9A_23_2"></a><a id="Tc_tqSiL-YhMkO00veV4M0JPw_23_5"></a><a id="Tc_8qcyO63uhEG-mpZwKrU1NQ_24_0"></a><a id="Tc_XF1HqKsJUEWMzVV_64h-9g_25_0"></a><a id="Tc_L8g--34MAkiH7-54WRN6rQ_26_0"></a><a id="Tc_7lUYzlOBo0u8aWn_s87lHg_27_0"></a><a id="Tc_xlc1v3jdgEmf7Bl35ibrAA_28_0"></a><a id="Tc_QJ1see3v20mB8f7Rjl-jPg_29_0"></a><a id="Tc_9FJguPxKJ0KJA64Vd4GZ9w_29_2"></a><a id="Tc_deFqBFOOoECjVZoeYu40zQ_29_5"></a><a id="Tc_q9vs8zwjjEWLoXNKOxYo9g_31_0"></a><a id="Tc_iwqaZ17hNk6sDZHXmskG4g_32_0"></a><a id="Tc_XxwiZi2DQ0eHEvJEY2h9vA_32_2"></a><a id="Tc_zL_KARwTxUu8y9SNN4KqFA_32_5"></a><a id="Tc_wiA3R5WTeEuE89QMwAIogQ_33_0"></a><a id="Tc_EDgJG_lJrk2SN7LO9eEWXw_34_0"></a><a id="Tc_9dFK1l8BlkmMMq2SbhHLIA_35_0"></a><a id="Tc_yV4ejaDuckOhIWSCy9JUuA_36_0"></a><a id="Tc_uyxu5i5ZlES9UpLTMZVGKA_37_0"></a><a id="Tc_UUVZGTzwp0ezipeo4pnZVQ_37_2"></a><a id="Tc_p4XJDlx5pEyv0D0LkdnpGA_37_5"></a><a id="Tc_WgAffp9y5kaV_cvEyLmlTg_38_0"></a><a id="Tc_D-4TWFy6XE699R2FNRfWAg_38_2"></a><a id="Tc_OOn4tzG-vUuzt9ni8cUcxQ_38_5"></a><a id="Tc_amLIC8-ZnEWcUk7rhVnmDw_40_0"></a><a id="Tc_26s9ZN_VZkSQ-KpYcv4U6Q_41_0"></a><a id="Tc_QI2qof7Qb0-aXiYj_1oNQA_41_2"></a><a id="Tc_AtNx8Y8aKUqiOzCEN-Udog_41_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_spkGkv0BQUy9FNb8tGs2Pg_6_3">10,642</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_zTU6isqLg0G64Jdazlyc2A_6_6">18,265</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_nQizOCYRwUSOZQCQBPtv2g_7_3">38,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_4mYf7YdvgkOz0SpYHlJXUw_7_6">20,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_lndJCifO40ONhFgbbAL06w_8_3">5,561</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_aBDI993MyEKegKBn0uGS2g_8_6">2,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_wW63Gx4ZXEGdI0RIUjz0kg_9_3">2,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_EGthmkd6VUibzAshodxKqg_9_6">2,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_P51-N45-WEeMnihMIM628g_10_3">14,730</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_R2Ydq5ccTE2c5AqjB5_ItQ_10_6">13,082</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_RemDLv7XM0aNeNFZHubmwA_11_3">71,224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_3gl2Yx6Lp0edhe1RY0-XtQ_11_6">55,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_A2ju21GpckyxLxlghWux1g_14_3">1,948</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc__cgEYMfctUuu9O_mpmThVA_14_6">1,799</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_jb4QcRSqikKE-QNg1L7ctA_15_3">5,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_-kYjrPODAkC703nsmqsjew_15_6">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_HU1PPQtiWE6xlZ5Yo8t7MA_16_3">5,245</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_q2Hh6RKm1EikVY-eQiKGVQ_16_6">5,567</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_4TPSCFPtFE-eHcohfk6bYA_17_3">83,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_Puuk60dQ9kGXFTQfsyJOMQ_17_6">67,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (NET OF CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_TrwJl4WeKkuqasdVtdqACQ_23_3">8,436</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_0qrBdHdP1Ee_dinPtSwP-g_23_6">7,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_3VsdDQQThUuKaGSSxxeX6Q_24_3">14,694</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_MrTCtC2_REq6AKfLYafuog_24_6">13,926</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_mj_YyMv4UUCxgR_WdwbzJQ_25_3">1,235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_YxwuZBF1ik-TJu6kAmnGtw_25_6">1,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_Yc4lIcj16EiVg6YnghL38A_26_3">15,160</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_f7icina7_0ueH7L4ITgsNg_26_6">5,394</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_SCr11D4BhkyGrlKw8lzM7A_27_3">3,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_Da1eKKEtCkGPO4w6p6KkFg_27_6">54,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Promissory note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_dHRZDvHEfUqZbvXAYmSqsA_28_6">4,086</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Ohe39GLJnkGjy2tdduNQiw_29_3">42,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_SrFOiqy-SEm31i0MrJwzZA_29_6">86,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtNoncurrent" scale="3" id="Tc_LsrxWQAkVkWRrDsMlXp0BA_32_3">27,816</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_fLSmJtvtzkG-c0APbX18MQ_33_3">5,895</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_uCP35cBv3keqCQM43BmB7Q_33_6">1,716</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_gfTTgP-j406eTiH0dmAwWg_34_3">2,353</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_aEX_HPW-xUKJnNI5SSU7BQ_34_6">2,263</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_fec9M2hOHkqgsUeUu3SWoQ_35_3">4,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_s4SfGbaQuE6ilUrHoIhWOQ_35_6">4,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other long term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_85iI6itkQ0Gl7INWBHmiJg_36_6">51</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_EaX_JO-v2kiNTA048IpWpw_37_3">40,505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_C6bHrwnMIkS-CtGj1sIOgg_37_6">8,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_UwN2QoedzkWLMmf03vZqjA_38_3">83,269</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_vpJQe0KCt0WQdXFli51fQw_38_6">94,971</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KzEfU9SqTkaEbTlmXUOkUw_40_3">213</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_oNOxpJGeLEyHDdHLoYxO7g_40_6">27,037</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders&#8217; equity (net of capital deficiency)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ZZuC0dZhJ06_d9BvFvsvkw_41_3">83,482</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_wxiNCcCIS0SOGSuiW9COQg_41_6">67,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8488e67_cd30_41d6_985c_7b2b2667ccf1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_wrU2reYHeESDq_X_ieUKqg_1_2"></a><a id="Tc__dD-_kzO102dJ3v1I-gw4g_1_8"></a><a id="Tc_oO6qr2YoG0CCEBRXtKj_uA_2_2"></a><a id="Tc_rE2MdHYKyUKkcxVd8dlWQQ_2_5"></a><a id="Tc_z555Kzzd2EK1-yCsrrfVBQ_2_8"></a><a id="Tc_e8YrNbEp9kiK0TC5w735HQ_2_11"></a><a id="Tc_s9H71N2RPEqn21T2ave0mQ_3_0"></a><a id="Tc_Mreksp6hUEa_faSeMeF9Eg_3_2"></a><a id="Tc_gcs_p7Jg9kWeZaaluWIzUg_3_5"></a><a id="Tc_CvMNYkRfc0-sv6ZiPkWMYQ_3_8"></a><a id="Tc_zNnBfN-yOEKy6x-5H5ik_w_3_11"></a><a id="Tc_s4LMpbW_XE2pflK7aEHssQ_4_0"></a><a id="Tc_bA-YSntjREW1wa4dAtckiw_5_0"></a><a id="Tc_DsQtWCV_V0qN6tDnzHBKGw_6_0"></a><a id="Tc_Bt8mdrt3CUm1THmO4ni_QQ_7_0"></a><a id="Tc_P3_q0e9JukWMBk_rfM_yWg_8_0"></a><a id="Tc__iTs1Zt1i0ayUdCoBxva7w_9_0"></a><a id="Tc_By6908dE50SyDDuXOCwf9A_10_0"></a><a id="Tc_QpTj8aaPxUWIFi_Qo659yw_11_0"></a><a id="Tc_5KE83VHEFE-K--Om5xBJJw_12_0"></a><a id="Tc_ctXwXrW_cU6crbji8RzMBg_13_0"></a><a id="Tc_Ybd9fCFYR0y5aasG4WIDKw_14_0"></a><a id="Tc_nbKkRMD61kSOMxmCg-QY4Q_14_2"></a><a id="Tc_J28KFaEjvkyR1TkQIwdn6A_14_5"></a><a id="Tc_aCDxS6NF_UC_reQevWJnHg_14_8"></a><a id="Tc_0HUGV7EHZUi4HZmc8p0c6g_14_11"></a><a id="Tc_7T5muAjR4kmGY_QeCq8rgw_15_0"></a><a id="Tc_2zKNlzN2SU2hOX3BDWqCZw_16_0"></a><a id="Tc_iFHr7mdAxUGCRyzdR3dchw_17_0"></a><a id="Tc_VPaZ6P1wzEKrLl1911RUug_18_0"></a><a id="Tc_58phkTD9TEGfFdaRK8KmtA_18_2"></a><a id="Tc_JUbEfj5Qq0ylicyYGl1fVw_18_5"></a><a id="Tc_xIH5rN_VRkeyKJM4HzPOBw_18_8"></a><a id="Tc_6IEEKvpQrECHyVER0i2DsQ_18_11"></a><a id="Tc_Ab-ZCbhO4EmJ8xBfV-Z9OQ_19_0"></a><a id="Tc_R8avfClEm0u3xTvubW-6wg_19_2"></a><a id="Tc_zkkDDdmec0KKOpd_WjasbA_19_5"></a><a id="Tc_uA7YEu_cS0SoBkocus5P_w_20_0"></a><a id="Tc_MraFIKlo4k2nk5ITHr0yTg_20_2"></a><a id="Tc_uOOfy64VfUmyPGtxT9yUpg_20_5"></a><a id="Tc_owGoq4LkNUGcztG-k8OhUw_20_8"></a><a id="Tc_7KqKBNuZV0Ot2WuaqPpqOA_20_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.7074051%;padding-left:0pt;padding-right:0pt;width:103.41%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_fCAhfegnYkmYa8xJ3eOd-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_FOFCzct2XUOHSB9wRzm3Ow_3_3">12,260</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_DsIEE72dY0ijxi72whl2Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_JtSJ0Qa7kEyWBAt8C9fZgQ_3_6">11,975</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yeoKiF-YDUOrT3vhZw5yGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_usWASzXfCk-YC_czujQNkg_3_9">4,506</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember__RK7HZ3EbEuarJ7s2oVtsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_tlbMJWjCqUagkaBusLdS1w_3_12">3,296</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Xo2XYmDaCUSxewIa-WYycw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_kDBm_e-g2kOtcrGjP7SBzA_4_3">17,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_XpT7MCVwU0eKoVnFArW5NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_kDM61TeR-EWMMHsuLS2nrg_4_6">31,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_iAnH6udRs0WIM3yRgdqIUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Nl8buSZTEEyTZGjFgh_--A_4_9">7,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z2g_D1kyFE6aa-f9W-PAug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_unIu-VSj10iG2v0Uk8Wt-Q_4_12">7,494</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_GTRA_5vFVk2j_EAUQz-DDA_5_3">29,801</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_i7Wec1ENhkajRQon6QHL0A_5_6">43,403</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_3hGSRiWTskGnOO8xf1Erjg_5_9">12,054</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_tlNPgkoAUUmR09Qoobqgrw_5_12">10,790</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_UXaW6tCThEueJFWWrehxkg_6_3">13,201</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_ujAhtiQEI0G_PvbYtR0RBA_6_6">8,121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_VWDEdav1l0KVbiG3czgXMA_6_9">3,703</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_a0AO9iNjFUmJDJ0swtW58Q_6_12">2,868</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_PM8BG-8MtUqH8347xY2PYg_7_3">22,093</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_EwA9jMSbrkmqVUjiaygazg_7_6">27,214</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_5UmuXfk5SEu1oghPX8bF0Q_7_9">7,282</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_lLCWNuJnyEmJP5GZvzI68Q_7_12">7,688</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_EnHdNIHt8kGZKEO1M8w9Ag_8_3">9,263</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_vzSLRiq810m1mK3Itk834A_8_6">8,197</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_hUWovraG7EG9Kf7dUYzRnQ_8_9">2,954</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_S8ItGGynjEerZ_i8JDgscg_8_12">2,816</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_mgM7amEK7UyagXnnB7t_iw_9_3">14,756</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_1CWEk5cQLkSYXoicnCei1Q_9_6">129</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_o6YfR4w1mkadZekuN_PD3w_9_9">1,885</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_pC0w0IIPzEauh4ROc0586w_9_12">2,582</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_1ChZ9m2oWUyYud51u6OeKg_10_3">6,613</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_Zlp2unmz-Uy0gcz6xfvX4g_10_6">7,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_8Ocp3mwAQECmB4uqBfGVCg_10_9">2,410</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_ZPCn02QkEUCycF28fcQLaQ_10_12">1,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_GQSu4HNB0UOhYII6vDNDAw_11_3">403</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_LgXqSo7QtU6kQB2UXy5S7Q_11_6">359</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_Hj7jwiybQkOS-xGj0U9JVg_11_9">96</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_EQX4YVD-0kSo5ST-TlGi7A_11_12">118</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES &#8211; NET</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_jAmXkSq-a0Wj8LKfGwDR4Q_12_3">6,210</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_AD5TXiaarkaHdqxK3pJZsg_12_6">6,791</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_WNIf0gpJdU6Fb1HIeXaPJA_12_9">2,314</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_UBxFsqYyGE-9fcQV6K2m0Q_12_12">1,855</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OTHER INCOME</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_mHPgbn4QDkSY7ahrvEyJVQ_13_3">51</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Ql-7v_U9EUOFesSdGvFGQg_14_3">20,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Pw_AR67syUe6TDt6PN_xnw_14_6">6,920</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UcwPFmnp-EidQH_vv_nMCA_14_9">4,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_JrMia4Iw_0i_mGUC-mHSVg_14_12">4,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Ls2p4Irw_0ar4AaG-VN61g;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_UU8DRaLLj0-x_oTzHQYL-g_15_3">0.48</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_-udCUrhU1EmoptK9Td-q7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_dM0pW_Ml8kaC-4mydCK7Wg_15_6">0.25</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_JnoPwAklSU-IzZCNO9kgXA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_hhLqgtco50SdO_BoWNW5NA_15_9">0.09</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_fpFZQPuAz02xrz-nrMCWPA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">$</span></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_9bI1krOSSESYBU23i7PtwQ_15_12">0.14</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_XJpe8v22hE-Dsy_po1DaCQ_17_3">43,761,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_D_MCsF-YkkK7dAb9itnWsQ_17_6">27,758,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_WrZp8J1MWECBzeanhoWhXA_17_9">45,556,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_0jJwczl8OEW-d3gHH2kbrQ_17_12">32,863,788</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_VID5cVVn_U-ANCDy0jyJ5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_HHJakNefDkedrywbmSYjTQ_18_3">217</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_R6xvGSBAO0OzR-4qkTKWaw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_5hqbtzJPBkijTjaYi9v6gQ_18_9">65</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JKiMKIkB9UmEZUv66KEFDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_s_CHJlTB30Cm-UC9WceOyw_19_3">524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0o9tvW5BwkWKJJJLxMSbvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_iYstyig-FEC113LSHxSdvw_19_6">635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Krs4XcDTxE-mc88POrcQMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_eWesRfLZfE-VGJmRldc4ig_19_9">154</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WiaTr_50-EC2jyC_GsZuBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vbhHur0Xa0CoKnJRczoYrw_19_12">562</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_nRNi-j4GhEuD86VBNDouHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tZWjuasp80CxRnjvKcJomA_20_3">1,216</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7FO9jabvyEuwVCPMPOvyvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_tSGBvMJp8UiQ4yMuPureZA_20_6">1,477</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ET9P1_n8jEmWQhl6pxUUhQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_mNhT2bREW02UQPK_g6P_TA_20_9">344</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_nPLZoO1ae0abxvTvACXCXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ZA90Tf-A8UKbs8BJyMVKMQ_20_12">852</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d89eec5e_357a_4111_86ce_812eb43d3102"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_8jSo-E--TUaruM21Vm_QtQ_1_7"></a><a id="Tc_eC8R7HrdNU2VG_C2CZA3NA_2_2"></a><a id="Tc_ysS3pmj9zk60WqOXff8jQQ_2_4"></a><a id="Tc_TQTtlkz1iUS_2ufeD4kItg_2_7"></a><a id="Tc_EnFF1o232EWLACENBPYbLw_2_10"></a><a id="Tc_HTipyDfxZkKBuJiMqrwIIQ_3_2"></a><a id="Tc_g1QjNwMKBUW2Oy7B7XlqJA_3_4"></a><a id="Tc_A8xu13ZlzEyhgSsTyqMGuQ_3_7"></a><a id="Tc_H1xVBF-eGE-7t-RzgVbPsg_3_10"></a><a id="Tc_pgTn7IF8c0CMqRNYjIqmeA_3_13"></a><a id="Tc_nlX2ESndyU-1LOm2f9Aq5A_4_2"></a><a id="Tc_a3XwMHTWXUyU5jiYJxVR9w_5_2"></a><a id="Tc_-szpxeTEGUSmCEX1RXjuWg_5_4"></a><a id="Tc_MEyOCFZrKUqDvpAv_uShQQ_6_0"></a><a id="Tc_N28y4ucsJk2ZKs9jW1MLeQ_6_4"></a><a id="Tc_pj9Dy9hnpUGjJNLn3-jjRQ_6_7"></a><a id="Tc_h2YuOyf4rEGeLdsWWO_Gqw_6_10"></a><a id="Tc_e4lWOV4RzEauac3GcnrIkA_6_13"></a><a id="Tc_Y3QDx1A4xke4hOh4MpnXUw_7_0"></a><a id="Tc__UvbUugaw0GibWPcLIwvZg_8_0"></a><a id="Tc_RvER2VU3302cpjGf7Q9Mug_9_0"></a><a id="Tc_QrtODBsk9kyqX-Lj178jxg_10_0"></a><a id="Tc_vJzWy30sE0ad6uwcG0Wxmg_11_0"></a><a id="Tc_GB-QcAgo0EeHoM4WIwF2LQ_11_6"></a><a id="Tc_62SgsFKtf0-yxUeV5WI0HQ_12_0"></a><a id="Tc_EmCEtE3klku82S4B_-pbcw_13_0"></a><a id="Tc_0jb-u1U9Iky13ExcsuhOQw_13_4"></a><a id="Tc_TCLTz5Km7Eq3MwF1LFBtLA_13_7"></a><a id="Tc_EPZPYBd3ZUmDQMExK4rrKQ_13_10"></a><a id="Tc_K_v7AeajEE-kj1syM3LsHA_13_13"></a><a id="Tc_ZmLIEuPZq0eGZ-N1yQfTTg_14_0"></a><a id="Tc_7FTcxZArzkmsNaPjS0cqLQ_14_4"></a><a id="Tc_R73Mq8yuHkqXkT4MTIHnSg_14_7"></a><a id="Tc_BoTzcJI8gEy7-lOJhqBSJg_14_10"></a><a id="Tc_GqgbjOHxmEC4kuwfOnUoiQ_14_13"></a><a id="Tc_SfuDtUXbQUiObYo23SPxeg_15_0"></a><a id="Tc_ntHOFnv5dEq4Az2psF2Bgw_16_0"></a><a id="Tc_ZTOJP9qEOEKFIdHYPnXKMA_17_0"></a><a id="Tc_99Q6rq8XVEaHwQz8bfHTvQ_18_0"></a><a id="Tc_er3McykHh0e9_Xj58O1BFg_19_0"></a><a id="Tc_6-H4y0-iPkGB6iUurzVVmg_20_0"></a><a id="Tc_s6cGXtmpPk-iFMvf67XNdw_20_6"></a><a id="Tc_MtzxaOrzNE2m43iLDl9kRA_20_8"></a><a id="Tc_x31GHotl80CADHjrnMCC8Q_20_11"></a><a id="Tc_6kduau5zMUCVQH06xQtzVg_20_14"></a><a id="Tc_QX5rPFtnKUiBwFCeHM83Pg_21_0"></a><a id="Tc_ctOecYJ5TEGOo6Jdxu8qvw_22_0"></a><a id="Tc_oAg-ob6tcEm6zL-7hr2NhA_23_0"></a><a id="Tc_PHyYpOCxHEOeyQR1Kha-cA_24_0"></a><a id="Tc_SFQMfnCEK06XnDlrYF0CeA_24_4"></a><a id="Tc_W-psqizU4kiJZXscDnbJUg_24_7"></a><a id="Tc_IslvM2k19Uu9Tlzui8UG-Q_24_10"></a><a id="Tc_xQzjkDqgUk6AFXUjoGTT5Q_24_13"></a><a id="Tc_oJxAYnePrEyswYrs5V-XPQ_25_0"></a><a id="Tc_-rnUJoazgk2XA5S6zrRanw_25_4"></a><a id="Tc_JCXp_nubSU2m3TQxlusoGw_25_7"></a><a id="Tc_X-jCYGuMwU6wAjvxvinVVA_25_10"></a><a id="Tc_9S3PQZNiHEmjRnj0zHvbxg_25_13"></a><a id="Tc_CDbiWbpHc0uGkWO9Oz7NwA_26_0"></a><a id="Tc_tT43-5At40aW9THRo243fg_27_0"></a><a id="Tc_pzrmfM6PKkSW7ZVCj9BE_g_28_0"></a><a id="Tc_8F5f4mmQDUm_XcF9GFMtLg_29_0"></a><a id="Tc_k3ETR5irmkeawMTcEx2HZA_30_0"></a><a id="Tc_llE0HMITPUm2S4Aoq56Hlw_30_6"></a><a id="Tc_lVMQ54f1HkuDewb1JeerCQ_31_0"></a><a id="Tc_ytFdeK7TaU6uMQlFUE75Bw_32_0"></a><a id="Tc_Xf1EsEBDXEexhsMGf6-lew_32_4"></a><a id="Tc_I57FmEm6MUmubkCDyhA9yA_32_7"></a><a id="Tc_SCU1cU7IKU6pRWylfELEfg_32_10"></a><a id="Tc_s4oTC0ItWESUh_FwtF1V-Q_32_13"></a><a id="Tc_5mvGDNKW50qSd3LYWsrjrA_33_0"></a><a id="Tc_17aWXSZHdkWRSWxbLR519w_33_4"></a><a id="Tc_zKLODjiap0ecBpASpEKszQ_33_7"></a><a id="Tc_dJoGlfXd9U6hkmLV5ba4jg_33_10"></a><a id="Tc_Ho9DjZ294EOsCPLQr48RFA_33_13"></a><a id="Tc_0bW7huJq80OcDebdjZZCZQ_34_0"></a><a id="Tc_Xc6Krn7WAUGXxx6xwbpkpA_35_0"></a><a id="Tc_2uKdFJa5cEmp1z_8FtQgXA_36_0"></a><a id="Tc_3mkcFL6_4UyJOSNG4uFEpg_37_0"></a><a id="Tc_Zego35qo30m_hWHsnhIppg_38_0"></a><a id="Tc_XKxfKFLDj0ONFI5-uLVQkA_39_0"></a><a id="Tc_Hn14dJfRHU-hKDF4nw442g_40_0"></a><a id="Tc_9qKoClKpW0GgLyHPn8mTYw_40_4"></a><a id="Tc_ElFSpThzIUePMQA_Bu02Xg_40_7"></a><a id="Tc_J8hYtXcI0ECWpgm0j6CW1w_40_10"></a><a id="Tc_h3ZsMa06XECqm0Ym-Sz_CA_40_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gAacYeLtwE-Mj1yvi-z7VA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_2CkcVuVuQEG7KItaDjm3Lw_6_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gAacYeLtwE-Mj1yvi-z7VA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xsW0tUXa-0ahJbEqkbJpLA_6_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DzXzpFAVKUa090qZyz2PWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_76Xs9hxU00WH3KxyJwzRYw_6_8">270,492</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SshBsuzbEE-H-tzxnt_IRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_WEotxEPguUG4lwMUBqoztA_6_11">340,829</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2019_rmjAbtU_mE681EqPesN7RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_UuwuwU7ylka-7NeddOUW0g_6_14">70,322</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and warrants, net of issuance cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw" decimals="INF" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" scale="0" id="Tc_bv08SIutWEiAUmKkUOwRvA_8_2">17,604,423</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_6pP8SszvR06E-UTzEwHyqg_8_5">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_vJm-jGsYd0GLgBjW-AZ4rw_8_8">41,325</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_ckpYzcFFcEWeBnpegvvCdA_8_14">41,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_xQRla6Vgvk6Uk6QSbUifDw_9_8">1,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_T-326tXar0qx5rOp0fyaNg_9_14">1,607</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_LC5aYmq5CEm0nrSnW315LA_10_2">694,073</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_iZ2Wz-GHL0GbzSJv9wZzsw_10_8">505</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_bUuoEXIyxESD7J-xIL1bjA_10_14">505</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_nFt_VGt_Zk-MAJJ9PTINCQ_11_2">200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_7WoiT681rUmYvIpse72l5w_11_8">472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_nhUWBhxkd02S0uQzr5iZGA_11_14">472</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VQUwy6ZsqUWKoDwiSQgUCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lPaDxYHiAEyR9Gq18mxteg_12_11">6,920</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_a2tCH-iMbE6cvSaHtoC9-g_12_14">6,920</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_J7-Sq9OR3kSfIYfoKZU3Tg_13_2">33,336,709</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_B5i1R3gUp0uBh-A8PZoDoA_13_5">33</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_67iC4kJN5EWDKR82GNj9iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1cTCN-Hi1Emy01krBSjEag_13_8">314,401</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XqPOXgGBqUa1Fz3o4j1BTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_B2ib645FF0WvfuCceUM_Bw_13_11">347,749</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_NRmU4p4YfU-nTPpvCUHYcw_13_14">33,315</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FhAO6ZCXfUeU1PtZmtoW6A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_NIZffxgW_ke3Yy9mBpWl-Q_14_2">34,765,280</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FhAO6ZCXfUeU1PtZmtoW6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XfEFGnl10E25NvWL07t09g_14_5">35</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QDIZWika_k258jbF39gQfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__mFyBoiE1EeKahRrR5kiMA_14_8">320,280</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ajr0YlG7z0mN2jc2ptdz3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_nS4QQ1_R_0WUlQ1Ud61kQQ_14_11">347,352</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_VrDaGSMNFkqHwzEKzofRsw_14_14">27,037</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_me7GFoP0YkmFe4qvGxo_OA_16_2">8,749,999</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_dQNRZLr8fkGNSYdHIo382A_16_5">9</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_vt2mFbN8s0-F40UMPgPKng_16_8">37,616</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_8cnx888DykWamkAfOgk_TA_16_14">37,625</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_FnsMO4D770WjajQaqxOl2w_17_2">1,867,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_ekNz7mfzVUSRUSsHCnZMcA_17_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_lSnzUc8fvUaiB3yjg971oQ_17_8">8,573</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_k5r2LAWfKkeYaxSuu1u8fQ_17_14">8,575</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bjamkKa_DU-mV3W5AmNW_A_18_8">1,176</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CI35Gm6jCUKr47_c5XJAmg_18_14">1,176</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_F1ubMBG6pEqEjb4SuKcYWw_19_8">781</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_NThaJ_6wQUeKSyPAKZgPuQ_19_14">781</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_gwNvOAk-mUub1bCcc4W3gg_20_2">173,816</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Reacquisition of equity component of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_-IBbjf7y5Em-_07y3G4tZA_21_8">12,019</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_17EMCWzLZUKviqN0FIQqjw_21_14">12,019</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equity component of convertible notes, net of transaction costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" sign="-" scale="3" id="Tc_GQExL1sDRE6Ot19JcnwSOg_22_8">12,027</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" sign="-" scale="3" id="Tc_uiwwfYF1rUSsyhAU2SF5Ig_22_14">12,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ahmxUbUVBkm9EcsPC2dvdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RjjlkDXwWk-XEGaovKCntA_23_11">20,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_O5mcOpTeAUG_k9bmR2Ke8g_23_14">20,915</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_c3mVXk-AU0S4yi7qfsOOrQ_24_2">45,556,647</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fOZQSzRXqEifowNe8TteDg_24_5">46</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K112MyLGIEyF188YEMII6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_GBeYGjDVlEWhW86MNiAoGw_24_8">368,434</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cfPZTTulqkernD2EnEhf1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_4FJXeoCGj024GN36fVIWKg_24_11">368,267</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_EVCjg42iY02Ng5oKM0OIoQ_24_14">213</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TNv1Z6zXV0WmttZRhAIl4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_ZkyIUdI8cEy4nBlfEeOeWw_25_2">32,442,636</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TNv1Z6zXV0WmttZRhAIl4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5WXMoBy9fUi3vp8TkkhhKg_25_5">33</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vALHgTVTI0qpDI5OS2no8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_yhOCHtxxNkCgYz7Q5BwCsQ_25_8">308,515</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q-w46iXNMEC75S22Wy4_XA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SS2VTbkY10S0oRFwuWGAgA_25_11">343,312</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_6_30_2020_nF71pgQNK0Sm4dLM4r805Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_UAhu5aOP_kqDPUuQA-0JEw_25_14">34,764</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2020:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Note receivable payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA" decimals="-3" format="ixt:numdotdecimal" name="plx:ReceivablesFromSaleOfCommonStockAndWarrants" sign="-" scale="3" id="Tc_1aaQyNxt206_GQnjhtCjuA_27_8">4,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="plx:ReceivablesFromSaleOfCommonStockAndWarrants" sign="-" scale="3" id="Tc_ixN6BuglTEOGZAf2KfSh7A_27_14">4,000</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_GgbwSqFZBUeI3PuPtvxlgA_28_8">909</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_y1UizjQZlkWjBNJbAnbkmw_28_14">909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-87NC5EOIESzFcXTIBQgjA" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_KVz_6BTRVUilpbpsqmJrNg_29_2">694,073</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_m3FkChneZUiA4l8Q5ahEsQ_29_8">505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_kK-DFU2fTEqgKD12hJyD6Q_29_14">505</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-87NC5EOIESzFcXTIBQgjA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_KAsebpcFckK4WP4du54Beg_30_2">200,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_erZ3_7ExaUOc5T-U44nEBQ_30_8">472</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueWarrantsExercises" scale="3" id="Tc_Chbw5OgDSkuTSDM8RR2CIw_30_14">472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MGJAPFogqkW3PHmVyWwQXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_667TF9BhZkCUHQLBMmD1Tg_31_11">4,437</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_cVeSmJVn90Sua4Zk8PFzcA_31_14">4,437</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_gYxgWB6MAE-BH4tEtEVhfQ_32_2">33,336,709</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bA6NRkbrcEKJ3rXh2c1STQ_32_5">33</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_67iC4kJN5EWDKR82GNj9iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2tBnYbdy6kqUDXX9BtnGVw_32_8">314,401</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XqPOXgGBqUa1Fz3o4j1BTw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_-K5CslMBdUuiYdwg1WaCqA_32_11">347,749</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_AkaVOPW1ikqv0dULHqk2Rg_32_14">33,315</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_osEJghx1vkyNcPXIkVFTwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Oi7uyOMTvEOr2dNaywPhVQ_33_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_osEJghx1vkyNcPXIkVFTwg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_N9mh5CmPkUWXegogaikbrA_33_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ObypWAjZfkumwrue2SoofQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Ot6aemRus0WfDR4q_oTz2g_33_8">367,863</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SzExwvidwEKr4i4UBC0FeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_H7BNVHQKCUiv3FhaBt2i3w_33_11">364,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_6_30_2021_6e4TEe_8H0S9ZKRRnpwe0A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AiTBMhKMUEerViaaUGSSEg_33_14">3,841</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2021:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Reacquisition of equity component of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_utSC0zXvDkCRe5BeD7xhGQ_35_8">12,019</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" scale="3" id="Tc_YTwumf-vxUejUCwkgeeBcQ_35_14">12,019</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equity component of convertible notes, net of transaction costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_vVnCyJwGzUGZDGlXPiBlAg_36_8">12,027</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="3" id="Tc_t5ELb6fNM0KVNlNVGzDuRw_36_14">12,027</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_2pamM6MIs0KEJDxHlMatJQ_37_8">344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_8dEbC3Qu_0W2Y4M8Uom9vQ_37_14">344</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_6m2ckR75-0amb7E9EOFHyw_38_8">219</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_S4fKgvYbZUaSlARXxu_a0w_38_14">219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3H5BKgTVfEanIQa3JfzDpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8w8TQnBa2kquOiw2mweXrA_39_11">4,199</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lbrHMPxpskud80tnWc9f7g_39_14">4,199</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Lz4nTLvqp0O3NIGXqO4b8Q_40_2">45,556,647</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7E8A3Tr7ZEeELwLttzNu7g_40_5">46</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K112MyLGIEyF188YEMII6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wtVXLZa5NUStxBdjYcB6rg_40_8">368,434</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cfPZTTulqkernD2EnEhf1g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zJMfQuweck-HK7yKwaZUuA_40_11">368,267</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pqm4OBnxfEm0w1nC7xMeCw_40_14">213</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">*</span></span>Represents an amount equal to less than $1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_SAq3biMH4k27spydBvx2bw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_v4vG-O2obkWditpM8bXXXA">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of September&#160;30, 2021 and 2020 - <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_xssjUyx8mUCwp61eFxqhkA"><ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_u6tWVFogzEOeBvYLKcgD2A">120,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1969ae3b_b04b_4ede_8d7d_86a45b16dd76"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_wqF6zkRItkGTSQE_n-wzow_1_2"></a><a id="Tc_D6S5WZHhqUKDK3pnxXkPVQ_2_2"></a><a id="Tc_AAMVH1f5jUarYp7eCxDpKw_2_5"></a><a id="Tc_CNSmsqFVXkiIoXsfKFtbHQ_3_0"></a><a id="Tc_pQaU37CTa0yBOz5NSog_7w_4_0"></a><a id="Tc_gpl9JjFkWk6Lb5U0owWQqA_4_2"></a><a id="Tc_hn5uCdbzXUO-RyJGlGIrmg_4_5"></a><a id="Tc_k8O1WTl-1kK8RPwR-M7qDQ_5_0"></a><a id="Tc_OW-RSKvF1Uea1w2OJzGF3A_6_0"></a><a id="Tc_toWHdDUmXUiamAqBAw5UfQ_7_0"></a><a id="Tc_V0aeU56Fh0SDHNPeVGyKqQ_8_0"></a><a id="Tc_dOe-kChk8kujjD9DU0a-nw_9_0"></a><a id="Tc_JvrvBSxTdkyQFzPa7iZXzQ_10_0"></a><a id="Tc_Sut2Xo1__0OKT5TLnHRRuQ_11_0"></a><a id="Tc_GqL3l8ExqEaWxsoT546LLA_12_0"></a><a id="Tc_5UOPkJ1DAUKX2Z4HE2gJVg_13_0"></a><a id="Tc_IpfOGgp-GUOJmBVJFU51NA_14_0"></a><a id="Tc_hU-uJagEBECUWiES4w5fTw_15_0"></a><a id="Tc_D8IzwEVoBUCRdDcpOTCtfQ_16_0"></a><a id="Tc_WLWKJJ8B5USVUByDqgqRKw_17_0"></a><a id="Tc_QsktyQNpsUOMkAc1YwnaQw_18_0"></a><a id="Tc_bggD2kgnkUe0fTa4SpbytA_19_0"></a><a id="Tc_V6QzPXWibUOUTP9dAC7rSg_20_0"></a><a id="Tc_gaZlz4ESjUatiZAEesRsig_21_0"></a><a id="Tc_t_N84lh_BkGFQV09an0saw_21_2"></a><a id="Tc_AkKZDekzzU6DiM-zQpWw7g_21_5"></a><a id="Tc_rc_Dj46-2ESISlISgf1tLw_23_0"></a><a id="Tc_5Gbz1k_9dU-EprZwnaCGnw_24_0"></a><a id="Tc_hfYix0MRhEO4uCBIkTfc5Q_24_2"></a><a id="Tc_oj9MQlsxlUe7z0S0pt5Wgw_24_5"></a><a id="Tc_XqEENgeizE-ewRR9CMMmyQ_25_0"></a><a id="Tc_EmebFnzAa0ubyn-YorHCiQ_26_0"></a><a id="Tc_QzX5cIi2ZkqkzuPoeMCN_g_27_0"></a><a id="Tc_mrlgcD6AFk2K9Y5UyHRXzA_28_0"></a><a id="Tc_FLiu1szbiUmvoTRNk7M-9Q_29_0"></a><a id="Tc_gg2TFs-Q6UugoYyHC5WEdg_30_0"></a><a id="Tc_LJznuYbJSUuSuj95Xpv5Rg_30_2"></a><a id="Tc_X5jE-woQLEmbCJw0U2ayZw_30_5"></a><a id="Tc_55cqrJ1980m968vskGgGsw_32_0"></a><a id="Tc_q6SRpuzzF0KjkuMwdOy7yw_33_0"></a><a id="Tc_DIBWEbuPHkKTFy3PQ9Oltg_33_2"></a><a id="Tc_YB_a39rmp0Ogn4OokXGa-A_34_0"></a><a id="Tc_Qe0PTbbFw02GqpeqmepzSA_35_0"></a><a id="Tc_PtS5DUkXxk6o9n7_GyPJIg_35_5"></a><a id="Tc_GnR49w05AUOkGAzkA8ZrCA_36_0"></a><a id="Tc_SdHjtDS_ekSBYNP_iZzr1Q_37_0"></a><a id="Tc_-0NDwz2Ks0ymbiLN7dDbGQ_38_0"></a><a id="Tc_Vcn_2hWZh0WxaDFEj4068g_38_2"></a><a id="Tc_W6YFebPFr0Waj15uie8Omg_38_5"></a><a id="Tc_KCbN1oJCqE-kAGFrQEo14g_39_0"></a><a id="Tc_NhjWDWJxKUKi5dLXdnkISQ_39_2"></a><a id="Tc_FDVFQvW8ZEmhgeN1ktSfyQ_39_5"></a><a id="Tc_yPHYY9vDoESdW0IpNSsPVg_40_0"></a><a id="Tc_k-sxQnz_tU6JlExGTHctJg_41_0"></a><a id="Tc_4dVFcCbntUmcJ5n1AAR4Bg_42_0"></a><a id="Tc_jcN0AcvNlk6zRLuRNxMZLg_42_2"></a><a id="Tc_qge5biRSAkWXvp9vFSxngQ_42_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_0djD6E62206f1duIx4caKA_4_3">20,915</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_QdN5Hp7oN0a5PCwWNxVY8w_4_6">6,920</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_OmDrugp_10unRJDTE7JjtA_6_3">1,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_fpfBxEk2A0KCTgqQx85raQ_6_6">2,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_kc8zthzwVUmGLp54korCWQ_7_3">859</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_M9YHxIGUNkik6CV_jbPLpQ_7_6">1,011</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_3mmNhysQPUK7v47PAcHbOQ_8_3">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_hbtVQYFVfkee7dB33jKYHw_8_6">284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_6NJf8D0yhkGcHloe-Gldzw_9_3">100</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" sign="-" scale="3" id="Tc_9M4wM0Ce2kuckm6GT-7xNw_9_6">488</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_g_7WkzEdakOMiI7ggAOgvw_10_3">75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_cFVLgHEuoEazC5JwvkG5pQ_10_6">11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc__wLO8o0KTEafa6qhsijqOQ_11_3">51</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss on extinguishment of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_NDWpxarVuUiPcUCtojP7DA_12_3">831</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_lX-x_jFifUm8TN1BxflvSg_13_3">2,569</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_sXw8oXv1ak6jzVQ-KO9J6Q_13_6">2,548</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in contracts liability (including non-current portion)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_CoCgWkh0ckm-iDs_5qxmmA_15_3">13,945</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_q0AdmlYriUan_kAwBibEbA_15_6">15,062</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in accounts receivable and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_kYKTFW0sj0q-zwwBESJ6hg_16_3">4,075</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_U3YoZxMbu0m6AEF5GQ3M9g_16_6">783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_XmFDGpQZlU-ez9Yj8VGsYw_17_3">168</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_clzN4-kw1kiKPfboUsjiHw_17_6">53</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_WKTu8RKWlEudrXhuoeOXog_18_3">1,648</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_XzqWSzDg6E-muy27-iKrsA_18_6">5,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts payable and accruals</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_K6u6Ruofwk67yHk6vWlqxw_19_3">1,070</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_RaSqVjb7fkWcPlN2MSTBFg_19_6">3,291</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_zGWdEXUGaE-gxCYe12d8aw_20_3">51</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_wPEgNJxSH0mPG-5MZGMz-w_20_6">463</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_miOb10FH-kyDpeRZHkFEVA_21_3">5,198</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_T9L4HOChYUuQCDPJ1Lp9Nw_21_6">18,556</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_VGUQ20-Nkk2ZyUkiC4HkFg_24_3">37,835</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_AiHLucUCPEemYjtlsqSyvA_24_6">27,500</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_kAc8W4QHckOL_gqjVBVvFw_25_3">20,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_Dcau7IPB_keE0fEt57E8tw_26_3">1,011</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_XYe7Edvg_Uq60ah8o6xt9w_26_6">380</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_XexDkv1t_0ib3vVT4PZmjQ_27_3">53</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decrease (increase) in restricted deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" sign="-" scale="3" id="Tc_JiViqdBGeUqoq0k10qc2hQ_28_3">359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" scale="3" id="Tc_VTAR5ZThKkKsrp1v_pV09w_28_6">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_bqvwcp2XAkOkqaPGkg8EUg_29_3">81</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" sign="-" scale="3" id="Tc_Rtl8Xnmc9UeTzWkaOdfbUA_29_6">340</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_hZ3QsSblA02QIPlB_bzYLg_30_3">18,515</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Y-__8UjKgU-xK6N2ULHWgQ_30_6">27,544</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payment for convertible notes redemption and transactions costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_7CaJhLN5w06Oub_brsRbIA_33_3">25,990</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net payment for promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_jE_WwY-jxEel6WZMgE_dqQ_34_3">4,086</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_NCPZISwWQUC7VK8MyvVILQ_35_3">37,625</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_OLLGWwMLiUiKMTiNEb4HfQ_35_6">41,343</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_gyfv9lNWz06unDP4BEvuVQ_36_3">8,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_FIGOS13pv0OAfOAxtAbS9A_37_6">472</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_40x3pdvXA02zZv-1LeR8bw_38_3">16,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_O3i-BK_ii0aYCLPVYUKx7g_38_6">41,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_8sdtdxdDGEqaj8iHyjQtYA_39_3">34</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_2YJPnJL7ckafx7Can60D3A_39_6">26</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET DECREASE IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_pP_xjM9SNEqFnAPDprpfHA_40_3">7,623</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_Wq6JZdHATUCSjRBQKWk8lg_40_6">4,259</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_1vdjUsJJOkebiUe72eIdFw_41_3">18,265</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2019_rmjAbtU_mE681EqPesN7RA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_JQFHo2kATUio6G87R7smGA_41_6">17,792</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_eloHEUAIH0aVPqJeVGWxbA_42_3">10,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc__tIHD5NjX0Ku1Ydefj0l-Q_42_6">13,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_D9ZW_nRWN066eKvIFfv1xA_1_2"></a><a id="Tc_0J78tE73q06AfaQT5DNr-g_2_2"></a><a id="Tc_9QtycNUCBEuc_V6fd3-m2w_2_5"></a><a id="Tc_sPJYQmxPckWWoj7FMs2ISw_3_0"></a><a id="Tc_KuLAFUU2zEyf59m1YldsJw_4_0"></a><a id="Tc_0lJMqpcTOE6gvKpU-WdnBg_4_2"></a><a id="Tc_8eiE80rVkUWU8hhMuhP13Q_4_5"></a><a id="Tc_gq2q5JcoZUOaSRXXRPmHUg_5_0"></a><a id="Tc_vR1b36g_zE2uOVsXmcwS5A_5_2"></a><a id="Tc_TyvoZi32M0q5Sq0ctZVilg_5_5"></a><a id="Tc__RsPOhTeYEOs74LtHzFR0w_6_0"></a><a id="Tc_hwYrfiV93Ui4sVgrp6EQoA_6_2"></a><a id="Tc_lLroH_ubV0ykm248giXA9A_8_0"></a><a id="Tc_d6kESzT-s06eUv0Bk28ycA_9_0"></a><a id="Tc_HOhOG0DioUyvCOH3JjjeqA_9_2"></a><a id="Tc_seVXmdfEdk67YQDauGhw5w_9_5"></a><a id="Tc_MYoV0Q5eVkSlSx44AROMhA_10_0"></a><a id="Tc_f2i_tdRju021ihKPVhp7HA_10_2"></a><a id="Tc_JFChbO3hbUmXG881wcOUUg_10_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_VAtZbtxN1ESlI9EcgYPNLw_4_3">387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_mJwwMG_LukCllA1IKkHP5g_4_6">95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_UAuk7TjsHEypCvsblHHOIA_5_3">309</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_Te-vDYxVIk-3hyBEpynqkA_5_6">564</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Transactions costs in connection with the exchange of convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" scale="3" id="Tc__X0IxQj_VkafmdulbQ5Qvg_6_3">774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_NzQt5LSKoEyLbktX5na1yA_9_3">3,288</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_RXljmaC9HUmemhULyxciSQ_9_6">2,172</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_6TPqTOfXQUCUvoBJVfxwwg_10_3">445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_kY08xNTlIU-Goi4vwVKlBQ_10_6">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As to extinguishment of convertible notes see Note 5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_OObOhFE0mEyXY9htecYDWw" continuedAt="Tb_OObOhFE0mEyXY9htecYDWw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_7KzyiuZ8_km5HZhzuFDznw" continuedAt="Tb_7KzyiuZ8_km5HZhzuFDznw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On August&#160;25, 2021, the Company completed exchanges (the &#8220;Exchanges&#8221;) of the Company&#8217;s outstanding <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Y89Z_vOrgkupgKhe3SN3CA">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u4SuBfYydEm3isvsquTltA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_ZRN32WRLy0Kf3Qw-HOYlSw">54.65</ix:nonFraction>&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_xWqcG6cCtkuO4rOnNEK3Ww">28.75</ix:nonFraction>&#160;million principal amount of newly issued <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_ZYEXEUak1EaaG6PnL2QlvA">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_5jvyfugVc0Cm9uLwhPM3Gw">25.90</ix:nonFraction>&#160;million in cash, and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" scale="6" id="Narr_u_-RprPTWEmOn7Mgz552cQ">1.1</ix:nonFraction>&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ" decimals="4" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_pX7Yw0yZLEm3C1aqWdEgVA">563.2216</ix:nonFraction> shares of Common Stock for each $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleBaseValueForConversionRate" scale="0" id="Narr_FGpNGVJDBEah_QJ5Fh7oxw">1,000</ix:nonFraction> principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_WQxHZ6S3aEmdvsehn0tO_Q">1.7755</ix:nonFraction> per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfPremiumToClosingPriceOfStock" scale="-2" id="Narr_ZJ3DySGbWUOHCdtZ7UJqfQ">32.5</ix:nonFraction>% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and, in October 2021, the final dosing of the last patient in the <i style="font-style:italic;">BALANCE</i> study was completed. See Part&#160;1, Item&#160;2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OObOhFE0mEyXY9htecYDWw_cont1" continuedAt="Tb_OObOhFE0mEyXY9htecYDWw_cont2"><ix:continuation id="Tb_7KzyiuZ8_km5HZhzuFDznw_cont1" continuedAt="Tb_7KzyiuZ8_km5HZhzuFDznw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix and Chiesi also announced that a meeting was held with the Rapporteur and Co-Rapporteur of the European Medicines Agency (&#8220;EMA&#8221;) on October&#160;8, 2021 regarding PRX-102. At the meeting, Chiesi and Protalix discussed the scope of the anticipated Marketing Authorization Application (&#8220;MAA&#8221;) submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission for PRX-102. This is an important step in the necessary pre-submission activities leading up to a MAA submission. Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study that the Company announced in June 2021, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, the Company and Chiesi expect to submit an MAA to the EMA for PRX-102 during the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#8217;s exclusive worldwide license agreement with SarcoMed USA Inc. (&#8220;SarcoMed&#8221;) with respect to PRX-110 for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during the three months ended September 30, 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_PIoT_NoejU-L2QS4flELFQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_2n2QvS9-6ESh7_5e2rTGmA">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_hAKdSmKW7U6VWH6p5lybLw" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_33PGfE0fz0S3M0k3lnHiYA">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_hAKdSmKW7U6VWH6p5lybLw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_J4LZgQ5wBkaYW_ZdyFq8fw">3,296,123</ix:nonFraction> shares of common stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_hAKdSmKW7U6VWH6p5lybLw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_aoS4o6X8f0a9oRLHqz7vzw">13.8</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_2_17_2021_To_2_17_2021_1i-AeCXmUEuYJ6FKsF7Dqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_g_ULM4iA5EqUdISaVk-x1Q">8,749,999</ix:nonFraction> shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_2_17_2021_To_2_17_2021_1i-AeCXmUEuYJ6FKsF7Dqw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_Vdje2EBlLUmlA7JY_N4wOg">40.2</ix:nonFraction>&#160;million at a price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_2_17_2021_P7ERVIdUQUOUY7klvL64CQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_MgEqXFBe6kakCbSrgvcUTA">4.60</ix:nonFraction> per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License </p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OObOhFE0mEyXY9htecYDWw_cont2" continuedAt="Tb_OObOhFE0mEyXY9htecYDWw_cont3"><ix:continuation id="Tb_7KzyiuZ8_km5HZhzuFDznw_cont2" continuedAt="Tb_7KzyiuZ8_km5HZhzuFDznw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_UgRSQaaG60edGgxVl9FI7g" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" scale="6" id="Narr_vQSWuy0-70aI4-MbrMj2yw"><ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_SZUr4ebLNES5P_WEJfhHrA" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" scale="6" id="Narr_p45vpFiu_UCGEGMD5-KV4A">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fO3KmyeTREaqgOM51FScaA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_M-Evk5iR2EKdlMiWmg9fDA">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, capped at $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fO3KmyeTREaqgOM51FScaA" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_giLdtGrmyEGWHMARs4nJLw">10.0</ix:nonFraction>&#160;million per year, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fO3KmyeTREaqgOM51FScaA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_KlZX368EI0-k1WA-a6aBWg">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5917jrg-_kWEb92bxu9mtA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_Doe6O1GuKUefXAUCbwIV4w">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5917jrg-_kWEb92bxu9mtA" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_qKdQY9gJ606la0vZi42V-Q">7.5</ix:nonFraction>&#160;million per year, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5917jrg-_kWEb92bxu9mtA" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_OuSM0mMqd06xL4mcYJUf5A">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3hEtaSNNrE-fNBLdsevplg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_uXJB1bDpPkOznzGU3M3FuA">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Ubpzjp7z0kmMySSYJsgF6Q" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_kKLlWNBO1kCjVfZstv9jdw">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_-_pc4KjjIESt-NNMJSZPIA" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_wlJmOgvCvkat5nhQaW8C6w">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_t77xAm2kAU-zv8pYeCND3Q" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_xg9a1_s9V02Vb0lvfGVuAA">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_LfY0cj9P4U6EKioM2_MD0A" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_l-_b8x5OvkqD4syIsdRFVA">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Vkt7LBou5EOkM2AjnrrdNQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_1UekG_E02E2yHk2nYS-sZg">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_mxIiF-Oq6kSHobdbWU0lig" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_f-k0YCi71EKSQ4exdglGuw">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of September 30, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OObOhFE0mEyXY9htecYDWw_cont3" continuedAt="Tb_OObOhFE0mEyXY9htecYDWw_cont4"><ix:continuation id="Tb_7KzyiuZ8_km5HZhzuFDznw_cont3"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_Jeuks2tCF0eucsAOyMUTlw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_oq_droLU10eZanVmDSC-hw" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_bQx_EtrGWk6N3SvRl_j67w">26,905,842</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_cSydejW5m0SgoUPlNDGF-w">21,405,733</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2020, respectively, and <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_IHZKEzoq9kex3A5_3R7t5g">27,962,842</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_YuUwWW2LpkOauCJA-t5_LQ">26,847,081</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes, 2024 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_5L3iziigI0Ou_QUaVUQxLw" continuedAt="Tb_5L3iziigI0Ou_QUaVUQxLw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_eXGUnuCXhEyws-3Rm25qEA" contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_L2L59hXyMEOR7OKOotcc8w" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_NL6ipRczVkixOLr5VUOWaQ">two</ix:nonFraction> performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OObOhFE0mEyXY9htecYDWw_cont4"><ix:continuation id="Tb_5L3iziigI0Ou_QUaVUQxLw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_5b31fb9c_2090_4681_83b1_6f700ccf3b30"></a><a id="Tc_sWY-eZ9cKUa0CNe7FtvYhA_1_2"></a><a id="Tc_bifn5YJpKUWuODvtYaj40A_1_5"></a><a id="Tc_ZVUf0ZYTOkmYQql-T5eBJg_2_0"></a><a id="Tc_WIC2x9C6V02I1er5s2dlfg_2_2"></a><a id="Tc_PzTBK-NuFUa7_QuBVuR_SA_2_5"></a><a id="Tc_-buP_YLWLEeW-VxVJn-i_w_3_0"></a><a id="Tc_J3hOfAcaZUO0XPAKLZj2SQ_3_2"></a><a id="Tc_18vJZQJo_0-bW8bh-r4Y7g_3_5"></a><a id="Tc_4qNjOohRlEed2OmLA5olDQ_4_0"></a><a id="Tc_H9chmub-tUqW7J7cbyFTuw_5_0"></a><a id="Tc_KtS5-wYQ3Eeu5f0RB94iyw_6_0"></a><a id="Tc_PMZmAgcXMUeUkQm1avEWGA_6_2"></a><a id="Tc_WxcoLJA5ikuTEDGLIT2--w_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_1GvXkuL6Z06Sgc-Uzdtmaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_PuZ12JjTl0qDCaceaPX4-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_-mpGOOkfSk6z_E4bgPdOpQ_3_3">3,170</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_N0Mb2O4aa0y5WDYMEidhEg_3_6">3,347</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_idSV-zhz40WXJXPYDxjXsw_4_3">3,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_1euWAIovH0y9PsEdU5ukvA_4_6">2,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_DA2txOJpuU-3cKLcHDy5lw_5_3">8,053</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_3DdAYFswF0-vdejNg5yXKA_5_6">6,848</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_ClDqXJFEnEm5sttQc3bfBQ_6_3">14,730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_9B3jsHqrN0y3Td46TgWqjQ_6_6">13,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Deg348Zr-k6Q_nvXiOBJyg" continuedAt="Tb_Deg348Zr-k6Q_nvXiOBJyg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d002d227_bf39_47c7_97b0_43f3ca0805ef"></a><a id="Tc_ezb3ghLxCEqXYhXHuA9kJQ_1_2"></a><a id="Tc_nGyDRPlfcEKMsGXCRpacJQ_1_5"></a><a id="Tc_tCSnwMBlk0SwvaYDoJDBjw_2_0"></a><a id="Tc_DGL_yUlsrUGhK1GfGvb3vg_3_0"></a><a id="Tc_bvPrj9-Vw06MRXuZIGqOfQ_4_0"></a><a id="Tc_vD4iuO_nu0-9vxaQm3yHvw_4_3"></a><a id="Tc_2NT_0swxOE-H2k_RzHXY3Q_4_6"></a><a id="Tc_XW9nbaylXUGv-PTs_8iiRw_5_0"></a><a id="Tc_zVNOu6Vq2U-oXAQBdgSamA_5_3"></a><a id="Tc_UN9y1ckJk0m37DG21__F-Q_5_6"></a><a id="Tc_uzcn9wWr4kqMjGlbBDSIBQ_6_0"></a><a id="Tc_0ko779586kePsjzAnuWgjw_6_3"></a><a id="Tc_VTNVwNk4FEeSJTImrEmCPg_6_6"></a><ix:continuation id="Tb_Deg348Zr-k6Q_nvXiOBJyg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of September&#160;30, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of September&#160;30, 2021, the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Z6NWekiCLE6G-qLdOHDf5g" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="Narr_r4J-p64rHEaOXQ59Bcifvw">3.27</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2021 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Z6NWekiCLE6G-qLdOHDf5g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_OG-ULsbPGkK6AEtTsyB21A">3.4</ix:nonFraction>&#160;million and the fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9_wMuN2NN0i7qwtMQCbLVA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="Narr_2IVcpGiyWEeJC-ZszqdFJg">28.75</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9_wMuN2NN0i7qwtMQCbLVA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_62x5Rbcr5UuPep47Ih49Yw">39.8</ix:nonFraction>&#160;million.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_c9iBJVgvmE6XPL7XnYJeDA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_IQ9RgYWoX02_y0RZ9VuDQQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes and 2024 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_fjePpaWSpkeew6EE71xYVQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_VbAOP13XRE2WJdovPb67wA_2_2">1.33</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_wgnkkX_RZkCtKFWS55dCIA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_Ir2fBFvtYkmFVvsYZ5ucxw_2_5">1.33</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_zGLIgBqMs0SokSMlmYxJWw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_NWGoYaC9Wk26qW8788ngSg_3_2">0.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2HD1crqgP0We3_b66UftRw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_hvG_m0ITek22PF6XMLcWnA_3_5">2.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_VfiXjGij6E2FnqQWtpJIoQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_MxV9Q7JCrEOZZwFCOCvxLw_4_2">0.04</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_VDBEZhK3uke05lvqCgGCcA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_C7Xtg5iny0W9JgRTpkf-oA_4_5">0.50</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_fyankMlPgUSx83FT7iCVmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_WFerxOzfkEKHkNG2I0kTuA_5_2">81.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ey6qGfWfJki49fNChKl-sw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_qBZp4cPhxEiALmSc9s177w_5_5">91.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_U-JzHzcc2UOd4vdE3TN_9g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_o_IjjZH1_0yTG39V-t_lkw_6_2">6.74</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_wKRANVGWK0CGjF_78kn1Wg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_XVvizB-pe0usl5JrDRf1ag_6_5">8.99</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_37bdf232_f28d_4755_b2b5_4a1dbd36dd54"></a><a id="Tc_U4nI9-L9nkqW70Mlde46OA_1_2"></a><a id="Tc_nCrXlpmda0-mFg0l3aB4fw_1_10"></a><a id="Tc_-Ntkg693KUC2sSFi5Ck_ug_2_0"></a><a id="Tc_2yU2XieM2UOQMQ0kudCMjg_2_2"></a><a id="Tc_jyITFmeSA0CyPQ_alEU6Gg_2_5"></a><a id="Tc_Uwk78Oux3UO-62nLEvLJzA_2_10"></a><a id="Tc__9dTX24t-E-bged2v0bLTQ_2_13"></a><a id="Tc_4dcvusX5BE2j1epks-se8g_3_0"></a><a id="Tc_oE-QK8m4i0m4HCeyBvKMGA_3_2"></a><a id="Tc_FZgQ1kp55EOYVHhtKW8PRQ_3_5"></a><a id="Tc_hNKqz7Y3fUq7pKj05aCfgg_3_10"></a><a id="Tc_fD6WLxA6jE-ETVYWcVQOSQ_3_13"></a><a id="Tc_q1eIGolcT0qkqWldxvnGug_4_0"></a><a id="Tc_XvvPyGltgUW9ao6ZxNwY6Q_4_2"></a><a id="Tc_HtfgpRaTdEyIFQjGN_jJeA_4_5"></a><a id="Tc_Rely4i0xpEGAs1pBYNMLxw_4_6"></a><a id="Tc_XmlaCe37okiA56uOfxI50Q_4_10"></a><a id="Tc_k7Bke4SbeUWKodVfOpxnww_4_13"></a><a id="Tc_xiUgYpJU1U-dVn3DhIOtcA_5_0"></a><a id="Tc_UyEP5qHsM0mu-nyTkv1d9w_5_2"></a><a id="Tc_mlYUHj1rLUKIe17z72FemA_5_5"></a><a id="Tc_606I3eVECk6NXDs3lUsmqQ_5_10"></a><a id="Tc_Wl4XwoUOIESNCF2DIwfFhw_5_13"></a><a id="Tc_ag2EHbwzoEaPSzTsE8u56g_6_0"></a><a id="Tc_PTOCYYrbwUmW8olCXPVf_g_6_2"></a><a id="Tc_lhh8DowL3UGrFtkvWN8-Jg_6_5"></a><a id="Tc_BhNrp-kSA0S9JQKeYUPSYw_6_10"></a><a id="Tc_SvfOO8tGpUWaJh2Dkmjrng_6_13"></a><a id="Tc_il93tf2MkkSZzFN2BEf-9g_7_0"></a><a id="Tc_S2Y86w8CIEixuDAD5DV_yg_7_2"></a><a id="Tc_maBpeIXy7Uut3s4FWJdBnw_7_5"></a><a id="Tc_VY2i2S6Gm0-UHQVSP1QgPQ_7_10"></a><a id="Tc_rMBNUie-50i81d1savynwg_7_13"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="plx:RevenueDisclosureTextBlock" id="Tb_1LfWdcQU_U-EhLmAFctKOg" continuedAt="Tb_1LfWdcQU_U-EhLmAFctKOg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_xSgG7j6dS0O1mg7-ZMUpHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_-Ye7tysNN0uIamEerOPohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_OjBi-AnYv0O7dfLX34UCEw_3_3">1,135</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_xXLYsWN7vUSK8B4I4_cOqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_WENU8Z9askOWDCOwBb8vqA_3_6">3,165</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_mydcMxM_oU2kJNHEONj5Ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_n2C_nAsuQ0GdaFUsv7iiZA_3_11">7,883</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_d2w1x6Wq0UWIzS1bPmcmPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_AdSjnIZTvEaQNdrWxxPDpg_3_14">5,844</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_CvN_3Qdilkmih_xyi8l8VQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_n7PTYm_nQ0-afFNSQu2KuA_4_3">3,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_JjbHSiTd-EinvS16jCvSmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_gliEAK772EeBkD7q6kNGuw_4_11">4,188</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_YONib1KiMUiXNGrGvXI9NA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_f8QBdEymsUurTTSALBcd3A_4_14">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_C4rvOPWVQUO7NyuzPVG_vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_O1gXrWZ7Y06lsccuex69Bg_5_3">171</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_lb46u3iL-Eq_NMiIYmE5Ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_xkvSUi1Z2k-01v_tfjD-Ow_5_6">131</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_QCMjIXNGnE6keq97DV1Ceg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_kSLbo8E-V06OzLjNHeew9g_5_11">189</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_lWJ_c72CZk-SxD9FOrYgfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_GK-HCbdgtUOI0BZnLbv0pA_5_14">131</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yeoKiF-YDUOrT3vhZw5yGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_jpAb8i12M06-Z3MWqswwfQ_6_3">4,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember__RK7HZ3EbEuarJ7s2oVtsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_GB0T0YuOvUqIsDT7HtN88Q_6_6">3,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_fCAhfegnYkmYa8xJ3eOd-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_38TdX-2WT0WCMsDz-OwE8w_6_11">12,260</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_DsIEE72dY0ijxi72whl2Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_XXx00fxLAk6AtZjGi7be_w_6_14">11,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_iAnH6udRs0WIM3yRgdqIUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_lKKajGZsGkicnoyNdCm9cw_7_3">7,548</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z2g_D1kyFE6aa-f9W-PAug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_JKHTe1r920OYnVMfTuNZag_7_6">7,494</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Xo2XYmDaCUSxewIa-WYycw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_90z0uG37JEiLfMvW_1FjaA_7_11">17,541</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_XpT7MCVwU0eKoVnFArW5NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bCnfAWI8ME-1B_XdwWeXEg_7_14">31,428</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"><span style="background-color:#ffffff;">During the nine months ended September&#160;30, 2021 and 2020, the Company recognized revenues of approximately </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iAbMMUv_L06GXvemRzxxLQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_HBwcRwGSVEmx5RGOPhF2Uw">16.5</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million and </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_osPvD8x1U0Wr7PmiN4rWyw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_H58yj3EU_Ums0JCgPqO9rg">31.4</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million, respectively, </span>from license and R&amp;D services mainly in respect of the Chiesi Agreements, after taking into consideration change in estimate as detailed below. <span style="background-color:#ffffff;">During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenues of approximately </span><span style="background-color:#ffffff;">$</span><ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_toBWVVxhOE2Xyr7X8eD-wQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_BxMQZf8ak0exgSSGVoP6Kw">6.5</ix:nonFraction><span style="background-color:#ffffff;">&#160;million and </span><span style="background-color:#ffffff;">$</span><ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_pjmKKZep_k-eRCW8jmhsEw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_YDRJRph5-EiBv00b8tMZNQ">7.5</ix:nonFraction><span style="background-color:#ffffff;">&#160;million, respectively, </span>from license and R&amp;D services mainly in respect of the Chiesi Agreements<span style="background-color:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">During the nine months ended September&#160;30, 2021, and following the CRL received from the FDA, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in a reduction to accumulated revenues recognized in respect of this performance obligation in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_4rTi-nl39kOEXFLSWbJdzA" decimals="-5" format="ixt:numdotdecimal" name="plx:ReductionToAccumulatedRevenueRecognized" scale="6" id="Narr_L2o3AJlzF06dsSQv23ToCA">4.1</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 36pt;"><span style="background-color:#ffffff;">During the three months ended September 30, 2021, the Company</span><span style="color:#212529;"> completed its obligations under a feasibility study it entered into with Kirin Holdings Company, Limited (&#8220;Kirin&#8221;) on March&#160;16, 2020, and the agreement expired, including the </span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1LfWdcQU_U-EhLmAFctKOg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#212529;">option to provide additional services. Following the expiration of the option, the Company recognized as revenue during the three-month period ended September&#160;30, 2021 the </span><span style="color:#212529;">$<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_OyqOeTcPvEeZzice06IGyg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_8LAhX_YCAUWrK_axzFaCcw">1.0</ix:nonFraction></span><span style="color:#212529;">&#160;million payment received in March 2020.</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_AJBy4i0hikaAVXPM_62ejQ" continuedAt="Tb_AJBy4i0hikaAVXPM_62ejQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; CONVERTIBLE NOTES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On August&#160;25, 2021, the Company completed the Exchanges of a substantial majority of the Company&#8217;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u4SuBfYydEm3isvsquTltA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_FMFIJ4u8ZEOdkaNBB3O8jQ">54.65</ix:nonFraction>&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_BHp5U2H-CECY8l8VTbnRnw">28.75</ix:nonFraction>&#160;million principal amount of newly issued 2024 Notes, $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="Narr_jeGldl0N7UOKBD_fZvlNMA">25.90</ix:nonFraction>&#160;million in cash, and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" scale="6" id="Narr_rJnZGc0vs0uj1lJps6i4nw">1.1</ix:nonFraction>&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is <ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ" decimals="4" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_dHBQ5Vu_0U200hCJrKKCtg">563.2216</ix:nonFraction> shares of Common Stock for each $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleBaseValueForConversionRate" scale="0" id="Narr_kXwQWfqzxkG0qv4CrFi5xA">1,000</ix:nonFraction> principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_keBGbcN84Ea05brJdgp_Hw">1.7755</ix:nonFraction> per share of the Common Stock), subject to adjustment in certain circumstances, which is based on a <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfPremiumToClosingPriceOfStock" scale="-2" id="Narr_rB1GhC4bX0-UsFQ76CzSoQ">32.5</ix:nonFraction>% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes will be paid semi-annually at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Ggzgc2uf3EKFGBDEr8E4Mw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_zzKIe8RBH0aYd4QqvaOXxA">7.50</ix:nonFraction>% per annum. The Notes will mature <ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_vfhkQ56Ww0a1Pq5YaRlmwg" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_UGZ1gC8Ad0a3z43AwZISUQ">three years</ix:nonNumeric> after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-family:'28mugxoulnobhnx';">Under the terms of the indentures governing each of the 2021 Notes and 2024 Notes, The Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-5" format="ixt:numdotdecimal" name="plx:MaintainOfMinimumCashBalance" scale="6" id="Narr_3Tjb_qdMGk-OWMp__OoiCA">7.5</ix:nonFraction></span>&#160;<span style="font-family:'28mugxoulnobhnx';">million. In addition, under the exchange a</span>greements the Company entered into with each of the institutional note holders that participated in the Exchanges (the &#8220;Exchange Agreements&#8221;), the Company agreed to maintain unrestricted cash of not less than <span style="font-family:'28mugxoulnobhnx';">$<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q" decimals="-4" format="ixt:numdotdecimal" name="plx:DebtInstrumentMinimumUnrestrictedCashToBeMaintained" scale="6" id="Narr_mEEsf10-mki5_xjV4TEWSg">3.27</ix:nonFraction></span><span style="font-family:'28mugxoulnobhnx';"> million, </span>which is the amount necessary to redeem or repay at maturity all of the 2021 Notes that remain outstanding following the closing of the Exchanges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges are considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_R3eVdAJPmU-INbiD0ErvuA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_dOh-34TysUS8wUW9pLhg2Q">0.8</ix:nonFraction>&#160;million due to derecognition of the liability component of $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cHP7im6RgECQAwEEf3hC_Q" decimals="-5" format="ixt:numdotdecimal" name="plx:DebtInstrumentDerecognitionOfLiabilityComponent" scale="6" id="Narr__4Z7TR2PdUeqH5LxCiLAnw">54.8</ix:nonFraction>&#160;million and the repurchase of the original equity component for $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_R3eVdAJPmU-INbiD0ErvuA" decimals="-5" format="ixt:numdotdecimal" name="plx:ReacquisitionOfEquityComponentOfConvertibleNotes" sign="-" scale="6" id="Narr_QZfyATu_GkC7HXk4Bz7B6Q">12.0</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">All of the Company&#8217;s outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_vfhkQ56Ww0a1Pq5YaRlmwg" decimals="-5" format="ixt:numdotdecimal" name="plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts" scale="6" id="Narr_Qe2fA9arkUKEftWXBRVSJA">12.0</ix:nonFraction>&#160;million was recognized in the Company&#8217;s additional paid in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Transaction costs in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_vfhkQ56Ww0a1Pq5YaRlmwg" decimals="-3" format="ixt:numdotdecimal" name="plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" scale="0" id="Narr_a9HvAzvcQ0q8FtmJxziEgw">869,000</ix:nonFraction> were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f9089be4_295f_44cd_9db5_d1ce52809182"></a><a id="Tc_Bo40CC6QzUWqfSK7MkYiEg_1_2"></a><a id="Tc_yOjT7HBTbkKiL0K8IP6vzA_1_5"></a><a id="Tc_b6Vk1qBh106TCs1JOmOAVA_2_0"></a><a id="Tc_XNNACT--oU6YOVZkSB31VA_3_0"></a><a id="Tc_ZOP0UBpwi0GQeX1jYShr6g_4_0"></a><a id="Tc_VspAE05CnkmloIuxak5kwg_4_3"></a><a id="Tc_RXvy_Myb8keNOcgNuiZ-zA_4_6"></a><a id="Tc_p6eS0AO98Ei3rcEh2Kjhhw_5_0"></a><a id="Tc_DWMkn_LCg02Q9ZxFfxSAjg_5_3"></a><a id="Tc_lLmAqFGR9kO-2XX29Fx11g_5_6"></a><a id="Tc_Jivy5gRCDEC-of8bU-3icQ_6_0"></a><a id="Tc_qvA-TC0s8EGrCJpJi5DJSw_6_3"></a><a id="Tc_t13MT1ifMEmZHLY0owquSQ_6_6"></a><ix:continuation id="Tb_AJBy4i0hikaAVXPM_62ejQ_cont1"><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_I0Grm-B4g0GE3UCgk-DBhw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_2RS6naTJlU2UIa9lFAtbwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_1972KmuibUyJZ-gIneryuQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_0AWAUa94wU6Z6UVc9oUlOg_2_2">1.34</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U9xEZDL-PEmh5wLjZtn6JA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_4hyIRVg3rkO6Jh1NpI6Fow_2_5">1.34</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WxYGSDFoFk2A-2JGt6XSSg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_WmE26GoRSEGU0hZn85pvUw_3_2">0.23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_VD26SZ1y0ESvFdYomEg95Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_Stq3OCia-EGcGHr_9PQeQg_3_5">3.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_uKHcMPfNtE6lZclLW6H1BQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_w0hDXE26b0imiBypxky9vA_4_2">0.05</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_hrtLH0ARGkuJLrKOpEM2VQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_rPunqLNyc0mh77yaea0P6A_4_5">0.44</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_wPu82-n0Ck6cnwIfWVVgng" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_06xyZcorREO7hxuFSXgFqQ_5_2">78.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_86dWT-PfXUCCzWKVSULmMQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_JeGVEP5KBEyNZCtZ_NmSew_5_5">91.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_E62ftnuUYUSTpfSddSfQnQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_vUHZnz6vbU-zZhNH6ZjHZQ_6_2">7.87</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_N3NNBZmbcUSZicNMNONsbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_4SAwvn_6XEyJMYsSEDx1Ug_6_5">7.66</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_M01pW6N5UE-KHabYc_wXyQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On July&#160;25, 2021, the Company granted to a new employee, with the approval of the Company&#8217;s compensation committee, <ix:nonNumeric contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_d2-gZTQqqESzz6ycksq9Ig">10-year</ix:nonNumeric>&#160;options to purchase&#160;<ix:nonFraction unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_dzmQu62MAUWRC2gxRO4XWg">50,000</ix:nonFraction>&#160;shares of Common Stock under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended. The options have an exercise price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="As_Of_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_S2ZvjQoxA0KSIEjlJS6ciQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Narr_K6CfxMbFrE68Ly9LjiIl0g">1.57</ix:nonFraction> per share and vest over a <ix:nonNumeric contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_GV_EtKKJGkqdQhOCp00Qaw">four-year</ix:nonNumeric> period in <ix:nonFraction unitRef="Unit_Standard_item_torZYRpNtkSE8e779rh00g" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" decimals="INF" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" scale="0" id="Narr_eYNPON5D20-GyJYvK39ojQ">16</ix:nonFraction>&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="As_Of_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_S2ZvjQoxA0KSIEjlJS6ciQ" decimals="0" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" scale="0" id="Narr_wvDgW8BaDkqLSgFGZ01_7g">55,000</ix:nonFraction>&#160;based on the following weighted average assumptions: share price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_G8xqRSUKv0GRavSfY6T3bg">1.57</ix:nonFraction>; dividend yield of <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_R93p0_MookK4j24ZDUR4AA">0</ix:nonFraction>% for all years; expected volatility of <ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_1OCWJloUBkS18cmzXGTd3g">84.3</ix:nonFraction>%; risk-free interest rate of&#160;<ix:nonFraction unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA" contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_gsqV_7IzAUysPdGYTnlBpg">0.88</ix:nonFraction>%; and expected life of <ix:nonNumeric contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_Jbn9Ti4TRkO1lMTdQI8TCA">six years</ix:nonNumeric>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_vedK3AEgtE2ogQCoUQ2ofw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On October&#160;13, 2021, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_m9nl_SJDHUWIRCUsIOV1yA" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromExpenseReimbursements" scale="6" id="Narr_s8JUfuTCeEW5kDhiSd5-TA">1.2</ix:nonFraction>&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On October&#160;14, 2021, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_10_14_2021_To_10_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_h9tz6gqia0KnVd70vTBKjw" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_J-YM---nqkyEvpt9aAAg9A">1.1</ix:nonFraction>&#160;million from sales to Pfizer and on October&#160;15, 2021, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg" contextRef="Duration_10_15_2021_To_10_15_2021_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_5jcweHS-wUeCpJ8p1sBaGQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfProducts" scale="6" id="Narr_rWcQFpYip0aD1YKJG2oq4Q">3.2</ix:nonFraction>&#160;million from sales of alfataliglicerase to Fiocruz.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On November&#160;9, 2021, the Company delivered the necessary funds under the indenture governing the 2021 Notes to effectively discharge the remaining outstanding 2021 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In accordance with ASC 855 &#8220;Subsequent Events&#8221; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d30392ac_01a9_43ad_9a1c_c82bad98e7fb"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS<br />AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2020. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors including those set forth under &#8220;Risk Factors&#8221; in our Quarterly Report on Form</i>&#160;<i style="font-style:italic;">10-Q for the quarter ended March</i>&#160;<i style="font-style:italic;">31, 2021.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to the timing and progress of the preparation of an updated BLA addressing the CRL for PRX-102;</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing, progress and likelihood of final approval by the FDA of a resubmitted BLA for PRX-102 and, if approved, whether PRX-102 will be commercially successful;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, the EMA or other foreign regulatory authorities may not accept or approve a marketing application filed for PRX-102 or any of our other product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make required payments under our outstanding 2024&#160;Notes or any other indebtedness as they come due and our ability to obtain additional financing and raise capital as necessary should the regulatory approval process become more extended;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the COVID-19 outbreak and variants, which may adversely impact our business, preclinical studies and clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>our dependence on performance by third-party providers of services and supplies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the impact of development of competing therapies and/or technologies by other companies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to our supply of drug product to Pfizer;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to the compliance by Fiocruz, an arm of the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On October&#160;15, 2021, we, together with Chiesi, announced the final dosing of the last patient in the <i style="font-style:italic;">BALANCE</i> study for the proposed treatment of Fabry disease.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On October&#160;11, 2021, we, together with Chiesi, provided a regulatory update regarding PRX-102 which included an announcement of the receipt of the official Type A (End-of-Review) meeting minutes from FDA regarding the CRL confirming a potential pathway for resubmission of a BLA for PRX-102.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;25, 2021, we completed the Exchanges of a substantial majority of our outstanding 2021 Notes with institutional note holders of a substantial majority of the 2021 Notes. In the Exchanges an aggregate of $54.65&#160;million principal amount of our outstanding 2021 Notes were exchanged for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 4.5pt 0pt 0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;13, 2021, we entered into the Exchange Agreements in connection with the Exchanges.</div><div style="margin-top:10pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We continue to actively advance all our clinical programs. We are in close contact with our principal investigators and clinical sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, our clinical trials have not been materially adversely affected by COVID-19. In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make further adjustments in the future.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In response to the local spread of COVID-19 at the end of March 2020, and with local directives issued in response thereof, we restructured the work day within our facilities to consist of two shifts thereby reducing the number of employees present in the facilities at any time and facilitating their ability to practice social distancing. Employees that were able to work from home were instructed to do so. Such efforts resulted in minor delays in the performance of administrative activities outside of the clinical programs.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In June 2020, after local directives allowed more flexibility with respect to social interactions, we returned to a regular work day. Since then, as the pandemic&#8217;s effect locally continued to change, and local Israeli directives continued to evolve to address the changing effects, we returned temporarily to the two-shift work day schedule and to again encourage employees that are able to work from home to do so for parts of September 2020. Our facility currently operates on a regular schedule with adherence to local guidelines.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.26pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will continue to evaluate the impact of the COVID-19 pandemic and its variants on our business as we learn more and the impact of COVID-19 on our industry becomes more clear. We intend to continuously assess the impact of COVID-19 on our trials, expected timelines and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20210930x10q005.jpg" alt="Graphic" style="display:inline-block;height:207.26pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:234.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell in Suspension Expression System for Therapeutic Proteins Development and Industrial Production: Executive Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20210930x10q006.jpg" alt="Graphic" style="display:inline-block;height:233.28pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20210930x10q007.jpg" alt="Graphic" style="display:inline-block;height:144.65pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">PRX-102 is our lead product candidate and we expect it to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time and, as a result, Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> accumulates, primarily in the blood and in the blood vessel walls. The accumulation leads to a narrowing of the blood vessels, which in turn leads to decreased blood flow and tissue nourishment. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease is forecasted to be approximately $1.9&#160;billion in 2021 (Global Data) and to continue to grow at a CAGR of approximately 9.5% (Global Data).</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The initial BLA submission included a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II clinical trial of PRX-102, including the related extension study succeeding our phase I/II clinical trial, interim clinical data </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">from our phase III <i style="font-style:italic;">BRIDGE</i> switch-over study and safety data from our on-going clinical studies of PRX-102 in patients receiving 1&#160;mg/kg every other week.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">On April&#160;28, 2021, we, together with Chiesi, announced the receipt of a CRL from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including a subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the FFDCA in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme, a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021 to discuss the FDA&#8217;s requirements for a BLA resubmission. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the clinical data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. We intend to continue to work collaboratively with the FDA resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we and Chiesi also held a meeting with the Rapporteur and Co-Rapporteur of the EMA on October&#160;8, 2021 regarding the submission plans for an MAA with the EMA. At the meeting, we and Chiesi discussed the scope of the anticipated MAA for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission for PRX-102. This is an important step in the necessary pre-submission activities leading up to a planned MAA submission. Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study that we announced in June 2021, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, we and Chiesi expect to submit an MAA to the EMA for PRX-102 during the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In December 2017, the European Commission granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease. Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time <span style="font-family:'Times-Roman';">PRX-102</span> is approved for marketing in the European Union, if at all, we expect that <span style="font-family:'Times-Roman';">PRX-102</span> will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January 2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. Enrollment has been completed in all three studies, and the final dosing of the last patient in the <i style="font-style:italic;">BALANCE</i> study took place in October 2021. In 2015, we completed a phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial of PRX-102. In the phase&#160;III clinical program, we are studying two alternative doses and regimens for PRX-102; 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and potentially provide a better quality of life for a subset of Fabry patients. Final results from the <i style="font-style:italic;">BRIDGE</i> study were released in December 2020 and topline results from the <i style="font-style:italic;">BRIGHT</i> study were released in February 2021. Interim one-year data from the <i style="font-style:italic;">BALANCE </i>study was released in June 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patients that completed the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial were offered, and patients that complete the <i style="font-style:italic;">BALANCE, BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies are offered, the opportunity to continue PRX-102 treatment as part of a long-term open-label extension study. Currently, 106 subjects that participated in the our PRX-102 clinical program have opted, with the advice of the treating physician, to continue PRX-102 treatment in one of our long-term extension studies; 10 subjects that completed an extension study from the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial, 18 subjects that completed the <i style="font-style:italic;">BRIDGE</i> study; 69 subjects that completed the <i style="font-style:italic;">BALANCE</i> study; and 29 subjects that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">completed the <i style="font-style:italic;">BRIGHT</i> study. Of the 29 subjects that completed the <i style="font-style:italic;">BRIGHT</i> study that are enrolled in a long-term extension study, 27 of them are being treated with 2&#160;mg/kg of PRX-102 every 4 weeks and two are being treated with 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span><i style="font-style:italic;">BALANCE</i> s<span style="background-color:#ffffff;">tudy is a 24</span>-<span style="background-color:#ffffff;">month, randomized, double blind, active control study of PRX</span>-<span style="background-color:#ffffff;">102 in Fabry patients with impaired renal function. We have completed enrollment of 78 patients in the trial, which is </span>designed to evaluate the safety and efficacy of PRX-102 compared to agalsidase beta (Fabrazyme) on renal function in Fabry patients with progressing kidney disease previously treated with Fabrazyme infused once every two weeks. On October&#160;15, 2021, we announced the last dosing of the last patient in the <i style="font-style:italic;">BALANCE</i> study. <span style="background-color:#ffffff;">Patients previously treated with </span>Fabrazyme <span style="background-color:#ffffff;">for approximately one year and on a stable dose for at least six months were screened and then randomized on a 2:1 ratio to 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background-color:#ffffff;">mg/kg of PRX-102 or 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background-color:#ffffff;">mg/kg of </span>Fabrazyme<span style="background-color:#ffffff;">. Randomization is being stratified by urinary protein to creatinine ratio (UPCR) of &lt;</span>&#160;<span style="background-color:#ffffff;">or</span>&#160;<span style="background-color:#ffffff;">&#8805;</span>&#160;<span style="background-color:#ffffff;">1</span>&#160;<span style="background-color:#ffffff;">g/g by spot urine sample. The study was designed such that no more than 50% of the patients enrolled in the study would be female. Approximately 40% of the enrolled patients were female.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of eGFR slope between Fabrazyme and PRX-102. eGFR is considered a reliable and accepted test to measure the level of kidney function and stage of kidney disease. Additional parameters being evaluated include: cardiac assessment, Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry clinical events and pharmacokinetic and other parameters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In June 2021, we, together with Chiesi, announced topline results from an interim analysis of the <i style="font-style:italic;">BALANCE </i>study. The primary endpoint of the interim analysis is the comparison of mean annualized changes (slope) of the eGFR<sub style="font-size:7.5pt;vertical-align:sub;">(CKD-EPI)</sub> after completion of at least 12 months of treatment between the two treatment arms (Fabrazyme and PRX-102). The interim efficacy analysis was conducted on two pre-defined analysis sets: Intention to Treat (ITT), consisting of all randomized patients who received at least one dose (77 patients), considered as the primary analysis for this interim review; and the Per Protocol (PP), consisting of all patients who completed at least 12 months of treatment with no major protocol violations (74 patients). The patient population (ITT analysis set) of the study is comprised of 47 males (61%) and 30 females (39%) with a mean age of 44.3 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set. At the time of this analysis, two patients discontinued participation due to treatment emergent adverse events (TEAEs). Of these two patients, one discontinued participation due to a related adverse event. No deaths were registered. Overall, safety data appears favorable and consistent with what was observed in previous clinical studies with PRX-102. Unblinded final data is anticipated to be released in the second quarter of 2022 after all remaining patients have completed the 24-month treatment period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span><i style="font-style:italic;">BRIDGE</i> study was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients. The trial, which is was completed in December 2019, enrolled patients then being treated with agalsidase alfa, marketed by Takeda Pharmaceutical Company Limited (acquired Shire&#160;Plc) as Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, for at least two years and on a stable dose for at least six months. Patients were screened and evaluated over three months while continuing Replagal treatment. Following the screening period, each patient was enrolled and switched from Replagal treatment to receive intravenous (IV)&#160;infusions of PRX-102 1&#160;mg/kg every two weeks for 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.4pt 0pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE </i>study showed substantial improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate, or eGFR, slope in both male and female patients who were switched from agalsidase alfa to PRX-102. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102.<span style="font-size:12pt;"> </span>In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.4pt 10pt 0pt;">the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 24.75pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of treatment <span style="letter-spacing:-2.9pt;"> </span>emergent adverse events were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate treatment emergent adverse events were nasopharyngitis, headache and dyspnea.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.05pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent antidrug antibodies over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.15;margin:0pt 5.2pt 10pt 0pt;">Baseline characteristics of the 20 patients that completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were<span style="vertical-align:super;"> </span>51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data from the interim analysis of the <i style="font-style:italic;">BRIDGE</i> study, which were first announced in February 2020, were used to support the PRX-102 BLA filing with the FDA, and we anticipate that the final analysis will be used to support the planned MAA submission to the EMA and the BLA resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span><i style="font-style:italic;">BRIGHT</i> study was a 12-month, open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of PRX-102 via IV infusions of 2&#160;mg/kg administered every 4 weeks. The trial, which was completed in June 2020, enrolled up to 30 patients with Fabry disease previously treated with a commercially available ERT (Fabrazyme or Replagal), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with stable kidney disease. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV&#160;infusions every 2 weeks to 2&#160;mg/kg of PRX-102 every 4 weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the 4-week dosing regimen as measured by eGFR and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><a id="_Hlk64553510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We announced topline results from the <i style="font-style:italic;">BRIGHT</i> study in February 2021. The topline results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was found to be well tolerated among treated patients, and stable clinical presentation was maintained in adult Fabry patients. No new patients developed treatment-induced anti-drug antibodies, or ADA, following the switch to PRX-102 treatment.</p><a id="_Hlk64641068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study enrolled 24&#160;adult males and 6&#160;adult females. The most common Fabry disease symptoms were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. All 30&#160;patients received at least one dose of PRX-102, and 29 patients (mean [SD] age was 40.5&#160;[11.3]&#160;years, ranging from 19 to 58&#160;years) completed the 12-month study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the study, while one patient was switched to PRX-102 1&#160;mg/kg every two weeks per protocol. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following screening, patients were enrolled and switched from their then current ERT to IV&#160;infusions of 2&#160;mg/kg of PRX-102 every four weeks for 52 weeks (a total of 14&#160;infusions). First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures showed plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change of 3.01&#160;nM from baseline (19.36&#160;nM) to Week&#160;52 (22.23&#160;nM). Mean absolute change of eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or BPI, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week&#160;52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. In a minimal amount of cases, patients that completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients. Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGRF levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed anti-drug antibodies (ADA), of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45.0&#160;million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15% - 35% (ex-US) and 15% - 40% (US). To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the two Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per year. Protalix Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi is also required to make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we amended the Chiesi Agreements in order to provide us with near-term capital. Chiesi agreed to make a $10.0&#160;million milestone payment to us before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen and liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease is a $1.5&#160;billion global annual therapeutic market that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil (marketed in Brazil as BioManguinhos alfataliglicerase) through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH. In 2020, we generated $8.0&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Alidornase alfa is our chemically-modified plant cell expressed recombinant human DNase I, administered via inhalation. Recombinant human DNase I enzymatically cleaves DNA but its activity is inhibited by actin, which is present in the blood and other target organs. PRX-110 is designed to be less susceptible to actin inhibition and have higher affinity to DNA, thus enhancing enzymatic activity. In-vitro studies have shown PRX-110 to have a highly improved catalytic efficiency and affinity to DNA, compared to dornase alfa (Pulmozyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, currently the only commercially available DNase therapy), even more so in the presence of actin. In February 2021, we entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment<span style="direction:rtl;"> </span>of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. The license agreement expired during the three months ended September&#160;30, 2021. We are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-115</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of refractory gout. Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. Refractory gout patients are those whom, despite treatment with existing ULTs, have high flare frequency, consistent tophi, and the inability to maintain therapeutic goals of urate levels. An estimated approximately 2% of the gout population is considered to have chronic refractory disease and are in need of other therapeutic options. One option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for treatment of chronic gout refractory to conventional therapy (no longer approved in the European Union) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis, induce strong immunogenic reactions and have other major side-effects. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of refractory gout which we are designing to have an improved half-life, reduced immunogenicity and potentially longer term efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of September&#160;30, 2021, we hold a broad portfolio of over 90 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 30 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international customers and markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended September&#160;30, 2021 compared to the three months ended September&#160;30, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $4.5&#160;million during the three months ended September&#160;30, 2021, an increase of $1.2&#160;million, or 36%, compared to revenues of $3.3&#160;million for the three months ended September&#160;30, 2020. The increase of $3.2&#160;million in sales to Brazil, resulting from timing differences, was partially offset by a decrease of $2.0&#160;million in sales to Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $7.5&#160;million for the three months ended September&#160;30, 2021 and September&#160;30, 2020. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. A revenue increase of $1.0&#160;million recognized from the Kirin feasibility study was offset by a $1.0&#160;million decrease in revenue generated under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $3.7&#160;million for the three months ended September&#160;30, 2021, an increase of $0.8&#160;million, or 28%, from cost of goods sold of $2.9&#160;million for the three months ended September&#160;30, 2020. <span style="background-color:#ffffff;">The increase in cost of goods sold was primarily the result of higher sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses were $7.3&#160;million for the three months ended September&#160;30, 2021, a decrease of $0.4&#160;million, or 5%, compared to $7.7&#160;million of research and development expenses for the three months ended September 30, 2020. The decrease is primarily the result of the completion of two out of the three phase III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $3.0&#160;million for the three months ended September&#160;30, 2021, an increase of $0.2&#160;million, or 7%, compared to $2.8&#160;million for the three months ended September&#160;30, 2020. The increase is primarily the result of an increase of $0.4&#160;million in corporate costs mainly related to insurance and a $0.2&#160;million increase in sales and marketing costs, partially offset by a decrease of $0.5&#160;million in share-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses, net were $2.3&#160;million for the three months ended September&#160;30, 2021 and $1.9&#160;million for the three months ended September&#160;30, 2020. <span style="background-color:#ffffff;">The increase resulted primarily from loss on extinguishment related to the Exchanges of our 2021 Notes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nine months ended September&#160;30, 2021 compared to the nine months ended September&#160;30, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We recorded revenues from selling goods of $12.3&#160;million during the nine months ended September&#160;30, 2021, an increase of $0.3&#160;million, or 3%, compared to revenues of $12.0&#160;million for the nine months ended September&#160;30, 2020. The increase of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">$2.0&#160;million in sales to Pfizer was partially offset by a decrease of $1.8&#160;million in sales to Brazil, both resulting from timing differences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $17.5&#160;million for the nine months ended September&#160;30, 2021, a decrease of $13.9&#160;million, or 44%, compared to revenues of $31.4&#160;million for the nine months ended September&#160;30, 2020. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The decrease resulted primarily from revenues recognized in connection with the progress of our clinical trials that have been completed during 2020 and includes a $4.1&#160;million reduction to accumulated revenues recognized due to updated costs estimation throughout the trials until completion. The decrease was partially offset by an increase of $1.0&#160;million of revenues recognized in connection with the Kirin feasibility study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $13.2&#160;million for the nine months ended September&#160;30, 2021, an increase of $5.1 million, or 63%, from cost of goods sold of $8.1&#160;million for the nine months ended September&#160;30, 2020. <span style="background-color:#ffffff;">The increase in cost of goods sold was primarily the result of certain one-time manufacturing costs incurred while preparing for the then anticipated FDA approval of the PRX-102 BLA and higher manufacturing costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses were $22.1&#160;million for the nine months ended September&#160;30, 2021, a decrease of $5.1&#160;million, or 19%, compared to $27.2&#160;million of research and development expenses for the nine months ended September&#160;30, 2020. The decrease is primarily the result of the completion of two out of the three phase III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $9.3&#160;million for the nine months ended September&#160;30, 2021, an increase of $1.1&#160;million, or 13%, compared to $8.2&#160;million for the nine months ended September&#160;30, 2020. The increase resulted primarily from an increase in corporate costs of $1.4&#160;million related mainly to insurance and funding which was partially offset by $0.3 million decrease in share-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses net were $6.2&#160;million for the nine months ended September&#160;30, 2021, a decrease of $0.6&#160;million, or 9%, compared to financial expenses net of $6.8&#160;million for the nine months ended September&#160;30, 2020. <span style="background-color:#ffffff;">The decrease resulted primarily from a decrease in expenses related to our outstanding convertible notes equal to $1.3</span>&#160;million offset by a $0.8&#160;million <span style="background-color:#ffffff;">loss on extinguishment related to the Exchanges of our 2021 Notes</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and bank deposits. At September&#160;30, 2021, we had $10.6&#160;million in cash and cash equivalents and $38.0&#160;million in short-term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the nine months ended September&#160;30, 2021, we raised gross proceeds equal to approximately $8.8&#160;million from sales of common stock under our ATM program through the sale of 1,867,552 shares of our common stock. In addition, we raised gross proceeds of approximately $40.2&#160;million from a public offering of our common stock before deducting the underwriting discount and estimated expenses of the offering. In connection with the offering, we issued 8,749,999 shares of our common stock at a purchase price per share of $4.60.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On August&#160;25, 2021, we completed the Exchanges of our outstanding 2021 Notes with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash and approximately </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">$1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate of the 2024 Notes is 563.2216 shares of our common stock per $1,000 principal amount of 2024 Notes, which is equivalent to an initial conversion price of approximately $1.7755 per share of common stock, subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the common stock on the NYSE American on August&#160;13, 2021. After giving effect to the Exchanges, $3.27&#160;million aggregate principal amount of the 2021 Notes are currently outstanding. The maturity date of the 2021 Notes is November&#160;15, 2021, on which date we are required to settle all the then outstanding 2021 Notes and pay all accrued but unpaid interest thereon. On November&#160;9, 2021, we delivered the necessary funds under the indenture governing the 2021 Notes to effectively discharge the remaining outstanding 2021 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The 2024 Notes were issued pursuant to an indenture entered into between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes are payable semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and will be guaranteed by our subsidiaries. The 2024 Notes are secured by perfected liens on all of our assets, including those of our subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and bank deposits as of September&#160;30, 2021 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $5.2&#160;million for the nine months ended September&#160;30, 2021. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the nine months ended September&#160;30, 2021 of $20.9&#160;million was increased by a $4.1&#160;million increase in accounts receivable and other assets and $1.6&#160;million increase in inventories, and was partially offset by a $13.9&#160;million increase in contracts liability, a $2.6&#160;million of amortization of debt issuance costs and debt discount, $2.0&#160;million in share-based compensation and $1.1&#160;million increase in accounts payable and accruals. Net cash used in investing activities for the nine months ended September 30, 2021 was $18.5&#160;million and consisted primarily of a net increase in bank deposits. Net cash provided by financing activities was $16.1&#160;million resulting from the sale of common stock under our former ATM program and from our public offering of common stock, net of the convertible notes and promissory note payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $18.6&#160;million for the nine months ended September&#160;30, 2020. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the nine months ended September&#160;30, 2020 of $6.9&#160;million was increased by a $15.1&#160;million decrease in contracts liability and a $5.1&#160;million increase in inventories, partially offset by an increase of $3.3&#160;million in accounts payable and accruals, $2.5&#160;million amortization of debt issuance costs and debt discount and a $2.1&#160;million in share-based compensation. Net cash used in investing activities for the nine months ended September&#160;30, 2020 was $27.5&#160;million and consisted primarily of an increase in bank deposits. Net cash provided by financing activities was $41.8&#160;million resulting from our issuance of common stock and warrants on March&#160;18, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. Our outstanding <span style="font-family:'28mugxoulnobhnx';">2021 Notes and 2024 Notes are </span>secured by a perfected lien on all of our assets<span style="font-family:'28mugxoulnobhnx';">. Under the terms of the indentures governing the 2021 Notes and 2024 Notes, we are required to maintain a minimum cash balance of at least $7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million. In addition, under the Exchange </span>Agreements, we agreed to maintain an amount of unrestricted cash that is not less than the amount necessary to redeem or repay at maturity all of the 2021 Notes that remain outstanding following the closing of the Exchanges. After the closing of the Exchanges, an aggregate principal amount of $3.27&#160;million of the 2021 Notes remained outstanding, which notes are required to be repaid not later than November&#160;15, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur significant expenditures in the near future as we increase our research and developments efforts with respect to our product candidates given the receipt of the CRL from the FDA discussed above, we expect to incur additional expenses in connection with any resubmission. We cannot anticipate the costs or the timing of the occurrence of such costs. In addition, to the extent we need to obtain additional financing in connection with this process or with any additional clinical testing that may be required, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v)&#160; payment of interest on our outstanding 2024 Notes. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our efforts, combined with those of Chiesi, to file for resubmission with the FDA and to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements. On July&#160;2, 2021, we entered into the Sales Agreement in connection with a new ATM program pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million. On the same date, we terminated our former ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material effect on our results of operations during the nine months ended September&#160;30, 2021 and September&#160;30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of September&#160;30, 2021 and September&#160;30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9b4c0d00_75a4_4f05_9aa8_2e415e016c80"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and approximately 52% of our expenses and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 43% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.255</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.479</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.442</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.229</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.441</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5a32759e_5a74_480e_8c2b_45fce53eb63c"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September&#160;30, 2021 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4b630537_1066_49ba_916f_ffdd013d7a89"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d06ddd6e_f9f5_47bb_a0a1_6ec9d55b2394"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Except as set forth below, there have been no material changes to the risk factors previously disclosed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020 and in our Quarterly Report for the three-month period ended March&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">If any holder of our 2024 Notes converts such notes prior to our receipt of stockholder approval to issue 20% or more of our total outstanding common stock in connection with our compliance with the terms of such notes, we may be obligated to settle a significant portion or all of such converted notes in cash.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 0pt 0pt;">Under the terms of the indenture for the 2024 Notes, we agreed to solicit stockholder approval prior to issuing 20% or more of our outstanding shares of common stock, calculated as of the date we entered into the exchange agreements in connection with the issuance of the 2024 Notes, in compliance with certain listing standards of the NYSE American. Unless and until we obtain such stockholder approval, we may be required to settle all conversions of the 2024 Notes substantially or entirely in cash. Absent such approval, we are left with limited financial and corporate flexibility with respect to our ability to satisfy obligations under the indenture with shares of our common stock which may have a material adverse effect on our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;margin:0pt 18pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_f9ad971f_2b7a_4e22_a819_fe4e9ed02dfb"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7eec34dc_1253_475d_a1be_0c42559aa930"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_966e3751_9a3a_4eca_8883_8a8569ef5519"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_456f122b_a221_47f7_9a57_c06b953e1e11"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_11a4c9d6_778c_4de5_9fb0_1794b2af99ac"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Indenture, dated as of December&#160;7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First Supplemental Indenture, dated as of July</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;25, 2017</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Supplemental Indenture, dated as of November&#160;27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;1, 2017</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032540/tm205240d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.7</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.9&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.8</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.10</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.9</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.11</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Supplemental Indenture, dated as of August&#160;24, 2021, by and among Protalix BioTherapeutics,&#160;Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent, and Wilmington Savings Fund Society, FSB, as the collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.12</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Indenture, dated as of August&#160;24, 2021, between Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.13</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex4d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Exchange Note (2024)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.3</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021011566/plx-20210812xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Exchange Agreement, dated as of August&#160;12, 2021 among Protalix BioTherapeutics, Inc. and the holders named therein</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">10.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;12, 2021</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated U.S. Security Agreement dated of August&#160;24, 2021 among Protalix BioTherapeutics, Inc., the guarantors party thereto, Wilmington Savings Fund Society, FSB, as collateral agent and The Bank of New York Mellon Trust Company, N.A., as Notes Trustee</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">10.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021012078/plx-20210824xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2021 Security Agreement/Debenture, made on August&#160;24, 2021 between Protalix Ltd. and Altshuler Shaham Trusts Ltd., as security trustee</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">10.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;26, 2021</p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="background-color:#ffffff;color:#333333;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fb42ea3a_7937_40ba_a34c_13018e511030"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;15, 2021</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;15, 2021</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20210930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/15/2021 12:11:39 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;15, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20210930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/15/2021 12:11:41 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;15, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20210930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/15/2021 12:11:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;15, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20210930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 11/15/2021 12:11:46 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;15, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20210930x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210930x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &?!#@# 2(  A$! Q$!_\0
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M?^]3:* '>8_]ZCS'_O4VB@!WF/\ WJ/,?^]3:* '>8_]ZCS'_O4VB@!WF/\
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M+BQ@FEB:*1XPS(Q!()'MQ5B@ HHHH **** "BBB@!5^\*M557[PJU0 4444
M%%%% !2$X%+6?J=UY4&Q3\[?RI-V5QI796OKOS]T<;850>>Q->9:;XHNKGQQ
M?:+)N^SQKL4;3]X=6SZ5W5R3Y:(K8_O&LW[%;VUQ-<+$J22G<TBCEOKZUS\U
MV;)66A4N;I%D' 1O]KI]:B,R2H<-DH-V <9^E9U_,Z2 'YANX)/:K=D0W# H
MV.F>128SF/ OBO4=<\1ZE87TDCI@M'D8$6#C %>TZ5*K0^7N)*^IZUQMOID"
M737D,4*3,FSS-F&(^O>MS3)'@<$MR.,@52E9DM71T]+358,H(YIV:Z#$****
M "BBB@ HHHH **** "BBJNHW9LK&2=4#N,!5)P"2<#/YT";25V6J*PY9-:L;
M6>XGGM9T$+/\D10QL!P.IW#\J:->=X-KV\]M,/+8>8BG>K-C( ;C\>13L8_6
M(KXDT;U%8L7B*-[A4DL[B*%F=!.VW867.1P<] ><5''XJM'29WAEC5(S(AW(
MQD4>P8XZCKBBS#ZQ2[F]16(/$D/V!;AK657=]D<9DC^<XSPV[;C\:LQZJEWH
MT]Y;C:\:/E6P=K*#P<'!_ T--%1KTY:)FE17.1>)X;G^SXH)',\K@2AK=U&-
MI)P2 .OO4B>*K8SW$3VTR-%&TH!9"6"]> Q*GV.*?*R%BZ+U4C?HK"/B0)OW
MZ;>+Y94R9"_*C=&//Z=:>/$*375S;V]K+(80WSADP64=",Y'U(Q2LREB*;TN
M;5%<W#XI"6-L]S:R><\0EF"N@V*>_+<YQG R:U+/51?7<L4-O*8H^#.2NPG
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ML!L)P<YW=>GM6[10!!9QS0V4,5P\;RH@5FC4JI(] 22*GHHH **** "BBB@
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MOGZTV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBLK6/$.G:%):)?RNC74GE
MQ!4+9/OZ"@#5HHKG?$NI:E87VF#3\.K.[30X'[U%7) /8^E '145S9\1QQZC
M/<-.SZ>+%)XT1026+8X[Y[8K0TW6OMUR]I/87-C=*GF"*XVDLG3(*DCZCJ*
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M 4444 %%%% !1110 4444 %%%% !1110!6?[Y^M-IS_?/UIM !1110 4444
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M))SZFNDM].:#6+V^,JE;E44(!RNT>M7Z*+@%%%% "K]X5:JJOWA5J@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K/\
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M5V%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKQ)(;5F^09 ( R3@#Z4_QE96X\6>#[,0K]F64H(\9&T%<"O0HXTBB2.- B(
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MYFVX.&X^7(/;- '345@MKUQ#>P6]S:V\'F;?G><A6SV0E,$CT)%;U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5G^^?K3
M:<_WS]:;0 445 ]W&DA3!)'7% $]%1PS"9E"@C<">:6>3R8W8+O*_P (.,T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3;NXO+4O=64EG.K%6C<[AQW5OXA[U<H BMK>*TMH[>%2L4:A5!.<#ZU+110
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MQ"ZR+&P5 [[2"-W/J#GFNA.G637ANS:PFX(P9"@SZ?RID6D:= I6*R@0%P^
M@^\.A_#M0@9AP:YJ:W"+.;9T^U2VA"1,I)168/\ >./NXQ^M0+XGU&#3[.YN
M%M9FO;<2H(D95B;<@^8Y.5^?KQTKIFTZT8'%O&K%VD#!1D.006^N">:K:=H.
MGZ;9"VBMHF'EB-V9!F0 8YH0&9-J^K1SW%DB13RP,A>:*$D[&4GB/=R01V/0
MYK/GUJ[O;VV%I=1HK36NZ2.-QY@;S-P*EN!E>G7US73G1=--K]F^PP>3NW;=
M@Z^OUIYTK3V0H;.#;A!C8/X?N_EVH0'-6GB"_DT^XEA6VB%G;M<.KJQ\WYGX
M!+<<)UYY/2I[;Q#?RRB=E@%L=0%GY6PA\$ ABV>H)Z8K<;1]-<1!K&W(B)*#
MRQ\N3G^?-2_8+/G_ $:+F7SC\@_UG][Z^]"W!EFBBB@ HHHH **** *S_?/U
MIM.?[Y^M-H \Q^+4OERZ:,D%HIA_*N-U&Y,-XI4]4D'Y_P#ZZZKXQG$^C^Z2
M_P!*X/5I"QM'SD.F?T6N"LM9?([J+TC\SIOAG-MUYV)_A/\ (5TEXQ%QK:-Q
M_I X_!JY'X:G.LSJ.OEMC\LUUNLC:]S<!LB=DS]0'!_I4RA_LJ?8;G_M#\R+
M1H7AU.W%I*(D>&)I(R?ED!Y/X\9&.];%_>6TOB.>W:10VXAE/!QC-8ND%FU"
MRPI;$$6['89(S^M87B.ZN(O%5S,4WJZ.5P<'&SD^_>KIW5%6[F51*53Y'HE\
M$D\9Z.Q53MM3D,,@&K]M?2C4$M(#$CLFXJRL%;(!! &<=ZRH[RUOM<L+N&0\
MV?*.,,A]".U.E$IU,[&VEX(H]PZ@97D?G7:FI+1G(VUN=3>75DJ&VO+F"-I$
MY620+D>O->-WPBM-7N[19$9 VZ-D8$$?6K^MZ>1KPMUOMTS#!20DLS<UR=V)
MH;HI*,21,01_,5$_Y1I]3:.YHCY6W=V+#(JNZG<,]?I45IF:/./RJ5H90<@N
M!]34(HI3*TE^FT#]VN3DXI9+S8<,C?@0:='YCSS91P,##YZUF7,C>80.WK3;
ML)*Y=:]A*_-N_%<UFWMU',XA@ '>1@N"!Z4]89Y$ 15)(X&.M43!-;3!)"$=
MF#9.<L<]*:O:XFC7T_3'N@PRP51D 'I2)I*S3A7N)43!).W=_*NJT2)+:QN+
MAUR!Q^E9$<\A9Y(0%=< 9]SBB2=M 1M>"-$M;;48[Y6:1E8A788XVCM^->G1
MS1ADW.-Q;H*\_P!#F6SL%DD;GS?F9CZJ*Z.#6(C-! N\$LH&(R!CZXK&I4G#
ME2-(4U)-FS?7L(@N5VL9 #SMX!^M<3<ZI<2R*J 11JRHO +-VR.PYK7EU(2Z
ME<VVXG;NR".P'7Z5CW42Q;)6/(3>/^ KD5S2]I6C)3Z/\#II*-.2?D+YK36]
MVLY,B^<BY<[L^WICBHM-E>:QMMP Q$&( Q]#5.ZG\C3H6&2TUPI(_!J=I,[-
M?W,/ $,$:X_"MJ$+23'7DG!I'.QWT*"3&3<FYV ^B[NU7--\1ZA%(MG9&-3)
M*P8L.IR?Z<5R@F/]JGG_ )>C_P"A5-#<F%K5@-K/>EMWL#C^OZ5RTH\E3G7<
M[*LE.GROL;=QJA?68 S%=I).6.!GG\N:B@F\Q5(_UA#?.K8(QD\$5D:DQCUR
M9"V[9N&[.<X&,U+ILR)$K-CF.?\ /:<5+HKGN5[;W4>K>%[R:RN93J%YY\WE
M /,%QN/';Z5JV>K6]M<7!D<Y8[EP<9'->=2:I,MK"Z2!6N"JY"CT[9^E-UW4
M#:J)/,D#+#SAL9/2NEU:UVHO9+H>?&A!VOU;/2/^$ELTL$C)YD5B,GW-9K>+
MK.XO(G3&(@5SG!.1CG%>6-J<ZW=G;?:7RZJ20Q[C-5+?6[IDD?SB1D+@@'K]
M17).I7D[2E^!T+#4TK_J>_:!>QWE@#&Q;;][/8Y/%:M</\-;E[G3KPN0=KJ.
M !V/I7<5Z]"_LU<\ZI'EDT@HHHK4@*P-;TV^OM:TR6SGFMA$LNZXC16V$KQD
M-P<UOT4 8MGX<AL[JTN!<RR20>879P,S,_5CZ?05"GA8+.J-J5P^G)+YR6)1
M=H?.?OXW%<\XKH** .='A9A<PXU6Y^QP7 N(K4QIM4YR1NZD<_A21^$]ES"3
MJEP]K!<FXBMC&FU2<D@D<D<]^E='10!@VGAIK68*-5NVL4+&*TPJJA;.<L.6
M')P#4$7@^+R$AN+Z:94@:!"(U0J"P8'([C%=+10!SK>%GN(YS?ZK<7=S(@C6
M9HD78@.<!1QDXY-:J:<J:O)J'FL6>$0[,<  YSFKM% &%-X<9[^::#5+JWM;
MAQ)/;1!0'8>C?>7/<#K3(_"^R=$;4KE].CE\Z.R*+M5LY^]C<0#SBN@HH QH
M_#T:65G;?:7(M;DW 8H/F.2<'\ZK#PJPN(<:K<_8X)_/BM3&NU3G)&[J1_*N
MBHH YX>%53R#%?RH8Q*C?NE.]9#DCVQZBFGPHR(([75KFVCDB6*Y1(T/G!1C
M.3]TX[BNCHH QD\.P1P7\,4SI'=Q)$!M!\L*,#'K5:^\*M?M#'-JDS6<80&!
MH(VY4=5<C<F<=JZ*B@"AJFGS7]JL5O?26C*?O+&LBL/1E88(K)B\(K:0VWV+
M4I[:>$ONE2)"'#_>&W&%]L=*Z6B@#FT\)FVM[866JW%M<P!T^T"-6+HQR00>
M/QJY!H$<#SM]KGD,UL+<M+\S=_F)[GFMBB@#+GT.*?P\NCM.X18EC$@49XZ'
M!X/TK.L_"DUI+<3_ -M7'GS0B+?';QQA,'(*J!CZ@]:Z6B@#GK+P_<Z6DTMM
M?"2\N)4,TOV>.-2HZC:HQG'?K6KJ&GKJ!MLRM'Y$ZS#:,YQVJY10!5U*R&I:
M?/:/(R"5=I8#)'YU6?26^W?;(;MHIA:BW4^6& YSNP>OTK3HH J0QWBWSF6<
M/;>4H5=B@[^YXY_"LZ]\-QWMY=S->2HERJ9147Y'7[K@G^72MRB@#"_X1Z>:
MT,5[JT]RYE20.840#:<X"J._<U8N=#2Y&H W#K]M*%L*/DV^GK6K10!R<'AR
M\N;W41/>W-O937.YH%5<3J ,'=U4<<XKHK6.ZCN+GS9 T&X>0NT#8N.G'7\:
MM44 8:>'I(+]I;;5)X+1Y#*]JL2'+'KAR-P!]*CF\+[Y+B2/49HG:X^TP,L:
MDP/WZ_>!]#7044 9MEIMS9I&&U.>=_,+S/*BGS<]@/X /05I444 %%%% "K]
MX5:JJOWA5J@ HHHH **** .<UG5]1M+VYCM?LPCM[83GS(RQ8[L8R","HFUZ
M_C>2V<PM.7C$;)"Q)W+NP%SR1]170RV5K.SM+;QNSIL8LH.Y?0^U1S:787"L
M);.%PV,Y0<XZ?E0!SL/BB[%OYD\467WPQX&,S*< 'D]<CC/KS6KJ>H7=I#9Q
M1[/M5P<$"(N>!DX7(_4BIGT2T+VZI&D5O#)YHACC4*7_ +QJU=6-K?(J74$<
MRJ=RAUS@T <%?ZIJ>IQ_:DO/L^RS+;$5L!M^TGA^OYUJV^O7UO)Y"6[/#;.D
M+?NB=^0,MO+<=>AS72+I.G)'L6QMPFW9M$8 VYSCZ9YI6TRQ>Z2Y:TA,Z#"N
M4&1Z4P.9O-8U.YT0W275K;B<@Q(H/FIAP,=?F]^F*UK^]OXKZPLK:6V1IXW9
MY)HRW*@= &'K5[^R-.+3-]B@W3#$AV#YA[U%>:'97UQ;23Q*Z6Z,JQ%05YQ_
MA2 P(O%&H3)<3B.!8X(HVV;"2S,<9SGA>_2K3:WJ$>I+I3-;M/(R;;A8CL4$
M$X*[NO''-;ZV%HA<K;0CS%"/A!\RCH#[5$ND:<MJUL+* 0L=S)L&"?6@#FM,
MUJ^MQ<02R1S%(;B?><G+*QP!D_=XZ5:M==U"]W.LEE D2Q^9YH(WEU!R#GCK
MP.<ULMHFEM"D)T^V,:$E4\L8&>OYT\Z58&6*7['!OA $;;!\H'3% =3%LM3O
M+/P;'?32"YN#@!G4@?,V 3R>!FH[FYU1]5T^W%]:"8-(&,08J1M4C<F[@\^M
M=%'8VL4#P1V\:PN260*-ISUXID&EV-MY?DVD,?EDE-J#@GK0!S,OBN]-F+B*
M.(^3"LDRB,D<G'+%@%]NIJ=->U"2.:3? -UV;:&-8&9N,\_>Y./H/>MM]#TN
M3;OT^V8*NT QC 'I4CZ7820- ]G"8F?>R[!@MZ_6@#GK7Q#J%ZRVZ?9H)D$K
M223*=AV-C'#?+[G)Q[U6CUW48+JXC$GV@W%VR1M'$91$H4'Y0&&X>G2NG.C:
M8T*PFPMO+5BX7RQ@$]33I=)T^82"2S@;S<%\H.<=* .;_P"$@U.Y$Z>7!$L-
MF\SJR$ER"PQPWR@X^HJPNL7ZR(LY2WAE3;"PA9PQVY'S[N#QT([=:WETRQ12
MJVD !C\H@(/N?W?IR>*:FE6$=R+E+.!9@,!P@S0!REEKE_;VUI&[1S3S00*)
MY%;@NS<L-V#C'MDUI7.KZE:X,LEJ8(B1-/!&90""1\RA@4X^N#]*V%TC3DC>
M-;* (Z[6&P8(SG'YFFG1-,81 V%OB+[G[L<=Z +J,'16!!!&013J ,# HH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@"L_WS]:;3G^^?K3: /)_C)_Q\Z+_NR_S%>?ZB0;'2'!^_"<
M_4-C^E>B?&"W>>YT?8\*D++Q),J9Y'3<1FO/UT2]N-)MS%Y,LT,S@HMS&V(R
M00>&]<_G7'5BW*5CKI22439^&3@>(W'J&'_CM=/J,YFMM1A7.;2\)/\ NG/^
M-<Q\/[*ZL?$Q2ZA:(D$C)!S\I]*Z.&W>77->ADBE"3MM5BI /7H:.5NBH=[B
ME)>U<NUANDWIM[JV*X&^&*,Y'8O_ /JJMXG"/KKX.%C$L)_[YS_(_I5.TDVW
M-GZXA_\ 1HJQK$OF:EK,1P6C+RC_ +XP?T-%+6E9]Q3^.Z,.WU.Y;5=8,3?-
M;HJCD_WO_K5U/AGQ#/=7:_:1P6,8<-QPV.AY'3]*X/1;D)JOB!W&5+1@_C)B
MI["\DBTQCNQY,K..QR7;/\A25))J2&YIII^1Z@@%WXU82:AY<4068@+RP')Y
M'8XP:Q?%>G69U.2:&4N)#O#$$8SV.16?X?U=T\6RDYD4PF13GGIG!/IS[UZ%
MY<&OZ!%<7=G"DS$B/R9!\@S@9W8].E;04G!)G/-)2LCSNULT,2X8 8ZC%0WR
MRVKIY2B16SG(Z?E77#0;B)?+CA7"GIO3_&LF]6>WG,(,:.OWE?GZ=*I)H3.2
MV71OVN/,VQF/9Y(&!G/WL]:W?#7@^Y\2BX9+J.WCC."[+NR?0"DN'=EQ(8L'
MKMJI:R1Q,-ID3>Q".00"?J*3:6Z!'<#P7;:5I[03ZK:)>[6:-W !P!GA3UKS
M>XFGU.ZBFDGM[H+.D*S)%Y8(()Z#'(KL->O7E\+V]M<0*9"Q!?JRC([GUXKE
M8# &CA!=F6XC P/E#$=_PS5W0CKX8!#HEPI_OBN3$BP%U+[3(0@.TMCGKBNO
MU0_9]+F3/5A7(8W1W'!)!3;['-*?0(ZLWKRYA&GV(C0A)+O #C).U,\_H:GM
M]0DGURT,DA9BT0R?H/\ &L6XFV1:9SN47\^,^T>*?93[M<M.W[V(<?2N:J_?
M1U4](LV8)&/B/5IB>%4KC\":35[F&.PB*R%ISE77/W5Q@'%9[ZBEMK-_9R-E
MV@FE(SC:QZ#_ +Y'ZU6U:4EY.1QM&?QIUFH0:0H7E)7%GN6<6$8#<72GG_=J
MQX:N/M6J:Q+ZL!^1(JBDA>1& !,+LW/M'_\ 7IG@.0RKJ#Y&3MS^.312^*/]
M=!U/AD<B'QJ;'_IY/_H53W+,)[&%A@H%./=FW?U%4XF$FJ!=P&ZY(R3T^:K=
MNPO->@P?,7SP/E_NC_ZPK"WYF\I?D2:@-FKRJ/X4_P#912VS!;*/(/*S?RHU
M&87&L7DP&T.C,!Z CBH4<BRA /7S1^@JK>\2Y>Z:NHWA@T+1Y<\[@WZ&H_&-
MX2;4 _?MP3BL[7Y"OAG1CV(_H:3Q7)NEL1G_ )=EK9QM?T1G&>WS*T=PQU>V
M)/W<#\A45BY^SD^LJ_UJ$-MU/)[;OY4EHQ6!1_TT!_0U@T;<^A[U\+8G&C74
MK#"R2C;^&:[RO/?A/-++I%ZLDA94E 1>R]:]"KOI_"C@D[R8445C:[J.K6$E
MBNF:5]N6:8).V['E+Z__ %^E62;-(S*GWF5?J0*6N4\86WVN^T:$:;;:B3,_
M^CW+A$;Y#U)!_E0!U096&58$>H.:6O/].NFT2RUG4H-,MK!H=L!TRV)<+)GA
MR, <YXQU%:%EX@UA;6]-_$\(CCWQW5WI[VZ!LXV[0S%O;')H ["BN&A\5ZG
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MUQ4EU%YK)K*&\-N8!"0[+N SOSP1Z8YJI%J/]FLDWV>*3;/=/EDRPP.Q[>]
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M:-+]Q>?:C;BU*H2(^0'QC.>C9Z57MM>U2[N8X1.RBY86T>(P"DB']ZW3T]:
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M:2X1Y4/DL,= HR@Y(PQ_K1?ZO=I?'_B8FWD&H10):@(1)"2/FP1GG)Y!]J+
M=?14:7$,A 26-B<X 8'..#^524 %%%% !1110 4444 %%%% %9_OGZTVG/\
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MWTFVDO1<N96(8.(VE8H&'0A>E7J* (C;0F>.;RQOC#!3Z9QG^52T44 %%%%
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M 1M#-=?9VD!+8/RQD@KZ9'XUT6I7-WHWAJ:?[2UU<QK_ *Z5%')/4A0!@9H
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MD61'+!75BIP<'.#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNZ'G[.F"?;>*ZK0K:,31W!?]X@**1_=[9]ZU1FSL8-+BGTU(Y6F65HP&*OD
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MI91[Y?-E2YMS*DA]3@A@?<$4_1/#EKI%K$A2)YXW:0.D>Q5+==JYX'YULT4
M16]K!:(R6\2QJS%R%[D]34M%% "K]X5:JJOWA5J@ HHHH S+F+6&URUDM[FV
M73%0B>)T)D9NV#6G110!S.O*BZK'/]KBM95A*AKR$26\@S]WJ"&^GZUE_P!J
MW5G9S;LV"-89MX5SM\P,<E,C/IQ7=44 <8=3OH;H[+F2ZN'C.R&.3E#MR-\1
M7IG^('FHY-2NEL4-IJ,]QO9/M32':(,YW?O-IV\]L<>U=O10!P:ZI<M<P17F
MK206QCE,;Q29WX/R_.5&[\!S[U&D]['>O--+-'=3FWWH3U4@Y.W%=TUI UVE
MT4S.BE%?)X!ZBIJ //[>]GMM(C6QOII6\EC/&<'R2&&W Q\O?ZU%>-</:W$
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M#2O;P:=:I&NG&?SY_.E=W4@YP@/ !/N,5T5% !P. ,#THHHH **** "BBB@
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ME;+-:))M(0*JJK @C Z'->A:?;8 PM96EZ8840,H!P-P!SS]:ZFUB  H0@>
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M5T.KA1XIGW@E3;#('>L#3G8ZWIQ?&5;:,#MN!'\S70Z]@>(GXQF#[V?8T/\
MAA]LSRS+8QLAPW[S'UP*[6>$+86<6[<\MPD^%Z@# S^IKCH$W1QJ02%\QV]
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MQVUP>) &4G[H(R.?6JIPO&S)J2]ZZ#0[]-7?4DM8!;VPM&\IF'[QBO<G//\
M3-=C:P_;H84("I<VA5F4<J>"O/MDUPGA!HDU>Y8#:DMC)\Q_B)/'X5Z-HK*+
M&QCW+O\ +!QGD@8']:W226ADW?<MZ3IZ65JD*%V"#&YSDD^I-:B1^U.AAVC
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ML?R'%3@5RW-K7W(H;6"W7$,4<8]$4#^52XI:*104444 %%%% !1110 4444
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M?W>O2K:VENMS]I6)1-L$>_OM':IJ* "BBB@!5^\*M557[PJU0 4444 %%%%
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MUM44 4M.TJTTN)TMEDRYW.\LK2.Y]V8DFKM%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !116-KLNO126(T6WMID:8"Y,QP53VYH
MV:KW>H66GHKWMY;VR,<!IY50$^Q)JQ7,>*8;F?4]%2TCLY)C-)A;Q2T?W#U
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M0!V]%<1_:FK"/3M0.KY2]N&1K41( @&>%.,]N<U-I%]K"OHUS>:HUS'?LR/
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M/R1XZ'@9W8YZYJ."345_LZ><7EQ<[(P8'$L9'."0P^7/<A_2NWHH !THHHH
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M>H733M=2(6B2/ 0'[K!L_I4.N:*9OME]$MQ//(D82* JKH4.0REN"?8UT-%
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AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20210930x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210930x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '3!#@# 2(  A$! Q$!_\0
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M/&>IK?D\,VLVIB\EO-0DC$PN!9O<%H!(#D,%(SP><9Q[46?AFUL+U9X+S41
MCEX[,W)\B-CDDA>O<\$D>U)=+@[:G/76J:MJAT.^>*UBTRXU6+R5C=O.4 N
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M:&*5)+Y95$^\ D+*H*(5SCYNIJO<:WK>F:MX@E#6ES&M[:06\3[P%\P*!SG
M&&R<=^:W;GPE9W21Q->ZDEL(4@EMX[DB.9%& '7'IUVXS3[GPK875Y/<-+=(
M)G@D>)) (]T1!1@,<'"@'GI1I<%L5H]<U. ZY!>)9M/IEG'.&A5@CNR.QX)S
MCY1[]:@7Q!K=_,R:3964OV6""6Y29V5I6D3?LC/1<#NV1_.M'5?"UCJUW-<3
M3WL)N(?(N([>?8DRC.-PQSC)QT]\U'=^$-/NV0F>^A7R$MYT@GV+<QJ,!9!C
MGCN,'F@-/Z^1A?VUK^G'Q%<LL%RL=_'$@$<LGV92BDLRJ22H!'"]\GI72^'-
M6;6=)%R\]E,X=D9[-F*''LPW*?53T]:CE\,6KRWDD5YJ%L;ITD(MKC8(W4;0
MR<<$@ $'(..E7-*TB#2()4ADGFDFD\V:>X??)*V ,L<#L . .E"!E^BBB@04
M444 %%%% !1110 ^'_6"BB'_ %@HI,N(Z?JM15+/U6HJ"7N127$$+!99XHR1
MD!W"G]33XY$E7=&ZNOJK C]*XGQ-:&\\80HNE6^I$6.?*GE\L#YSSGU_QJYY
ME[I5CHUG96MKICW5VT<D*8F1003D'UXS6O)HGW,O:6DU;8ZRFNZ1H6=U11U+
M$ 5R!U_5([2:U::%KM=3%BMR8@  >=Q7IFH]1U348K;7K:ZEM[DV9@$9:W7:
M=Q&25.1G^5"IM_UZ?Y@ZJ7]>O^1VM%<AJ6KZQ'/K[VUU#'#IJQNB- &+97)4
MGT]^M-OM?UF74)8--MY&,$$4NR. 2"1G7.&)8%5[9'-)4VP]HCL:*XZ^U_6Y
M-1FM["TF#V\$<C1+ LFYV7)5R6&T=LBK]M?:I?>)9;43K;6\,$$SQ&(,V6^\
MN>WUH]FTKC]HFSH$=)%W(ZNOJI!%.KB]/U349+?1+>UDM[<WDUPLA6W7: I.
M"%&!G^?>GPZ_JDUG:VOG0K=S:C)9FY\H8"ISNV],GTI^S8O:H[&BL30;Z]N;
MS5K>]FCE-I<")&2,*,;<]*VZAJQ:=T%%%%(84444 %%%% !1110 4444 %%%
M% !1110!%/\ ZL?6B/I27/\ JA_O"EB^[0!+1110 48(Z@U1UF<VVB7TPBFE
M*0.WEP,5=N.BD<@^XKS#2KB5;_45\/M;"2;2)F1;%IG5I@1CYI/O2 $]!]>M
M*X['J>HW\.EV9NKG>(PZ)\JY.68*./J14MU/]EB\PPS2_,%VQ)N;DXSCT&<G
MVKS2=-"ET6ZCT*2^*.+476&?RUD\Y.6+<B;KG'8<]JNZG91:3<:WI]DLD=H)
M-/G$>]F =IL,1DGK@9IBZ7/0\'\/6@\=C7E<2WC^+G:?4;6WU@:@V$-O</<&
M+S.%&&V&,KWVX Z\UT%O%-_PD0\/[9/LUA.^H[SG:T; F),]\.S\?[ I=+C:
MU.OMIOM5M'.(9HMZYV2IM=?8CL:EP?2O--#T>UUJ738=0226%-!5@GF,HW><
MV"<$9([4V.YLY;329_$TUQ]G_LN,V;[I,-<!F#$%>LF F,_XTWI_7K_D%M;?
MUT_S/3:,'T-<98M>GX26K6)F-U_9ZE2F?,QGYL=]VW./>N?OVTP:9K/_  C+
MS_V;_9<ANRC2%1-O79][_EIC=G'MFAZ-H%JCTZZN8K*TFNKAO+AA0R.Q!X4#
M)--ANA/.\:Q3 +&D@D:,A&#9X![D8Y';(KSFZM-,O+/6X=$2>>R.ER->*QD(
M-T""A^;GS.&SCVS3)TM9H+F+3Y&6R>'25B:%V&%,K9VGJ.]']?F'3^O(]0P?
M0_E44,_G2SQB&9?*8+N=,!^ <J>XYQGUKSW5-"L[2#Q-]G6>,:<89K)1.^()
M&4%F49ZD]<YJ#Q)?:7;W.L0:E;0SRSZBBVINF=88F\A,NY4YP >@Z]*5_P"O
MN"QZ=@^AH ).,5Y'=6VGVVD:5;V.J6<^ACSC<7-TDSP-<Y4X8(RE>,[03@?6
MM5%MTM=$7Q)>27&D>7+Y<P2:-#+Y@\L,#\_"Y"D]:86.[L=3MM0L#>PEA &D
M4EUP1L8JW'U4TRUUFSO;J""W9W:>U%W&VPA6C)P#]>>E<_X7MH[OX=O;/'))
M'+]J79+G<P,CX![YZ5@^'='TC5_['M6B\RU71/WD:2.H\[S1OS@@Y#9X[&CK
M_79A;^OF>FX/H:,'TKR.\FN;K3M"?5+RUCL3IR[)-02=T:8.0>8V7Y]H7&??
M'>M[3; W?B'3AJ;RWSVVC+.K%7CWR+,=K;6.=V.FZC^OS_R"QWV#Z&C!]#7D
MFC7D$GBK2Y[-88'N#,MVD<D\DHS&Q"SN_P N[(Z#G(XX%6_"_P!D,6@MHKW#
M:UY!^W[V<CR_+;&_/RXW;-OZ=Z L>H8/H:*\K\)Q7$NL6Q.HVPU%HW%_ EO<
M>>Y*'(F+,4&&Q@X'MP:N:3?6NH0^$M(/F2RP":"]C96&QO)8%'SCD^E 6U.[
MM=3@OA;/;+-+#<1M(DPC.S ..3V)[#O@U=P1U%>3Z6C0:'8Q:&K+>)I=\K+%
MG<LX9-PP?XL=/>NJ\)'0OMD_]@R7C1FW4W )8PB3/??SYO7..W6@&==@^AHP
M?0UY??\ ]G-J6O\ SW/]OC43_9HC:3(;;']P#Y<?WL]NM7;BP9H_%&HQ)<->
M1ZAY1>)FWI 1&91&!T)&[H,TE_7X?Y@U8[R]O(-.LY;NZ?RX(5W.Q!.!4_)'
M0UY9J5MI5YHVO1Z CS:(EBLC!3(8A<+)G*[N=P7.['MFH-:5)-7D"ZA96ML(
M8O['>2&XD81[!@P>6P!;=G(()Z9XICL>JQS^9<30B*9?*V_.R85\C/RGOCOZ
M5+@^AKSG5()+K4[FVN))3YFI:8DC(60G,9W8QR,TW4K&VL;37M+CN38Z=;WE
MM(B2+++" T>61]IW",GK@C!H_K\O\Q)7/2*,'T-<MX,G6;PW,L<"QPQ2.L3Q
M2O)#(N,[HR_S!>V.@.<5S'AC^SV70FTQ[EM6\L_VCN:0_N=C??S\N,[=OZ=Z
M'H"/4,'T-4-5U:#2((I)X[B5II!%%%;Q&1W8@G  ]@3]!7 V5C96O@[P_<WJ
MS#3[O#ZK+O<[\(PC\P@Y" X![=,T0Z98:C>Z7MMWFTE=8*:>92_^I\G<P7)S
ML\Q<C/IQQ1;6P=+G?1ZM!)=V]LT-S%-<>;L66+;Q&1D_0Y&/6K^".QKS>(WW
ME*UCO-Z&UCR<==V\8Q_2JGAR+<U[]EU>)%:QE%VMA:W)E5R!AWWLP\P'/'!/
M-(=M?F>IX(ZBC!]#7!?#^6!+R\M;1;6:$0JS75C)-Y1;.,,DF=LG<X)R.N*Q
M/'%Y"=4U-DCCAU&U*>0\DD[7! "G?$J_(B=>3Z$FF)*YZQ@^AJKJ5_#I6FSW
M]SO\B!=[[%R<>PK@=4TV">+Q9K#><;VTN4DM9%E8>41%&<J <<YY]:K^*S8,
MGB#^TVG_ +9)_P!! +\V^$QL ^7;G=NSWZ]J 1Z@.>E&#Z&N:\80+=6ND6[[
M_+EU.!) C%25(;(R.<$<5Q_B*U:W\07%K)=VEC'"D::4)H;AW1 @_P!3Y; %
MMV<@@GIGB@%J>FWUY%IVGW%[/N\FWC:1]JY. ,G J:-Q+$DBYVNH89'8C->9
M^)_L>W6QK<EP=5^RC^SBHD7<GE#=L XY;=N![=:FU;48=-M?%5I.\BW-[8Q/
M:QA&)D MPI*XXX(.?2CN"5['I&#Z5%;S_:!(1#-'LD9/WB;=V.X]5/8]Z\^O
MSIW]LW7]M27ZWP6W.D_9B^\IL7/E#[I;=NW9[=>*%L(M4UNTM+Q9'MWU;43)
M'O90P"#@X/3VHMK_ %Y!T/1L'T-%>:*+*!(+76FE'AZUO;V ;W?8KJZ^4KD<
MX W;<GK^%;_@UDE\'7#0RW(C:YN_+D(+2A=[8.#R6QVHZ7"QUF".QJ.XFCM;
M:6XF.R*)"[L1T4#)/Y5YAX>NX=/CU..TC&HA;&1Y9]/EGC<L,8$J/G;*<_>4
MYZ\51LQ97,NKVUN+1K*;1YI7CM&G:-I4(():3[SCV_'K2;&D>K:7J":K81WD
M4%S%')G:MQ$8WQV./0]14@O(#?M8A\W"Q"8I@\(3@'/U!KRS5K)+26QMII[*
MRTY;"%K(74=PZB1@2YC,;#]YDCKD],5KKHUM=^(TAOY,ZG>:&@CNF5XV>52<
MN >A "D@\BF]_P"O/_(GI_7D>AU%<S?9K:2<PS2A!G9"F]V^@[USWABYGUBZ
MO-8N4:-PJ62H>@9.92/K(2,_[-8&JV$,D'C74'1VN89O+A<NWR*R1[MHSCGO
M0-'HH!..#533=1@U6U:XMM_EK+)"=ZX.Y&*G\,BN F>&T\?>:DB7UX]X@$),
M\-U$IP"%_@>(#GH!C/.:=X<6:'4%?4&9K*6ZO8[!HP?W$_FN26'=F&=I[8QU
M- 6/2,'THKSGP-)!;Z\UK:M#>[X6,UW TZ,"",?:(Y,@2'U!SUXQ7HU !111
M0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!\/^L%%$/^L%
M%)EQ'3]5J*I9^JU%02]S+U/PYI6L7"SW]KYLB+L!\QEP,Y['WI;;P]I=I%;Q
MP6VU+:8SQ#>QVN1@GD\\5IT57,[6N3RQO>QBZGH,=QI]U#9QVZR7,PGD^T!F
M5F]<@Y4^XZ56TSPND45^NH+"RWC)NA@9]JA.GS'YB2>2371T4U-I6$X1;N49
M-'L9A>AX,_;@%N/F/S@# [\<>E177A_2[UXWN+0.R((QAV&Y1T5L'YA['-:=
M%+F?<?*NQFWF@:7?RK+<VBLRJ$^5BH91T4@$ CV-68K"V@O);N*(+-*BQLP)
MP57H,=!BK-%%WL'*M[%"#1=/MFM3%!M-JSM#\[':6^]WYS[U1U/P\DNG&VL(
MK9=UQ]H=9RY#,>I#*=RGW%;M%"D[W!Q35C&\/Z,^DI=M*T7F7,OF%(<[$ &
M 3R?J:V:**&VW=A&*BK(****0PHHHH **** "BBB@ HHHH **** "BBB@"&Z
M_P!4/]X40_=IMY_J1_O"E@^Z* )Z*** "C)]:** #)/>BBB@ R?6BBB@ K*U
M308=4G29KW4+9PNQOLER8Q(N<X8=/7D8/O6K10,BMK>&SM8K:W01PQ($1!T4
M#@"HM2L(=5TVXL+DOY,Z%'V-@X]C5JB@0#@ 9/%%%% !1110 9/K1D^IHHH
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M+3^Z*=10%AOEI_=%'EI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J*
ML-\M/[HH\M/[HIU% 6&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%AOEI_=%'
MEI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J* L-\M/[HH\M/[HIU%
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MUH<;%TJ\:OP_\#[R6BBBD;!1110 4444 %%%% !1110 4444 %%%% !1110
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M1>< H,D6X;<C@<<Y/O[4 =;17*3>-4L]+EFOK,6U[%=?9#;R7"!-Y7<#YAP
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M@C< K@8.0>O48-'6P'=T5RD/B*6-'M[.RN+V]EO+E(XI)U "QM\S%B/E49
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MQ]51K*"V2W>.6Q20_*,;HV)S&QQ[X.,5=G\*7 OYI+#6;BRM;HHUU"B N[*
MN5DSE"0H!X/X5TV15::^@@O;:TD8B:YW>6-I.=HR>>W%.^H'(WOAG4(-;TW^
MSKR2(F>]N&NA '6(R;2%92>1U'49QVK0_P"$.7R(U:_D>;;<F:9HQF5YUPS8
M! &.P]!BNF+  DG@=:JVVI6]V8?LY>2.:+SDE6,["N1_%C&>>G6EY 8MOX26
M#3M5M/MI;[?9QVI;R_N;(O+W8SSGKBL[5/A\=1EN2FJ+#'<VZ02[K-))!M39
M\CL<H".2/<X(S7:Y%+G-#=]P,*RTC^PY-3U R279GABW0QQ?,?*CVX49Y)]*
MA\&Z2^F:3))-')%+=2F012_?BCZ1QG_=0#CMS71U6OKZ#3K*6[N&*PQ#+$*3
MCG'0?6G?6X6Z&+-X8N?[4N)[/69[2RNIEGN;:.,;F<8!VR9R@.T9&#WZ9K,3
MP \>HQ3KJJB&&^%XB?8D\QCO+$/+G<W4XZ8XZXKM<BER*0/4XC0/#-_+;0_;
M[Z>.RCOI;G[ T(!+B9F0E^NWHV,?CCBEB^'[1:A!.-57R;>]%XB?8T\QSN+$
M22YW-U.#QVZUVN0*,C-&P/6YRMEX.GMI+>&;69)].AN6NQ:^0JYD,A=<OG.T
M$YQZCKVI6\%JUF;?[>W-O>0;O*_Y^'W9Z_P]/?VKI(+N"Y>=(9 [0/Y<@'\+
M8!Q^1'YU-D8S0!RT_@]YKB[9=2*0W*VV^,P@D/"5(8'/0A<8]\TL/A&2UU5I
MK;45CL6G:X-L;.-GW,VX@2'D*23QC//!%;]M?V]W/=0PL2]M((I05(PVT-^/
M!%)87]OJ5J+FV8M&69,E2.58J>ON#3OU#I8P7\(RW'B*'4[O4EGCMYO.A7[(
MBS*><*91R4YZ8Y &2:T-1LY%US3=2BC9Q&'MYE49.R3!W?@RKGV)K8R,XK(/
MB33@EFRO-(;R1HX5CA9F)5MK$@#@ ]2>*2[ 9VF>$9-+OXS#J2_V?$Y>.V^R
M1^8,DG:9>I4$^@/3FJ_B:UU.VCL[Z![R>^@EE"7%G:+)Y<;_ ,#1%@6& !D'
MJ :Z>XOH+6XMH)6(DN7*1 *3DA2Q^G -5!KUD;JSM=MQY]VF](_L[Y1>F7X^
M09X^;% &7X4TO5+/28C<W#QRRWLUU,LT2F21')P#@X1NAXSCI6WIJ7@T\+J+
MK)<;GR50*"NX[> 3_#CO5T'-%# \UTW2=6GUK3+ QZE%IFFW)E$-U;HJ(FUU
M"B4,?,^]@8 P.M=%I/A&;2;B-4U-7L8%*PP?8XU<#& &DZL!GL >!DFNGR.M
M!(49-'0.I@0>%TAL=#M6NBZZ63DF/_7 QLF#SQ][WJ#1O"<VD7<6-3$EC;C$
M,'V2-7 Q@!I.K8]@#QR36]87T&I6,-Y;,6AF7<A*D$CZ&K&11U#H<I:>"4BA
M@M[J_-S;0PW5NJ>2$)BF*\$YZC!YQSGM6AHNAW^G3A[W6Y[Z.*+R8(C&(U5>
M.6P?G?@#/'?CFMS-07EW#86<UW.Q6*%&D<@9P ,G@47L!AW_ (6DN-5FO;/4
M%M1<E3<(UJDI) QE"WW3@#L1QTJ>;PXLL&M1?:B!J<83.P?N\1[,]>?7M6I)
M>1I;1W&V1TD*!=D98_,1@X'0<\GM5C(HMT"_4\[\0Z9JOVF^T[3$U%([^-5D
M*6Z/#*VP+N\PMF/@ ,"#G'%=&/"X.H"\-V01<PW&P1_\\XC'C.>^<YKH,CK1
MD47%8YV^\*)>27<PNS'/+=K=POY081,(PF"IX8$ YZ=:;)X4DGTQ(I]15KV*
M<3Q7"VD:HC8*X\OH5P3D$D\]172YI,B@9S\7AF7R['[1J EEMKP719+98U;"
ME=H5>@YSDDFI!X; U?[?]J.?MIN]FSUB\O;G/XYK=SSBC(H_K^ON X[6]'GT
MY'O[(WDMTU\]RDEM LC0[T"D&,L-ZG'8@]#VJ_X0L;VUTR[DOS+YUW=23_O5
M"/@@ 9 X4\=.PQ71<=*3(H!ZG'6/@1K*_L9_[35HK*<RQHMFBL^0P_>.#EC\
MQYX^E:EOX:6#3]'M#=%AITOF;C'_ *SY67&,\?>]^E;%M<I=6Z3HLB*W02(4
M8<XY!Y%0SZI:VIG^T,\20A-TCQL$.\X #8P3GC Z9'K1Y 8EMX3N+>ZL-VL2
M266GS>9;6S0C*KM9=K-G+8#<''0=^M7]7T6:^N[>^L;XV5] K1B7RA(K(V"5
M*DCN 1SQ6QFB@#%LO#YL[X73WTUP_P!B^RLTPRS'>6+$_CTQQ6;_ ,(8\,-G
M]BU)(KB"V2UDDEM%E61%)(.TGY2,GG/?O769%17%Q':VTMQ*<1Q(7<@9P ,F
MBX;F2GAX+-/(;MF,U@MF28P#P6._C _BZ "HKCPPL]M##]K*^7ILFGY\OKN"
MC?U[;>GOUK:M;F*\M(;F$DQ2HLB$C&01D5+D4/M_7]:@<VWA6X2X=K+69[2"
M=8Q=1QQC<Y10NY&SE"0 #UJE>^ VNKRXD35%CBFN1<X-HC2;@P;:9"<E>.!Q
MCCFNRS1G-.^MPZ6,^QTL65K=PB8O]HGEFSMQMWL3C\,U4L?#PLAHH^TE_P"S
M(&A'R8\S<H&>O'W?>MO.:JIJ%N^IR:>KG[1'$LS+M.-K$@'/3JII 88\*SVT
M5L^GZH;:\@$J&8P!U='<OM*D]B>#FG+X4>T2U?3M3EM[N(.LL[Q+)YP=][[E
MX .[D$=/>NDR*,B@'J<K%X+$5A':G4'?9:7-KO:(9/G-NW'GJ/U]JL7GA.*]
M>1GNW4M:0VZ%$ *-$Y=9 ?7../:MN[O+>QM);JYE6.")2SNW114P8$ ^M ',
M77A2\U"Q9+[6FN+KSDE1GM@85V@@#R<X(Y)//7![5!#X)E@MY@NJC[0]Y%>)
M(+555'1=N-@(&TCMV]374QW*27,T 20-#MRS1D*<C/RD\'WQTJ8'- '--X5E
MCQ/9ZFUO>I<3S)-Y(==LIRR,I/(X'.1TJ;3O#"V%]:WAO'FFB\]IF= #,\I4
MEN/NXV@ >E;V14-I>V]]:K<VTJR0L2%=>AP<']0:%H#U,*30I(K*UTI&::*2
M_:ZFD*8"H)#+M^N[:/S-:&JZ0VH7>GW,=R(9+24N08]XD5EVLN,C&1W[5:EU
M&VAU&WL'<BXGC>2-=IP53&[G_@0I+S48+#)G$NT1/*SK$S*JH,G) P#Z#OVH
MZ 8MEX4EMI[2.;5))].L7\RUM3$JE" 0NYQRP4'C@=LYJ]J^AC5KB&4W!B\J
M">' 3.?,7;GKVJ8:W9>29G>2.(>5B22-E5O,QL"DCD\@<=">:T<\4,%W,FUT
M06USI\WV@M]CLC:8V8WYV_-UX^YT]ZY^/PWJ=IK5K!87\ENEOI@A^UFW#JY\
MTDJ5)ZXY'/YUU\-Y#/-<11L2UNX23C@,0&QGZ$5/D8S1Y_U_6H&%I_ABWT^[
MBECF9XH[$V9C<9+Y?<6)]22>,=Z@L?"TUM<6:W&JRW-C8-NM+8Q*I0@%5W./
MO8!..![YK;FOK>"X2W>3]^\;R)& 2S*N,D ?4?G4EO.MQ;1SJKJKJ& ="K $
M9Y!Y!]C0!AQ^$K02:QY\SS1:D"@C(QY"')95/NQ+?4U+HVA76FW#2W.HI=*$
MV1JEI'%@>K$<L?I@>U7VU6TCDV2L\1-P+9/,C90[D9 7(^88[CC@^E7<T SG
MM0\.7ESJMU?6>L/9_:HHX94$"O\ *N[D$GAOFX/;T-,E\'P$O]GNY(-L-O';
ME5!,+0EBK<_>SNP1]?6NDHH YN/PM*^^>]U-KB]DG@D>80A%VQ-N5%4'@<GG
M)ZTA\)R>=Y']J2?V1]H^T_8O*7.[?OV[^NS=SC&?>NEHH \[?3-5FUJ'3;>/
M4(;"'45NO+EMT\I0)-Y(E#<@]0N,@GGI6]_PBDL,=O)8ZF;>]@DG99C '5DE
M?>R,I/.#C!SVKIJ*.@%;3[1K&QBMWN9KET'S33'+.<Y)/^':K-%% !1110 4
M444 %%%% !1110!R^J3/HWB@:M-:S36DMJ("\*;S$P;/(]#6+JWFWND^(=7-
MM+;V]Q'#'$LJ[6?:PRV.W7BO0JK:A80:G8R6ERI:&3 8!L'@YZ_A5*5CAK81
MS4DI:.[MYM6W['%BSANKB^33+.9;4Z:RW"/&P#3=5X/5AZTME%&4T3[/ RHN
MG7"N!&5Q)M7=GCKG/UKNU4(H4= ,"EIN7]??_F*.!2:=_P /-/3[OQN>>Z9H
M]N9/#:R6A*SVTOVD$'#X (#^V>@-2Z6DB6_AWS8Y"D-Q<@AE)VH V!],5WM%
M#G<4,OC&UGVZ=N7_ .1_$\[T5M.?4;[48K$Q7)B=+.QBA:,[0#DE@,;C]>*-
M%@$^JD):I'!<Z<Z/%' ZHSY^ZQ;[S#UKT2BAR%' 6M=K1WV]//Y=K=#@=%A"
MQ>&5A@:.2-YQ-F,KB3RSG/'TYIMA X;38X[>X77DN]UY*R,,IN.XLW0J1C K
MT"BCGUN.. 2BES;>7DE]^F_FSSMM/"Z;/>K XNUUH[) #N53(,X]L5Z)114M
MW5CHH8=4FVNO_!_S"BBBD= 4444 %%%% !1110 4444 %%%% !1110!0U;_C
MT7_?']:+'[@I-7XLU_ZZ#^M%B?D% &A10** ,W7[H66@7UP1.1'"Q_<'#_@>
MWU[5YI#)#=_V[8V\T<EI)I#S&*VOY;E3*K9!WMWZ9"\>M>N]13%AB0 +&B@
M@84#K2L.YY3?QZ;:)?W.GW+*[Z!&]M(MT[;L,P8J2W.,#Z?C5[Q1;)IT=U:P
MRW A_LGS6WS,Y+FX3+<D\_Y%>C_9X< >4F , ;1P*<T:,<LBGC'([55];_UU
M$M/Z]/\ (\VOI819ZVF@WUS<V2V:RS,)WEV3B0$X8G(8J&RHZ8' IWB2_L]>
M.N?9+DW-HFDQN&BD.PL)&.00><=_UKT=45 0J@ G)P.II%AC486-0,;<!1T]
M*0+0\KUB=SJ<B0ZI9VUK#;Q'3'GO9U)0I]^/9D2'=GKN/ JUKEVUIX@6ZN+]
M+FY1(,6L=W);SHV!GRD^[(&Y)!&><<5Z5Y,6$'EI\GW?E'R_3TI3&C.KE%++
MT8CD4[BL5;067VR\-O(&N"Z_:%\TL4;:, C/R_+C@8]:XI+BU;7;A[[4;N+7
M4U(QV]M'(QW0Y&Q1'T,97DMCCGFO0 J@DA0"W4@=:3RT,@DVKO QNQSCZTA]
M#SG2KJ$W>DR07]S)X@EN=NHV[3.V$^;>&C/"JO&#@=NM/T6U-I9^&]42[NVN
MKNZ:&8O<.RO&1(0NTG'&T8XSQ7H8C0.7"J&/5L<F@1H H"+A3D#'2@#S#1;L
M6^HW$*7POY9H+@O<6]Y(6!"D@S0O_JSQ@$8Y.*@O+O[.-.NYM0$\B6%LR6IO
M9()U.T9,0Y64MW!!/:O51%&K,P106^\0.OUH,,9*'RURGW?E''T]* /--5'V
M&_\ $LEA(T-W+/;/-OFD!6!@N]L D@9X)4<<XZ5';^>^BW%O%JL$EHU]9HAL
M+J:01%I &Q(_/([ G'XUZAY:;R^U=Q&"<<XI!#&J!!&H4'( 48S0M 9YMKFG
MV=J-4L)99_[.M+NQG'FW+GR@[$2'<6R!@9Y/'6NG\52QQZ=8+)/)#I;W"+=S
M1R%<1;3C+#D*6V@G/0]:Z-HT;=N13N&&R.OUJIJ>G#4;00"ZN+4A@RR6[A6!
M'L001[$$4 <'ILEK/JJI97<EU8KK2)"[RM)\OV5N%8\D=<&KJ2ZFSS:=;M,]
MSH=K.58DGS9&!$&?7Y,GZUUFEZ/!I<#HLDL\LC^9)-,07=L 9X  X &  *73
M-*CTQ9R)YKB:>3S)9IR"S'& . !@  #BA]OZV!=S@ENK*+2I'T35M1FN'M4:
M_P!LC2F/YT#N<YV2!2_RC'0\<5(\MIY.K0:%K$J:3]D1I+DS231Q3&3H'R6&
MY<[L'CKQ7HRQHA8JH!8Y.!C)I%B1$**BJI[ 8% 'GFC7)&E7,]H2PTJXCN-]
MO>O<P2H01(J,W/W<DJ2<'%689I#>:5JLIF8WC7MVJ+RPC\L; H/?:%X]377:
MEI4>HZ>;+SIK:%C\XMR%+KW4\'@]\<^]7$BCC1%1%"QC:@ ^Z.G%,$>5Z/=P
MWFOV<$$X,5_:3BYCCU&6X=CL!&\G 1QSPN#UI;">2VT&R72;B7*Z-(9/*D9V
M1_-C$A R?F4;N.U>IK#&ARL: YSPH'/K0L4:'*HJGGH .M+^OS_S \RU"XM(
M['5H_#VHW$VGG3]\TBW+RB.;S%"D.22&(W9 /8<"NCL4M_#_ (HNH!=RI9-I
MPNIC<W#. X<@OECQD=>U=4(8PA01H%)R1M&#39[:*YADBD4%9$*-ZE3U&:=P
M_K\C*\4W%W'X5OI]-8^?Y64=,DA21DC'/W<GBN#@>3^Q=:6'4K&XLS;*S16M
MS-.%D\P?,6DS@D9RN?3BO5414144851@#T%-$,:H4$:!2<D!1@TEHP/.=3NH
MUN-3EDO[E/$D5X4L+=9G&8]P\L+'T96'4X/4\BGW-L5M]<UD75V+NTU?;!BX
M<(B[HP5VYP0<G.17HAC0R!RJ[P,!L<BCRT((V+ACDC'4T+3^O0'J>9:[=VJ_
MVD]WJ-S#K8U!8H8!<.O[CS5V@(#@J5Y+8Z]ZA\0ZM&FM7$\$_DWL%_'$/-OY
M/-"AU!Q"!M$9!/+=1SGD5W-QX8ANM1-S/?WSP-()3:-(#$6!!'4;L9 .W./:
MMDPQLQ8QH688)*C)%"TM_78'U/,+]1IYUZ.QF$,CZL@O/,N) $MV0$,V"652
MQ(W#''&<#B2TF9=*2*[U2%]"-\J3RV=S,R1)Y9^7S6YVE]N2#QG&17IGEIN9
MMBY888XZBD$48C\L(H3&-N./RH6BL#U=SEO!)MC)KGV.=Y[;[<!%([EB5\I,
M?,>2/0^E8NE6JV=GH^J0SW N)=7DMW'GML,;2R KLSMQQGIG->B*BIG:H&>N
M!1Y:  ;%P#D#'0^M.^P=&CRN#5HW\3Z7<6LYCGFU'RIDDOY))RA+#;)%C8@Z
M8'7IBK^E6$$VJ>'+@H[S*EZR@3,H)67*]#CJ3VY[YQ7HGDQABWEIDD$G:.2*
M41H""$48SC Z9I+H#U.4N;G4;G5-$;4K"*RE%U*%2.X\T,/(?G.!CFN:TJVD
M9HM1MO.EU-?#YEB8S.V9-S*.,X/'8]_>O42JD@D D=,CI2+&B$%448&!@=J
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M]>M)@<YK<CQ^&M-*.R$W-F,JV.#(F17.I9&1([W[;>K/+KLMJ66Y8 1-(P*
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MDCN2)#"X;>#PISG&,<5HVL]SMNH)TNI1X=M)H6\LE7FD880J>Y\H Y[%J[W
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M4.H"_AN;VZDO9;>1D660Q9*\'(7H,>@%0D6UO;QV6IRS+X?MM3NX)"TK[5
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M?6][!;SV[M&Q0.1CD-M.0<#!X)YJWJ/A26[CU);>ZBC%S/!-'$Z$Q[8T"['
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M:4.FW>[$DELX)[=:<MW8%;2YK:;XP@OC;O/I]Y96]S;-<P3SA=LB*H9NA)&
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MQ(O 5T!>LUSIL)N=/DL]EK:M&JDD$,222W3G/X4/?^O/_@ O/^MO^";4/BV
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MBX6*]%6/(7U-'D+ZFBX6*]%6/(7U-'D+ZFBX6*]%6/(7U-'D+ZFBX6,76_\
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M -=%_K3--^X*?KO_ !XK_P!=%_K3--^X* -8=**!THH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M73?GKR0-PZ]: )E\;:-*)Q#+,[QPO,@-O(HF51DE"1\_;IFI?#_B>UURTLB
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M5_LXW1\[S/)W>6WE^9_<WXV[O;.:L:OKMAH<<+WTCIYS%(PD;.68 G "@DG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*:$0.7"@,P +8Y.*=10 4444 %%%% !1110 4444 1I!#'(\B1(KORS*H!;Z
MGO4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!FZY_P >*_\ 71?ZTS3?]6*?K?\
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M?;^$M-MTA^:YDDCF:<S2R[GD=HS&2Q/7Y3@>F!6]10!SEAX*TK3]HC>[D2.
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M9=Z;A@X]Q^%6LC.*8!10"#29'//2@!:**KW=[;V-L;BYD"1!E7=[L0H'YD4
M6**,\XHR,XH **3(QG-+UH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6-;FTGMSYD!(5U9P1UY%7]6\->;%#'9AF$FHK=S[I,$#&#M-7?\ A&K$VES
M[SR&YD6269WR[%3E><=!BA."L_ZZ?\$3C-W7]=?^ 95YXLN8M5NH;>U$D-M,
M(F01NSOTR00-HQGH>M3WNNZC;^(%TB.&W:2X97@D)( CYW;AGJ,<5I2Z#:R7
M\EVLUU$97#RQQ2E4D8="0.?R-1S^&K&YGFN)&F-S)*LHG##?&5Z!3C@>U).&
MF@W&IKJ8.N7UTD.N"TV0/'>0(T@+;G# >_'X8XK1N_$%WIO]HP7,<+74,<;V
MP0$+*7^7'/HU:%QX?L[F._60R_Z:Z22$-@AE P5XXZ52N=$FO?$.G3RQ@VU@
MN1,\@9YCQ@$#T/.::<7H_P"M$#C-7:_K5F_%YGDIYVWS=HW[>F<<XI]%%9&P
M4444 %%%% %'5O\ CS'_ %T']:;8_<%.U7_CT'_70?UI++[@H OBB@44 4M7
MO_[,TBZO I9XD)10,EG/"C\217'Z-;:SX?U329-2M+6*WD3[#<2PW!D+R,Q=
M78;1CYRP[_>KO2 >HH(!ZC-(?2QYCX8^Q*-"%A+<?VU]I(N8][X%ON?=N4_*
M$QC!]:KEIO[!D?=)O_LB3YLG/_'YZUZJ !T 'T%&U?[H_*F%];G C3K>'6_$
M\MFI34[>XAO8UWMET" G@G&&.\?C71^&6^WV5QJLF_;J4YF16R,0_=0>WRC/
MXUHZEIZ:G926KS30K)@,\#;7([C..AZ&K$,4<$,<,2!(XU"(HZ  8 I+:PF>
M96,.FV>EV]M<%X=+34[I=259'&UOF\H2$'(7&/TS77>$&+6-[Y#2OIPNV%@T
MI))BPO0GDKNW8SVKH=HYX'/7CK2T(;U/+/#OVUO$-I)<:C;)J?VAOM<.)S,R
MY;*N"=@7'0X X'-7H7*-J!=Y_P"S6M;K^QB[''W3YGO_ +F?X<UZ)@9S@9]:
MBNK6.[M)K:0$1RQM&VWJ 1@X_ TFM+#OK<\VLFM/L,3:-/<R3G2)CJ>^1VP?
M)&S=G@-NZ8[4FK6)L])T%?.B@T^XMO.NI;R28H\Y5,%RIR.,XY KTJUMH[2T
MAMH\F.*-8UW=2%&!G\!4N 1@@8],53U?]>9*V1Y?J$?_ !(-':_U>WD1#-Y:
MW/GQ0RKN&WYQ\P91PI.<CGFF:S<))#IE]/(4E%BGEV%W/,DF03S%(O#.>.H)
M^[ZUZF0",$ CW%*0#C(!QTS2&<]XEFNG\(-+"MQ$S"%IPF?-2(LOF8QW"YZ>
M]<KJ3V@T:X7PY<S?V4;R'[2\C2- B%6W;6!W[<[=V#QGZUZ728 &  !Z4,%H
M>8VENT^E6=M]OCN+"76($06AE5%0HV]59CD@^QXR:FNX-+T+4/$L<5LZNR6H
M5%G=,1$ ,Q;DA >I'/:O2,# &!@=..E&!Z#TZ4?U^0'D^GSXM]8@M)4^RK<6
M#Q+;22-&,R@,5+\D''..*U&T](K:]UE7G^W1:^R1OYK85#.JE=N<;2">U>B;
M5_NC\J,#&,#UZ4UI_7I_D)[6.3\:M:+?:$NH2R1V1N9A,4=E!7RC]XKSM]:Q
M8+2+4)M)LPUR^C2ZG<+;!I'!>#R<XSG)3=G'M7>76G07=Y974A;S+-V>, \$
MLI4Y]>#5K XX''3VI#;_ *^\\VU(V\<^IB26Y7Q+'=;=-C1WSY8*^6$7H4Q]
M[/OFJU_;BR778;(I S:RIOM[2$"W*9!;:<A"^>1_*O4\#.<<^M)@<\#GKQ1;
M^ON"YYQIHF32+417T5S:_P!MV@A^S"7RT&1N"L_+#//4CK3M'L$M+'P]JL;3
M_;9]4:&5VE8@QL\H*[2<8X':O1<# &!@=!BC XX''M3_ *_+_(+Z6_KK_F><
M>&9([;Q:D44ZW\LSRB69)95F0<G,\;?+[ C':KWBBULD\5-<S)B>71;E86+-
M\T@'0#.,[2>*[G R3@9/4^M! /4 _44FKJP7UN<#;6L>AMITUJMV_P!IT262
MX1)69I61$*D9SAN2!BL32S;WFJ3VMMY+6UWI5QYT5O/-*'D ! 9FZN/;^M>L
MX'' XZ4!0.@ ^@H>O]>O^8+1(Y;2Y[6U^&D,UDDLL4=ADI;N=Y;;\P!Y(.[/
MTKB(KI5.M1V$T(MY=%FD(M)I9$,@9<'<_5@">E>P@ #   ]J3:N,;5QZ8H>K
M;$M$D>;^)+$6']E6XF@M]*>!I9'O))C&]P2IRS*<YQR,G'6NGT?^T%\#_N[G
M[5>"WE\B7:R[CSL^_P ^@R>O%="0",$ CT(I:'U&NAY?;'2CJ.FMIDMP\_V"
M[-YYCN2)?)&=V[H^<\"JMQHME<:3JUU-;L]POA^UE#F1\[RK9/7G[H_*O6=H
M]!^5&T?W1Z=*/Z_/_,$[?UZ?Y'GFH0M8G5;:U\^*QB73EF$3,62#YO,VGKTZ
MGKC-'VG2;&?3[W3;JY_L6VU/,DKLS0QAH6'R,>2N[&<\ FO1,#TI,#&,#'IC
MBF(X&QD34]7A?#O;S:[< ;LC*&V(^H!_K5_P;96+>!'L8H\@^=%<1[FR'R00
M><@XV]*Z_ ]!^5* !T 'TI6TL.YY9I/]BII>BQZM*\>D+I_R@2NJ?:PW[P,0
M<[@,8'UQ78Z0^IGP*&_>M?\ V>7R#,/G/WO+W9[XV]:Z':N,;1CKC%+3>MPZ
MGF'A3;]O#SZE:-$;60ZC"@G+GY>3*7)"L#GT[XI)GN(O#6KB_DNUN/LB&P+G
M#_9/,&.G_+3IN[_=KT_:.>!SUXZU5U+3H-4L);.XW"*4 ,4.&&"#P?P%(#SO
M4S:+INN?\(_/<M8_8D,[^8[!;CSEQ@MR&VYSCVI_BBQ6PUB*S,]M::6EL&MO
MM<DY4REF+D,AR7Z=3]*]+P,$8&#VQ00#U /UH"YY?KVZ%-,GOM1CN;E+!-L,
M[36[2,,_-$P_Y:'C(()X'K4FJW"P^)TOF<SW3>0R6,DLL5S%D+E8\?(XZYXZ
MYYKTT@'J <>M)@9S@9'>GUN(Q/$987.A;2PSJD0.#U&U_P!*Y70[!+.Q\,ZI
M&T_VRYOVAF=I6(:-C+\I!.,# Q7HV >HI,#C@<=.*%H/^OS.5\5-9_VGIRZU
M(Z:*8Y?,(=E0S?+M#E><8W8]ZPK2"!]0\-W=\)3 MY=16<MPS!C'UA!^O;/4
M8KT@@$8(!'H:" >H!^M*P'G&@V L+#PI?6GFB\NO,BE+2,5=?+D(4J3@ $#'
M%4O"XNVU>UDDU&W%^5<WT"B<S-\IR) 257!Z' ' QUKU/ XX''3CI1@9)P,G
MJ?6AZA<YOP+916_A6QN0)#<74*O,\CLQ8C('4\8''%<SX?2#_A)&LO.%_P#:
MA-'<31RRI,BD'F:-N!Z C&#C%>E@ # &!360,K#[I88++P:;U=Q+16."4W>H
MVFH175U/;'2+)K)KB-68F5CRX Y/[M4]_F-8>RSN?#&IV[10S6EM+;3FXM;B
M5X/]9AL!N58+DD9/'->G:7ID.DVA@A>60LYDDEF;<\C'JS'UZ?E5S:,8P,>F
M.*0SRG4_M$GB&[_XF5M:S+,HT[?Y[2>3A=AC"G:P(Z\'OFM*^T\2_P!NZB9;
ME;R'6(HX7CE9?+5O*5MHZ<ACVKT3 R#@<=..E&!Z#\J:T_KT!L\^U2P@L8?$
M&GPWDEG8QW%K(OFM))&-RDL&(.X*Q')S6WX&N%FT>:..(+%#.5C>.9I8I!@'
M,9;G;VQV.:Z; YX'/7WI0 !@# H6@/4****!!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!)#_K111#_K114LI#KC[R_2H:FN/O+]*AIH3W"BBBF(
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH I:I_QZ#_ 'Q_6DLON"G:G_QZC_?']:2S^X* +M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% $D/^M%%$/^M%%2RD3LBMU%)Y2>E/HI#&>4GI1Y2>E/
MHH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE
M)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2
M>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH S]3B3[,./XQ19
MPIL'%2:E_P >Z_[XHM/N"@"SY2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E
M/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!G
ME)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y
M2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B
M@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4G
MI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z
M4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &
M>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'
ME)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z
M* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2
M>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4G
MI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH
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M <#HN@W2WFA&\L&V6\NHN_F*"$WR90GZCI4NE:!+9VOATC3_ "I;>_GDF(0
MHC"4 D^AROZ5W-% =SS+PO:S7VG:#!!H[0FVNC=R:@0H5E#/D ]2S9P14,OA
M_5+>/3+J6WU/RUM'MVCLEC:1&,K-RK@\$$<CTYKTVUM(+*V2WMHEBA3.U%&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSJ.S="/S!H$7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2:]EFNA?)>S3LH!E9%V@8'"C%=!12 Y;5_!IU2ZFF34Y(!+=+<O'Y(=&*H$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M '11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\
M=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T
M4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_ '11
ML7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\ =%&Q
M?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T4;%_
MNBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_ '11L7^Z
M*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\ =%&Q?[HH
MHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T4;%_NBBB
L@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@!0J@Y  HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20210930x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210930x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $B!#@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ([ABEM*RG#!"0?PKS8_$74P2/L]OQ[&O2+K_ (])O^N;?RKP
M=_OM]: .O_X6-J?_ #[V_P"1H_X6-J?_ #[V_P"1KCJ* .Q_X6-J?_/O;_D:
M/^%C:G_S[V_Y&N.HH ['_A8VI_\ /O;_ )&C_A8VI_\ /O;_ )&N.HH ['_A
M8VI_\^]O^1H_X6-J?_/O;_D:XZB@#L?^%C:G_P ^]O\ D:/^%C:G_P ^]O\
MD:XZB@#L?^%C:G_S[V_Y&C_A8VI_\^]O^1KCJ* .Q_X6-J?_ #[V_P"1H_X6
M-J?_ #[V_P"1KCJ* .Q_X6-J?_/O;_D:/^%C:G_S[V_Y&N.HH ['_A8VI_\
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M8VI_\^]O^1H_X6-J?_/O;_D:XZB@#L?^%C:G_P ^]O\ D:?+\0=3AD*>1 V
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MZ 'J#R:@TXWO]EZ2VFRQ1VHF<S!V4?NMWOU&/2CJ'0X>+29Y;&*\\R%(99Q
M"[8PWJ>.!56:W:&XDB#+)L."T9W*?<&NT,EJT-N;9D\G^V@5P>,>OTJWNNGA
MN1HLUNEV+YS<[V493MG/5?I1_7Y?YA_7YGG@5FZ*3]!5M-+N7T\7V%6W,PAW
M,?XL9_+WKN?#@-O!-,+F"1FO")A Z1HH]23R5]A4=Q/<-I-];VLJJL.I'?&&
M48B//3TS1_7Y <+=6K6UT]OYD<Q0XW0MN4_0U"%8D@ Y'7BO06>1M0UM=+EB
M753*A0LP!,>.=I/%,DNXK;4-6FMI(OM*:>OFLF"IER,D=O2@#@2"IP00?>DK
MH_%4QNH](N796GELU,C#J3GO7.4 =C\.O^0W/_UQ/\Z*/AU_R&Y_^N)_G10!
MZ=11G-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 177_'I-_US;^5>#O]]OK7O%U_QZ3?]<V_E7@[
M_?;ZT -HHHH **** "BBB@ J>SNY+&Z2XA"&1.F]0P_(U!10!-=74U[=27$[
M[Y9#EC4-%% !1110 4444 %%%% !1110 4444 %%%% !5B^_Y"%S_P!=6_F:
MKU8OO^0A<_\ 75OYF@"O1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% $]Y_Q^3?[QJ"I[S_C\F_WC4% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %3WG_ !\M]%_D*@J>\_X^6^B_R% $%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 3VG^O/\ USD_] -05/:?Z\_]<Y/_
M $ U!0 4444 %%%% !1110 5I:=KE]I<4D5NT9C<AF22,.,CO@UFT4 3WEW/
M?W4ES<N7ED.68U!110!:N]0N+V.WCG8%;>/RX\#&%HFU"XN+*WM)&!A@SY8
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ML+_S\7WHV?[%TS_GPM_^_8H_L73/^?"W_P"_8K&_X3_P]_S]2?\ ?EO\*/\
MA/\ P]_S]2?]^6_PHY)=@^O87_GXOO1L_P!BZ9_SX6__ '[%']BZ9_SX6_\
MW[%8W_"?^'O^?J3_ +\M_A1_PG_A[_GZD_[\M_A1R2[!]>PO_/Q?>C9_L73/
M^?"W_P"_8H_L73/^?"W_ ._8K&_X3_P]_P _4G_?EO\ "C_A/_#W_/U)_P!^
M6_PHY)=@^O87_GXOO1L_V+IG_/A;_P#?L4?V+IG_ #X6_P#W[%8W_"?^'O\
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M'O\ GZD_[\M_A1_PG_A[_GZD_P"_+?X4<DNP?7L+_P _%]Z-G^Q=,_Y\+?\
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MZD_[\M_A1R2[!]>PO_/Q?>C3N-(TY(@4LH%.]!D(.A8 _I4W]BZ9_P ^%O\
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MT4451QA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#/];_]\M1[2/</[*QG\GY'$45W'_"L[_\ Y_[?_OEJ7_A65_\ \_\ ;_\
M?+4>TCW%_96,_D_(X:BNY_X5C?\ _/\ V_\ WRU+_P *QO\ _H(6_P#WRU'M
M(]P_LK&?R?D<+17=?\*QOO\ H(6__?+4R+X:7TL8<7]N 2?X6]:/:1[A_96,
M_D_(XBBN[_X5A?\ _00MO^^6H_X5A??]!"V_[Y:CVD>X?V5C/Y/R.$HKN_\
MA6%]_P!!"V_[Y:C_ (5A??\ 00MO^^6H]I'N']E8S^3\CA**[O\ X5A??]!"
MV_[Y:C_A6%]_T$+;_OEJ/:1[A_96,_D_(X2BN[_X5A??]!"V_P"^6H_X5A??
M]!"V_P"^6H]I'N']E8S^3\CA**[O_A6%]_T$+;_OEJ/^%87W_00MO^^6H]I'
MN']E8S^3\CA**[O_ (5A??\ 00MO^^6H_P"%87W_ $$+;_OEJ/:1[A_96,_D
M_(X2BN[_ .%87W_00MO^^6H_X5A??]!"V_[Y:CVD>X?V5C/Y/R.$HKN_^%87
MW_00MO\ OEJ/^%87W_00MO\ OEJ/:1[A_96,_D_(X2BN[_X5A??]!"V_[Y:C
M_A6%]_T$+;_OEJ/:1[A_96,_D_(X2BNXE^&E]$@8W]N?F5?NMW(']:?_ ,*P
MOO\ H(6W_?+4>TCW#^RL9_)^1PE%=W_PK"^_Z"%M_P!\M1_PK"^_Z"%M_P!\
MM1[2/</[*QG\GY'"45W?_"L+[_H(6W_?+4?\*POO^@A;?]\M1[2/</[*QG\G
MY'"45W?_  K"^_Z"%M_WRU'_  K"^_Z"%M_WRU'M(]P_LK&?R?D<)17=_P#"
ML+[_ *"%M_WRU'_"L+[_ *"%M_WRU'M(]P_LK&?R?D<)17=_\*POO^@A;?\
M?+4?\*POO^@A;?\ ?+4>TCW#^RL9_)^1E>";+SM6:Z8?+ O'^\>/\:]&#52T
M#PE+HUFT33QO([;F90?PK7&F2#_EHOY5A.5V?39=A9T*"C):[L@#4\-4PTZ0
M?\M%I18./XUJ+G?RR(@U/#5(+%_[ZTX6;_WQ1<=F1@TX&G_9&_O"E^S-_>%
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MG_YXK_WW_P#6HWS_ //%?^^__K4 2T5%OG_YXK_WW_\ 6HWS_P#/%?\ OO\
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MYEQ_S[K_ -_/_K4>9<?\^Z_]_/\ ZU $]%0>9<?\^Z_]_/\ ZU'F7'_/NO\
MW\_^M0!/14'F7'_/NO\ W\_^M1YEQ_S[K_W\_P#K4 3T5!YEQ_S[K_W\_P#K
M4>9<?\^Z_P#?S_ZU $]%0>9<?\^Z_P#?S_ZU'F7'_/NO_?S_ .M0!/14'F7'
M_/NO_?S_ .M1YEQ_S[K_ -_/_K4 3T5!YEQ_S[K_ -_/_K4>9<?\^Z_]_/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** ([C_CVE_P!P_P JT$^XOTK.N3BUF/\ L-_*N:'BZ^ QY<7'M0!V]%<1
M_P )??\ _/.+\J/^$OO_ /GG%^5 ';T5Q'_"7W__ #SB_*C_ (2^_P#^><7Y
M4 =O17$?\)??_P#/.+\J/^$OO_\ GG%^5 ';T5Q'_"7W_P#SSB_*C_A+[_\
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MKAH_%=]%&J+'%A1@<4[_ (2^_P#^><7Y4 =O17$?\)??_P#/.+\J/^$OO_\
MGG%^5 ';T5Q'_"7W_P#SSB_*C_A+[_\ YYQ?E0!V]%<1_P )??\ _/.+\J1O
M%VH'HL0_X#0!W%%<+_PEFI?],O\ OBKEKXCO9XR28]P.#A: .NHKF/[<O?5/
M^^:/[<O/5/\ OF@#IZ*YG^W+WU3_ +YH_MR\]4_[YH Z:BN9_MR\]4_[YH_M
MR\]4_P"^: .FHKF?[;O/5/\ OFE_MN\]4_[YH Z6H+3_ (]E^K?S-8/]MWGJ
MG_?-,BUB[CC"J4QD_P /O0!U%%<U_;=YZI_WS2_VU>>J?]\T =)17-_VU>>J
M?]\T?VU>>J?]\T =)17.?VU=^J?]\T?VS=^J?]\T ='17._VS=^J?]\T?VS=
M^J?]\T =%17/?VS=^J?]\T?VQ=^J?]\T =#17/\ ]L77JG_?-']KW7JG_?-
M'045@?VO=>J?]\TO]K77JG_?- &]16#_ &M<^J?]\TO]JW/JO_?- &[16'_:
MMSZK_P!\T?VI<^J_]\T :MW_ *D?]=$_]#%3U@3:E</& 2OWE/3T(-2_VG<>
MJ_E0!M45B_VG<>J_E2_VE<>J_E0!LT5C_P!I7'JOY4O]HS^J_E0!KT5D_P!H
M3^J_E2_VA/ZK^5 &K167]OF]5_*C[?-ZK^5 7-2BLS[=-ZK^5+]MF]5_*BPK
MFE16=]LE]1^5+]LE]ORHL%S0HJA]KD]1^5+]JD]ORHL%R]15+[5)[?E3OM+^
MWY4[!<MT55^T/[?E2^>_M18+EFBJ_G-[4HE;VHL%PD_X^X/HW\A13"Y:[ASZ
M-_2BD,B'^ON/^NG]!3J:/]?<?]=/Z"N>\1W!^TQ6XD:,^6S@M*8US^ R3[4
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M(O5@AXK8CNH5N]+_ 'R!(W8O\W"_-WIJ31O<64ZW$<<<!/F M@_>R<#OD>E
M&.()3Y>(G/F<)\OWOIZTX6EPT;2""0HN<L%.!6Q!+!/+82B:*)(96+AV"E1N
MR.._X4U)8Y>)Y(#"I?;(DNV1!D\8[_D: ,RRM5NGE#2%%CC,A(7<<#VR*=)9
MQFT-S;S-(BN$<,FT@GIW.>E2Z7-'!)=,[)S;N%#]&/'%68KR![:!_P!W#Y,P
M:6%1@2#LP]<>E &7):SQ!3)#(N[[NY2,TYK.Y1U1K>4,_P!T%#D_2M:2Y6(2
M&.2U5I)E9&#E\X/WCR=OY9J6U\IKVV.Z-)S,3MBEWJ1C[W4XH Q19SB9(Y89
MD+] (R2?H.]-^R7'EK)Y$NQONML.#6Q92QVCQQSW$;,9R^0X(48(R3[TP7$)
MGTT&<*(X2"0V,-D\$]NU &?#IMU+=Q6[0O&TAP"ZD?C3/L5SN<"WE.PX;"'B
MMF*X@B6Q\Q[="ESN98WW!1ZD\U"I0M9[;F&/[/(3)^\'KG(]>/2@#+CL[J9-
M\5O*ZDXRJ$BHO+?87V-M!P3C@'TK4O+U#;P/;N%*W$D@4'E><CBDU=XE2)(>
M!+^_8>A/:@"H;&0VUO+'F1IBP"*N3Q43VT\;*KPR*S_=!4C/TK6L+F&--.W2
MHI1I2V6QMR.,T6=U EI;"25=XEDY)Y7*X!_.@"F=+EC@ADD656D=D\L1Y88&
M<XJL+6<Q&40R&,=7VG%;5M)';P6,<MU"S)+(S8D!V@CCFJMV1<K#+#<QQHD.
MQE,F"",Y&.IS0!G_ &2X\H2^1)Y9_BVG'YU/<Z;-:EA*LG$:OE4..<=3VZUJ
M>= !<'S8"C6^U',F7<X'!';]*:US;J\TIEC9'MX@%##)(VY&/7@T 8S6MPB*
M[P2*K="5.#1):7,*[I8)47.,LA'-:S31QW%[.]Q')'.P\L!\G[V>1VP/6EFN
MXVNM487"?.ZF-BV0<-U'K0!CRVT\"AI89$4]"RD9J*M;4'CEMY))&A$[29_<
MR[ED]21V_2LF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ JU82;)]IZ,,?C56IK1"]R@].30!L4444 %+244 +12
M4M @I:2B@!:%Z4E"]* '44E+0 M%)10 ZBDHH =2TVEH 7-+3:6@!V:7-,S2
MT .S2YIN:7-,!V:7--S2YH =FES3,TN: !_N_B/YU)FHG/R_B/YT_- #\TH-
M,S2YH >#2YIF:7- $F:4&F9I<T /S2@TP&E!H DS2@TP&E!H ?FG U'FES0!
M(#3@:C!I0:!$@-.!J,&E!H D!IP-1YI0:8$H-*#48-.!H <IS>0_1OZ44V,_
MZ9#]&HJ6- /]?<?]=/Z"AXHW(+HK%>A(SB@?Z^X_ZZ?T%.H&,$,2XVQH,# P
MHX%(8(2JJ8D*K]T%1@?2I** &>3$8_+\I-G]W:,?E1Y4>U5\M<*<J,=/I3Z*
M &F-"Q8HNXC!..2/2FF"(A08D(7[ORCCZ5)10!&;>%D"-#&5'12HP*5X8Y%"
MO&C*.@*@@4^B@ P,8QQZ5&+>%1\L,8X(X4=ZDHH 8(HU*D1J"HP"!T%(((58
M,L2 @YR%'6I** *]S9QW3P.Q97A?>C+U^GT-3*BH"%4*"<G Q3J* &A$#EPJ
MAB,%L<FFB"$-N$488'.0HSGUJ2B@!OEH)"X1=Y&"V.<4K(KC#J&'H1FEHH :
MR*^-RAL'(R,X-#11NZLR*67H2.13J* *ZVB+>O=Y)D90G/10/2K%%% !1110
M 4444 %%%% $5U_QZ3?[C?RKSSRW_N-^5>B7'_'M+_N'^574BCV+^[7IZ4 >
M7>6_]QORH\M_[C?E7J7E1_\ /-?RH\J/_GFOY4 >6^6_]QORH\M_[C?E7J7E
M1_W%_*D\F/\ YYK^5 'EVQ_[C?E1L?\ N-^5>H^3'_SS7\J3R8_^>:_E0!Y?
ML?\ NM^5&Q_[K?E7I_D1_P#/-?RI/L\?_/-?RH \QV/_ '3^5.C::&021[E<
M="!TKTLV\?\ SS7\J0VT?_/-?RH \S*N3G:?RI-C?W3^5>EFUC_YYK^5(;2/
M_GFOY4 >:[6_NG\J-K?W3^5>D&SC_N+^5--DG_/-?RH \Z7>K!@""#D<4Z1Y
M9G+R%F8]S7H)L4_N+^5--@G]Q?RH \]VGT-&#Z&O0#IZ?W%_*FG3D_YYK^5
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M "[_ -2/^NB?^ABIZI75I;K""(4'[Q!T_P!H5-]CMO\ GBGY4 3T5!]CMO\
MGBGY4?8[;_GBGY4 3T5!]CMO^>*?E1]CMO\ GBGY4 3T5!]CMO\ GBGY4?8[
M;_GBGY4 3T5!]CMO^>*?E1]CMO\ GBGY4 3T5!]CMO\ GBGY4?8[;_GBGY4
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M>O45Y#_PFOB'_H(?^08__B:/^$U\0_\ 00_\@Q__ !-'LV'UN'9GKU%>0_\
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M6B=L8S@]?RQ6E65H-O)#:32RH4>XG>7:PP0#T_05JTGN:0O;4****104444
M%%%% !1110 4444 %%%% $%Y_P >-Q_US;^5>+G[Q^M>T7G_ !XW'_7-OY5X
MN?O'ZUK2ZG%C.AJRZ?8VMM927$]QNN8_,^2,$+R1W/M4=SHMS#J5S:1@2>0?
MF?(5<'H23P.M:/\ ;L-M'I(6.WN$AAVRJ\*EE.X]&(R#WXIWVRRVW]L;F&Y\
MZ99DEN0^&'/!VX.>?I5W=_O_ #,.6+7W?E_F4;;0Y&M+V>YW1&V(4QY7<6/U
M(JO)HNH13&%[?:X&6!=?E'J>>/QK5N]4MIK2]C$R%CY"IM0J&"]<9S^M/FU"
MRFU?5I1/&WG;?),V[RFY&=P'7VS1=@XP_KYF'_9=[]J^S>0WF[=^,C&WUSTQ
M[U:&@W2V%W<R@1F#9\A9?F#=QS_^NM>YU2QF,MN+B(":Q6$2JA54<-G&,< X
MJA:2VEII][;&\CD=FAD7"MM;:22HX]Z+O^O4.2*_KR,Z32KZ*+S7MV"\9Y!*
MYZ9'49]Z=<:1?VJ2/-!M$8!?YE)7Z@'(ZBM@WUE%>ZC>BZ607:;4B .Y<L#E
MOIBFQ7<-WXMN%5C):WA,3$9Y4]_P(S^%%V')'N8)M)UEAC,9#S ,@]0>E7WT
M>-)9+<ZA +F,$LAR!D=1N/&:)]15/$0O$7='#( B_P"RO _05>MIM/M]0EN7
MN;6:TD)<Q26X>0YSQRO'X&FV[7$HQO8PA:7)MS<"WE,(X,@0[?SZ4HL[II/+
M%M,7P&V[#G!Z'%=(NJ61EM[L786&.R\@VF#G=@C'I@GFG7%_I\AN[M;Q,RV*
M0K%M;=N  (/&.U%W<:IQ[G.ZEIUQI=ZUK<KAU .<<'([54K5\17$-YK4UU;R
MK)'*%88SD?*!@Y^E95.-[:F<DE)V"BBBF2%%%% !6_ITWFV:Y/*_*:P*W-+B
M\NUW'JYS^%2RX;E^BDI<U)L+3I/]:_U-,I\G^M?_ 'C0/H)FBDHH$.S1244
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M[2_[A_E6@GW%^E $.^Y_YX1_]_3_ (4;[G_GA'_W]/\ A4]% $&^Y_YX1_\
M?T_X4;[G_GA'_P!_3_A4]% $&^Y_YX1_]_3_ (4;[G_GA'_W]/\ A4]% $&^
MY_YX1_\ ?T_X4;[G_GA'_P!_3_A4]% $&^Y_YX1_]_3_ (4;[G_GA'_W]/\
MA4]% $&^Y_YX1_\ ?T_X4;[G_GA'_P!_3_A4]% $&^Y_YX1_]_3_ (4;[G_G
MA'_W]/\ A4]% $&^Y_YX1_\ ?T_X4;[G_GA'_P!_3_A4]% $&^Y_YX1_]_?_
M +&C?<_\\(_^_O\ ]C4]% $&ZY_YX1_]_?\ [&DW7/\ SPC_ ._I_P *L44
M5]US_P \(_\ OZ?\*-US_P \(_\ OZ?\*L44 5]UQ_SPC_[^_P#UJALVG^PV
M^(8R/+7!,F.WTJ]4%C_R#[;_ *Y+_(4 )FX_YX1_]_?_ +&C-Q_SPC_[^_\
MUJL44 5\W'_/"/\ [^__ %J,W'_/"/\ [^__ %JL44 5\W'_ #PC_P"_O_UJ
M,W'_ #PC_P"_O_UJL44 5\W'_/"/_O[_ /6HS<?\\(_^_O\ ]:K%% %?-Q_S
MPC_[^_\ UJ,W'_/"/_O[_P#6JQ10!7S<?\\(_P#O[_\ 6HS<?\\(_P#O[_\
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M ._I_P *GHH @WW/_/"/_OZ?\*-]S_SPC_[^G_"IZ* (-]S_ ,\(_P#OZ?\
M"C?<_P#/"/\ [^G_  J>B@"#?<_\\(_^_I_PHWW/_/"/_OZ?\*GHH @WW/\
MSPC_ ._I_P *-]S_ ,\(_P#OZ?\ "IZ* (-]S_SPC_[^G_"C?<_\\(_^_I_P
MJ>B@"#?<_P#/"/\ [^G_  HWW/\ SPC_ ._I_P *GHH I73W'DC,,8'F)_RT
M_P!H>U3;[G_GA'_W]/\ A1=_ZD?]=$_]#%3T 0;[G_GA'_W]/^%&^Y_YX1_]
M_3_A4]% $&^Y_P">$?\ W]/^%&^Y_P">$?\ W]/^%3T4 0;[G_GA'_W]/^%&
M^Y_YX1_]_3_A4]% $&^Y_P">$?\ W]/^%&^Y_P">$?\ W]/^%3T4 0;[G_GA
M'_W]/^%&^Y_YX1_]_3_A4]% $&^Y_P">$?\ W]/^%&^Y_P">$?\ W]/^%3T4
M 0;[G_GA'_W]/^%&^Y_YX1_]_3_A4]% $&^Y_P">$?\ W]/^%&^Y_P">$?\
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M\2HK#&2&YX^E7]JO>SVR1O S7,@640AXVYZ-Z 5S#2R.P9Y'8CH2<XH$TH#
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M,BN?]4/^NB?^A"IQ4%S_ *H?]=$_]"%3B@ I124HH *6DI:!BT444@%HHHH
M*6DI: "BBB@!:***0!1110,*6DI: "BBB@""3_C[@^C?R%%$G_'W!]&_D**
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MO%_WP*** #[+;_\ /"+_ +X%'V6W_P">$7_? HHH 0VMO_SPB_[X%)]EM_\
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:XO\ O@444 /CMX$D#+#&K#H0H!%%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>plx-20210930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/15/2021 12:11:14 PM-->
<!--Modified on: 11/15/2021 12:11:14 PM-->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2021" targetNamespace="http://www.protalix.com/20210930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:plx="http://www.protalix.com/20210930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" id="DisclosureConvertibleNotesTables">
        <link:definition>30503 - Disclosure - CONVERTIBLE NOTES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" id="DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" id="DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesDetails" id="DisclosureConvertibleNotesDetails">
        <link:definition>40501 - Disclosure - CONVERTIBLE NOTES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails" id="DisclosureConvertibleNotesFairValueIncomeApproachDetails">
        <link:definition>40502 - Disclosure - CONVERTIBLE NOTES (Fair Value Income Approach) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40601 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40701 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureConvertibleNotes" id="DisclosureConvertibleNotes">
        <link:definition>10501 - Disclosure - CONVERTIBLE NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10601 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10701 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ChiesiExUSAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="PaymentOnNetSalesPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <xsd:element name="SevenPointFivePercentageConvertibleNotesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_EmployeeStockIncentivePlan2006Member" name="EmployeeStockIncentivePlan2006Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_MaintainOfMinimumCashBalance" name="MaintainOfMinimumCashBalance" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_DebtInstrumentConvertibleConversionShareNumber" name="DebtInstrumentConvertibleConversionShareNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_DebtInstrumentConvertibleBaseValueForConversionRate" name="DebtInstrumentConvertibleBaseValueForConversionRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" name="UpfrontNonrefundableNonCreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ReceivablesFromSaleOfCommonStockAndWarrants" name="ReceivablesFromSaleOfCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_AlfataligliceraseMember" name="AlfataligliceraseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_IncreaseDecreaseInRestrictedDeposit" name="IncreaseDecreaseInRestrictedDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_KirinHoldingsCompanyLimitedMember" name="KirinHoldingsCompanyLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PercentageOfPremiumToClosingPriceOfStock" name="PercentageOfPremiumToClosingPriceOfStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_ReductionToAccumulatedRevenueRecognized" name="ReductionToAccumulatedRevenueRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" id="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" id="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SupplyAndTechnologyTransferAgreementWithFiocruzMember" id="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromExpenseReimbursements" id="plx_ProceedsFromExpenseReimbursements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentMinimumUnrestrictedCashToBeMaintained" id="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtInstrumentDerecognitionOfLiabilityComponent" id="plx_DebtInstrumentDerecognitionOfLiabilityComponent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ReacquisitionOfEquityComponentOfConvertibleNotes" id="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquityComponentOfConvertibleNotesNetOfTransactionCosts" id="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromSaleOfProducts" id="plx_ProceedsFromSaleOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>plx-20210930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/15/2021 12:11:14 PM-->
<!--Modified on: 11/15/2021 12:11:14 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637725750732639087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637725750732639087" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637725750732639087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637725750732639087" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637725750732639087" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637725750732639087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637725750732639087" xlink:to="plx_ShortTermBankDeposits_637725750732639087" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637725750732649085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637725750732639087" xlink:to="us-gaap_AccountsReceivableNetCurrent_637725750732649085" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637725750732649085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637725750732639087" xlink:to="us-gaap_OtherAssetsCurrent_637725750732649085" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637725750732649085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637725750732639087" xlink:to="us-gaap_InventoryNet_637725750732649085" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637725750732649085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637725750732649085" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637725750732649085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637725750732649085" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637725750732649085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637725750732649085" order="4" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637725750732649085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637725750732649085" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637725750732649085" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637725750732649085" xlink:to="us-gaap_LiabilitiesNoncurrent_637725750732649085" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637725750732649085" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637725750732659096" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637725750732649085" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637725750732659096" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637725750732649085" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637725750732659096" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637725750732649085" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637725750732659096" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637725750732649085" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637725750732659096" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637725750732649085" xlink:to="us-gaap_LiabilitiesCurrent_637725750732659096" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637725750732659096" xlink:to="us-gaap_AccountsPayableTradeCurrent_637725750732659096" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637725750732659096" xlink:to="us-gaap_AccountsPayableOtherCurrent_637725750732659096" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637725750732659096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637725750732659096" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637725750732659096" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637725750732669089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637725750732659096" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637725750732669089" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637725750732669089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637725750732659096" xlink:to="us-gaap_ConvertibleDebtCurrent_637725750732669089" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637725750732669089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637725750732659096" xlink:to="us-gaap_NotesPayableCurrent_637725750732669089" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637725750732669089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637725750732669089" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637725750732669089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637725750732669089" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637725750732669089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637725750732669089" xlink:to="us-gaap_CostOfRevenue_637725750732669089" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637725750732669089" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637725750732679089" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637725750732669089" xlink:to="us-gaap_Revenues_637725750732679089" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637725750732669089" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637725750732679089" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637725750732679089" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637725750732679089" xlink:to="us-gaap_OtherNonoperatingExpense_637725750732679089" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637725750732679089" xlink:to="us-gaap_OtherNonoperatingIncome_637725750732679089" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherIncome_637725750732679089" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637725750732679089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_NetIncomeLoss_637725750732679089" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_ShareBasedCompensation_637725750732689088" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_Depreciation_637725750732689088" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637725750732689088" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637725750732689088" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637725750732689088" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637725750732689088" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637725750732689088" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637725750732689088" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637725750732689088" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637725750732689088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637725750732689088" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637725750732699096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637725750732699096" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637725750732699096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_IncreaseDecreaseInInventories_637725750732699096" order="13" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637725750732699096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637725750732699096" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637725750732699096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750732679089" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637725750732699096" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750732699096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750732699096" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637725750732699096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750732699096" xlink:to="plx_IncreaseDecreaseInBankDeposits_637725750732699096" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637725750732699096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750732699096" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637725750732699096" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637725750732699096" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750732699096" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637725750732699096" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637725750732709095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750732699096" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637725750732709095" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637725750732709095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750732699096" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637725750732709095" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637725750732709095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750732699096" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637725750732709095" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750732709095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750732709095" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637725750732709095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750732709095" xlink:to="us-gaap_RepaymentsOfNotesPayable_637725750732709095" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637725750732709095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750732709095" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637725750732709095" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637725750732709095" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750732709095" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637725750732709095" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637725750732719089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750732709095" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637725750732719089" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637725750732719089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750732709095" xlink:to="us-gaap_ProceedsFromWarrantExercises_637725750732719089" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637725750732719089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637725750732719089" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637725750732719089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637725750732719089" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637725750732719089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637725750732719089" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637725750732719089" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637725750732719089" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>plx-20210930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/15/2021 12:11:14 PM-->
<!--Modified on: 11/15/2021 12:11:14 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureConvertibleNotesTables" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureConvertibleNotesDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureConvertibleNotesFairValueIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20210930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesTables" xlink:type="extended" xlink:title="30503 - Disclosure - CONVERTIBLE NOTES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_KirinHoldingsCompanyLimitedMember" xlink:label="plx_KirinHoldingsCompanyLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_KirinHoldingsCompanyLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReductionToAccumulatedRevenueRecognized" xlink:label="plx_ReductionToAccumulatedRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReductionToAccumulatedRevenueRecognized" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - CONVERTIBLE NOTES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentDerecognitionOfLiabilityComponent" xlink:label="plx_DebtInstrumentDerecognitionOfLiabilityComponent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentDerecognitionOfLiabilityComponent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_MaintainOfMinimumCashBalance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained" xlink:label="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails" xlink:type="extended" xlink:title="40502 - Disclosure - CONVERTIBLE NOTES (Fair Value Income Approach) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="plx_EmployeeStockIncentivePlan2006Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="plx_AlfataligliceraseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromExpenseReimbursements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_ProceedsFromSaleOfProducts" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>plx-20210930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/15/2021 12:11:14 PM-->
<!--Modified on: 11/15/2021 12:11:14 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Promissory note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity (net of capital deficiency)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES - NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">OTHER INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Amount of receivables from sale of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Receivables From Sale of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Note receivable payment</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition Of Equity Component Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition Of Equity Component Of Convertible Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition of equity component of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_lbl" xml:lang="en-US">Reacquisition of equity component of convertible notes</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity Component Of Convertible Notes Net Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity Component Of Convertible Notes Net Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_lbl" xml:lang="en-US">Equity component of convertible notes, net of transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Purchase of bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInRestrictedDeposit" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase (Decrease) In Restricted Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Decrease (increase) in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment for convertible notes redemption and transactions costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Net payment for convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Net payment for promissory note</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET DECREASE IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">The transaction costs in connection with exchange of convertible notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">Debt Conversion, Transaction Costs in Connection with Exchange of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_lbl" xml:lang="en-US">Transactions costs in connection with the exchange of convertible notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">CONVERTIBLE NOTES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of liability component based on income approach</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's disaggregation of revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non-Creditable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Amount of accrued and unpaid interest exchanged in cash in debt conversion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Exchange in Cash, Accrued and Unpaid Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_lbl" xml:lang="en-US">Convertible notes exchange in cash, accrued and unpaid interest</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Number of shares for basis conversion</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Base value for conversion rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price per share</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfPremiumToClosingPriceOfStock" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of premium to closing price of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of Premium to Closing Price of Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaintainOfMinimumCashBalance" xlink:to="plx_MaintainOfMinimumCashBalance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required to be maintained under long term debt agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Maintain of Minimum Cash Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MaintainOfMinimumCashBalance_lbl" xml:lang="en-US">Minimum cash balance required</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Share Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Volatility</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term Debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_KirinHoldingsCompanyLimitedMember" xlink:label="plx_KirinHoldingsCompanyLimitedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_KirinHoldingsCompanyLimitedMember" xlink:to="plx_KirinHoldingsCompanyLimitedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_KirinHoldingsCompanyLimitedMember_lbl" xml:lang="en-US">Kirin Holdings Company, Limited [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_KirinHoldingsCompanyLimitedMember_lbl" xml:lang="en-US">Kirin Holdings Company, Limited [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" xml:lang="en-US">Change in Accounting Method Accounted for as Change in Estimate [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReductionToAccumulatedRevenueRecognized" xlink:label="plx_ReductionToAccumulatedRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReductionToAccumulatedRevenueRecognized" xlink:to="plx_ReductionToAccumulatedRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReductionToAccumulatedRevenueRecognized_lbl" xml:lang="en-US">Amount of reduction to accumulated revenues recognized in respect of performance obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReductionToAccumulatedRevenueRecognized_lbl" xml:lang="en-US">Reduction To Accumulated Revenue Recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Mature term</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentDerecognitionOfLiabilityComponent" xlink:label="plx_DebtInstrumentDerecognitionOfLiabilityComponent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentDerecognitionOfLiabilityComponent" xlink:to="plx_DebtInstrumentDerecognitionOfLiabilityComponent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentDerecognitionOfLiabilityComponent_lbl" xml:lang="en-US">Amount of derecognition of liability component.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentDerecognitionOfLiabilityComponent_lbl" xml:lang="en-US">Debt Instrument, Derecognition Of Liability Component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentDerecognitionOfLiabilityComponent_lbl" xml:lang="en-US">Derecognition of liability component</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained" xlink:label="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained" xlink:to="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained_lbl" xml:lang="en-US">Amount of minimum unrestricted cash balance to be maintained under the exchange agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained_lbl" xml:lang="en-US">Debt Instrument, Minimum Unrestricted Cash To Be Maintained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained_lbl" xml:lang="en-US">Minimum unrestricted cash balance to be maintained</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_EmployeeStockIncentivePlan2006Member" xlink:to="plx_EmployeeStockIncentivePlan2006Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">It represent the employee stock incentive plan for the particular period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_EmployeeStockIncentivePlan2006Member_lbl" xml:lang="en-US">2006 Employee Stock Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">New employee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting Period</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_lbl" xml:lang="en-US">Number of equal quarterly increments</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share based compensation arrangement by share based payment award grant date fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend Yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected Volatility Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Interest Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to supply and technology transfer agreement with Fiocruz.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil Agreement with Fiocruz</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AlfataligliceraseMember" xlink:to="plx_AlfataligliceraseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">This member stands for the product, alfataliglicerase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AlfataligliceraseMember_lbl" xml:lang="en-US">Alfataliglicerase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromExpenseReimbursements" xlink:to="plx_ProceedsFromExpenseReimbursements_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">The cash inflow from expense reimbursements in a collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from Expense Reimbursements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromExpenseReimbursements_lbl" xml:lang="en-US">Proceeds from expense reimbursements</label>
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfProducts" xlink:to="plx_ProceedsFromSaleOfProducts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">The amount of proceeds from sale of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds From Sale Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfProducts_lbl" xml:lang="en-US">Proceeds from sales</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>plx-20210930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7908.23199 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/15/2021 12:11:14 PM-->
<!--Modified on: 11/15/2021 12:11:14 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureConvertibleNotes" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotes" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureConvertibleNotesTables" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureConvertibleNotesDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureConvertibleNotesFairValueIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637725750733079105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637725750733079105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637725750733079105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637725750733079105" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637725750733079105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637725750733079105" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637725750733079105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637725750733079105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637725750733079105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637725750733079105" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637725750733079105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637725750733079105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637725750733079105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637725750733079105" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637725750733079105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637725750733079105" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637725750733089104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637725750733089104" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637725750733089104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637725750733089104" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637725750733089104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637725750733089104" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637725750733199100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637725750733199100" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637725750733199100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637725750733199100" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637725750733199100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637725750733199100" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637725750733199100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637725750733199100" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637725750733199100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637725750733199100" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637725750733199100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637725750733199100" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637725750733209127" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637725750733209127" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637725750733209127" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637725750733209127" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637725750733209127" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637725750733209127" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637725750733209127" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637725750733209127" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637725750733209127" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637725750733209127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637725750733209127" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637725750733219131" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637725750733219131" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637725750733219131" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637725750733219131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637725750733219131" xlink:to="us-gaap_AssetsCurrentAbstract_637725750733219131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637725750733219131" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637725750733219131" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637725750733219131" xlink:to="plx_ShortTermBankDeposits_637725750733219131" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637725750733219131" xlink:to="us-gaap_AccountsReceivableNetCurrent_637725750733219131" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637725750733219131" xlink:to="us-gaap_OtherAssetsCurrent_637725750733219131" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637725750733219131" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637725750733219131" xlink:to="us-gaap_InventoryNet_637725750733219131" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637725750733219131" xlink:to="us-gaap_AssetsCurrent_637725750733229159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637725750733219131" xlink:to="us-gaap_AssetsNoncurrentAbstract_637725750733229159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637725750733229159" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637725750733229159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637725750733229159" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637725750733229159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637725750733229159" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637725750733229159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637725750733219131" xlink:to="us-gaap_Assets_637725750733229159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637725750733229159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637725750733229159" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637725750733229159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637725750733229159" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637725750733229159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637725750733229159" xlink:to="us-gaap_AccountsPayableTradeCurrent_637725750733229159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637725750733229159" xlink:to="us-gaap_AccountsPayableOtherCurrent_637725750733229159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637725750733229159" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637725750733229159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637725750733229159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637725750733229159" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637725750733229159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637725750733229159" xlink:to="us-gaap_ConvertibleDebtCurrent_637725750733239142" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637725750733229159" xlink:to="us-gaap_NotesPayableCurrent_637725750733239142" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637725750733229159" xlink:to="us-gaap_LiabilitiesCurrent_637725750733239142" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637725750733229159" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637725750733239142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637725750733239142" xlink:to="us-gaap_ConvertibleDebtNoncurrent_637725750733239142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637725750733239142" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637725750733239142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637725750733239142" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637725750733239142" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637725750733239142" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637725750733239142" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637725750733239142" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637725750733239142" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637725750733239142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637725750733229159" xlink:to="us-gaap_LiabilitiesNoncurrent_637725750733239142" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637725750733229159" xlink:to="us-gaap_Liabilities_637725750733249113" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637725750733229159" xlink:to="us-gaap_StockholdersEquity_637725750733249113" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637725750733229159" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637725750733249113" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637725750733249113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733249113" xlink:to="srt_ProductOrServiceAxis_637725750733249113" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637725750733249113" xlink:to="srt_ProductsAndServicesDomain_637725750733249113" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637725750733249113" xlink:to="us-gaap_ProductMember_637725750733249113" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637725750733249113" xlink:to="us-gaap_LicenseAndServiceMember_637725750733249113" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733249113" xlink:to="us-gaap_StatementLineItems_637725750733249113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_Revenues_637725750733249113" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637725750733249113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_CostOfRevenue_637725750733249113" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637725750733259108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637725750733259108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_OperatingIncomeLoss_637725750733259108" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_OtherNonoperatingExpense_637725750733259108" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_OtherNonoperatingIncome_637725750733259108" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_NonoperatingIncomeExpense_637725750733259108" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_OtherIncome_637725750733259108" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_NetIncomeLoss_637725750733259108" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_EarningsPerShareBasic_637725750733259108" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_EarningsPerShareDiluted_637725750733259108" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637725750733259108" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637725750733259108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733249113" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637725750733259108" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637725750733269114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733269114" xlink:to="us-gaap_IncomeStatementLocationAxis_637725750733269114" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637725750733269114" xlink:to="us-gaap_IncomeStatementLocationDomain_637725750733269114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637725750733269114" xlink:to="us-gaap_CostOfSalesMember_637725750733269114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637725750733269114" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637725750733269114" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637725750733269114" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637725750733269114" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733269114" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637725750733269114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637725750733269114" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637725750733269114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637725750733269114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733269114" xlink:to="us-gaap_StatementEquityComponentsAxis_637725750733269114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637725750733269114" xlink:to="us-gaap_CommonStockMember_637725750733269114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637725750733269114" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637725750733269114" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637725750733269114" xlink:to="us-gaap_RetainedEarningsMember_637725750733269114" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637725750733269114" xlink:to="us-gaap_EquityComponentDomain_637725750733269114" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733269114" xlink:to="us-gaap_StatementLineItems_637725750733269114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="us-gaap_StockholdersEquity_637725750733269114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="us-gaap_SharesOutstanding_637725750733269114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637725750733269114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637725750733269114" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637725750733269114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637725750733269114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637725750733269114" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637725750733269114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637725750733269114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637725750733269114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement_637725750733269114" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637725750733269114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637725750733286406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637725750733286406" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637725750733286406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637725750733286406" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637725750733286406" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637725750733286406" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_637725750733286406" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_637725750733289110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_637725750733289110" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_637725750733289110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_637725750733289110" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_637725750733289110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_ReceivablesFromSaleOfCommonStockAndWarrants_637725750733289110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="plx_ReceivablesFromSaleOfCommonStockAndWarrants_637725750733289110" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_637725750733289110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_637725750733289110" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_637725750733289110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_637725750733289110" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637725750733289110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="us-gaap_NetIncomeLoss_637725750733289110" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637725750733289110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="us-gaap_StockholdersEquity_637725750733289110" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637725750733289110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733269114" xlink:to="us-gaap_SharesOutstanding_637725750733289110" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637725750733299101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_637725750733299101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_NetIncomeLoss_637725750733299101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_ShareBasedCompensation_637725750733299101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_Depreciation_637725750733299101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637725750733299101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637725750733299101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637725750733299101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637725750733299101" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637725750733299101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637725750733299101" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637725750733299101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637725750733299101" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637725750733299101" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637725750733309099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637725750733299101" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637725750733309099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637725750733299101" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637725750733309099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637725750733299101" xlink:to="us-gaap_IncreaseDecreaseInInventories_637725750733309099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637725750733299101" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637725750733309099" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637725750733299101" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637725750733309099" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637725750733299101" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637725750733309099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" xlink:to="plx_IncreaseDecreaseInBankDeposits_637725750733309099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637725750733309099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637725750733309099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637725750733309099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637725750733309099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637725750733319099" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637725750733319099" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637725750733309099" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637725750733319099" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637725750733319099" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637725750733319099" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637725750733319099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637725750733319099" xlink:to="us-gaap_RepaymentsOfNotesPayable_637725750733319099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637725750733319099" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637725750733319099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637725750733319099" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637725750733319099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637725750733319099" xlink:to="us-gaap_ProceedsFromWarrantExercises_637725750733319099" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637725750733319099" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637725750733319099" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637725750733319099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637725750733319099" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637725750733319099" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6377257507333190991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6377257507333190991" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637725750733319099" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637725750733319099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637725750733319099" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637725750733319099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637725750733337183" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637725750733319099" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637725750733337183" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_637725750733339132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637725750733319099" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_637725750733339132" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637725750733339132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637725750733339132" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637725750733339132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637725750733339132" xlink:to="us-gaap_InterestPaidNet_637725750733339132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_637725750733339132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637725750733339132" xlink:to="plx_InterestReceivedNet_637725750733339132" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637725750733339132" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637725750733339132" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637725750733349102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637725750733349102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637725750733349102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637725750733349102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637725750733349102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637725750733349102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotes" xlink:type="extended" xlink:title="10501 - Disclosure - CONVERTIBLE NOTES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422967633303" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637725750733349102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422967633303" xlink:to="us-gaap_DebtDisclosureTextBlock_637725750733349102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10601 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637725750733349102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637725750733349102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10701 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637725750733349102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_637725750733349102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637725750733359118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637725750733359118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637725750733359118" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637725750733359118" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637725750733359118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637725750733359118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733359118" xlink:to="us-gaap_DebtInstrumentAxis_637725750733359118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637725750733359118" xlink:to="us-gaap_DebtInstrumentNameDomain_637725750733359118" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733359118" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637725750733359118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733359118" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733359118" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733359118" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733359118" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733359118" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733359118" xlink:to="us-gaap_FairValueInputsLevel3Member_637725750733369129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733359118" xlink:to="us-gaap_StatementLineItems_637725750733369129" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733369129" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637725750733369129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_637725750733369129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesTables" xlink:type="extended" xlink:title="30503 - Disclosure - CONVERTIBLE NOTES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422967819664" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422967819664" xlink:to="us-gaap_StatementTable_637725750733369129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733369129" xlink:to="us-gaap_DebtInstrumentAxis_637725750733369129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637725750733369129" xlink:to="us-gaap_DebtInstrumentNameDomain_637725750733369129" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733369129" xlink:to="plx_ConvertibleNotesDue2021And2024Member_637725750733369129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733369129" xlink:to="us-gaap_StatementLineItems_637725750733369129" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637725750733369129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733369129" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637725750733369129" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_637725750733379105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637725750733379105" xlink:to="us-gaap_TypeOfArrangementAxis_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637725750733379105" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733379105" xlink:to="plx_AmendedPfizerAgreementMember_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733379105" xlink:to="plx_ChiesiAgreementsMember_637725750733379105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_637725750733379105" xlink:to="plx_ChiesiUSAgreementMember_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_637725750733379105" xlink:to="plx_ChiesiExUSAgreementMember_637725750733379105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733379105" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637725750733379105" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637725750733379105" xlink:to="dei_LegalEntityAxis_637725750733379105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637725750733379105" xlink:to="dei_EntityDomain_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637725750733379105" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637725750733379105" xlink:to="srt_StatementGeographicalAxis_637725750733379105" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637725750733379105" xlink:to="srt_SegmentGeographicalDomain_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637725750733379105" xlink:to="country_BR_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637725750733379105" xlink:to="srt_RangeAxis_637725750733379105" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637725750733379105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637725750733379105" xlink:to="srt_RangeMember_637725750733379105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637725750733379105" xlink:to="srt_MinimumMember_637725750733389530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637725750733379105" xlink:to="srt_MaximumMember_637725750733389530" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637725750733379105" xlink:to="us-gaap_DebtInstrumentAxis_637725750733389530" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637725750733389530" xlink:to="us-gaap_DebtInstrumentNameDomain_637725750733389530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733389530" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733389530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733389530" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733389530" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637725750733379105" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637725750733389530" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637725750733389530" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637725750733389530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637725750733389530" xlink:to="plx_AtMarketEquityOfferingMember_637725750733389530" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637725750733389530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637725750733379105" xlink:to="plx_SignificantAccountingPoliciesLineItems_637725750733389530" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637725750733399101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637725750733399101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637725750733399101" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637725750733399101" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_SharesIssuedPricePerShare_637725750733399101" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637725750733399101" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637725750733399101" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637725750733399101" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_637725750733399101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_AgreementAmendmentPaymentReceivable_637725750733399101" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637725750733409096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637725750733409096" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637725750733409096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637725750733409096" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637725750733409096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_PaymentOnNetSalesPercentage_637725750733409096" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637725750733409096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637725750733409096" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637725750733409096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637725750733409096" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637725750733409096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637725750733409096" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_637725750733409096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_637725750733409096" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_637725750733419121" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_637725750733419121" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_637725750733419121" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_637725750733419121" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_ConvertibleDebtCurrent_637725750733419121" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637725750733419121" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_RevenuePerformanceObligationNumber_637725750733419121" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="us-gaap_DebtInstrumentFaceAmount_637725750733419121" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_637725750733419121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637725750733389530" xlink:to="plx_MaintainOfMinimumCashBalance_637725750733419121" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637725750733434597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637725750733434597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637725750733434597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637725750733434597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637725750733434597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637725750733434597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637725750733434597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637725750733434597" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733439105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733439105" xlink:to="us-gaap_DebtInstrumentAxis_637725750733439105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637725750733439105" xlink:to="us-gaap_DebtInstrumentNameDomain_637725750733439105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733439105" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733439105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733439105" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733439105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733439105" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733439105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733439105" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733439105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733439105" xlink:to="us-gaap_FairValueInputsLevel3Member_637725750733439105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733439105" xlink:to="us-gaap_MeasurementInputTypeAxis_637725750733439105" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637725750733439105" xlink:to="us-gaap_MeasurementInputTypeDomain_637725750733439105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733439105" xlink:to="us-gaap_MeasurementInputSharePriceMember_637725750733439105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733439105" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637725750733439105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733439105" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637725750733439105" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733439105" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637725750733439105" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637725750733439105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733439105" xlink:to="plx_MeasurementInputYieldMember_637725750733439105" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733439105" xlink:to="us-gaap_StatementLineItems_637725750733449095" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733449095" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637725750733449095" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733449095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733449095" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733449095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733449095" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733449095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733449095" xlink:to="us-gaap_FairValueInputsLevel3Member_637725750733449095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733449095" xlink:to="us-gaap_DebtInstrumentAxis_637725750733449095" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637725750733449095" xlink:to="us-gaap_DebtInstrumentNameDomain_637725750733449095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733449095" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733449095" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733449095" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733449095" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637725750733449095" xlink:to="us-gaap_StatementLineItems_637725750733449095" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733449095" xlink:to="us-gaap_DebtInstrumentCarryingAmount_637725750733449095" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_637725750733449095" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733449095" xlink:to="us-gaap_ShortTermBorrowings_637725750733449095" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733449095" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637725750733459097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637725750733459097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733459097" xlink:to="srt_ProductOrServiceAxis_637725750733459097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637725750733459097" xlink:to="srt_ProductsAndServicesDomain_637725750733459097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637725750733459097" xlink:to="us-gaap_ProductMember_637725750733459097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637725750733459097" xlink:to="us-gaap_LicenseAndServiceMember_637725750733459097" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733459097" xlink:to="us-gaap_TypeOfArrangementAxis_637725750733459097" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637725750733459097" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733459097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733459097" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637725750733459097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733459097" xlink:to="plx_ChiesiExUSAgreementMember_637725750733459097" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_KirinHoldingsCompanyLimitedMember" xlink:label="plx_KirinHoldingsCompanyLimitedMember_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733459097" xlink:to="plx_KirinHoldingsCompanyLimitedMember_637725750733459097" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733459097" xlink:to="srt_StatementGeographicalAxis_637725750733459097" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637725750733459097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637725750733459097" xlink:to="srt_SegmentGeographicalDomain_637725750733459097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637725750733459097" xlink:to="plx_PfizerMember_637725750733469123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BR" xlink:label="country_BR_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637725750733459097" xlink:to="country_BR_637725750733469123" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637725750733459097" xlink:to="plx_ChiesiMember_637725750733469123" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733459097" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis_637725750733469123" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_637725750733469123" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_637725750733469123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain_637725750733469123" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_637725750733469123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733459097" xlink:to="us-gaap_StatementLineItems_637725750733469123" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733469123" xlink:to="us-gaap_Revenues_637725750733469123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReductionToAccumulatedRevenueRecognized" xlink:label="plx_ReductionToAccumulatedRevenueRecognized_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733469123" xlink:to="plx_ReductionToAccumulatedRevenueRecognized_637725750733469123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - CONVERTIBLE NOTES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422968636206" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637725750733469123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422968636206" xlink:to="us-gaap_StatementTable_637725750733469123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733469123" xlink:to="us-gaap_DebtInstrumentAxis_637725750733479107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637725750733479107" xlink:to="us-gaap_DebtInstrumentNameDomain_637725750733479107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733479107" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733479107" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733479107" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733479107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733469123" xlink:to="us-gaap_StatementLineItems_637725750733479107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="us-gaap_DebtInstrumentFaceAmount_637725750733479107" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_637725750733479107" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest" xlink:label="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest_637725750733479107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_637725750733479107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_637725750733479107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_637725750733479107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_637725750733479107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637725750733479107" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="us-gaap_DebtInstrumentTerm_637725750733479107" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_637725750733479107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_637725750733479107" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentDerecognitionOfLiabilityComponent" xlink:label="plx_DebtInstrumentDerecognitionOfLiabilityComponent_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_DebtInstrumentDerecognitionOfLiabilityComponent_637725750733489239" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ReacquisitionOfEquityComponentOfConvertibleNotes" xlink:label="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_ReacquisitionOfEquityComponentOfConvertibleNotes_637725750733489239" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts" xlink:label="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts_637725750733489239" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt" xlink:label="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt_637725750733489239" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MaintainOfMinimumCashBalance" xlink:label="plx_MaintainOfMinimumCashBalance_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_MaintainOfMinimumCashBalance_637725750733489239" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained" xlink:label="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733479107" xlink:to="plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained_637725750733489239" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails" xlink:type="extended" xlink:title="40502 - Disclosure - CONVERTIBLE NOTES (Fair Value Income Approach) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_637041422968636206" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_637041422968636206" xlink:to="us-gaap_StatementTable_637725750733489239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733489239" xlink:to="us-gaap_DebtInstrumentAxis_637725750733489239" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637725750733489239" xlink:to="us-gaap_DebtInstrumentNameDomain_637725750733489239" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733489239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733489239" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637725750733489239" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637725750733489239" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637725750733499110" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733489239" xlink:to="us-gaap_MeasurementInputTypeAxis_637725750733499110" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637725750733499110" xlink:to="us-gaap_MeasurementInputTypeDomain_637725750733499110" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733499110" xlink:to="us-gaap_MeasurementInputSharePriceMember_637725750733499110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733499110" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637725750733499110" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733499110" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637725750733499110" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733499110" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637725750733499110" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637725750733499110" xlink:to="plx_MeasurementInputYieldMember_637725750733499110" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733489239" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733499110" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637725750733499110" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733499110" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637725750733499110" xlink:to="us-gaap_FairValueInputsLevel3Member_637725750733499110" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637725750733489239" xlink:to="us-gaap_StatementLineItems_637725750733499110" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637725750733499110" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637725750733499110" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637725750733499110" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637725750733509097" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637725750733509097" xlink:to="us-gaap_PlanNameAxis_637725750733509097" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637725750733509097" xlink:to="us-gaap_PlanNameDomain_637725750733509097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_EmployeeStockIncentivePlan2006Member" xlink:label="plx_EmployeeStockIncentivePlan2006Member_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637725750733509097" xlink:to="plx_EmployeeStockIncentivePlan2006Member_637725750733509097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637725750733509097" xlink:to="us-gaap_GranteeStatusAxis_637725750733509097" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637725750733509097" xlink:to="us-gaap_GranteeStatusDomain_637725750733509097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637725750733509097" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637725750733509097" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637725750733509097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637725750733509097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637725750733509097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637725750733509097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637725750733509097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements_637725750733509097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637725750733509097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue_637725750733509097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637725750733519214" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637725750733519214" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637725750733519214" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637725750733519214" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637725750733509097" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637725750733519214" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637725750733519214" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637725750733519214" xlink:to="us-gaap_SubsequentEventTypeAxis_637725750733519214" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637725750733519214" xlink:to="us-gaap_SubsequentEventTypeDomain_637725750733519214" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637725750733519214" xlink:to="us-gaap_SubsequentEventMember_637725750733519214" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637725750733519214" xlink:to="us-gaap_TypeOfArrangementAxis_637725750733519214" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637725750733519214" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733519214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637725750733519214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733519214" xlink:to="plx_ChiesiAgreementsMember_637725750733519214" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637725750733529148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733519214" xlink:to="plx_AmendedPfizerAgreementMember_637725750733529148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_637725750733529148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637725750733519214" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_637725750733529148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637725750733529148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637725750733519214" xlink:to="srt_ProductOrServiceAxis_637725750733529148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637725750733529148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637725750733529148" xlink:to="srt_ProductsAndServicesDomain_637725750733529148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_AlfataligliceraseMember" xlink:label="plx_AlfataligliceraseMember_637725750733529148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637725750733529148" xlink:to="plx_AlfataligliceraseMember_637725750733529148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637725750733529148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637725750733519214" xlink:to="us-gaap_SubsequentEventLineItems_637725750733529148" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromExpenseReimbursements" xlink:label="plx_ProceedsFromExpenseReimbursements_637725750733529148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637725750733529148" xlink:to="plx_ProceedsFromExpenseReimbursements_637725750733529148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210930.xsd#plx_ProceedsFromSaleOfProducts" xlink:label="plx_ProceedsFromSaleOfProducts_637725750733529148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637725750733529148" xlink:to="plx_ProceedsFromSaleOfProducts_637725750733529148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>plx-20210930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20210930.xsd" xlink:type="simple"/>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cfPZTTulqkernD2EnEhf1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K112MyLGIEyF188YEMII6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SzExwvidwEKr4i4UBC0FeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ObypWAjZfkumwrue2SoofQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_6e4TEe_8H0S9ZKRRnpwe0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ajr0YlG7z0mN2jc2ptdz3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QDIZWika_k258jbF39gQfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XqPOXgGBqUa1Fz3o4j1BTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_67iC4kJN5EWDKR82GNj9iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q-w46iXNMEC75S22Wy4_XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vALHgTVTI0qpDI5OS2no8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_nF71pgQNK0Sm4dLM4r805Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SshBsuzbEE-H-tzxnt_IRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DzXzpFAVKUa090qZyz2PWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_osEJghx1vkyNcPXIkVFTwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FhAO6ZCXfUeU1PtZmtoW6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TNv1Z6zXV0WmttZRhAIl4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gAacYeLtwE-Mj1yvi-z7VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2021_P7ERVIdUQUOUY7klvL64CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_-Ye7tysNN0uIamEerOPohA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_C4rvOPWVQUO7NyuzPVG_vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_CvN_3Qdilkmih_xyi8l8VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_toBWVVxhOE2Xyr7X8eD-wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yeoKiF-YDUOrT3vhZw5yGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_iAnH6udRs0WIM3yRgdqIUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_OyqOeTcPvEeZzice06IGyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:KirinHoldingsCompanyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_mydcMxM_oU2kJNHEONj5Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_QCMjIXNGnE6keq97DV1Ceg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_JjbHSiTd-EinvS16jCvSmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iAbMMUv_L06GXvemRzxxLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_fCAhfegnYkmYa8xJ3eOd-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Xo2XYmDaCUSxewIa-WYycw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_xXLYsWN7vUSK8B4I4_cOqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_lb46u3iL-Eq_NMiIYmE5Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_pjmKKZep_k-eRCW8jmhsEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember__RK7HZ3EbEuarJ7s2oVtsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z2g_D1kyFE6aa-f9W-PAug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_d2w1x6Wq0UWIzS1bPmcmPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_lWJ_c72CZk-SxD9FOrYgfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_YONib1KiMUiXNGrGvXI9NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_osPvD8x1U0Wr7PmiN4rWyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_DsIEE72dY0ijxi72whl2Xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_XpT7MCVwU0eKoVnFArW5NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2021_To_2_17_2021_1i-AeCXmUEuYJ6FKsF7Dqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3H5BKgTVfEanIQa3JfzDpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ahmxUbUVBkm9EcsPC2dvdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MGJAPFogqkW3PHmVyWwQXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VQUwy6ZsqUWKoDwiSQgUCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_c9iBJVgvmE6XPL7XnYJeDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_I0Grm-B4g0GE3UCgk-DBhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:ConvertibleNotesDue2021And2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_wgnkkX_RZkCtKFWS55dCIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_VDBEZhK3uke05lvqCgGCcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ey6qGfWfJki49fNChKl-sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2HD1crqgP0We3_b66UftRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_wKRANVGWK0CGjF_78kn1Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_fjePpaWSpkeew6EE71xYVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_VfiXjGij6E2FnqQWtpJIoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_fyankMlPgUSx83FT7iCVmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_zGLIgBqMs0SokSMlmYxJWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_U-JzHzcc2UOd4vdE3TN_9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U9xEZDL-PEmh5wLjZtn6JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_hrtLH0ARGkuJLrKOpEM2VQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_86dWT-PfXUCCzWKVSULmMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_VD26SZ1y0ESvFdYomEg95Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_N3NNBZmbcUSZicNMNONsbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_1972KmuibUyJZ-gIneryuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_uKHcMPfNtE6lZclLW6H1BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_wPu82-n0Ck6cnwIfWVVgng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WxYGSDFoFk2A-2JGt6XSSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_E62ftnuUYUSTpfSddSfQnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Ggzgc2uf3EKFGBDEr8E4Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u4SuBfYydEm3isvsquTltA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9_wMuN2NN0i7qwtMQCbLVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Z6NWekiCLE6G-qLdOHDf5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_PIoT_NoejU-L2QS4flELFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_rmjAbtU_mE681EqPesN7RA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ET9P1_n8jEmWQhl6pxUUhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Krs4XcDTxE-mc88POrcQMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_R6xvGSBAO0OzR-4qkTKWaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_nRNi-j4GhEuD86VBNDouHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JKiMKIkB9UmEZUv66KEFDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_VID5cVVn_U-ANCDy0jyJ5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_nPLZoO1ae0abxvTvACXCXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WiaTr_50-EC2jyC_GsZuBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7FO9jabvyEuwVCPMPOvyvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0o9tvW5BwkWKJJJLxMSbvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_SZUr4ebLNES5P_WEJfhHrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_UgRSQaaG60edGgxVl9FI7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-87NC5EOIESzFcXTIBQgjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-25</startDate>
            <endDate>2021-07-25</endDate>
        </period>
    </context>
    <context id="As_Of_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_S2ZvjQoxA0KSIEjlJS6ciQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">plx:EmployeeStockIncentivePlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-25</instant>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_hAKdSmKW7U6VWH6p5lybLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_L2L59hXyMEOR7OKOotcc8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_4rTi-nl39kOEXFLSWbJdzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_R3eVdAJPmU-INbiD0ErvuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2021_To_10_15_2021_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_5jcweHS-wUeCpJ8p1sBaGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">plx:AlfataligliceraseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-15</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_14_2021_To_10_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_h9tz6gqia0KnVd70vTBKjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-14</startDate>
            <endDate>2021-10-14</endDate>
        </period>
    </context>
    <context id="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_m9nl_SJDHUWIRCUsIOV1yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_-_pc4KjjIESt-NNMJSZPIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_t77xAm2kAU-zv8pYeCND3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3hEtaSNNrE-fNBLdsevplg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Ubpzjp7z0kmMySSYJsgF6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cHP7im6RgECQAwEEf3hC_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-25</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_vfhkQ56Ww0a1Pq5YaRlmwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-25</startDate>
            <endDate>2021-08-25</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_mxIiF-Oq6kSHobdbWU0lig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Vkt7LBou5EOkM2AjnrrdNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_LfY0cj9P4U6EKioM2_MD0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5917jrg-_kWEb92bxu9mtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fO3KmyeTREaqgOM51FScaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_9xptzgs0gkyakgmyzK1ZtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_eXGUnuCXhEyws-3Rm25qEA">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_item_torZYRpNtkSE8e779rh00g">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA">
        <measure>plx:Y</measure>
    </unit>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="2"
      id="Hidden_Ls2p4Irw_0ar4AaG-VN61g"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">-0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="2"
      id="Hidden_-udCUrhU1EmoptK9Td-q7w"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="2"
      id="Hidden_JnoPwAklSU-IzZCNO9kgXA"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="2"
      id="Hidden_fpFZQPuAz02xrz-nrMCWPA"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">-0.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="0"
      id="Hidden_sKnaYkqH5kO4ygWQnm54lA"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">43761769</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="0"
      id="Hidden_slnbF_-hAE60gHfCBySPxA"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">27758104</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="0"
      id="Hidden_MKbFHQ2t90uvUpUJfZ7rHg"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">45556647</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="0"
      id="Hidden_y11AAqeeiE2a1D_XWn11kQ"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">32863788</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_KOn-ZQMu7kW60vByH792og_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_0cXmEXaqRUKdKdh_SMVONA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_086CLQxT102WTksWDCO4Sg_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_2DwqG3W0RE6F99_lbd2S7g_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_Er6M5e4E6kWKSfnMtCM1sA">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_FgiDAbqpmUu_NDx_lVCLWg">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_2CGCfk7askiK66PJzgn3mw">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_Hq5TjgHiqEKS5tC2BQT6aw">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_i9j5WZ-Gs0aets-Qj8AspA">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_pQLzAs-R-UOjfFNZQHrEjA">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_jAWUb8v0wEW4GldOgkOR3Q">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_EFU8yG-gW0CFTox7Tdfx6g_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_jaBvosEd1kGY0gM5gBEvQQ">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_gDHhrsfxOUC1f8Gvv9HDBA">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_VLxr2ay1CkWCmaRBgPbulA">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_HNk1aTGjGE-jGx5R8DurRg">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_7r2hY1g9Wk-GBB4ySIRJlA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_QOpGhBgsFESIWXExFoWHSQ_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_wDyFlQpEiE6q0B0ZZVqRUg">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_B6_OwKRBiU-K_Zvw6FXKZA">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_ceBD3WK8WkGKMiRC7eOdQA_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_nd-TOs1jHEWaCglmd0yo4A_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_du4rd0ACX0WjD8QFYpugWg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_Z1Jpxfk4MkSRg_vOd3nUyw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_0NRBQTe6akOr1Lf_nTQj3w">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_zyJYdxKew0i3oxg_JM3cFQ_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_IIeMvq7uu0qvkITkwtJcew_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tc_XE8PIXiAHEeDygvZGz_iZQ_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Narr_wtFATSL6o0uEFx_s5U5ePw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_1_2021_9xptzgs0gkyakgmyzK1ZtA"
      decimals="INF"
      id="Narr_xvSTJez38EyB6j5fQtn63Q"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">45556647</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_spkGkv0BQUy9FNb8tGs2Pg_6_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">10642000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_zTU6isqLg0G64Jdazlyc2A_6_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">18265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_nQizOCYRwUSOZQCQBPtv2g_7_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">38017000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_4mYf7YdvgkOz0SpYHlJXUw_7_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">20280000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_lndJCifO40ONhFgbbAL06w_8_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">5561000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_aBDI993MyEKegKBn0uGS2g_8_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_wW63Gx4ZXEGdI0RIUjz0kg_9_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2274000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_EGthmkd6VUibzAshodxKqg_9_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_P51-N45-WEeMnihMIM628g_10_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">14730000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_R2Ydq5ccTE2c5AqjB5_ItQ_10_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">13082000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_RemDLv7XM0aNeNFZHubmwA_11_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">71224000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_3gl2Yx6Lp0edhe1RY0-XtQ_11_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">55723000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_A2ju21GpckyxLxlghWux1g_14_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1948000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc__cgEYMfctUuu9O_mpmThVA_14_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1799000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_jb4QcRSqikKE-QNg1L7ctA_15_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">5065000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_-kYjrPODAkC703nsmqsjew_15_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4845000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_HU1PPQtiWE6xlZ5Yo8t7MA_16_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">5245000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_q2Hh6RKm1EikVY-eQiKGVQ_16_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">5567000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_4TPSCFPtFE-eHcohfk6bYA_17_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">83482000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_Puuk60dQ9kGXFTQfsyJOMQ_17_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">67934000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_TrwJl4WeKkuqasdVtdqACQ_23_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">8436000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_0qrBdHdP1Ee_dinPtSwP-g_23_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7221000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_3VsdDQQThUuKaGSSxxeX6Q_24_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">14694000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_MrTCtC2_REq6AKfLYafuog_24_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">13926000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_mj_YyMv4UUCxgR_WdwbzJQ_25_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_YxwuZBF1ik-TJu6kAmnGtw_25_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_Yc4lIcj16EiVg6YnghL38A_26_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">15160000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_f7icina7_0ueH7L4ITgsNg_26_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">5394000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_SCr11D4BhkyGrlKw8lzM7A_27_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3239000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_Da1eKKEtCkGPO4w6p6KkFg_27_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">54427000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_dHRZDvHEfUqZbvXAYmSqsA_28_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4086000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_Ohe39GLJnkGjy2tdduNQiw_29_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">42764000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_SrFOiqy-SEm31i0MrJwzZA_29_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">86474000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_LsrxWQAkVkWRrDsMlXp0BA_32_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">27816000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_fLSmJtvtzkG-c0APbX18MQ_33_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">5895000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_uCP35cBv3keqCQM43BmB7Q_33_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1716000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_gfTTgP-j406eTiH0dmAwWg_34_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2353000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_aEX_HPW-xUKJnNI5SSU7BQ_34_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2263000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_fec9M2hOHkqgsUeUu3SWoQ_35_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4441000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_s4SfGbaQuE6ilUrHoIhWOQ_35_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4467000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_85iI6itkQ0Gl7INWBHmiJg_36_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">51000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_EaX_JO-v2kiNTA048IpWpw_37_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">40505000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_C6bHrwnMIkS-CtGj1sIOgg_37_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">8497000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_UwN2QoedzkWLMmf03vZqjA_38_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">83269000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_vpJQe0KCt0WQdXFli51fQw_38_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">94971000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_KzEfU9SqTkaEbTlmXUOkUw_40_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">213000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_oNOxpJGeLEyHDdHLoYxO7g_40_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_ZZuC0dZhJ06_d9BvFvsvkw_41_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">83482000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_wxiNCcCIS0SOGSuiW9COQg_41_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">67934000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_fCAhfegnYkmYa8xJ3eOd-g"
      decimals="-3"
      id="Tc_FOFCzct2XUOHSB9wRzm3Ow_3_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12260000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_DsIEE72dY0ijxi72whl2Xw"
      decimals="-3"
      id="Tc_JtSJ0Qa7kEyWBAt8C9fZgQ_3_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">11975000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yeoKiF-YDUOrT3vhZw5yGA"
      decimals="-3"
      id="Tc_usWASzXfCk-YC_czujQNkg_3_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4506000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember__RK7HZ3EbEuarJ7s2oVtsg"
      decimals="-3"
      id="Tc_tlbMJWjCqUagkaBusLdS1w_3_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3296000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Xo2XYmDaCUSxewIa-WYycw"
      decimals="-3"
      id="Tc_kDBm_e-g2kOtcrGjP7SBzA_4_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">17541000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_XpT7MCVwU0eKoVnFArW5NQ"
      decimals="-3"
      id="Tc_kDM61TeR-EWMMHsuLS2nrg_4_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">31428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_iAnH6udRs0WIM3yRgdqIUA"
      decimals="-3"
      id="Tc_Nl8buSZTEEyTZGjFgh_--A_4_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7548000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z2g_D1kyFE6aa-f9W-PAug"
      decimals="-3"
      id="Tc_unIu-VSj10iG2v0Uk8Wt-Q_4_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7494000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_GTRA_5vFVk2j_EAUQz-DDA_5_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">29801000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_i7Wec1ENhkajRQon6QHL0A_5_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">43403000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_3hGSRiWTskGnOO8xf1Erjg_5_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12054000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_tlNPgkoAUUmR09Qoobqgrw_5_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">10790000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_UXaW6tCThEueJFWWrehxkg_6_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">13201000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_ujAhtiQEI0G_PvbYtR0RBA_6_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">8121000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_VWDEdav1l0KVbiG3czgXMA_6_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3703000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_a0AO9iNjFUmJDJ0swtW58Q_6_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2868000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_PM8BG-8MtUqH8347xY2PYg_7_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">22093000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_EwA9jMSbrkmqVUjiaygazg_7_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">27214000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_5UmuXfk5SEu1oghPX8bF0Q_7_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7282000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_lLCWNuJnyEmJP5GZvzI68Q_7_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7688000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_EnHdNIHt8kGZKEO1M8w9Ag_8_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">9263000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_vzSLRiq810m1mK3Itk834A_8_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">8197000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_hUWovraG7EG9Kf7dUYzRnQ_8_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2954000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_S8ItGGynjEerZ_i8JDgscg_8_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2816000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_mgM7amEK7UyagXnnB7t_iw_9_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-14756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_1CWEk5cQLkSYXoicnCei1Q_9_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-129000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_o6YfR4w1mkadZekuN_PD3w_9_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-1885000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_pC0w0IIPzEauh4ROc0586w_9_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-2582000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_1ChZ9m2oWUyYud51u6OeKg_10_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">6613000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_Zlp2unmz-Uy0gcz6xfvX4g_10_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7150000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_8Ocp3mwAQECmB4uqBfGVCg_10_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2410000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_ZPCn02QkEUCycF28fcQLaQ_10_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1973000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_GQSu4HNB0UOhYII6vDNDAw_11_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">403000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_LgXqSo7QtU6kQB2UXy5S7Q_11_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">359000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_Hj7jwiybQkOS-xGj0U9JVg_11_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">96000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_EQX4YVD-0kSo5ST-TlGi7A_11_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">118000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_jAmXkSq-a0Wj8LKfGwDR4Q_12_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-6210000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_AD5TXiaarkaHdqxK3pJZsg_12_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-6791000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_WNIf0gpJdU6Fb1HIeXaPJA_12_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-2314000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_UBxFsqYyGE-9fcQV6K2m0Q_12_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-1855000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_mHPgbn4QDkSY7ahrvEyJVQ_13_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">51000</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_Ql-7v_U9EUOFesSdGvFGQg_14_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-20915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_Pw_AR67syUe6TDt6PN_xnw_14_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-6920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_UcwPFmnp-EidQH_vv_nMCA_14_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4199000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_JrMia4Iw_0i_mGUC-mHSVg_14_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4437000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="2"
      id="Tc_UU8DRaLLj0-x_oTzHQYL-g_15_3"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">-0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="2"
      id="Tc_dM0pW_Ml8kaC-4mydCK7Wg_15_6"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="2"
      id="Tc_hhLqgtco50SdO_BoWNW5NA_15_9"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="2"
      id="Tc_9bI1krOSSESYBU23i7PtwQ_15_12"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">-0.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="0"
      id="Tc_XJpe8v22hE-Dsy_po1DaCQ_17_3"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">43761769</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="0"
      id="Tc_D_MCsF-YkkK7dAb9itnWsQ_17_6"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">27758104</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="0"
      id="Tc_WrZp8J1MWECBzeanhoWhXA_17_9"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">45556647</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="0"
      id="Tc_0jJwczl8OEW-d3gHH2kbrQ_17_12"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">32863788</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_VID5cVVn_U-ANCDy0jyJ5g"
      decimals="-3"
      id="Tc_HHJakNefDkedrywbmSYjTQ_18_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_R6xvGSBAO0OzR-4qkTKWaw"
      decimals="-3"
      id="Tc_5hqbtzJPBkijTjaYi9v6gQ_18_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">65000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_JKiMKIkB9UmEZUv66KEFDQ"
      decimals="-3"
      id="Tc_s_CHJlTB30Cm-UC9WceOyw_19_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_0o9tvW5BwkWKJJJLxMSbvQ"
      decimals="-3"
      id="Tc_iYstyig-FEC113LSHxSdvw_19_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">635000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Krs4XcDTxE-mc88POrcQMA"
      decimals="-3"
      id="Tc_eWesRfLZfE-VGJmRldc4ig_19_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_WiaTr_50-EC2jyC_GsZuBA"
      decimals="-3"
      id="Tc_vbhHur0Xa0CoKnJRczoYrw_19_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">562000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_nRNi-j4GhEuD86VBNDouHw"
      decimals="-3"
      id="Tc_tZWjuasp80CxRnjvKcJomA_20_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1216000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_7FO9jabvyEuwVCPMPOvyvg"
      decimals="-3"
      id="Tc_tSGBvMJp8UiQ4yMuPureZA_20_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_ET9P1_n8jEmWQhl6pxUUhQ"
      decimals="-3"
      id="Tc_mNhT2bREW02UQPK_g6P_TA_20_9"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">344000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_nPLZoO1ae0abxvTvACXCXA"
      decimals="-3"
      id="Tc_ZA90Tf-A8UKbs8BJyMVKMQ_20_12"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">852000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gAacYeLtwE-Mj1yvi-z7VA"
      decimals="INF"
      id="Tc_2CkcVuVuQEG7KItaDjm3Lw_6_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gAacYeLtwE-Mj1yvi-z7VA"
      decimals="-3"
      id="Tc_xsW0tUXa-0ahJbEqkbJpLA_6_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DzXzpFAVKUa090qZyz2PWA"
      decimals="-3"
      id="Tc_76Xs9hxU00WH3KxyJwzRYw_6_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">270492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SshBsuzbEE-H-tzxnt_IRA"
      decimals="-3"
      id="Tc_WEotxEPguUG4lwMUBqoztA_6_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-340829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_rmjAbtU_mE681EqPesN7RA"
      decimals="-3"
      id="Tc_UuwuwU7ylka-7NeddOUW0g_6_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-70322000</us-gaap:StockholdersEquity>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw"
      decimals="INF"
      id="Tc_bv08SIutWEiAUmKkUOwRvA_8_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">17604423</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw"
      decimals="-3"
      id="Tc_6pP8SszvR06E-UTzEwHyqg_8_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">18000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ"
      decimals="-3"
      id="Tc_vJm-jGsYd0GLgBjW-AZ4rw_8_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">41325000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_ckpYzcFFcEWeBnpegvvCdA_8_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">41343000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ"
      decimals="-3"
      id="Tc_xQRla6Vgvk6Uk6QSbUifDw_9_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1607000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_T-326tXar0qx5rOp0fyaNg_9_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1607000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw"
      decimals="INF"
      id="Tc_LC5aYmq5CEm0nrSnW315LA_10_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">694073</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ"
      decimals="-3"
      id="Tc_iZ2Wz-GHL0GbzSJv9wZzsw_10_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">505000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_bUuoEXIyxESD7J-xIL1bjA_10_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">505000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sead0GK75EKfN_HmxZJYfw"
      decimals="INF"
      id="Tc_nFt_VGt_Zk-MAJJ9PTINCQ_11_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">200000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_pp98grIyvEGGFdL9XleXvQ"
      decimals="-3"
      id="Tc_7WoiT681rUmYvIpse72l5w_11_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">472000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_nhUWBhxkd02S0uQzr5iZGA_11_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">472000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_VQUwy6ZsqUWKoDwiSQgUCQ"
      decimals="-3"
      id="Tc_lPaDxYHiAEyR9Gq18mxteg_12_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-6920000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_a2tCH-iMbE6cvSaHtoC9-g_12_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-6920000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w"
      decimals="INF"
      id="Tc_J7-Sq9OR3kSfIYfoKZU3Tg_13_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">33336709</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w"
      decimals="-3"
      id="Tc_B5i1R3gUp0uBh-A8PZoDoA_13_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_67iC4kJN5EWDKR82GNj9iQ"
      decimals="-3"
      id="Tc_1cTCN-Hi1Emy01krBSjEag_13_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">314401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XqPOXgGBqUa1Fz3o4j1BTw"
      decimals="-3"
      id="Tc_B2ib645FF0WvfuCceUM_Bw_13_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-347749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw"
      decimals="-3"
      id="Tc_NRmU4p4YfU-nTPpvCUHYcw_13_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-33315000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FhAO6ZCXfUeU1PtZmtoW6A"
      decimals="INF"
      id="Tc_NIZffxgW_ke3Yy9mBpWl-Q_14_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">34765280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FhAO6ZCXfUeU1PtZmtoW6A"
      decimals="-3"
      id="Tc_XfEFGnl10E25NvWL07t09g_14_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QDIZWika_k258jbF39gQfw"
      decimals="-3"
      id="Tc__mFyBoiE1EeKahRrR5kiMA_14_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">320280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ajr0YlG7z0mN2jc2ptdz3A"
      decimals="-3"
      id="Tc_nS4QQ1_R_0WUlQ1Ud61kQQ_14_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-347352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_VrDaGSMNFkqHwzEKzofRsw_14_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ"
      decimals="INF"
      id="Tc_me7GFoP0YkmFe4qvGxo_OA_16_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ"
      decimals="-3"
      id="Tc_dQNRZLr8fkGNSYdHIo382A_16_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg"
      decimals="-3"
      id="Tc_vt2mFbN8s0-F40UMPgPKng_16_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">37616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_8cnx888DykWamkAfOgk_TA_16_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">37625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ"
      decimals="INF"
      id="Tc_FnsMO4D770WjajQaqxOl2w_17_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ"
      decimals="-3"
      id="Tc_ekNz7mfzVUSRUSsHCnZMcA_17_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg"
      decimals="-3"
      id="Tc_lSnzUc8fvUaiB3yjg971oQ_17_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">8573000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_k5r2LAWfKkeYaxSuu1u8fQ_17_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">8575000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg"
      decimals="-3"
      id="Tc_bjamkKa_DU-mV3W5AmNW_A_18_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1176000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_CI35Gm6jCUKr47_c5XJAmg_18_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1176000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg"
      decimals="-3"
      id="Tc_F1ubMBG6pEqEjb4SuKcYWw_19_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">781000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_NThaJ_6wQUeKSyPAKZgPuQ_19_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">781000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jKqAHNkx7EybatLpinGgNQ"
      decimals="INF"
      id="Tc_gwNvOAk-mUub1bCcc4W3gg_20_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">173816</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg"
      decimals="-3"
      id="Tc_-IBbjf7y5Em-_07y3G4tZA_21_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_17EMCWzLZUKviqN0FIQqjw_21_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-E9Rx8Fr9Uqmz5gsHdbElg"
      decimals="-3"
      id="Tc_GQExL1sDRE6Ot19JcnwSOg_22_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_uiwwfYF1rUSsyhAU2SF5Ig_22_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ahmxUbUVBkm9EcsPC2dvdA"
      decimals="-3"
      id="Tc_RjjlkDXwWk-XEGaovKCntA_23_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-20915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_O5mcOpTeAUG_k9bmR2Ke8g_23_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-20915000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg"
      decimals="INF"
      id="Tc_c3mVXk-AU0S4yi7qfsOOrQ_24_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg"
      decimals="-3"
      id="Tc_fOZQSzRXqEifowNe8TteDg_24_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K112MyLGIEyF188YEMII6g"
      decimals="-3"
      id="Tc_GBeYGjDVlEWhW86MNiAoGw_24_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">368434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cfPZTTulqkernD2EnEhf1g"
      decimals="-3"
      id="Tc_4FJXeoCGj024GN36fVIWKg_24_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-368267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_EVCjg42iY02Ng5oKM0OIoQ_24_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">213000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TNv1Z6zXV0WmttZRhAIl4Q"
      decimals="INF"
      id="Tc_ZkyIUdI8cEy4nBlfEeOeWw_25_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TNv1Z6zXV0WmttZRhAIl4Q"
      decimals="-3"
      id="Tc_5WXMoBy9fUi3vp8TkkhhKg_25_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_vALHgTVTI0qpDI5OS2no8w"
      decimals="-3"
      id="Tc_yhOCHtxxNkCgYz7Q5BwCsQ_25_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">308515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_q-w46iXNMEC75S22Wy4_XA"
      decimals="-3"
      id="Tc_SS2VTbkY10S0oRFwuWGAgA_25_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-343312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_nF71pgQNK0Sm4dLM4r805Q"
      decimals="-3"
      id="Tc_UAhu5aOP_kqDPUuQA-0JEw_25_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-34764000</us-gaap:StockholdersEquity>
    <plx:ReceivablesFromSaleOfCommonStockAndWarrants
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA"
      decimals="-3"
      id="Tc_1aaQyNxt206_GQnjhtCjuA_27_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4000000</plx:ReceivablesFromSaleOfCommonStockAndWarrants>
    <plx:ReceivablesFromSaleOfCommonStockAndWarrants
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_ixN6BuglTEOGZAf2KfSh7A_27_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4000000</plx:ReceivablesFromSaleOfCommonStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA"
      decimals="-3"
      id="Tc_GgbwSqFZBUeI3PuPtvxlgA_28_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_y1UizjQZlkWjBNJbAnbkmw_28_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">909000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-87NC5EOIESzFcXTIBQgjA"
      decimals="INF"
      id="Tc_KVz_6BTRVUilpbpsqmJrNg_29_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">694073</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA"
      decimals="-3"
      id="Tc_m3FkChneZUiA4l8Q5ahEsQ_29_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">505000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_kK-DFU2fTEqgKD12hJyD6Q_29_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">505000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-87NC5EOIESzFcXTIBQgjA"
      decimals="INF"
      id="Tc_KAsebpcFckK4WP4du54Beg_30_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">200000</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Wbt3DyytJ0Kva5u3E-pSRA"
      decimals="-3"
      id="Tc_erZ3_7ExaUOc5T-U44nEBQ_30_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">472000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <plx:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_Chbw5OgDSkuTSDM8RR2CIw_30_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">472000</plx:StockIssuedDuringPeriodValueWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MGJAPFogqkW3PHmVyWwQXg"
      decimals="-3"
      id="Tc_667TF9BhZkCUHQLBMmD1Tg_31_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="-3"
      id="Tc_cVeSmJVn90Sua4Zk8PFzcA_31_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4437000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w"
      decimals="INF"
      id="Tc_gYxgWB6MAE-BH4tEtEVhfQ_32_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">33336709</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PWoSb_pJkkiesW3ZmdBk3w"
      decimals="-3"
      id="Tc_bA6NRkbrcEKJ3rXh2c1STQ_32_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_67iC4kJN5EWDKR82GNj9iQ"
      decimals="-3"
      id="Tc_2tBnYbdy6kqUDXX9BtnGVw_32_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">314401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_XqPOXgGBqUa1Fz3o4j1BTw"
      decimals="-3"
      id="Tc_-K5CslMBdUuiYdwg1WaCqA_32_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-347749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw"
      decimals="-3"
      id="Tc_AkaVOPW1ikqv0dULHqk2Rg_32_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-33315000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_osEJghx1vkyNcPXIkVFTwg"
      decimals="INF"
      id="Tc_Oi7uyOMTvEOr2dNaywPhVQ_33_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_osEJghx1vkyNcPXIkVFTwg"
      decimals="-3"
      id="Tc_N9mh5CmPkUWXegogaikbrA_33_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ObypWAjZfkumwrue2SoofQ"
      decimals="-3"
      id="Tc_Ot6aemRus0WfDR4q_oTz2g_33_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">367863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_SzExwvidwEKr4i4UBC0FeQ"
      decimals="-3"
      id="Tc_H7BNVHQKCUiv3FhaBt2i3w_33_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-364068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_6e4TEe_8H0S9ZKRRnpwe0A"
      decimals="-3"
      id="Tc_AiTBMhKMUEerViaaUGSSEg_33_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3841000</us-gaap:StockholdersEquity>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg"
      decimals="-3"
      id="Tc_utSC0zXvDkCRe5BeD7xhGQ_35_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_YTwumf-vxUejUCwkgeeBcQ_35_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12019000</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg"
      decimals="-3"
      id="Tc_vVnCyJwGzUGZDGlXPiBlAg_36_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_t5ELb6fNM0KVNlNVGzDuRw_36_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12027000</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg"
      decimals="-3"
      id="Tc_2pamM6MIs0KEJDxHlMatJQ_37_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_8dEbC3Qu_0W2Y4M8Uom9vQ_37_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">344000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ksb85QoQqEyqwDSuuZkxxg"
      decimals="-3"
      id="Tc_6m2ckR75-0amb7E9EOFHyw_38_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">219000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_S4fKgvYbZUaSlARXxu_a0w_38_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">219000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3H5BKgTVfEanIQa3JfzDpQ"
      decimals="-3"
      id="Tc_8w8TQnBa2kquOiw2mweXrA_39_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4199000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="-3"
      id="Tc_lbrHMPxpskud80tnWc9f7g_39_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4199000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg"
      decimals="INF"
      id="Tc_Lz4nTLvqp0O3NIGXqO4b8Q_40_2"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_h1_O3rPcu0m5cYvvIe_Upg"
      decimals="-3"
      id="Tc_7E8A3Tr7ZEeELwLttzNu7g_40_5"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K112MyLGIEyF188YEMII6g"
      decimals="-3"
      id="Tc_wtVXLZa5NUStxBdjYcB6rg_40_8"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">368434000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_cfPZTTulqkernD2EnEhf1g"
      decimals="-3"
      id="Tc_zJMfQuweck-HK7yKwaZUuA_40_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-368267000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_pqm4OBnxfEm0w1nC7xMeCw_40_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">213000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw"
      decimals="INF"
      id="Narr_SAq3biMH4k27spydBvx2bw"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="INF"
      id="Narr_v4vG-O2obkWditpM8bXXXA"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw"
      decimals="0"
      id="Narr_xssjUyx8mUCwp61eFxqhkA"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="0"
      id="Narr_u6tWVFogzEOeBvYLKcgD2A"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_0djD6E62206f1duIx4caKA_4_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-20915000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_QdN5Hp7oN0a5PCwWNxVY8w_4_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-6920000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_OmDrugp_10unRJDTE7JjtA_6_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1957000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_fpfBxEk2A0KCTgqQx85raQ_6_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2112000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_kc8zthzwVUmGLp54korCWQ_7_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">859000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_M9YHxIGUNkik6CV_jbPLpQ_7_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1011000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_3mmNhysQPUK7v47PAcHbOQ_8_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-118000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_hbtVQYFVfkee7dB33jKYHw_8_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">284000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_6NJf8D0yhkGcHloe-Gldzw_9_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">100000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_9M4wM0Ce2kuckm6GT-7xNw_9_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-488000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_g_7WkzEdakOMiI7ggAOgvw_10_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">75000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_cFVLgHEuoEazC5JwvkG5pQ_10_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">11000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc__wLO8o0KTEafa6qhsijqOQ_11_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_NDWpxarVuUiPcUCtojP7DA_12_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-831000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_lX-x_jFifUm8TN1BxflvSg_13_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2569000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_sXw8oXv1ak6jzVQ-KO9J6Q_13_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2548000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_CoCgWkh0ckm-iDs_5qxmmA_15_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">13945000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_q0AdmlYriUan_kAwBibEbA_15_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-15062000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_kYKTFW0sj0q-zwwBESJ6hg_16_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4075000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_U3YoZxMbu0m6AEF5GQ3M9g_16_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-783000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_XmFDGpQZlU-ez9Yj8VGsYw_17_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-168000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_clzN4-kw1kiKPfboUsjiHw_17_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-53000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_WKTu8RKWlEudrXhuoeOXog_18_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1648000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_XzqWSzDg6E-muy27-iKrsA_18_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">5126000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_K6u6Ruofwk67yHk6vWlqxw_19_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1070000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_RaSqVjb7fkWcPlN2MSTBFg_19_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3291000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_zGWdEXUGaE-gxCYe12d8aw_20_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-51000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_wPEgNJxSH0mPG-5MZGMz-w_20_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-463000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_miOb10FH-kyDpeRZHkFEVA_21_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-5198000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_T9L4HOChYUuQCDPJ1Lp9Nw_21_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-18556000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_VGUQ20-Nkk2ZyUkiC4HkFg_24_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">37835000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_AiHLucUCPEemYjtlsqSyvA_24_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">27500000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_kAc8W4QHckOL_gqjVBVvFw_25_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">20000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_Dcau7IPB_keE0fEt57E8tw_26_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1011000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_XYe7Edvg_Uq60ah8o6xt9w_26_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">380000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_XexDkv1t_0ib3vVT4PZmjQ_27_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">53000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_JiViqdBGeUqoq0k10qc2hQ_28_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-359000</plx:IncreaseDecreaseInRestrictedDeposit>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_VTAR5ZThKkKsrp1v_pV09w_28_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4000</plx:IncreaseDecreaseInRestrictedDeposit>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_bqvwcp2XAkOkqaPGkg8EUg_29_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">81000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_Rtl8Xnmc9UeTzWkaOdfbUA_29_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-340000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_hZ3QsSblA02QIPlB_bzYLg_30_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-18515000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_Y-__8UjKgU-xK6N2ULHWgQ_30_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-27544000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_7CaJhLN5w06Oub_brsRbIA_33_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">25990000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_jE_WwY-jxEel6WZMgE_dqQ_34_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4086000</us-gaap:RepaymentsOfNotesPayable>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_NCPZISwWQUC7VK8MyvVILQ_35_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">37625000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_OLLGWwMLiUiKMTiNEb4HfQ_35_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">41343000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_gyfv9lNWz06unDP4BEvuVQ_36_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">8575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_FIGOS13pv0OAfOAxtAbS9A_37_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">472000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_40x3pdvXA02zZv-1LeR8bw_38_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">16124000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_O3i-BK_ii0aYCLPVYUKx7g_38_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">41815000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_8sdtdxdDGEqaj8iHyjQtYA_39_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-34000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_2YJPnJL7ckafx7Can60D3A_39_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">26000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_pP_xjM9SNEqFnAPDprpfHA_40_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-7623000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_Wq6JZdHATUCSjRBQKWk8lg_40_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-4259000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_1vdjUsJJOkebiUe72eIdFw_41_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">18265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_rmjAbtU_mE681EqPesN7RA"
      decimals="-3"
      id="Tc_JQFHo2kATUio6G87R7smGA_41_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_eloHEUAIH0aVPqJeVGWxbA_42_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">10642000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2020_ogc5MDO1m0WFsQHOqf1LSw"
      decimals="-3"
      id="Tc__tIHD5NjX0Ku1Ydefj0l-Q_42_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">13533000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_VAtZbtxN1ESlI9EcgYPNLw_4_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">387000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_mJwwMG_LukCllA1IKkHP5g_4_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">95000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_UAuk7TjsHEypCvsblHHOIA_5_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">309000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_Te-vDYxVIk-3hyBEpynqkA_5_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">564000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc__X0IxQj_VkafmdulbQ5Qvg_6_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">774000</plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_NzQt5LSKoEyLbktX5na1yA_9_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3288000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_RXljmaC9HUmemhULyxciSQ_9_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2172000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="-3"
      id="Tc_6TPqTOfXQUCUvoBJVfxwwg_10_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">445000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="-3"
      id="Tc_kY08xNTlIU-Goi4vwVKlBQ_10_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">68000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_OObOhFE0mEyXY9htecYDWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On August&#160;25, 2021, the Company completed exchanges (the &#x201c;Exchanges&#x201d;) of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#x2019;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;), $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; studies have been completed, and, in October 2021, the final dosing of the last patient in the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study was completed. See Part&#160;1, Item&#160;2, Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that they received a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) regarding the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#x201c;FFDCA&#x201d;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix and Chiesi also announced that a meeting was held with the Rapporteur and Co-Rapporteur of the European Medicines Agency (&#x201c;EMA&#x201d;) on October&#160;8, 2021 regarding PRX-102. At the meeting, Chiesi and Protalix discussed the scope of the anticipated Marketing Authorization Application (&#x201c;MAA&#x201d;) submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission for PRX-102. This is an important step in the necessary pre-submission activities leading up to a MAA submission. Based on the interim analysis of the 12-month data generated from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study that the Company announced in June 2021, and in combination with previously reported positive data from the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; studies, the Company and Chiesi expect to submit an MAA to the EMA for PRX-102 during the first quarter of 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#x2019;s exclusive worldwide license agreement with SarcoMed USA Inc. (&#x201c;SarcoMed&#x201d;) with respect to PRX-110 for use in the treatment&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during the three months ended September 30, 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of common stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and bank deposits as of September 30, 2021 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 26,905,842 and 21,405,733 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2020, respectively, and 27,962,842 and 26,847,081 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes, 2024 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_7KzyiuZ8_km5HZhzuFDznw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On August&#160;25, 2021, the Company completed exchanges (the &#x201c;Exchanges&#x201d;) of the Company&#x2019;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#x201c;2021 Notes&#x201d;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#x2019;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;), $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; studies have been completed, and, in October 2021, the final dosing of the last patient in the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study was completed. See Part&#160;1, Item&#160;2, Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that they received a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) regarding the biologics license application (&#x201c;BLA&#x201d;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#x201c;FFDCA&#x201d;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix and Chiesi also announced that a meeting was held with the Rapporteur and Co-Rapporteur of the European Medicines Agency (&#x201c;EMA&#x201d;) on October&#160;8, 2021 regarding PRX-102. At the meeting, Chiesi and Protalix discussed the scope of the anticipated Marketing Authorization Application (&#x201c;MAA&#x201d;) submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission for PRX-102. This is an important step in the necessary pre-submission activities leading up to a MAA submission. Based on the interim analysis of the 12-month data generated from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study that the Company announced in June 2021, and in combination with previously reported positive data from the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; studies, the Company and Chiesi expect to submit an MAA to the EMA for PRX-102 during the first quarter of 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#x2019;s exclusive worldwide license agreement with SarcoMed USA Inc. (&#x201c;SarcoMed&#x201d;) with respect to PRX-110 for use in the treatment&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during the three months ended September 30, 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of common stock for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and bank deposits as of September 30, 2021 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"
      decimals="INF"
      id="Narr_Y89Z_vOrgkupgKhe3SN3CA"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u4SuBfYydEm3isvsquTltA"
      decimals="-4"
      id="Narr_ZRN32WRLy0Kf3Qw-HOYlSw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">54650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"
      decimals="-4"
      id="Narr_xWqcG6cCtkuO4rOnNEK3Ww"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">28750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"
      decimals="INF"
      id="Narr_ZYEXEUak1EaaG6PnL2QlvA"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"
      decimals="-4"
      id="Narr_5jvyfugVc0Cm9uLwhPM3Gw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">25900000</us-gaap:RepaymentsOfConvertibleDebt>
    <plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"
      decimals="-5"
      id="Narr_u_-RprPTWEmOn7Mgz552cQ"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1100000</plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest>
    <plx:DebtInstrumentConvertibleConversionShareNumber
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"
      decimals="4"
      id="Narr_pX7Yw0yZLEm3C1aqWdEgVA"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">563.2216</plx:DebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentConvertibleBaseValueForConversionRate
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"
      decimals="0"
      id="Narr_FGpNGVJDBEah_QJ5Fh7oxw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"
      decimals="4"
      id="Narr_WQxHZ6S3aEmdvsehn0tO_Q"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">1.7755</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <plx:PercentageOfPremiumToClosingPriceOfStock
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"
      decimals="3"
      id="Narr_ZJ3DySGbWUOHCdtZ7UJqfQ"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.325</plx:PercentageOfPremiumToClosingPriceOfStock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_PIoT_NoejU-L2QS4flELFQ"
      decimals="INF"
      id="Narr_2n2QvS9-6ESh7_5e2rTGmA"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_hAKdSmKW7U6VWH6p5lybLw"
      decimals="-5"
      id="Narr_33PGfE0fz0S3M0k3lnHiYA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_hAKdSmKW7U6VWH6p5lybLw"
      decimals="INF"
      id="Narr_J4LZgQ5wBkaYW_ZdyFq8fw"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_hAKdSmKW7U6VWH6p5lybLw"
      decimals="-5"
      id="Narr_aoS4o6X8f0a9oRLHqz7vzw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_17_2021_To_2_17_2021_1i-AeCXmUEuYJ6FKsF7Dqw"
      decimals="INF"
      id="Narr_g_ULM4iA5EqUdISaVk-x1Q"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_17_2021_To_2_17_2021_1i-AeCXmUEuYJ6FKsF7Dqw"
      decimals="-5"
      id="Narr_Vdje2EBlLUmlA7JY_N4wOg"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">40200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_17_2021_P7ERVIdUQUOUY7klvL64CQ"
      decimals="2"
      id="Narr_MgEqXFBe6kakCbSrgvcUTA"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">4.60</us-gaap:SharesIssuedPricePerShare>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_UgRSQaaG60edGgxVl9FI7g"
      decimals="-5"
      id="Narr_vQSWuy0-70aI4-MbrMj2yw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">25000000.0</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_SZUr4ebLNES5P_WEJfhHrA"
      decimals="-5"
      id="Narr_p45vpFiu_UCGEGMD5-KV4A"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">25000000.0</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fO3KmyeTREaqgOM51FScaA"
      decimals="-5"
      id="Narr_M-Evk5iR2EKdlMiWmg9fDA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fO3KmyeTREaqgOM51FScaA"
      decimals="-5"
      id="Narr_giLdtGrmyEGWHMARs4nJLw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_fO3KmyeTREaqgOM51FScaA"
      decimals="-5"
      id="Narr_KlZX368EI0-k1WA-a6aBWg"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5917jrg-_kWEb92bxu9mtA"
      decimals="-5"
      id="Narr_Doe6O1GuKUefXAUCbwIV4w"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5917jrg-_kWEb92bxu9mtA"
      decimals="-5"
      id="Narr_qKdQY9gJ606la0vZi42V-Q"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_5917jrg-_kWEb92bxu9mtA"
      decimals="-5"
      id="Narr_OuSM0mMqd06xL4mcYJUf5A"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_3hEtaSNNrE-fNBLdsevplg"
      decimals="INF"
      id="Narr_uXJB1bDpPkOznzGU3M3FuA"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Ubpzjp7z0kmMySSYJsgF6Q"
      decimals="INF"
      id="Narr_kKLlWNBO1kCjVfZstv9jdw"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_-_pc4KjjIESt-NNMJSZPIA"
      decimals="INF"
      id="Narr_wlJmOgvCvkat5nhQaW8C6w"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_t77xAm2kAU-zv8pYeCND3Q"
      decimals="INF"
      id="Narr_xg9a1_s9V02Vb0lvfGVuAA"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_LfY0cj9P4U6EKioM2_MD0A"
      decimals="-5"
      id="Narr_l-_b8x5OvkqD4syIsdRFVA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_Vkt7LBou5EOkM2AjnrrdNQ"
      decimals="-5"
      id="Narr_1UekG_E02E2yHk2nYS-sZg"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_mxIiF-Oq6kSHobdbWU0lig"
      decimals="2"
      id="Narr_f-k0YCi71EKSQ4exdglGuw"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_Jeuks2tCF0eucsAOyMUTlw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_oq_droLU10eZanVmDSC-hw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 26,905,842 and 21,405,733 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2020, respectively, and 27,962,842 and 26,847,081 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes, 2024 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2020_To_9_30_2020_E9M6Id5MEE6hW-WAHU7Ipw"
      decimals="INF"
      id="Narr_bQx_EtrGWk6N3SvRl_j67w"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">26905842</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_9_30_2020_3CssU-TlhUedt9F13FO33w"
      decimals="INF"
      id="Narr_cSydejW5m0SgoUPlNDGF-w"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">21405733</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw"
      decimals="INF"
      id="Narr_IHZKEzoq9kex3A5_3R7t5g"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">27962842</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      decimals="INF"
      id="Narr_YuUwWW2LpkOauCJA-t5_LQ"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">26847081</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_5L3iziigI0Ou_QUaVUQxLw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_L2L59hXyMEOR7OKOotcc8w"
      decimals="INF"
      id="Narr_NL6ipRczVkixOLr5VUOWaQ"
      unitRef="Unit_Standard_agreement_eXGUnuCXhEyws-3Rm25qEA">2</plx:RevenuePerformanceObligationNumber>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_1GvXkuL6Z06Sgc-Uzdtmaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,170&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,053&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_PuZ12JjTl0qDCaceaPX4-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,170&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,507&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,053&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,730&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_-mpGOOkfSk6z_E4bgPdOpQ_3_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3170000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_N0Mb2O4aa0y5WDYMEidhEg_3_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3347000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_idSV-zhz40WXJXPYDxjXsw_4_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3507000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_1euWAIovH0y9PsEdU5ukvA_4_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">2887000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_DA2txOJpuU-3cKLcHDy5lw_5_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">8053000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_3DdAYFswF0-vdejNg5yXKA_5_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">6848000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-3"
      id="Tc_ClDqXJFEnEm5sttQc3bfBQ_6_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">14730000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_qI8q3VicqkWwfR_w319gxA"
      decimals="-3"
      id="Tc_9B3jsHqrN0y3Td46TgWqjQ_6_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">13082000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_Deg348Zr-k6Q_nvXiOBJyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;As of September&#160;30, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;Based on a Level 3 measurement, as of September&#160;30, 2021, the fair value of the $3.27&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2021 Notes is approximately $3.4&#160;million and the fair value of the $28.75&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2024 Notes is approximately $39.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes and 2024 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.04&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.74&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.99&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Z6NWekiCLE6G-qLdOHDf5g"
      decimals="-4"
      id="Narr_r4J-p64rHEaOXQ59Bcifvw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3270000</us-gaap:ShortTermBorrowings>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Z6NWekiCLE6G-qLdOHDf5g"
      decimals="-5"
      id="Narr_OG-ULsbPGkK6AEtTsyB21A"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3400000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9_wMuN2NN0i7qwtMQCbLVA"
      decimals="-4"
      id="Narr_2IVcpGiyWEeJC-ZszqdFJg"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">28750000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_9_wMuN2NN0i7qwtMQCbLVA"
      decimals="-5"
      id="Narr_62x5Rbcr5UuPep47Ih49Yw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">39800000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_c9iBJVgvmE6XPL7XnYJeDA"
      id="Tb_IQ9RgYWoX02_y0RZ9VuDQQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes and 2024 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.33&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.04&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.74&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.99&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_fjePpaWSpkeew6EE71xYVQ"
      decimals="2"
      id="Tc_VbAOP13XRE2WJdovPb67wA_2_2"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">1.33</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_wgnkkX_RZkCtKFWS55dCIA"
      decimals="2"
      id="Tc_Ir2fBFvtYkmFVvsYZ5ucxw_2_5"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">1.33</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_zGLIgBqMs0SokSMlmYxJWw"
      decimals="2"
      id="Tc_NWGoYaC9Wk26qW8788ngSg_3_2"
      unitRef="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA">0.13</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_2HD1crqgP0We3_b66UftRw"
      decimals="2"
      id="Tc_hvG_m0ITek22PF6XMLcWnA_3_5"
      unitRef="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA">2.92</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_VfiXjGij6E2FnqQWtpJIoQ"
      decimals="2"
      id="Tc_MxV9Q7JCrEOZZwFCOCvxLw_4_2"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.04</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_VDBEZhK3uke05lvqCgGCcA"
      decimals="2"
      id="Tc_C7Xtg5iny0W9JgRTpkf-oA_4_5"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.50</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_fyankMlPgUSx83FT7iCVmA"
      decimals="2"
      id="Tc_WFerxOzfkEKHkNG2I0kTuA_5_2"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">81.16</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_ey6qGfWfJki49fNChKl-sw"
      decimals="2"
      id="Tc_qBZp4cPhxEiALmSc9s177w_5_5"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">91.77</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_U-JzHzcc2UOd4vdE3TN_9g"
      decimals="2"
      id="Tc_o_IjjZH1_0yTG39V-t_lkw_6_2"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">6.74</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_wKRANVGWK0CGjF_78kn1Wg"
      decimals="2"
      id="Tc_XVvizB-pe0usl5JrDRf1ag_6_5"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">8.99</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_1LfWdcQU_U-EhLmAFctKOg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.98%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,135&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,165&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,883&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,844&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,548&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,494&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,541&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,428&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the nine months ended September&#160;30, 2021 and 2020, the Company recognized revenues of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$16.5&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million and &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$31.4&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million, respectively, &lt;/span&gt;from license and R&amp;amp;D services mainly in respect of the Chiesi Agreements, after taking into consideration change in estimate as detailed below. &lt;span style="background-color:#ffffff;"&gt;During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenues of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$&lt;/span&gt;6.5&lt;span style="background-color:#ffffff;"&gt;&#160;million and &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$&lt;/span&gt;7.5&lt;span style="background-color:#ffffff;"&gt;&#160;million, respectively, &lt;/span&gt;from license and R&amp;amp;D services mainly in respect of the Chiesi Agreements&lt;span style="background-color:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"&gt;During the nine months ended September&#160;30, 2021, and following the CRL received from the FDA, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in a reduction to accumulated revenues recognized in respect of this performance obligation in the amount of $4.1&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the three months ended September 30, 2021, the Company&lt;/span&gt;&lt;span style="color:#212529;"&gt; completed its obligations under a feasibility study it entered into with Kirin Holdings Company, Limited (&#x201c;Kirin&#x201d;) on March&#160;16, 2020, and the agreement expired, including the &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="color:#212529;"&gt;option to provide additional services. Following the expiration of the option, the Company recognized as revenue during the three-month period ended September&#160;30, 2021 the &lt;/span&gt;&lt;span style="color:#212529;"&gt;$1.0&lt;/span&gt;&lt;span style="color:#212529;"&gt;&#160;million payment received in March 2020.&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_xSgG7j6dS0O1mg7-ZMUpHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.98%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,135&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,165&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,883&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,844&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,188&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 171&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 131&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,260&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,548&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,494&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,541&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,428&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_-Ye7tysNN0uIamEerOPohA"
      decimals="-3"
      id="Tc_OjBi-AnYv0O7dfLX34UCEw_3_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1135000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_xXLYsWN7vUSK8B4I4_cOqA"
      decimals="-3"
      id="Tc_WENU8Z9askOWDCOwBb8vqA_3_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3165000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_mydcMxM_oU2kJNHEONj5Ew"
      decimals="-3"
      id="Tc_n2C_nAsuQ0GdaFUsv7iiZA_3_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7883000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_d2w1x6Wq0UWIzS1bPmcmPg"
      decimals="-3"
      id="Tc_AdSjnIZTvEaQNdrWxxPDpg_3_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">5844000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_CvN_3Qdilkmih_xyi8l8VQ"
      decimals="-3"
      id="Tc_n7PTYm_nQ0-afFNSQu2KuA_4_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_JjbHSiTd-EinvS16jCvSmQ"
      decimals="-3"
      id="Tc_gliEAK772EeBkD7q6kNGuw_4_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4188000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_YONib1KiMUiXNGrGvXI9NA"
      decimals="-3"
      id="Tc_f8QBdEymsUurTTSALBcd3A_4_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_C4rvOPWVQUO7NyuzPVG_vg"
      decimals="-3"
      id="Tc_O1gXrWZ7Y06lsccuex69Bg_5_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">171000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_lb46u3iL-Eq_NMiIYmE5Ug"
      decimals="-3"
      id="Tc_xkvSUi1Z2k-01v_tfjD-Ow_5_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">131000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_QCMjIXNGnE6keq97DV1Ceg"
      decimals="-3"
      id="Tc_kSLbo8E-V06OzLjNHeew9g_5_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">189000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_lWJ_c72CZk-SxD9FOrYgfA"
      decimals="-3"
      id="Tc_GK-HCbdgtUOI0BZnLbv0pA_5_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">131000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_yeoKiF-YDUOrT3vhZw5yGA"
      decimals="-3"
      id="Tc_jpAb8i12M06-Z3MWqswwfQ_6_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4506000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember__RK7HZ3EbEuarJ7s2oVtsg"
      decimals="-3"
      id="Tc_GB0T0YuOvUqIsDT7HtN88Q_6_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3296000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_fCAhfegnYkmYa8xJ3eOd-g"
      decimals="-3"
      id="Tc_38TdX-2WT0WCMsDz-OwE8w_6_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12260000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_DsIEE72dY0ijxi72whl2Xw"
      decimals="-3"
      id="Tc_XXx00fxLAk6AtZjGi7be_w_6_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">11975000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_iAnH6udRs0WIM3yRgdqIUA"
      decimals="-3"
      id="Tc_lKKajGZsGkicnoyNdCm9cw_7_3"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7548000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_z2g_D1kyFE6aa-f9W-PAug"
      decimals="-3"
      id="Tc_JKHTe1r920OYnVMfTuNZag_7_6"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7494000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Xo2XYmDaCUSxewIa-WYycw"
      decimals="-3"
      id="Tc_90z0uG37JEiLfMvW_1FjaA_7_11"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">17541000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_XpT7MCVwU0eKoVnFArW5NQ"
      decimals="-3"
      id="Tc_bCnfAWI8ME-1B_XdwWeXEg_7_14"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">31428000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iAbMMUv_L06GXvemRzxxLQ"
      decimals="-5"
      id="Narr_HBwcRwGSVEmx5RGOPhF2Uw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">16500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_osPvD8x1U0Wr7PmiN4rWyw"
      decimals="-5"
      id="Narr_H58yj3EU_Ums0JCgPqO9rg"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">31400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_toBWVVxhOE2Xyr7X8eD-wQ"
      decimals="-5"
      id="Narr_BxMQZf8ak0exgSSGVoP6Kw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">6500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2020_To_9_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_pjmKKZep_k-eRCW8jmhsEw"
      decimals="-5"
      id="Narr_YDRJRph5-EiBv00b8tMZNQ"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7500000</us-gaap:Revenues>
    <plx:ReductionToAccumulatedRevenueRecognized
      contextRef="Duration_1_1_2021_To_9_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_4rTi-nl39kOEXFLSWbJdzA"
      decimals="-5"
      id="Narr_L2o3AJlzF06dsSQv23ToCA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">4100000</plx:ReductionToAccumulatedRevenueRecognized>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_OyqOeTcPvEeZzice06IGyg"
      decimals="-5"
      id="Narr_8LAhX_YCAUWrK_axzFaCcw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1000000.0</us-gaap:Revenues>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_AJBy4i0hikaAVXPM_62ejQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; CONVERTIBLE NOTES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On August&#160;25, 2021, the Company completed the Exchanges of a substantial majority of the Company&#x2019;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#x2019;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances, which is based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes will be paid semi-annually at a rate of 7.50% per annum. The Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#x2019;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;Under the terms of the indentures governing each of the 2021 Notes and 2024 Notes, The Company is required to maintain a minimum cash balance of at least &lt;/span&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;$7.5&lt;/span&gt;&#160;&lt;span style="font-family:'28mugxoulnobhnx';"&gt;million. In addition, under the exchange a&lt;/span&gt;greements the Company entered into with each of the institutional note holders that participated in the Exchanges (the &#x201c;Exchange Agreements&#x201d;), the Company agreed to maintain unrestricted cash of not less than &lt;span style="font-family:'28mugxoulnobhnx';"&gt;$3.27&lt;/span&gt;&lt;span style="font-family:'28mugxoulnobhnx';"&gt; million, &lt;/span&gt;which is the amount necessary to redeem or repay at maturity all of the 2021 Notes that remain outstanding following the closing of the Exchanges.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges are considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $0.8&#160;million due to derecognition of the liability component of $54.8&#160;million and the repurchase of the original equity component for $12.0&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;All of the Company&#x2019;s outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#x2019;s nonconvertible debt borrowing rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature of approximately $12.0&#160;million was recognized in the Company&#x2019;s additional paid in capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Transaction costs in the amount of approximately $869,000 were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.66&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_u4SuBfYydEm3isvsquTltA"
      decimals="-4"
      id="Narr_FMFIJ4u8ZEOdkaNBB3O8jQ"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">54650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"
      decimals="-4"
      id="Narr_BHp5U2H-CECY8l8VTbnRnw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">28750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"
      decimals="-4"
      id="Narr_jeGldl0N7UOKBD_fZvlNMA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">25900000</us-gaap:RepaymentsOfConvertibleDebt>
    <plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"
      decimals="-5"
      id="Narr_rJnZGc0vs0uj1lJps6i4nw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1100000</plx:DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest>
    <plx:DebtInstrumentConvertibleConversionShareNumber
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"
      decimals="4"
      id="Narr_dHBQ5Vu_0U200hCJrKKCtg"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">563.2216</plx:DebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentConvertibleBaseValueForConversionRate
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"
      decimals="0"
      id="Narr_kXwQWfqzxkG0qv4CrFi5xA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_gd1316wgJUaV1_Ydsz5NkQ"
      decimals="4"
      id="Narr_keBGbcN84Ea05brJdgp_Hw"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">1.7755</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <plx:PercentageOfPremiumToClosingPriceOfStock
      contextRef="Duration_8_25_2021_To_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_84YulW-hU02binKR5le2pw"
      decimals="3"
      id="Narr_rB1GhC4bX0-UsFQ76CzSoQ"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.325</plx:PercentageOfPremiumToClosingPriceOfStock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_Ggzgc2uf3EKFGBDEr8E4Mw"
      decimals="4"
      id="Narr_zzKIe8RBH0aYd4QqvaOXxA"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_vfhkQ56Ww0a1Pq5YaRlmwg"
      id="Narr_UGZ1gC8Ad0a3z43AwZISUQ">P3Y</us-gaap:DebtInstrumentTerm>
    <plx:MaintainOfMinimumCashBalance
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-5"
      id="Narr_3Tjb_qdMGk-OWMp__OoiCA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">7500000</plx:MaintainOfMinimumCashBalance>
    <plx:DebtInstrumentMinimumUnrestrictedCashToBeMaintained
      contextRef="As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q"
      decimals="-4"
      id="Narr_mEEsf10-mki5_xjV4TEWSg"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3270000</plx:DebtInstrumentMinimumUnrestrictedCashToBeMaintained>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_R3eVdAJPmU-INbiD0ErvuA"
      decimals="-5"
      id="Narr_dOh-34TysUS8wUW9pLhg2Q"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-800000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <plx:DebtInstrumentDerecognitionOfLiabilityComponent
      contextRef="As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_cHP7im6RgECQAwEEf3hC_Q"
      decimals="-5"
      id="Narr__4Z7TR2PdUeqH5LxCiLAnw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">54800000</plx:DebtInstrumentDerecognitionOfLiabilityComponent>
    <plx:ReacquisitionOfEquityComponentOfConvertibleNotes
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_R3eVdAJPmU-INbiD0ErvuA"
      decimals="-5"
      id="Narr_QZfyATu_GkC7HXk4Bz7B6Q"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">-12000000.0</plx:ReacquisitionOfEquityComponentOfConvertibleNotes>
    <plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_vfhkQ56Ww0a1Pq5YaRlmwg"
      decimals="-5"
      id="Narr_Qe2fA9arkUKEftWXBRVSJA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">12000000.0</plx:EquityComponentOfConvertibleNotesNetOfTransactionCosts>
    <plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_vfhkQ56Ww0a1Pq5YaRlmwg"
      decimals="-3"
      id="Narr_a9HvAzvcQ0q8FtmJxziEgw"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">869000</plx:DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_I0Grm-B4g0GE3UCgk-DBhw"
      id="Tb_2RS6naTJlU2UIa9lFAtbwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.34&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.44&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 78.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.87&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.66&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_1972KmuibUyJZ-gIneryuQ"
      decimals="2"
      id="Tc_0AWAUa94wU6Z6UVc9oUlOg_2_2"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">1.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_U9xEZDL-PEmh5wLjZtn6JA"
      decimals="2"
      id="Tc_4hyIRVg3rkO6Jh1NpI6Fow_2_5"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">1.34</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_WxYGSDFoFk2A-2JGt6XSSg"
      decimals="INF"
      id="Tc_WmE26GoRSEGU0hZn85pvUw_3_2"
      unitRef="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA">0.23</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_VD26SZ1y0ESvFdYomEg95Q"
      decimals="INF"
      id="Tc_Stq3OCia-EGcGHr_9PQeQg_3_5"
      unitRef="Unit_Standard_Y_IAQtZCGBc0iG3vYNAU_eYA">3.03</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_uKHcMPfNtE6lZclLW6H1BQ"
      decimals="2"
      id="Tc_w0hDXE26b0imiBypxky9vA_4_2"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.05</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_hrtLH0ARGkuJLrKOpEM2VQ"
      decimals="2"
      id="Tc_rPunqLNyc0mh77yaea0P6A_4_5"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.44</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_wPu82-n0Ck6cnwIfWVVgng"
      decimals="2"
      id="Tc_06xyZcorREO7hxuFSXgFqQ_5_2"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">78.95</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_86dWT-PfXUCCzWKVSULmMQ"
      decimals="2"
      id="Tc_JeGVEP5KBEyNZCtZ_NmSew_5_5"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">91.35</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_E62ftnuUYUSTpfSddSfQnQ"
      decimals="2"
      id="Tc_vUHZnz6vbU-zZhNH6ZjHZQ_6_2"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">7.87</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_8_25_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_N3NNBZmbcUSZicNMNONsbg"
      decimals="2"
      id="Tc_4SAwvn_6XEyJMYsSEDx1Ug_6_5"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">7.66</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_M01pW6N5UE-KHabYc_wXyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;On July&#160;25, 2021, the Company granted to a new employee, with the approval of the Company&#x2019;s compensation committee, 10-year&#160;options to purchase&#160;50,000&#160;shares of Common Stock under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended. The options have an exercise price equal to $1.57 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $55,000&#160;based on the following weighted average assumptions: share price equal to $1.57; dividend yield of 0% for all years; expected volatility of 84.3%; risk-free interest rate of&#160;0.88%; and expected life of six years.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      id="Narr_d2-gZTQqqESzz6ycksq9Ig">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      decimals="INF"
      id="Narr_dzmQu62MAUWRC2gxRO4XWg"
      unitRef="Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_S2ZvjQoxA0KSIEjlJS6ciQ"
      decimals="2"
      id="Narr_K6CfxMbFrE68Ly9LjiIl0g"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      id="Narr_GV_EtKKJGkqdQhOCp00Qaw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      decimals="INF"
      id="Narr_eYNPON5D20-GyJYvK39ojQ"
      unitRef="Unit_Standard_item_torZYRpNtkSE8e779rh00g">16</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue
      contextRef="As_Of_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_S2ZvjQoxA0KSIEjlJS6ciQ"
      decimals="0"
      id="Narr_wvDgW8BaDkqLSgFGZ01_7g"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">55000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      decimals="2"
      id="Narr_G8xqRSUKv0GRavSfY6T3bg"
      unitRef="Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A">1.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      decimals="2"
      id="Narr_R93p0_MookK4j24ZDUR4AA"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      decimals="3"
      id="Narr_1OCWJloUBkS18cmzXGTd3g"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      decimals="4"
      id="Narr_gsqV_7IzAUysPdGYTnlBpg"
      unitRef="Unit_Standard_pure_Z5TjRJ5CfkKCsxjFave3dA">0.0088</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw"
      id="Narr_Jbn9Ti4TRkO1lMTdQI8TCA">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg"
      id="Tb_vedK3AEgtE2ogQCoUQ2ofw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On October&#160;13, 2021, the Company collected approximately $1.2&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On October&#160;14, 2021, the Company collected approximately $1.1&#160;million from sales to Pfizer and on October&#160;15, 2021, the Company collected approximately $3.2&#160;million from sales of alfataliglicerase to Fiocruz.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On November&#160;9, 2021, the Company delivered the necessary funds under the indenture governing the 2021 Notes to effectively discharge the remaining outstanding 2021 Notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In accordance with ASC 855 &#x201c;Subsequent Events&#x201d; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <plx:ProceedsFromExpenseReimbursements
      contextRef="Duration_10_13_2021_To_10_13_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_m9nl_SJDHUWIRCUsIOV1yA"
      decimals="-5"
      id="Narr_s8JUfuTCeEW5kDhiSd5-TA"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1200000</plx:ProceedsFromExpenseReimbursements>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_10_14_2021_To_10_14_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_h9tz6gqia0KnVd70vTBKjw"
      decimals="-5"
      id="Narr_J-YM---nqkyEvpt9aAAg9A"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">1100000</plx:ProceedsFromSaleOfProducts>
    <plx:ProceedsFromSaleOfProducts
      contextRef="Duration_10_15_2021_To_10_15_2021_srt_ProductOrServiceAxis_plx_AlfataligliceraseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_5jcweHS-wUeCpJ8p1sBaGQ"
      decimals="-5"
      id="Narr_rWcQFpYip0aD1YKJG2oq4Q"
      unitRef="Unit_Standard_USD_4bN3bLtoVEahVux9absZBg">3200000</plx:ProceedsFromSaleOfProducts>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_bv08SIutWEiAUmKkUOwRvA_8_2"
          xlink:label="Tc_bv08SIutWEiAUmKkUOwRvA_8_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of September&#160;30, 2021 and 2020 - 120,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_bv08SIutWEiAUmKkUOwRvA_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_LC5aYmq5CEm0nrSnW315LA_10_2"
          xlink:label="Tc_LC5aYmq5CEm0nrSnW315LA_10_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_LC5aYmq5CEm0nrSnW315LA_10_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_KVz_6BTRVUilpbpsqmJrNg_29_2"
          xlink:label="Tc_KVz_6BTRVUilpbpsqmJrNg_29_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_KVz_6BTRVUilpbpsqmJrNg_29_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_FnsMO4D770WjajQaqxOl2w_17_2"
          xlink:label="Tc_FnsMO4D770WjajQaqxOl2w_17_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_FnsMO4D770WjajQaqxOl2w_17_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_nFt_VGt_Zk-MAJJ9PTINCQ_11_2"
          xlink:label="Tc_nFt_VGt_Zk-MAJJ9PTINCQ_11_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_nFt_VGt_Zk-MAJJ9PTINCQ_11_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_KAsebpcFckK4WP4du54Beg_30_2"
          xlink:label="Tc_KAsebpcFckK4WP4du54Beg_30_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_KAsebpcFckK4WP4du54Beg_30_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gwNvOAk-mUub1bCcc4W3gg_20_2"
          xlink:label="Tc_gwNvOAk-mUub1bCcc4W3gg_20_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gwNvOAk-mUub1bCcc4W3gg_20_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_2CkcVuVuQEG7KItaDjm3Lw_6_2"
          xlink:label="Tc_2CkcVuVuQEG7KItaDjm3Lw_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_2CkcVuVuQEG7KItaDjm3Lw_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ZkyIUdI8cEy4nBlfEeOeWw_25_2"
          xlink:label="Tc_ZkyIUdI8cEy4nBlfEeOeWw_25_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ZkyIUdI8cEy4nBlfEeOeWw_25_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_gYxgWB6MAE-BH4tEtEVhfQ_32_2"
          xlink:label="Tc_gYxgWB6MAE-BH4tEtEVhfQ_32_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_gYxgWB6MAE-BH4tEtEVhfQ_32_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_J7-Sq9OR3kSfIYfoKZU3Tg_13_2"
          xlink:label="Tc_J7-Sq9OR3kSfIYfoKZU3Tg_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_J7-Sq9OR3kSfIYfoKZU3Tg_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_NIZffxgW_ke3Yy9mBpWl-Q_14_2"
          xlink:label="Tc_NIZffxgW_ke3Yy9mBpWl-Q_14_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_NIZffxgW_ke3Yy9mBpWl-Q_14_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Oi7uyOMTvEOr2dNaywPhVQ_33_2"
          xlink:label="Tc_Oi7uyOMTvEOr2dNaywPhVQ_33_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Oi7uyOMTvEOr2dNaywPhVQ_33_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Lz4nTLvqp0O3NIGXqO4b8Q_40_2"
          xlink:label="Tc_Lz4nTLvqp0O3NIGXqO4b8Q_40_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Lz4nTLvqp0O3NIGXqO4b8Q_40_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_c3mVXk-AU0S4yi7qfsOOrQ_24_2"
          xlink:label="Tc_c3mVXk-AU0S4yi7qfsOOrQ_24_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_c3mVXk-AU0S4yi7qfsOOrQ_24_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_me7GFoP0YkmFe4qvGxo_OA_16_2"
          xlink:label="Tc_me7GFoP0YkmFe4qvGxo_OA_16_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_me7GFoP0YkmFe4qvGxo_OA_16_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ujAhtiQEI0G_PvbYtR0RBA_6_6"
          xlink:label="Tc_ujAhtiQEI0G_PvbYtR0RBA_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ujAhtiQEI0G_PvbYtR0RBA_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_a0AO9iNjFUmJDJ0swtW58Q_6_12"
          xlink:label="Tc_a0AO9iNjFUmJDJ0swtW58Q_6_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_a0AO9iNjFUmJDJ0swtW58Q_6_12"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_UXaW6tCThEueJFWWrehxkg_6_3"
          xlink:label="Tc_UXaW6tCThEueJFWWrehxkg_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_UXaW6tCThEueJFWWrehxkg_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_VWDEdav1l0KVbiG3czgXMA_6_9"
          xlink:label="Tc_VWDEdav1l0KVbiG3czgXMA_6_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_VWDEdav1l0KVbiG3czgXMA_6_9"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_EwA9jMSbrkmqVUjiaygazg_7_6"
          xlink:label="Tc_EwA9jMSbrkmqVUjiaygazg_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_EwA9jMSbrkmqVUjiaygazg_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_lLCWNuJnyEmJP5GZvzI68Q_7_12"
          xlink:label="Tc_lLCWNuJnyEmJP5GZvzI68Q_7_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_lLCWNuJnyEmJP5GZvzI68Q_7_12"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_PM8BG-8MtUqH8347xY2PYg_7_3"
          xlink:label="Tc_PM8BG-8MtUqH8347xY2PYg_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_PM8BG-8MtUqH8347xY2PYg_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5UmuXfk5SEu1oghPX8bF0Q_7_9"
          xlink:label="Tc_5UmuXfk5SEu1oghPX8bF0Q_7_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5UmuXfk5SEu1oghPX8bF0Q_7_9"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_vzSLRiq810m1mK3Itk834A_8_6"
          xlink:label="Tc_vzSLRiq810m1mK3Itk834A_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_vzSLRiq810m1mK3Itk834A_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_S8ItGGynjEerZ_i8JDgscg_8_12"
          xlink:label="Tc_S8ItGGynjEerZ_i8JDgscg_8_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_S8ItGGynjEerZ_i8JDgscg_8_12"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_EnHdNIHt8kGZKEO1M8w9Ag_8_3"
          xlink:label="Tc_EnHdNIHt8kGZKEO1M8w9Ag_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_EnHdNIHt8kGZKEO1M8w9Ag_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_hUWovraG7EG9Kf7dUYzRnQ_8_9"
          xlink:label="Tc_hUWovraG7EG9Kf7dUYzRnQ_8_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_hUWovraG7EG9Kf7dUYzRnQ_8_9"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026292269672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,556,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026292325512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,642<span></span>
</td>
<td class="nump">$ 18,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">38,017<span></span>
</td>
<td class="nump">20,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">5,561<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">2,274<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">14,730<span></span>
</td>
<td class="nump">13,082<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">71,224<span></span>
</td>
<td class="nump">55,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,948<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,065<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,245<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">83,482<span></span>
</td>
<td class="nump">67,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">8,436<span></span>
</td>
<td class="nump">7,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">14,694<span></span>
</td>
<td class="nump">13,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">15,160<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="nump">54,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">42,764<span></span>
</td>
<td class="nump">86,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible notes</a></td>
<td class="nump">27,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">5,895<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,353<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,441<span></span>
</td>
<td class="nump">4,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">40,505<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">83,269<span></span>
</td>
<td class="nump">94,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</a></td>
<td class="nump">213<span></span>
</td>
<td class="num">(27,037)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (net of capital deficiency)</a></td>
<td class="nump">$ 83,482<span></span>
</td>
<td class="nump">$ 67,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026292340120">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 12,054<span></span>
</td>
<td class="nump">$ 10,790<span></span>
</td>
<td class="nump">$ 29,801<span></span>
</td>
<td class="nump">$ 43,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(3,703)<span></span>
</td>
<td class="num">(2,868)<span></span>
</td>
<td class="num">(13,201)<span></span>
</td>
<td class="num">(8,121)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(7,282)<span></span>
</td>
<td class="num">(7,688)<span></span>
</td>
<td class="num">(22,093)<span></span>
</td>
<td class="num">(27,214)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(2,954)<span></span>
</td>
<td class="num">(2,816)<span></span>
</td>
<td class="num">(9,263)<span></span>
</td>
<td class="num">(8,197)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,885)<span></span>
</td>
<td class="num">(2,582)<span></span>
</td>
<td class="num">(14,756)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,410)<span></span>
</td>
<td class="num">(1,973)<span></span>
</td>
<td class="num">(6,613)<span></span>
</td>
<td class="num">(7,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">96<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">359<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES - NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,314)<span></span>
</td>
<td class="num">(1,855)<span></span>
</td>
<td class="num">(6,210)<span></span>
</td>
<td class="num">(6,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">OTHER INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (4,199)<span></span>
</td>
<td class="num">$ (4,437)<span></span>
</td>
<td class="num">$ (20,915)<span></span>
</td>
<td class="num">$ (6,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE OF COMMON STOCK - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE OF COMMON STOCK - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="nump">32,863,788<span></span>
</td>
<td class="nump">43,761,769<span></span>
</td>
<td class="nump">27,758,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="nump">32,863,788<span></span>
</td>
<td class="nump">43,761,769<span></span>
</td>
<td class="nump">27,758,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="nump">$ 3,296<span></span>
</td>
<td class="nump">$ 12,260<span></span>
</td>
<td class="nump">$ 11,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,548<span></span>
</td>
<td class="nump">$ 7,494<span></span>
</td>
<td class="nump">$ 17,541<span></span>
</td>
<td class="nump">$ 31,428<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026291390856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">$ 635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 344<span></span>
</td>
<td class="nump">$ 852<span></span>
</td>
<td class="nump">$ 1,216<span></span>
</td>
<td class="nump">$ 1,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026373047256">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 270,492<span></span>
</td>
<td class="num">$ (340,829)<span></span>
</td>
<td class="num">$ (70,322)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14,838,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">41,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares', window );">Issuance of common stock and warrants, net of issuance cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">694,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,920)<span></span>
</td>
<td class="num">(6,920)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">314,401<span></span>
</td>
<td class="num">(347,749)<span></span>
</td>
<td class="num">(33,315)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,336,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">308,515<span></span>
</td>
<td class="num">(343,312)<span></span>
</td>
<td class="num">(34,764)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">694,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsExercises', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReceivablesFromSaleOfCommonStockAndWarrants', window );">Note receivable payment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,437)<span></span>
</td>
<td class="num">(4,437)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">314,401<span></span>
</td>
<td class="num">(347,749)<span></span>
</td>
<td class="num">(33,315)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">33,336,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">320,280<span></span>
</td>
<td class="num">(347,352)<span></span>
</td>
<td class="num">(27,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,765,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,027)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,915)<span></span>
</td>
<td class="num">(20,915)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">368,434<span></span>
</td>
<td class="num">(368,267)<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">367,863<span></span>
</td>
<td class="num">(364,068)<span></span>
</td>
<td class="nump">3,841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,019)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 368,434<span></span>
</td>
<td class="num">$ (368,267)<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of September&#160;30, 2021 and 2020 - 120,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Notes Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reacquisition Of Equity Component Of Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReacquisitionOfEquityComponentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReceivablesFromSaleOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables from sale of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReceivablesFromSaleOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026289451944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026291766456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,915)<span></span>
</td>
<td class="num">$ (6,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,957<span></span>
</td>
<td class="nump">2,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="nump">118<span></span>
</td>
<td class="num">(284)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">100<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(75)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="nump">831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">2,569<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability (including non-current portion)</a></td>
<td class="nump">13,945<span></span>
</td>
<td class="num">(15,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable and other assets</a></td>
<td class="num">(4,075)<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,648)<span></span>
</td>
<td class="num">(5,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accruals</a></td>
<td class="nump">1,070<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,198)<span></span>
</td>
<td class="num">(18,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Purchase of bank deposits</a></td>
<td class="num">(37,835)<span></span>
</td>
<td class="num">(27,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,011)<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInRestrictedDeposit', window );">Decrease (increase) in restricted deposit</a></td>
<td class="nump">359<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(81)<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(18,515)<span></span>
</td>
<td class="num">(27,544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment for convertible notes redemption and transactions costs</a></td>
<td class="num">(25,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Net payment for promissory note</a></td>
<td class="num">(4,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="nump">37,625<span></span>
</td>
<td class="nump">41,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">8,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">16,124<span></span>
</td>
<td class="nump">41,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET DECREASE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(7,623)<span></span>
</td>
<td class="num">(4,259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">18,265<span></span>
</td>
<td class="nump">17,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">10,642<span></span>
</td>
<td class="nump">13,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">309<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt', window );">Transactions costs in connection with the exchange of convertible notes</a></td>
<td class="nump">774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">3,288<span></span>
</td>
<td class="nump">2,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 445<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction costs in connection with exchange of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026288049176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On August&#160;25, 2021, the Company completed exchanges (the &#8220;Exchanges&#8221;) of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and, in October 2021, the final dosing of the last patient in the <i style="font-style:italic;">BALANCE</i> study was completed. See Part&#160;1, Item&#160;2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix and Chiesi also announced that a meeting was held with the Rapporteur and Co-Rapporteur of the European Medicines Agency (&#8220;EMA&#8221;) on October&#160;8, 2021 regarding PRX-102. At the meeting, Chiesi and Protalix discussed the scope of the anticipated Marketing Authorization Application (&#8220;MAA&#8221;) submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission for PRX-102. This is an important step in the necessary pre-submission activities leading up to a MAA submission. Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study that the Company announced in June 2021, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, the Company and Chiesi expect to submit an MAA to the EMA for PRX-102 during the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#8217;s exclusive worldwide license agreement with SarcoMed USA Inc. (&#8220;SarcoMed&#8221;) with respect to PRX-110 for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during the three months ended September 30, 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of common stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of September 30, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 26,905,842 and 21,405,733 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2020, respectively, and 27,962,842 and 26,847,081 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes, 2024 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026291315448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,170</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,053</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,848</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026288157160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of September&#160;30, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">Based on a Level 3 measurement, as of September&#160;30, 2021, the fair value of the $3.27&#160;million aggregate principal amount of the Company&#8217;s outstanding 2021 Notes is approximately $3.4&#160;million and the fair value of the $28.75&#160;million aggregate principal amount of the Company&#8217;s outstanding 2024 Notes is approximately $39.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes and 2024 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.04</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.74</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.99</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026289510248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,165</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,883</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,844</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,548</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,494</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,541</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,428</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"><span style="background-color:#ffffff;">During the nine months ended September&#160;30, 2021 and 2020, the Company recognized revenues of approximately </span><span style="background-color:#ffffff;">$16.5</span><span style="background-color:#ffffff;">&#160;million and </span><span style="background-color:#ffffff;">$31.4</span><span style="background-color:#ffffff;">&#160;million, respectively, </span>from license and R&amp;D services mainly in respect of the Chiesi Agreements, after taking into consideration change in estimate as detailed below. <span style="background-color:#ffffff;">During the three months ended September&#160;30, 2021 and 2020, the Company recognized revenues of approximately </span><span style="background-color:#ffffff;">$</span>6.5<span style="background-color:#ffffff;">&#160;million and </span><span style="background-color:#ffffff;">$</span>7.5<span style="background-color:#ffffff;">&#160;million, respectively, </span>from license and R&amp;D services mainly in respect of the Chiesi Agreements<span style="background-color:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">During the nine months ended September&#160;30, 2021, and following the CRL received from the FDA, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in a reduction to accumulated revenues recognized in respect of this performance obligation in the amount of $4.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 0pt 36pt;"><span style="background-color:#ffffff;">During the three months ended September 30, 2021, the Company</span><span style="color:#212529;"> completed its obligations under a feasibility study it entered into with Kirin Holdings Company, Limited (&#8220;Kirin&#8221;) on March&#160;16, 2020, and the agreement expired, including the </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="color:#212529;">option to provide additional services. Following the expiration of the option, the Company recognized as revenue during the three-month period ended September&#160;30, 2021 the </span><span style="color:#212529;">$1.0</span><span style="color:#212529;">&#160;million payment received in March 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026288029256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>CONVERTIBLE NOTES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE NOTES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; CONVERTIBLE NOTES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On August&#160;25, 2021, the Company completed the Exchanges of a substantial majority of the Company&#8217;s outstanding 2021 Notes with certain institutional note holders. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 2024 Notes, $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the issue date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances, which is based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The 2024 Notes were issued pursuant to an indenture entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes will be paid semi-annually at a rate of 7.50% per annum. The Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and are guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes are secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-family:'28mugxoulnobhnx';">Under the terms of the indentures governing each of the 2021 Notes and 2024 Notes, The Company is required to maintain a minimum cash balance of at least </span><span style="font-family:'28mugxoulnobhnx';">$7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million. In addition, under the exchange a</span>greements the Company entered into with each of the institutional note holders that participated in the Exchanges (the &#8220;Exchange Agreements&#8221;), the Company agreed to maintain unrestricted cash of not less than <span style="font-family:'28mugxoulnobhnx';">$3.27</span><span style="font-family:'28mugxoulnobhnx';"> million, </span>which is the amount necessary to redeem or repay at maturity all of the 2021 Notes that remain outstanding following the closing of the Exchanges.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">For accounting purposes, as the terms of the 2021 Notes and the 2024 Notes are substantially different, the Exchanges are considered an extinguishment of debt. The Company allocated the fair value of the consideration transferred to the participating note holders between the 2021 Notes and their equity component based on the fair value of the liability component before the extinguishment, and the remainder was allocated to the equity component. As a result, the Company recognized a loss from extinguishment in the statement of operations equal to $0.8&#160;million due to derecognition of the liability component of $54.8&#160;million and the repurchase of the original equity component for $12.0&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">All of the Company&#8217;s outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board Accounting Standards Codification (ASC) 815 requiring that the Company determine whether the embedded conversion option must be separated and accounted for separately. ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer&#8217;s nonconvertible debt borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company accounted for the 2024 Notes as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted. The equity component with respect to the cash conversion feature of approximately $12.0&#160;million was recognized in the Company&#8217;s additional paid in capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Transaction costs in the amount of approximately $869,000 were allocated to the liability and equity component. The debt discount and debt issuance costs regarding the issuance of the 2024 Notes are deferred and amortized over the convertible notes period using the effective interest rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026289515096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; STOCK TRANSACTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">On July&#160;25, 2021, the Company granted to a new employee, with the approval of the Company&#8217;s compensation committee, 10-year&#160;options to purchase&#160;50,000&#160;shares of Common Stock under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended. The options have an exercise price equal to $1.57 per share and vest over a four-year period in 16&#160;equal quarterly increments. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $55,000&#160;based on the following weighted average assumptions: share price equal to $1.57; dividend yield of 0% for all years; expected volatility of 84.3%; risk-free interest rate of&#160;0.88%; and expected life of six years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026292213624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On October&#160;13, 2021, the Company collected approximately $1.2&#160;million from expense reimbursements in connection with its collaboration with Chiesi. On October&#160;14, 2021, the Company collected approximately $1.1&#160;million from sales to Pfizer and on October&#160;15, 2021, the Company collected approximately $3.2&#160;million from sales of alfataliglicerase to Fiocruz.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On November&#160;9, 2021, the Company delivered the necessary funds under the indenture governing the 2021 Notes to effectively discharge the remaining outstanding 2021 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In accordance with ASC 855 &#8220;Subsequent Events&#8221; the Company evaluated subsequent events through the date the condensed consolidated financial statements were issued. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026286697416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On August&#160;25, 2021, the Company completed exchanges (the &#8220;Exchanges&#8221;) of the Company&#8217;s outstanding 7.50% Senior Secured Convertible Notes due 2021 (the &#8220;2021 Notes&#8221;) with institutional note holders of a substantial majority of the 2021 Notes. The Exchanges involved the exchange of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of newly issued 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), $25.90&#160;million in cash, and approximately $1.1&#160;million in cash representing accrued and unpaid interest through the closing date. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in certain circumstances. This initial conversion price represents a premium of approximately 32.5% relative to the closing price of the Common Stock on the NYSE American on August&#160;13, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies which are referred to as the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and, in October 2021, the final dosing of the last patient in the <i style="font-style:italic;">BALANCE</i> study was completed. See Part&#160;1, Item&#160;2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) regarding the biologics license application (&#8220;BLA&#8221;) for PRX-102 for the treatment of adult patients with Fabry disease. The PRX-102 was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, and was subsequently accepted by the FDA and granted Priority Review designation. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items. In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company and Chiesi participated in a Type A (End of Review) meeting with the FDA on September&#160;9, 2021. As part of the meeting minutes provided by the FDA, which included the preliminary comments and meeting discussion, the FDA, in principle, agreed that the data package proposed to the FDA for a BLA resubmission has the potential to support a traditional approval of PRX-102 for the treatment of Fabry disease. The planned data package for the BLA resubmission, given the changed regulatory landscape in the United States, will include the final two-year analyses of the <i style="font-style:italic;">BALANCE</i> study. The Company intends to continue to work collaboratively with the FDA to resolve the issues noted in the CRL and provide a new, alternative drug to Fabry patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix and Chiesi also announced that a meeting was held with the Rapporteur and Co-Rapporteur of the European Medicines Agency (&#8220;EMA&#8221;) on October&#160;8, 2021 regarding PRX-102. At the meeting, Chiesi and Protalix discussed the scope of the anticipated Marketing Authorization Application (&#8220;MAA&#8221;) submission for the European Union, and the Rapporteur and Co-Rapporteur were generally supportive of a planned MAA submission for PRX-102. This is an important step in the necessary pre-submission activities leading up to a MAA submission. Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study that the Company announced in June 2021, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, the Company and Chiesi expect to submit an MAA to the EMA for PRX-102 during the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which has successfully completed a phase II efficacy and safety study; the Company&#8217;s exclusive worldwide license agreement with SarcoMed USA Inc. (&#8220;SarcoMed&#8221;) with respect to PRX-110 for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery expired during the three months ended September 30, 2021; we are continuing to evaluate potential strategic marketing partnerships and collaboration programs with biotechnology and pharmaceutical companies for this product candidate for various respiratory indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). During the term of the sales agreement with BofA Securities, the Company sold a total of 3,296,123 shares of common stock for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the full amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of September 30, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 26,905,842 and 21,405,733 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2020, respectively, and 27,962,842 and 26,847,081 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes, 2024 Notes and outstanding warrants for the three and nine months ended September&#160;30, 2021, respectively, because their effect would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026380078824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,170</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,507</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,053</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,848</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,730</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026289559208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables) - Notes 2021 and 2024<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes and 2024 Notes&#160;(a Level 3 valuation) as of September&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.33</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.04</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.50</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.74</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.99</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026289518440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's disaggregation of revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.98%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,135</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,165</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,883</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,844</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,188</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 171</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 131</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:39.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,548</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,494</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,541</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,428</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026289510248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member', window );">Notes 2021 and 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the 2024 Notes and 2021 Notes (a Level 3 valuation) as of August&#160;25, 2021. The value was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.34</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.44</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 78.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.87</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.66</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_ConvertibleNotesDue2021And2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026280805720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Debt, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,427,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,962,842<span></span>
</td>
<td class="nump">26,905,842<span></span>
</td>
<td class="nump">26,847,081<span></span>
</td>
<td class="nump">21,405,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Maintain of Minimum Cash Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 54,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="nump">$ 25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest', window );">Convertible notes exchange in cash, accrued and unpaid interest</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleConversionShareNumber', window );">Debt Instrument Convertible Conversion Share Number | shares</a></td>
<td class="nump">563.2216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate', window );">Debt Instrument Convertible Base Value For Conversion Rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price | $ / shares</a></td>
<td class="nump">$ 1.7755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfPremiumToClosingPriceOfStock', window );">Percentage of Premium to Closing Price of Stock</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Revenue, Performance Obligation, Number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued and unpaid interest exchanged in cash in debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Base Value For Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleBaseValueForConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Conversion Share Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfPremiumToClosingPriceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium to closing price of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfPremiumToClosingPriceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNonCreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026286262888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,170<span></span>
</td>
<td class="nump">$ 3,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">3,507<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">8,053<span></span>
</td>
<td class="nump">6,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 14,730<span></span>
</td>
<td class="nump">$ 13,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026292170216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details) - Fair Value, Inputs, Level 3<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 25, 2021 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">1.33<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">0.13<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">81.16<span></span>
</td>
<td class="nump">78.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">6.74<span></span>
</td>
<td class="nump">7.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">1.33<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="nump">3.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="nump">0.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">91.77<span></span>
</td>
<td class="nump">91.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">8.99<span></span>
</td>
<td class="nump">7.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026287916552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Additional Information (Details) - Fair Value, Inputs, Level 3<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term Debt</a></td>
<td class="nump">$ 3,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">3,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">28,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 39,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026292090088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Company's disaggregation of revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 12,054<span></span>
</td>
<td class="nump">$ 10,790<span></span>
</td>
<td class="nump">$ 29,801<span></span>
</td>
<td class="nump">$ 43,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_KirinHoldingsCompanyLimitedMember', window );">Kirin Holdings Company, Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">3,296<span></span>
</td>
<td class="nump">12,260<span></span>
</td>
<td class="nump">11,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">3,165<span></span>
</td>
<td class="nump">7,883<span></span>
</td>
<td class="nump">5,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,188<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Chiesi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">7,548<span></span>
</td>
<td class="nump">7,494<span></span>
</td>
<td class="nump">17,541<span></span>
</td>
<td class="nump">31,428<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member] | Chiesi US Agreement and Chiesi Ex US Agreement [Member] | Change in Accounting Method Accounted for as Change in Estimate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReductionToAccumulatedRevenueRecognized', window );">Reduction To Accumulated Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member] | Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="nump">$ 31,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReductionToAccumulatedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction to accumulated revenues recognized in respect of performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReductionToAccumulatedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_KirinHoldingsCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_KirinHoldingsCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026376297304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 25, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,990,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(831,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,019,000<span></span>
</td>
<td class="nump">12,019,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,027,000<span></span>
</td>
<td class="num">(12,027,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt', window );">Transactions costs in connection with the exchange of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">774,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaintainOfMinimumCashBalance', window );">Minimum cash balance required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained', window );">Minimum unrestricted cash balance to be maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,270,000<span></span>
</td>
<td class="nump">3,270,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 54,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentDerecognitionOfLiabilityComponent', window );">Derecognition of liability component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,800,000<span></span>
</td>
<td class="nump">54,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes', window );">Reacquisition of equity component of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,000,000.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Net payment for convertible notes</a></td>
<td class="nump">25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest', window );">Convertible notes exchange in cash, accrued and unpaid interest</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate', window );">Base value for conversion rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleConversionShareNumber', window );">Number of shares for basis conversion</a></td>
<td class="nump">563.2216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share</a></td>
<td class="nump">$ 1.7755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfPremiumToClosingPriceOfStock', window );">Percentage of Premium to Closing Price of Stock</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Mature term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts', window );">Equity component of convertible notes, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt', window );">Transactions costs in connection with the exchange of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 869,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued and unpaid interest exchanged in cash in debt conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The transaction costs in connection with exchange of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Base Value For Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleBaseValueForConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Conversion Share Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentDerecognitionOfLiabilityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of derecognition of liability component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentDerecognitionOfLiabilityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum unrestricted cash balance to be maintained under the exchange agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Notes Net Of Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaintainOfMinimumCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum cash balance required to be maintained under long term debt agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaintainOfMinimumCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfPremiumToClosingPriceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium to closing price of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfPremiumToClosingPriceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReacquisitionOfEquityComponentOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reacquisition Of Equity Component Of Convertible Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReacquisitionOfEquityComponentOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026291538696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONVERTIBLE NOTES (Fair Value Income Approach) (Details) - Fair Value, Inputs, Level 3<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 25, 2021 </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">1.33<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">0.13<span></span>
</td>
<td class="nump">0.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">81.16<span></span>
</td>
<td class="nump">78.95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes | Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">6.74<span></span>
</td>
<td class="nump">7.87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | $ / shares</a></td>
<td class="nump">1.33<span></span>
</td>
<td class="nump">1.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input | Y</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="nump">3.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="nump">0.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">91.77<span></span>
</td>
<td class="nump">91.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes | Yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">8.99<span></span>
</td>
<td class="nump">7.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026291190616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - 2006 Employee Stock Incentive Plan - New employee<br></strong></div></th>
<th class="th">
<div>Jul. 25, 2021 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements', window );">Number of equal quarterly increments | item</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue', window );">Grant Date Fair Value | $</a></td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share price</a></td>
<td class="nump">$ 1.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility Rate</a></td>
<td class="nump">84.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="nump">0.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal quarterly increments over which the awards vest under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=plx_EmployeeStockIncentivePlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140026393529272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 15, 2021</div></th>
<th class="th"><div>Oct. 14, 2021</div></th>
<th class="th"><div>Oct. 13, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromExpenseReimbursements', window );">Proceeds from expense reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Amended Pfizer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Brazil Agreement with Fiocruz | Alfataliglicerase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfProducts', window );">Proceeds from sales</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromExpenseReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from expense reimbursements in a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromExpenseReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from sale of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=plx_AlfataligliceraseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=plx_AlfataligliceraseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M)T-A%GB.KWF0<#;CFX?\^7+Q!UI/[[ZC^6QT,YO/UK.IL9%#"VEX8]J_9(^
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MG07KHMH SK!)QT3">V>&Y=:L2IHGB\+KP8R6YH7K/@U\;MH#YR\^Y(:#T'-
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M\(YV#OF-OJ3,ZO9_\-#)>@.0K&M6YEUC;D&>%IO/^$L7B*<T0%T#)#5 R-
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MNCZSR_3,@YX@$&]O UWQ=:@T!+AKM6L_)W#^9W!A!Z*@M;\+OAQE95T#COJ
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M/DX:P/>[#$+Q]$$^H/J=Q\7_ 5!+ P04    " !Y.F]3E@Z%PZ<:   U3@
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M(KI)W%<0MMY(;[!YW6[HE'?XL;P%2W9ZIRCVD&1W:M-6>+R )X8/%+)8RXF
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M\]GQY-G1@CFSF$^.\/'D\/"NEZ 891?[X4RT\="#BPGC3U*TXG-Q5I*\?$2
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M?F%3R\;3 :25\Z9HE,F#0NKZ7]PU//04YN,G%.)&(0Y^UX:"E^^$%R='UFS
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MYYY,1T0VHVMC:%'9<7$M- Z?]C'':1^D<<#W&R%T:Y@-NO\?EG\#4$L#!!0
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M#U55F4INI+ 'X2865B2E"?2P; 5LXP4**>O!"K,J+')KA;-[-<YK(MV^G*\
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MXSQ\8FN/AP^5'[G!D& Q :] &D>S:8^9\/$OO#A=^ ]N2^V<SOWC1G#,*W0
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MSXY?^1^?RF3>K&&2R>S$JN H7HOISV6-3>1]NA'E&B<YB'AQX3\-K ?90\3
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MIS)U90F.7>"[M_,08,@)5^RCZ0$$^5RO@542@$A)^\&:\%^WAGO_S57[?L2
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M-%J&PQH4'C+)I6 >-UN&][T-Q\F;N S$F;0JG&ZIH%O3V6%!I4NK^/94Q.0
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MC,5UL$5BBDFHPW]8-:7S3R64O K0-1R6C>?3%JMO))2R:@V'K9J4AC3QT"W
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M!9^>>4GYUJJMMY&!^+I.Q)_8+7W4-0D@3$AXP*CL4(]=J%_B&27< :99.%7
M-KM5>N>1OH,MCJV1Q^@3:(TF#$S%@R5+UP:1KA7ZK?TBN_:S%;Y!1#W53*:Y
MJ-I&^F_4U?&J\ZE:B]*[*KNW<&8*XD!]0;4J0BX06#*=VK&L$8MC([*D;.#N
MJ#<@,IK;E-1L F0U'D:YI2C&ZV(7I0Y#Y=$P/%A7<*#&ZA55AEFWW YDG[R'
M/5%[8CH/5SB]PFVI P FF3U%$IG>NDD&Q>!PQ8_QV(N=T% 6ZU'Q9K6B[KT%
M2@5-91O-<"!3/,)*NL&$4M,]=ZM"RS2E@[G8!<SH9F<XG/+$7#NY=QL7M?O
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M1D+ @O\'K,C-LVSXT-V9RR@68K.MJ-R\5 ])T^^-O4D0QI!,-*<1IE6'\LV
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M(RQ;/TB0;JC8YZL27@!-W% VH^@>?*0^81&=VGLHMG3L%(^\&HV@T$LB8>B
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M\G\W4D"@] "^7VGD\.X7VB#\];V?_P=02P,$%     @ >3IO4\%[!/28 @
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M!Y#ABI7"SM3V*];[\0DNE3#^%[:5;S<-8%D:J_(:3!GD7%;_[+FNPQZ@'W\
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MNGJ!5!.K"O_57RA+;P@_W-"C#;5SH/65HJK7$Q>@>0:._P-02P,$%     @
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MQC0<C(<>R':BM((6C>OB:Z'-3'#+R@QAE%;!G!="Z!?!.NC&^OP'4$L#!!0
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M!\#G"\[C[8W\:5_QX]WS_P-02P,$%     @ >3IO4\BEQP58 @  &08  !D
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MB7Z@F5%%CX(MX(AT4$D'1Z5O8:XT1:G$1F\G=84>@,J- #/9T]6//(KE>O\
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M4JD0E-ZS(0NQZM@YVX'VWY_MI#GN6NC3O21>>V=V9BUOO!?R166(&EYSQM7
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M5@__2UD]#96AQ:ILE@NAL?66TQ2?4Y#& ?<3(?2+8?IO\T"'OP!02P,$%
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M2CQS[[5'.HM,WK8>8K8QVL9IWJ3D'QB+90-&QL)YL+A3NV!DPM>P8%Z62[D
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MOCNW_.N_&>U:&*GLP9]UOXQFGU!+ 0(4 Q0    ( 'DZ;U,'04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ >3IO4^X#P [O    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ >3IO4YE<G",0!@  G"<  !,
M     ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !Y.F]3
MLVBT/%<%   M%@  &               @($."   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ >3IO4^W\A^&/!0  GA4  !@
M     ("!FPT  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M 'DZ;U-M/QIBY04  *L8   8              " @6 3  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    " !Y.F]3C>\.W44#   ."P  &
M            @(%[&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ >3IO4P\-A@(R"   12P  !@              ("!]AP  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( 'DZ;U.&3;PH7 (  *\%
M   8              " @5XE  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    " !Y.F]3M=(&OIX(  #S(0  &               @('P)P
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ >3IO4Y8.A<.G
M&@  -4X  !@              ("!Q#   'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( 'DZ;U."^?E$D0(  "0&   8              "
M@:%+  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !Y.F]3
ML3"&S;4%   \#@  &0              @(%H3@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( 'DZ;U-!K;4+C@0  $L,   9
M      " @514  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ >3IO4^3(OB5Y"   C14  !D              ("!&5D  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !Y.F]3/0%Y^74#  !1!P
M&0              @(')80  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( 'DZ;U-'1I _7P,  ,('   9              " @75E  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ >3IO4P[8;/78
M&@  B4\  !D              ("!"VD  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    " !Y.F]3P7L$])@"   :!@  &0
M@($:A   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( 'DZ
M;U,Q2,ATAP,  !(*   9              " @>F&  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ >3IO4U68#,+W @  X@<  !D
M         ("!IXH  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    " !Y.F]3+_4I< 0#  "]!@  &0              @('5C0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( 'DZ;U-.W:T)Q@@  ,@K
M   9              " @1"1  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ >3IO4\BEQP58 @  &08  !D              ("!#9H
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " !Y.F]3'$>Q
MIX@#  "-#@  &0              @(&<G   >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( 'DZ;U.)#P/Z8@(  -H%   9
M  " @5N@  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M>3IO4T<KB=PO!   01   !D              ("!]*(  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    " !Y.F]3GZ=<IZ@$  "W$@  &0
M            @(%:IP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( 'DZ;U/)]^(O:@,  &,.   9              " @3FL  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ >3IO4VWR*^I9 P
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M96QS+RYR96QS4$L! A0#%     @ >3IO4S3K@50  P  .1,   \
M     ( !B[H  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( 'DZ;U,O ()4
M3 $  &L1   :              "  ;B]  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( 'DZ;U,BX&C7>P$  #H2   3
M  "  3R_  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     D "0 LPD  .C
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>127</ContextCount>
  <ElementCount>247</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - CONVERTIBLE NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotes</Role>
      <ShortName>CONVERTIBLE NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30503 - Disclosure - CONVERTIBLE NOTES (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesTables</Role>
      <ShortName>CONVERTIBLE NOTES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotes</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails</Role>
      <ShortName>REVENUES - Company's disaggregation of revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40501 - Disclosure - CONVERTIBLE NOTES (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40502 - Disclosure - CONVERTIBLE NOTES (Fair Value Income Approach) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails</Role>
      <ShortName>CONVERTIBLE NOTES (Fair Value Income Approach) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureConvertibleNotesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40601 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20210930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40701 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="plx-20210930x10q.htm">plx-20210930x10q.htm</File>
    <File>plx-20210930.xsd</File>
    <File>plx-20210930_cal.xml</File>
    <File>plx-20210930_def.xml</File>
    <File>plx-20210930_lab.xml</File>
    <File>plx-20210930_pre.xml</File>
    <File>plx-20210930xex31d1.htm</File>
    <File>plx-20210930xex31d2.htm</File>
    <File>plx-20210930xex32d1.htm</File>
    <File>plx-20210930xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20210930x10q005.jpg</File>
    <File>plx-20210930x10q006.jpg</File>
    <File>plx-20210930x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20210930x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 127,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20210930x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20210930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 283,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 13
   },
   "keyCustom": 45,
   "keyStandard": 202,
   "memberCustom": 17,
   "memberStandard": 19,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - CONVERTIBLE NOTES",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotes",
     "shortName": "CONVERTIBLE NOTES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - STOCK TRANSACTIONS",
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "shortName": "STOCK TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_I0Grm-B4g0GE3UCgk-DBhw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_c9iBJVgvmE6XPL7XnYJeDA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_ConvertibleNotesDue2021And2024Member_I0Grm-B4g0GE3UCgk-DBhw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - CONVERTIBLE NOTES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
     "shortName": "CONVERTIBLE NOTES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q",
      "decimals": "-3",
      "lang": null,
      "name": "plx:ShortTermBankDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_2_17_2021_To_2_17_2021_1i-AeCXmUEuYJ6FKsF7Dqw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_2_17_2021_To_2_17_2021_1i-AeCXmUEuYJ6FKsF7Dqw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_fjePpaWSpkeew6EE71xYVQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
     "shortName": "FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Z6NWekiCLE6G-qLdOHDf5g",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_Z6NWekiCLE6G-qLdOHDf5g",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
     "shortName": "REVENUES - Company's disaggregation of revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_TypeOfArrangementAxis_plx_KirinHoldingsCompanyLimitedMember_OyqOeTcPvEeZzice06IGyg",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfConvertibleDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - CONVERTIBLE NOTES (Details)",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
     "shortName": "CONVERTIBLE NOTES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_R3eVdAJPmU-INbiD0ErvuA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_fjePpaWSpkeew6EE71xYVQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - CONVERTIBLE NOTES (Fair Value Income Approach) (Details)",
     "role": "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
     "shortName": "CONVERTIBLE NOTES (Fair Value Income Approach) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - STOCK TRANSACTIONS (Details)",
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_7_25_2021_To_7_25_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_plx_EmployeeStockIncentivePlan2006Member_mdWhhq2bIkulxYekrM1Ffw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_10_13_2021_To_10_13_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_m9nl_SJDHUWIRCUsIOV1yA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "plx:ProceedsFromExpenseReimbursements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_10_13_2021_To_10_13_2021_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_m9nl_SJDHUWIRCUsIOV1yA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "plx:ProceedsFromExpenseReimbursements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_khStze5kwkqROyvLATXHAw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_R6xvGSBAO0OzR-4qkTKWaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_7_1_2021_To_9_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_R6xvGSBAO0OzR-4qkTKWaw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gAacYeLtwE-Mj1yvi-z7VA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gAacYeLtwE-Mj1yvi-z7VA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_pAA6farcFUOEf3ryCcTO7A",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "As_Of_9_30_2021_SnVbO1VIqEaItXW8HhXA1Q",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_X-VrCrKHfE6XM7G_EkktQg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_4bN3bLtoVEahVux9absZBg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210930x10q.htm",
      "contextRef": "Duration_1_1_2021_To_9_30_2021_IoIo4lCce06sis_Uo494Kg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 36,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brazil [Member]"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AlfataligliceraseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the product, alfataliglicerase.",
        "label": "Alfataliglicerase"
       }
      }
     },
     "localname": "AlfataligliceraseMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi [Member]"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi US Agreement and Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "localname": "ConvertibleNotesDue2021And2024Member",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued and unpaid interest exchanged in cash in debt conversion.",
        "label": "Debt Conversion, Converted Instrument, Exchange in Cash, Accrued and Unpaid Interest",
        "terseLabel": "Convertible notes exchange in cash, accrued and unpaid interest"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentExchangeInCashAccruedAndUnpaidInterest",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The transaction costs in connection with exchange of convertible notes.",
        "label": "Debt Conversion, Transaction Costs in Connection with Exchange of Convertible Debt",
        "terseLabel": "Transactions costs in connection with the exchange of convertible notes"
       }
      }
     },
     "localname": "DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtInstrumentConvertibleBaseValueForConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Base Value For Conversion Rate",
        "label": "Debt Instrument Convertible Base Value For Conversion Rate",
        "terseLabel": "Base value for conversion rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBaseValueForConversionRate",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtInstrumentConvertibleConversionShareNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Conversion Share Number",
        "label": "Debt Instrument Convertible Conversion Share Number",
        "terseLabel": "Number of shares for basis conversion"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionShareNumber",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_DebtInstrumentDerecognitionOfLiabilityComponent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of derecognition of liability component.",
        "label": "Debt Instrument, Derecognition Of Liability Component",
        "terseLabel": "Derecognition of liability component"
       }
      }
     },
     "localname": "DebtInstrumentDerecognitionOfLiabilityComponent",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtInstrumentMinimumUnrestrictedCashToBeMaintained": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum unrestricted cash balance to be maintained under the exchange agreements.",
        "label": "Debt Instrument, Minimum Unrestricted Cash To Be Maintained",
        "terseLabel": "Minimum unrestricted cash balance to be maintained"
       }
      }
     },
     "localname": "DebtInstrumentMinimumUnrestrictedCashToBeMaintained",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_EmployeeStockIncentivePlan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent the employee stock incentive plan for the particular period.",
        "label": "2006 Employee Stock Incentive Plan"
       }
      }
     },
     "localname": "EmployeeStockIncentivePlan2006Member",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component Of Convertible Notes Net Of Transaction Costs",
        "label": "Equity Component Of Convertible Notes Net Of Transaction Costs",
        "terseLabel": "Equity component of convertible notes, net of transaction costs"
       }
      }
     },
     "localname": "EquityComponentOfConvertibleNotesNetOfTransactionCosts",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Gain on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Purchase of bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInRestrictedDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit",
        "label": "Increase (Decrease) In Restricted Deposit",
        "negatedLabel": "Decrease (increase) in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedDeposit",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in liabilities for property, plant and equipment.",
        "label": "Increase In Liabilities For Property Plant And Equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "IncreaseInLiabilitiesForPropertyPlantAndEquipment",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, in shares.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, value.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_KirinHoldingsCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kirin Holdings Company, Limited [Member]",
        "label": "Kirin Holdings Company, Limited [Member]"
       }
      }
     },
     "localname": "KirinHoldingsCompanyLimitedMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_MaintainOfMinimumCashBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum cash balance required to be maintained under long term debt agreements.",
        "label": "Maintain of Minimum Cash Balance",
        "terseLabel": "Minimum cash balance required"
       }
      }
     },
     "localname": "MaintainOfMinimumCashBalance",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yield",
        "label": "Yield"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PercentageOfPremiumToClosingPriceOfStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of premium to closing price of stock.",
        "label": "Percentage of Premium to Closing Price of Stock"
       }
      }
     },
     "localname": "PercentageOfPremiumToClosingPriceOfStock",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer [Member]"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromExpenseReimbursements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from expense reimbursements in a collaboration agreement.",
        "label": "Proceeds from Expense Reimbursements",
        "terseLabel": "Proceeds from expense reimbursements"
       }
      }
     },
     "localname": "ProceedsFromExpenseReimbursements",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net of issuance cost.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost",
        "verboseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from sale of products.",
        "label": "Proceeds From Sale Of Products",
        "terseLabel": "Proceeds from sales"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProducts",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation [Member]"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ReacquisitionOfEquityComponentOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reacquisition Of Equity Component Of Convertible Notes",
        "label": "Reacquisition Of Equity Component Of Convertible Notes",
        "negatedLabel": "Reacquisition of equity component of convertible notes",
        "terseLabel": "Reacquisition of equity component of convertible notes"
       }
      }
     },
     "localname": "ReacquisitionOfEquityComponentOfConvertibleNotes",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ReceivablesFromSaleOfCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables from sale of common stock and warrants.",
        "label": "Receivables From Sale of Common Stock And Warrants",
        "negatedLabel": "Note receivable payment"
       }
      }
     },
     "localname": "ReceivablesFromSaleOfCommonStockAndWarrants",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ReductionToAccumulatedRevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction to accumulated revenues recognized in respect of performance obligation.",
        "label": "Reduction To Accumulated Revenue Recognized"
       }
      }
     },
     "localname": "ReductionToAccumulatedRevenueRecognized",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2021 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Grant Date Fair Value",
        "terseLabel": "Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantDateFairValue",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal quarterly increments over which the awards vest under the share based payment arrangement.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Increments",
        "terseLabel": "Number of equal quarterly increments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyIncrements",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to supply and technology transfer agreement with Fiocruz.",
        "label": "Brazil Agreement with Fiocruz"
       }
      }
     },
     "localname": "SupplyAndTechnologyTransferAgreementWithFiocruzMember",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_UpfrontNonrefundableNonCreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non-Creditable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNonCreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20210930",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r149",
      "r183",
      "r216",
      "r217",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r313",
      "r316",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r149",
      "r183",
      "r216",
      "r217",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r313",
      "r316",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r120",
      "r200",
      "r202",
      "r293",
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r120",
      "r200",
      "r202",
      "r293",
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r149",
      "r183",
      "r207",
      "r216",
      "r217",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r313",
      "r316",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r149",
      "r183",
      "r207",
      "r216",
      "r217",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r313",
      "r316",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r121",
      "r122",
      "r200",
      "r203",
      "r315",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r121",
      "r122",
      "r200",
      "r203",
      "r315",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r124",
      "r125"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r234",
      "r235",
      "r236",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r219",
      "r221",
      "r239",
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r221",
      "r232",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r69",
      "r169",
      "r177",
      "r178",
      "r268"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r78",
      "r109",
      "r112",
      "r118",
      "r127",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r245",
      "r247",
      "r256",
      "r275",
      "r277",
      "r295",
      "r305"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r44",
      "r78",
      "r127",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r245",
      "r247",
      "r256",
      "r275",
      "r277"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r33",
      "r71"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r65",
      "r259"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET DECREASE IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r89",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r89",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A change from one acceptable accounting method to another based upon a revision in estimated future benefits or obligations.",
        "label": "Change in Accounting Method Accounted for as Change in Estimate [Member]"
       }
      }
     },
     "localname": "ChangeInAccountingMethodAccountedForAsChangeInEstimateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r81",
      "r82",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r198",
      "r199",
      "r201"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r198",
      "r199",
      "r201"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r54",
      "r78",
      "r127",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r256"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r163",
      "r170",
      "r171",
      "r172",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "CONVERTIBLE NOTES"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r77",
      "r79",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r175",
      "r176",
      "r177",
      "r178",
      "r269",
      "r296",
      "r297",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r18",
      "r173",
      "r297",
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r148",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price per share"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r146",
      "r175",
      "r176",
      "r267",
      "r269",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39",
      "r77",
      "r79",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r175",
      "r176",
      "r177",
      "r178",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Mature term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r14",
      "r204",
      "r205",
      "r206",
      "r215",
      "r294",
      "r304"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r69",
      "r131"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's disaggregation of revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r52",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r94",
      "r96",
      "r98",
      "r99",
      "r100",
      "r103",
      "r104",
      "r250",
      "r251",
      "r300",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r52",
      "r86",
      "r87",
      "r88",
      "r89",
      "r90",
      "r96",
      "r98",
      "r99",
      "r100",
      "r103",
      "r104",
      "r250",
      "r251",
      "r300",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r47",
      "r48",
      "r49",
      "r81",
      "r82",
      "r83",
      "r85",
      "r91",
      "r93",
      "r106",
      "r128",
      "r195",
      "r196",
      "r234",
      "r235",
      "r236",
      "r242",
      "r243",
      "r249",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r317",
      "r318",
      "r319",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of liability component based on income approach"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r161",
      "r175",
      "r176",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r252",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r161",
      "r175",
      "r176",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r252",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r161",
      "r175",
      "r176",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r70",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r69",
      "r179",
      "r180"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of convertible notes",
        "terseLabel": "Loss on extinguishment of convertible notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r218",
      "r220",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r68",
      "r291"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase (decrease) in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Decrease in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r64",
      "r66",
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r27",
      "r129"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r3",
      "r42",
      "r277"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r29",
      "r129"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r28",
      "r129"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r78",
      "r113",
      "r127",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r246",
      "r247",
      "r248",
      "r256",
      "r275",
      "r276"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r78",
      "r127",
      "r256",
      "r277",
      "r298",
      "r307"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (net of capital deficiency)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r78",
      "r127",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r246",
      "r247",
      "r248",
      "r256",
      "r275",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r18",
      "r19",
      "r78",
      "r127",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r246",
      "r247",
      "r248",
      "r256",
      "r275",
      "r276"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and R&amp;D Services [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Risk free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Share Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r65",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r45",
      "r46",
      "r49",
      "r51",
      "r70",
      "r78",
      "r84",
      "r86",
      "r87",
      "r88",
      "r89",
      "r92",
      "r93",
      "r97",
      "r109",
      "r111",
      "r114",
      "r117",
      "r119",
      "r127",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r251",
      "r256",
      "r299",
      "r309"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS FOR THE PERIOD",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL EXPENSES - NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r109",
      "r111",
      "r114",
      "r117",
      "r119"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r272"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r43",
      "r277"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r311"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "OTHER INCOME"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r59",
      "r61"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r20",
      "r204",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r222",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r12",
      "r13",
      "r132",
      "r277",
      "r302",
      "r308"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Payment for convertible notes redemption and transactions costs",
        "terseLabel": "Net payment for convertible notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Net payment for promissory note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r241",
      "r292",
      "r332"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r81",
      "r82",
      "r83",
      "r85",
      "r91",
      "r93",
      "r128",
      "r234",
      "r235",
      "r236",
      "r242",
      "r243",
      "r249",
      "r317",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r50",
      "r78",
      "r107",
      "r108",
      "r110",
      "r115",
      "r116",
      "r120",
      "r121",
      "r123",
      "r127",
      "r135",
      "r136",
      "r137",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r256",
      "r301"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r30",
      "r31",
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r222",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend Yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r220",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "New employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Term of award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r227",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r15",
      "r277",
      "r296",
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r41",
      "r47",
      "r48",
      "r49",
      "r81",
      "r82",
      "r83",
      "r85",
      "r91",
      "r93",
      "r106",
      "r128",
      "r195",
      "r196",
      "r234",
      "r235",
      "r236",
      "r242",
      "r243",
      "r249",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r317",
      "r318",
      "r319",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r106",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureConvertibleNotesDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesFairValueIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureConvertibleNotesTables",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r195",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r24",
      "r25",
      "r78",
      "r126",
      "r127",
      "r256",
      "r277"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r182",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r266",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r266",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r266",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r266",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r278",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r95",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r94",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e777-108305"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r333": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r334": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r335": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r336": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r337": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r338": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001558370-21-015862-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-015862-xbrl.zip
M4$L#!!0    ( 'DZ;U/!\)QOR X  )V    0    <&QX+3(P,C$P.3,P+GAS
M9.U=6W/;MA)^/S/G/_#HI>F#+$M.TF-/W XMRXFFLN1*<M(\=2 2DC"A  8
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MN^L)R5;FFHAKMD*$!MTG&@8!=<M5B<0+!;3QG%"BE8& <7IJ-(T-1_@1,C6
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M")4W,&(W''?/=/Q(GUY6INK^SD]>0CX!TO%W.5YI5_\<6<IT3X;<X:1:KS1
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MP\C_5JM^8.RLUD,^;=9IXFAN$!P-'6.RFGE<A(OA23..%-+:6$">(TK.>MH
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M"]&]"W^>HTS.B>;$.&1:T?09=89MK-<>TAD:BI(-IL\,V8X(:UVC;,Z)T^1
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MIPQ-0A+N4H06(!UK?WT!D)(H"@#!;\CA=)JUI /@?.,<X #XY9]/:\]Z!)A
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M B^Z3V\%-W.D*$TKT(,>,[+[*+6$F24F5!BM1A<V)63L%C8+H&_"7/@1VWX
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MJ(WH%"9.!'G=\3V-EENFDI=.[*T5$BI@<9R$EO&RLY "6G<:&BZ:%P126,*
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MZ2#FD2YD()&(L?O_#G$"7,6K4)&NP#OCL9Y3O( G7V,OR:X/B(Y+KP@ @.S
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M;DH,T1"GP3JB3DROJ?BW= R<5JYK2=CH0@#'&+N+6#9'<VSK!MF5M6:!U90
M>9>1^!HV=$5:0_X\*G).P\F2EN)WI:P#OE+FYI@%\Y S$)IR7H4!E^MG+]E>
M'>(DW-'H-HL\&O=6"Y6AV*61L'KCU)(8@(4:\&=JIADI\H71(AFQ$<G)89TZ
M]RVU6Y9ZG9**2P'X=QY_*P!L.@B#BS4_D4O('J;B,, \,FMVQ7@MU@_%!7GC
M7I2A#L5TU6+I[;6)-P C53%E:ID9/BD(8.V/3Q N0^'F50CG9,*5:C/ %!KR
M\\#CHT_2XRXQ;Y>F^UO@@X>MYYN'F(YY<Y(8N"FB_>.K;B)EQU1F6"C'45U8
MTU1NX3< 1+Y#90W*J8G3%3AO.; _!$6[QTPG2=E)+HPCHQZDXXMK?NX#HPGB
MH$>BF\YO&CPS30XC3_DJ70O.4.9;B2#ZB;:$,( 9ML&-Z=1:0AS.E-I!&B:"
MIQ9A$"O3>^<5)O5QX(Y%JLMML3GNO,K0$QN*-741W6P]JZ,T /LS9[/SFC<E
MR=>$*5%2HCJ<36D??5!>#^]+@O,D,<<?EH'SY+<9LP^Q/S[&K'4DAF+,[6*V
MQ'>5^ ,PW#;FC&.\?+=6$#J[B1X3X^TJ:[YCA3 O%] /X;D0&NW*$=XW<1=>
MT4M=" S][KO,',VQ!WS7O;\[[N<QQ3!Q?)TI]B)IZU7/X9DAK./C/DI2: D-
MRBP-1#8P3PV5H9AI*XM=S34G.*3+W[T)7R]),9U]FBS[*$DA#?,VY_Y+)_CU
MFO+435EXMPW!?EC73(0LG*N'1@GCFK"D"=]Z^3JS<ESGIOAD2WU7G%0^,K*6
M@[='R:98.0,FR5 Q8K5'"7//F-@ZH@@_#$ ^,+W9,/,Y:TK=4KGOY3:,DA5;
M?&L,V0C+OC5W$"8S:0,4%+LVYDMCW'PMYP4;/_Q2K:H? ZD+OL'*%,JN91\O
M788I!,J*Z"\+@<YCXR955OL22C-*F->(12%_>"MWS6O&5"X]C .W[3I.%P)(
MEX@[BUBY0VR,;?\*<4?6F@J:$N#O0 L2^:6<D;B5,^(15/2K.:>+6IIR]]F]
M(Q"-JD2S:80-%]/9"KM00#+#[D)6[- <W;XA=N7-</ZS:8O&U_=[EC6;%OLS
M2L--;?'Z9SJ-&ZWN)5A#V-XJA5'O<1LH ]GH*OAJJ-%J2XLJ=NER.(Q(>$CX
M1_GKY/"G\_04\1E'NDUVXCB$"DPTW2![I=/%TE.NZ=(->>-LVE>RW?.T\G+O
M]3GD.78+;2J6(BFR?9@0%M@W851VG?PX31();%G_&%/!76IW%%:VWC8D@;;H
M[L2?>N4-3NE=94;\.CT.EH6TL9??IPD]/J%:!2_&]28.J4X^#!C^H=1IAU$#
M/H3J[_!I4&?%W22MG!5[N6Q#/BO.;P:?>E:L)30HLS00V< \-52&8J:M++8>
ME]Y,9^/9U7 J^"]H^GQJ7'FR2U.-18N!HY8&0I3U3P-N7=%:>9&\X)AAB.*)
M1>T.S'(KW>5(UW%\U=FH0,)66RY;A2593<G2&V^Q_)$W.Q&G[F+"++;7B3H0
MX^>/]*49SP;"5\'QS5[&OLKFR["H!M]DI,7:Q:N/*<803-U @KH![-D8>G$<
M1J]<_\^29I!5CU&]+,X?H\R H()+RUGK$?1P4Q..[@!9TD)G8NCI#$=RW'(\
MD%?KX36S^+-],1#F,]27E'3^+&FEM@]>[D/O70%$B_),_%G:X@5#PBB3C'3V
M/&VEEI/M:SY#4XV!'.U*N\'@F$V!AW^,JQ5(=7@K14(]LM5PU**"TY(*EDT2
M_VCV>)F49@516W&"!N>^,1D_150=FSVWCSE5Z(\1U&;<I]@#\1"I0YR\T&CM
MQ>K3("T*OE]0B:%R"75X5&\@9Z;%:%(DDF/A>P!#.;+?P=RS2?--!'A/CB(.
M/Z![6B!WP '<X\Y9<D)#/6?I)BD_9]F7)-WD\@WBK&6RV8CW"=*7CQ9.0N<!
MR,V6[O /)'H]LZ6 NC1P-Q(XYGB,F&6#[()OW22[,]><(#@)F!XR(@2H0%EK
M;JNPV^(?2J1P9K\^A+VYF5RMX+7VR3^O?AK//D[(8KR:$/%Y2>8S\8S[>'8M
M/DS^\3#]-+Z%-]X1316$JPE8Y%"E'5#]H@1YS]/CFEE8:17'<F^*'E9TOVTF
M<-P%3E>7'8Y=#JR[+ SQFD?(C.RHX=9&Y8S)W/G5OZL@"(:() %S1'*V:IY5
M<(:SLAE$[\\F*W(]N5I,QLL)F0[7Y=[XX1<HB<(^%BDV@2M9!D*E>C^,#Q%M
MR4LYG2R>6^RC.^J.[A2:**[K=(:ESH@ W1%)*9=2SL #R39&I""/7@CA3/VR
M?+B_OYW<,4<P7OR+^8F;^>)NO)JR-1K[KU0C@3D.60H0F<U7 #:__00_%%E#
M_9=2F :E>DDBB=;H>M>1-/!NI'06M'X_Q9@ ZFV5CEQJ2]:5:F%E9_7II:\]
M?Q:M<A\*IU)#;^).@W)I,\)(U1^!&^/=<.M3XD%?-ZU5$IX_)HX70/PJ6Z Q
M@:NUA]L>N3B)(E(BT^F=4,EU.IZ<_72H4WEM9DP!Q8MP<_&0%<XF&55P<?GV
M!OQ;O>CV>5_(:,\N/$]G5,MND[#4&[3<&P']4JK'YO,>.;$ZHG0E MF2(GD2
M'M]>%:F=_"TM_BA(0/D7\"Q()GM;?G*OE.VO6GKNE&PMTQ-9E!5.K[Q+[^R6
MTHK3)]C$0S(I67'K-K<1V5.)=A=!Y^T1_O!>07Y$2@VD[_")UX4JW3,I=<]Y
ML]%-%DUGUIE&&KI,82 M1:LTB.NMY6&_]WFFC.-G6^%IP+S_CEMA2T3(&!MG
M'=51N/*:R1#5^OJH$U_-J$0)F^2A&U(B<.YXC$'6U(DB5@(OU]/EU>U\^;"8
MY,=C/(R"6FZ=.2P:)_>.Y\ZH^K7,&A16T70IL]6ZZ!40A-+GDO8EVWP!10!L
M!)-4>KR1/@OI_4[A)$0 C2R66&ZO=MY)O#T#ZS%$**B*%\"H1%V54!AA/B6S
M12"O 8(4JE/PT599,4H1^/;,2ZG8CKN9\I[K9 8Z@@L &'&SSAQG_8SY\+EX
M+82YH/O0]];MM\9U"$B/F[>*4'G.7 EM_P'S%E::BX[IQ]GT9GHUGJW(^.IJ
M_C#CISOW\]OIU72"N=JX=&(OACIH-,X<TCAPE]Y3X&V\-02,&[*NZ$MRZ:NO
M?YQ&$D<5^^B&LK*>0L^Z.I_.;$/A.4E1!K @R@\12F1)09=DA,EG($TX;;0=
MQADZ9+@>('MS[M4XST.+@;4/:16BNB=1@B/L3UIX:2Y#9I_8]G6^&)S>M,T,
M>I3!:([6L^O@AZ [;8XH1ZDDV0S Z1XCRR ,X<;QHD^.?Z %XVUK<3T*CB&8
MB%$V!!V\=4-H9Z:A/#?CZ8)\&M\^3,C=9 PA0 @*#DR/VCQJ"\YP-$GK4[4(
M@]"E-D\$.(0CE=SJ,!:S1XDS--M84#8Y'.B"KD.V"$\7Y-=T0Z.(NNF/+3ZW
M&PFL"D7=Q:Q6+3+'1ZADU)6Y9GK*A$WX#\?-]M((=MIL^Q*V#=A^/+N=]2RL
MK89$B6ZWL2/-O&#TX(4/MUBS0EZBXP6\4'I((D'4;JR[LR0I@M6EMS;VW5V"
M$RRPI[D \BV,8Q4J8!S_KF>][,GED-9]MHZ-YEV/.=N/+5;3R]L)W$\8D)*T
M+:.5T$-0$^W260&*K"AM7H1GC@TL_M!-@D'I>LXU+QZTIT',Y]X%]:$V(\]D
M6VZ=B#XZ,76S>OAMCO-$HDB6TTM75 SL)(KV[; '=IN'%ZOYU=_):C&>+>$*
MVGR&J>V\,-8V]%VVKH&K+,DK%!4U]_4=\)&R$KL*6,E+-$6VGYG8C;.F$I;P
M_T0$!5[@=F@3R<F"#LK:#H\Q_>W G,3DV6#64(-C9?CJV:^F],IA$7)X=8Q(
M,EHOEY-_/$QF*P*;,]3* G766YVQ&GX8"J-WMBI@=)5I]3$Y/!$(B'&(HV7H
M0^^E4<&9D_ %5)KE&P8Q3_-XU04'#7#LQPB-!<E"A:T(*!%#0ZZ:M5@X'I24
M+C!%IM%Y+FRJXH2]\O]9X!+$E<XI,GVD 4/P\5,>:SE<KWH3[XJ,FL9H*)HD
M8;$%$RLUT8@M=1)B@3Y*S7\(5M2OC/M2LB)FX4TG@B,9**?%PPQF5M6*A51>
MTTR82D5-/8K](IHF_#1+2:984 *.<#SKAM->,?,HR6YYY70F50PX@\IH,#,5
M [RAY"X8F$LKT@"R%,P4*SO:+2$.<;(Y5;RH0,0,,ZRWU#WX;/F99XU>':*(
M?5K!RU*M40=C=*0@1$?Q*C$)0US[(8I.C#5W^RDZK'5R B.2DB"?.9$A6-@Y
MY$0^2)\&<1+Q'?KXQ5/52Y<!XAV?RUFNGYQ7H5 .S64LR,_+"TCR&6 ;&HZF
M%3-G1Z_#G>/5@S?MX$/0D";[:CTI8)&UI<Y(F\Z,"&"0SP+G*-V1QDI+A7#X
MXX[7!PHPX\!E__S['=T]TJ@FD#F:_8AI%W&RH*D)#DK<U)PQV3NB(J  %8N*
MZB_5I,OF,[PN6R)"$_RJ)S1B-R'S!('%4ZD5WH=P%^3R-?_XDT<CIL7;UUNV
M%O<U,[$I,O+M$"/1I-=$M)AX]T4,V-)=',EQN +.QI_PI_E<GCOJ0.H"3Q9J
M"JF=^SO20%;*+H)*==.$ )Z*FG/745-/6%;TK:O38'](8FYXWTO7'T88R'JH
M%D*J=4UP/!U3\:+1*'A/!)!&A*.1[X>@1[RF;LS6#J5RVJG]N/-@0==L5R\>
M IB%093]R0]D )\OF%9TO0V\WPXT-@I,66H;6;=M=*S42L[9,)Z]G5\JW5Q0
MFE%2(^:30DZ9%*0'%*3#[+QRA"\KE_T*SQ7OPP!ZD6=FPQ-U7L"^I,39[Z/0
M66]Q;Q@X3T\1?>+RSC?I:8"13S/$1;LO8"Y8[5I .R)&]K\I5\UX4047E#,[
M\QF.V9XB7]GLX&:$$[S^*88+I36ITYND_96OU]>- M8ED0P3)/O1,7-1LMA8
M.P9*9,R4K:86M98O ^3_LAOV.K<TB#//BK4PWXSA;>\GVG("I8#%F5FTC)=G
M$BF@]9E#PT7S/CZ#Y6EU!;0(!(3!A5/ZKE+]'CV65>(V%LNY$J]E5K4Q@\Y4
MD$JK'B=LI=YJ-Q+VB[ >PU^S@'*)BH$2]WUZ-F9MN-2]WWB_TVC,UB&\4>6I
MF1[<_GK A/UL):"#15D#M#,D*;?-48C (3D2^2S0SK,P5DW[/0K0WW'PEJT;
MO)RNW)GJ !&.?+4LYX>\4BB<8UT-*\U"!1RX&.D81U=/X[EG]7Q8MKM:)226
M@BJ9KFIH \S:Q-S*@VJ<'Y8&GO3$(9^\F ^Z%!9KV#6,5P=> H@P]$HN5(,_
M>;$R_@]QW@1;+.:\QL:.P!0?S3UT$[#F-,R0$6>[3APV="UX[R#,=J?Q+'..
ML$$Y@]U4=M@Q77_S%#Z_=ZDG-M?L [<J;E'LCU]NZ9/C3X+$2UXET1@IA%VK
MT# )>B_YV9JG5+;=O*D$4$2 ]14]:1];T9XTH:?YL_U1E;&7#6GY-ZOCV6RX
M>:$N'<:^XP?W40B/D[U<>N%J2R-G3P^)MXZGP3J,]J&XF*V<V;H@VY_6NHN6
MS6GFF"@36E?VF@^TIP0(HT#*)$B%1CXEV#V,L"Y>?S'E.$I*\63V5SV6S+[Z
M9<D&ED^Y'VGXQ'C;>FM'EHW; FO7H(P8!_O1 EKSJ@9<2 I+%&"]GS:8:09]
MJO,KG4A;8!$THXWQ7#-4@'8U0\]%BV;TE:F:K:7XJ6GT*M0C_:-84Z5?_'*Y
MJ E2_L'NB#=9@N$MOK4VEO4FF\4M(N=WS\=R] LX U(X]M)O]LVUP5AFGOD/
M5LVQUFKS*A%_UQS%(_.FI>O?QJ](P]A<P=9^LC^4^GMA8C![3_<W&LX[+_!V
MAYUR0&N_VQ]2*8/9H%9^M#JLDI8; YO"8#G;.^=%/[35WQ&&5L9@/K3E'^T.
M;;/EYM *F/X2&B%#\C[T@N3&>Z;WE(G"=KM/M'[[4AEXZ$H (='Q*!'SI,=.
MV%9/:8YAK:%0_)8L!SN[3BUIX(71$A+OH7JY['JO^I)Y'T2'HWO=NZ)-'\TI
MXB3I]L2V[G)[LJ6:"^XQ<$#VP +9,![@YY0)]EL01NS_G OU57C+-^#/UF<
M<+S-]UA>VG,])WI=.E!AAY=:UV0$:^#QRDMK!:B7EY8"HY27UG#2S"MWQ#T+
M#H>?^EMB&HJ@S#>EI$[MW7431"1%,A:IHE&M6/95RY"E-AWK/3,WN7.B7VDB
M7G"8;S84+OZI,W.UX B9N0;LYYFY&EB<S-Q6AHZ?TL<)G"D1T0"AXAF1,&W"
M[EQ]A)CCU9VHQVKI>MJM%]!I0G?U";8+XL"NJ35$,KJJEF/9W:UU8*G[Y2X@
M0#B%_MQFR9VG88=,K^\CK^B4LHQM& CZ8R9$KCAZ<)R]DPE/RCDU!KP1V0G,
MW#V2/>!:WM <+\@\6QRDB"3#)!S5_FNK9QP4S-4UGX^F<7R@+I<CJ\BM6O&I
MX9'6TFT"5);0*F#[*V<])TT]XO!$((R$#10%WI'>_#FK#$?/8@][IB%!PDM^
M; Z!Z_!(27 54==+X(_TX<0%75/O67&%_Q@B]N>ZXT7-IK_N%%!FQ&/9E#Y'
M[NQ@.05>^2#(CDC MAH%99ZJ#5^M<_ID+QJ &NII"X1!,^6%'8N39W*SG0MA
M2S0:Q.#=(^]IF\1VY]S>NBHE1"J4^!7;@A9)B9&"6G^;>-?EI>H=?\P'+&9M
M\5HAX57X3*-K*#86[J%U_C"J;(_6E0+"5O\X(?/=?S=TG(# ,3Q*#3=;/:4&
MO!=T(#  1DA%FC8O;<OH$K<@S+YAE%.#S8W5<L"@EVXHJ)"4#$GID%5(."52
M(D4XK=Y,,EWX\H1XG_?A?%-G/)6'S>O_HHXLVG8,$?N&>;RHF6UVIX!BGL>R
MV=%"VZW3"]B\^TI>60NXEMI;CV1;UQ(EV-<V[+,P75@- \'^)M'\$AL4#X /
M)JM?(RR$R=)<F'R";$?!F11-^6K. /E:,T<U6(6==VI[B\)H@SVV)3KA@C3D
M=$X#L1@H&K@)H_%ZZS%/(_S7@CX=?*#Y"K=9P]V.1FO/\>\\G\9)&%#9\KE'
MVA@7JWONF.+2=4^$D2YD]\J]Y.(SSS&>!NGRM*3SA+5!2HW 5%@T0\9P/3IO
MB!0M6;[\_>;[I[<-=[JQZ,.5]$<:?XM^:K>H]N['TAW$IOXTYJ5[B01NDJIW
M$A!IX[&WDL7P"K"YQ4 4;UU8S"YO%'?CWW-7-2(">4  VY^DRYYY,*,)G(/%
M14:CI)NTT @WV-N9SZ^LJT%Q[JBW\=.6@)/%NIV8..6L669>FP-_U3Z@"8F!
MM.7KZ9TERY;>\X P',*12('5XTMJ/J/$;[<_TU)=RK3(=3QYV=,@IC$<=<&1
ML<X23J"%\>;:B8(7#[$=20CI=;:3N&VN"\OT2+F&:5;2G$]G5)#E#V#S](&<
MKNVWVLXI?KDV<4:19"1)2E-CQ;V(KJEHC]0#H  =>@'M1=%ID%#6X\G"22@O
M!.$JW=TQ!(;PZJB)B.IW2'78R"^3MK/6_E9I1H, D1$19,YMKJW9*B?+F8O%
M;-2ZRSF/%.1=>8GW=6^K(>!2W%.*V?29WEBB;L'XY&6=!EJNG'@[7J^C W79
MCN0AV#N>F_$H<;N]4;:_4NJY4[)U4T]D4591O?(NJ9>=Y?DX I'/H >.2KS,
M#FC:!'Q%UJP5^-<%G[;..;.[N#IOKW!W79 ?D;R!BA//VH#>@%9&9%SJ1-%2
M[NGM']"<MX^N&A="::D[UKP[-#K5JQ\M1"IQ58C.<R=G!\7-IJX$<+QB=Q'+
MSL\<&\W'=66Q;8U%R@I:T!&)M$10LNZR_C!"MCJ>DR45/_)[ 2(G&H+9C_ N
M86G2.;\7N71BRA]2O FC@GU83'817$=E0/ZD7=A6IZ(F,2S/TL9G)\L#8NES
MH7"@4#+$Q;GV09V]S%L7^#B/TUEJ+MDSEPP<3N%JI%M:M/B1U*GRVR(?C';%
M6OPA1(\,!%0'CS3(R+&C5L[:0T<E$J.RY2'<^>M+QI(4_+(?1%O$M-_?06L>
M])EO[B.Z\PZ[57CEAW%V.3&]MR@[43-&13B"[2A6?AYKB(=S.-N)N>9Y9N4T
M=B\(\*QJ02+5L>S&J>7CV3YENR]D2TFD-P:SLB&8SU$&B>=Z_@'.:GA9)O[T
M^.1E[1]<ZMXP#89'B@])^M+QQ(F@@D6<W8\4@2F%O^F)-M+3E7UV3.5!RSX(
MVW_FLC^NF]'-$FU2$"<9=0(C0TKTP7"R%HIKMZ,T:ZBWR2@]KF0-\"HN3&7F
MC[XGGNA6QJE,D.Q/0.:B9%-/.P;*I&/*EB0QB"..2 F5%+@CC%B3;6'0]D$W
MSEH_5:C!A[#+:;*OWM04L,A[F#HC[5L6P%#X4(P-2JL ;!$5K+U]GEK;X^50
M+X!:7?--6HX:#EXN'1_,3&+&>G","Y_M[!=7.]6P2)<XVQA2U@SG1YZ/ I1$
M4%,-2J*R5?<C7.<49*F;WLCT0RC$1J.=."'-+VA:S@,]1MP4!59!F>B 15(T
M^W&]OL<,<=Z:!FQFA:SRA?/ESF%2>XX?SRC/:H]I]-RX$](%$6<N,Q>I/*NU
M8UF?WTQ9DF0*I8@CPE!)CCOBF=0A7"80^#C3WM%R@3"[#&$(1O-S&/TZ#>ZC
M<$WC;E:CPT0VFW:AI':C1L,SG#:>=)8#N) SDF(/S78ZBY;)LX]"-O?'@["?
M&S8KQEOJ?@Q#MYO]Z#"1[:==**G]J-'P[*>-)YW]9+B$(P_-?#I+EHOS!!B(
MQG/C>!$_.Q[',4WB<>#>>LZCY_,8XAUU8GAJ8!XL(*X(]PP8 *\#EOYY";DJ
M@,\W)"NZW@;>;P<:KR0%1>PTB6.N-KJQ;.?G;,^Z@SB_,$W[8TVFN1UI SS]
M8QKL#XFX8),3) 5%\IG3Q'P%H<0M9W;%6M2\G:$&Q[&3-O;+.JZ"M:Z?>D::
MF_.Z0A% P'] 0R:&]N$,'<)PU$?]4(8:>A JI'T80Z5$O;_9>+(:\=-#?B(O
M?5?#'&T8*J421Z=8=1QT]9(S)"_$+,^I0E0HN-JZ3JB[HI'\*<DNB,-0*K5(
M.K5J8J$KEHJEAFIE@/R08$#*M?#B7V\B2LLW)CLIF8[ ,)2M742=TJFQT96O
MC;5FA)<AD W#P,YKKDO"7>ZGT&<;#+;+>>VD@ K<8>B>5C"=VDD1T35.PU5#
MV0JP_D[2:^S\RZ.^JWR]3 N-<([>SGQ^C*X&Q3E%;^.G,?@<PN[1=S\\HB4U
MU?DW2FII(@TAP4DEBCK-J8Z!G.PD9Z<]Y:FQ21V,=ETY4?0*H4+SM+DZRA T
M2RZ&YDY0!1[[&I"$F89.W8;!TP5/) +D$?D8A:B'B<MM&"6PN[D,HRC\ CG2
M"F&ED%AO7RF9KKYZU0!#>.]*P8,D.,$@"]5 U(G272_@)#^NN/9BN&W#/*!*
M1XPP<72F@U!E'3) LZY3QCQIZWL(_U,Z&"JA][:B_[L7><%/H>^"XL.=#"=X
MO?5V7D+5ZWH#'/NK>V-!LC5^*P+*2M^0JX;B<#R2(9(4<T127/)98#?B]&?=
M$M@6YOA[JAOO=QHI%;[Z,\)]4PE[^9W2TF\X]T8;##3&\Z,?/CH^E"IB0O(;
M_I>1\[OGV[T#VLZG .E?O:ZV'HT]I7I5?\9XD:+)7O&H1/$;TKL0=09:U$NH
M%D^9F":.WPA^G57)#+@5("<I65_+R.Q)B?P9[TF<>)"!?/G:DL9AAHJTD.P@
M5F4E:8!G?REIS)3J10\VDY;>:<^PR>/K0+) U!*VYH.8H0Y-"_4Y(B9X ]+"
MUKP1K1:.!I-$TI3PCB;;T$W_IBZ\BA%G4!G_VG.RTT@.16N[=X->F\WI#4#+
MNS)KIOV"*LG)\A6QP_8Y.7#NI7M?BBZH>UCSM-20M7_8P:,KU$TOH"_H.GP*
MV!K8E2QMC#$QRB%T$JJHB6"$AE08H0-OF@+#448'+LXZ!:7B]88H)P::QV2!
M/!E>PZ=4C"#,BQ'8O4][6C?DV/".:0D_>[F %!0&<U $H6BCTPP!.(1#H3++
MZJ,@@$(^ "I8:#]*7$G2Q'IAMV/9! W/=PY_\NC8A#:#DJS7-/4.H@Q0=@OB
M%2)R84 ;!YE'4< NQ6HLI+P,:ROZ $JP&O*HF4?<,@7XPL]HP$MV@HC]8O2G
M2]BP^PHA>)DN)T5R6MBE5H\7MGT0S^1)T@(1#P'D248>9.)"58E5>$GO\EH>
MK8(;4L'V*)V$E7L5(Q(#\"P=^-1XEUU:/N10(E.M):(H^P*/ N8O(& 5?>FO
M1YH)36G'E*F)ZC!L17M)24$1VR>=(O9=Y^''3,A9;]FVPH>2H7!;!4I7PZNH
M\/H9-YG2"VGQY6L!DS[X./[B1*[N-G*/])&2?_KNH$K*4%_$[2<:]<MY,STI
MI<_+T +VQ2.@DW(;Y>?[8C@"* -F+Y+RE@9PL_B>B3=S=KICJ"H(CKK+V"QK
M;/EWZTK7;+QYZ,W^(@"#?Q24<:L]]*D#X8ZZ^B"G"H$V\MK#F=+8GW $(UW^
M3W9[/WREE%?$G@90/]M[IM @X__/REP(,S3["_PNXF0K>A,<E"6\.6/-"CCP
M[F_Z)K=8?:>T1%EWXF74R!YT"TXVQ,/=4>*M#[X305C9"UV[*_03! 8 DN&+
M^NXDIT" !*+#_,AF\X3R%S8/L6:>E,#AN$TEPV7/V0"R[CP5'#0SCP0<$8#X
M$VB%;^TL*H4<@$ZHYU,)&*Y>:&?6NF;@9S@T=Q3%7B#S;]I\ABX$L*Z==!6Q
M>AO%%!OADDHWUIKO^M$O^4P]"!U4['Q5&]];+Z#3A.[4=Y].)XRMLZ=VB5R7
MCZ6*J..GL2PO*M,2#&F)A4 3A+>![L$?VWOHL=Y#DY>]%W'@>[[XUHU /_01
M;:G/#FJ85!_$<2RK/\[[-S!XU#MKB8BFSK(]?*;18ZA/OCAW7T$Z!W_X'7"P
M?<DQWG:^!\"8KV_C:2HLOR3=MU_7M?3&YNKV3NME\E8W\W9F\S89SN%]TC;A
MLC^TRLNB\W85U_^M.B,KG2BVJRYYQT07+W]__8:=T^2%1FLOA@.LGZGWM&62
MC5EW.T\T_464(CQ3KQNW_C:=6,?.[=.Q&3;]YIQ=)[G.Z@!+G(Q(Q@M)F<E^
M553HM),=B]O7U1[@[M(-?=^)XN+UY#?I.?G_/M$8+JB(Z4+UI'F_3;PQ'ZCI
MIEX<G83^V_%F2N;/X;)$9"9M[9R;QO-Y)//^THMY]!G]T9R+]TCGFW\<G(CU
MC_\Z#=:B[%I]%WB^9NSG )RSN[*<@7.T@9)C<#Y!FH<;' .B*O2W@^.3WS),
MR$9(44G()GGR9>NMMSPA@<=?8O+,#*N42LSG;R+\S3[U-T[!LMVD!8L]*/SL
MI=X?7V;^^%+FC]-!F&](WBPIVK6?G3PP_</WV7R+?^TD-"]'UF>OR:B_(0^M
M[IR3'7.3]-ORQRK^%8\W".>Y+CL1I[JHDSI9OII[@J:("Q??-U#V[AE:>R-.
MMV,W&?I:(O&U(DI)H*U2=< WY&&-N\I(T+>PNY;&8VOAAU;_C,;%&]NCG];9
MYSN(:67A[>ST3Y'/\@%.(X@Y .\YP/XG>^1'EX[NB_)CC8==%N05C_U<>\^>
M2P,7'F;I>PS,VWUC_K-KA_;B,4T;?3L^LIM$Y_"*I=+1)1YXLHUX"BMC@RPD
MKQ$-W 6>V+VYZ-B/D)RE XJG?VQ[OGK+?R#?)^_4LWN_:K-_#/\GDPG% Q:,
M_-%\H%$7F_;#6_6'L@?Z; R"O-T_@"_4=>C9/*&LT;?M!]42V?2"_#5*8(-D
M?/Q1G&"'_C7LA+=PS4,W'4#>N3:CYTP-OK&+(,9=V,O-D-;6WLY5$4-14!9Y
M>*4\K7>G5F:;/NSP&-/?#DR<R3/[G[;>E104R6]HV*Y8O 3.OJTJF6A:60Y*
M..P JCO5N=>_-Z*$'H:>:%X548"B:XO^[9"&P@SCK1")$-HJ%QKXP2B.NN*%
M$G@(RJ.M?J%0GP$4P:@*HJ]W(8<=A.)HJEC( +$51EN;HJXL_:7*'?9[_W4<
ML!73>AN$?OCTNF(KKWA#HW%6*O9G+]G>>.$Z.ORNK$EV)!V$]+=3!,X3W8XA
M@I/2=CRGDJ<BTJ)FD#S G[W@NY ]C:#@+.3>)R&)>8/\:;DD;Y(D:9M%_6'R
MA;5*TF8MYZ_UV"?I2WICJ5B]6>G8WSB)XWM/OK>F$=L(*>U0"6G?TEJ8SFQ)
M 89B+5I>FG4*MEY,=AR"Q G3^+BHY1>%\*S*B#AUBG95O9M #>CAK$)NVXH;
M*<$'L19IL*]9CMSBE1?2,F*P8[X]K0:0_-WA*%Q3ZL8WK'\A=!/$=$&]W>,A
MBI6WJ0QP$%XH-A4D?[:X#0'G+6,SKB3>DHIZ]6SMX(=?"'0,H8( B2H4(#?1
M(6NX-/P8IB5O\H6#70=ZK+09GA SQ2155/OIZ/U((Q^TLQC\TH%B\/=B-FVS
M]#HPKHG+69?9=A42W:AE[$BMV<G?)ME7]"-V1(7]=!%D^:61SJ+DR@T8!%#@
MAEZ&A&NDW03(>[_"-?N<M\ FZ%_9E]E7[']PK/*W_P]02P,$%     @ >3IO
M4UK-6!:@,0  @D$# !0   !P;'@M,C R,3 Y,S!?<')E+GAM;.U]79/BN);M
M^XVX_X%;\S!]'JH*\IN.TS-!DF0UT9F0#63U]'VI<-H"?-O8M&VRDO[U5Y)M
ML+$D2[:,A;)B8DYG@22T]EKZVMJ2_OW?;RNG]0K\P/;<7SYT/K4_M(!K>I;M
M+G[YL D^&H%IVQ_^^[_^]__Z]__Y^/%_;B</+<LS-RO@ABW3!T8(K-9W.URV
M9MYZ;;BM1^#[MN.T;GW;6H!6J_OIZM-UMWWSZ>R\T^VV/GZ,2[HU IC3<UNX
MR+-/G=TW_;A4S_VYU>E\[EQ^/FN?=5J=LY\[G9\[%ZVGQUW21UC/N<V1UK'=
MOWY&__,"?[8%(;O!+Q^68;C^^?/G[]^_?WI[\9U/GK^ V=OGGY.$'Z*4/[\%
M=B;U]_,D;>?S_SP^3,TE6!D?;3<(#=?<YT+%D/)!.W0_XV]ATL#^.<#Y'SS3
M"#$)A?5J45.@?WU,DGU$'WWLG'T\[WQZ"ZRD7KEJ%8"'W]J,]#O8T,ZMUK]]
MSP$3,&]A?#^'VS7XY4-@K]8.*A!_MO3!_)</:^?M(^*JW3UOH]K]QUVLJN2_
M/=<:N*$=;H?NW/-7V#8?6JCXY\DP4Y^U[X6&8[]],KW59Y3@,U]9GRO6>!I"
MG:+B^YYK 1?J&?X1>(YM(?W>&@XRRW0)0!CP5ERHR'KKO_LV&,_':^!CHTD"
M0BN["41/A@\_6H+0-@VG3G@'/W0\K/VEX2Y ,'2GH6?^M?0<"W;W@[\WL#WT
MC;4-H=V!N6W:L-_?RC> V*^K:96:-5*A*D>TEQ$L[QWO>PU=0*KHJGCN[,!T
MO&#C@ZF]<.'DP#1@]V^:W@;V_^[B"?X\M",W!N[BY-5[Z+Y"JWA^J5IF,LNK
MT[UA^U\-9P,>@8'^C7@3KQRY%'FUG  (?E/&;/N<\FH#Q0ZGU:']XH"1%Y:I
M5;X$B:T#]30SWW #PQ0:V)E%2*S?YB4 ?V^@0@9(T66JEROA2'U+37U,S7W-
MS( RJ];C)$74V^^4K2BK+/E]4-E:'N:OKS\J6T-:.4=J77<@-&Q'=N/:E5I+
MVRI=9U(9];:N!]MXL1TT\?16:\^%G_QA!#B1A3TV8W?HPHJ"WAK6VS"7I:%)
M_?%Z;=*S+!L-<(:3<A](!<[^!?F]$[*OX6ZG\!MCL?#! O_@>)Y\7QJ<\ _4
MU[^5QD MJ+ZZ[C0AJ7&)EE_CO+)\?TTMJ;Y99OG*T@J*Z[KV00 _QZW@ 58M
MKB J18HK,VT#\!8"N."V=I_:(?J5=KO=;;<^MI*"TG\:KM6*2FVEB\5UA[5W
M/#/S"PYR57M^ULP(10!A8.]P ,Q/"^_ULP5L[)%'?V 2, 'P']_Z'E1H[R4(
M?4AO4I)CO #GEP^$[S_769?$#C-8(J$JZ:^_79U?7Y]=7E^VK\_/V]?=3OLR
M5;DTS3T_6U'#-Y.RX9\YYK-.]3C%YS7V]GPTE[:SXW/N>RNBC>)?\SAK[?D6
M\'_YT/G0V@2P+MXZ&H$^M""*.?!]8#U$-J#6$E<1&^I(!/V^,?P0^,YV M:>
M3Y(-)>7IT<8#(&;PC,"@#2>-X19_=YRF@SIJ/(<II.8PZ>EQPX4@)N=< 7*>
M /Q).&Q8=T;(ZN RZ4Z/EN+JQYQ<G$"7%PW']S:<P6U6+\ GT':8Y'08XZIY
M3-9E@PTHJN<$+&R$PPU'QHK4?DC)3HT,CMK'A%R=3.M!JQT?=M#8S'C#J8_\
M/OZV[UET'IFY3HU6<3 QR]>--[N9\3:T('KLM$.5*.@(*>E/C3$1&#%7-XUS
MU;,L:,@@_@]<X8(.E2="VBRX&PCN0FF.>"'$_'05Y.=,@)^ST^>'#"%9 K=5
M(:@/_QS[,^^[6T3//N6)DE, (*&&Y)YHA!H\>([])]][M:,H3R8_!\DS&#M=
MB+%]"B3QH$B8:M(-D:GTDQ>$AO-_[35SFD=*?*(L%6-(.&K2&X$:?,\'!H65
M]->GPT-AK1/+DWP.Q[(\"BUWGI:>2_<E'"8Y'0:X:IZPT*0S80K,#?JESMG+
M#&W)$%@X3'(Z+'#5/&&!Y$$X%@LSWT!G6Z;;U8OG$"C(?'\Z]B^N=F)\TL)>
M-?=-HJ;!FXE#HRE^-U*R#/:S=K=S=JTH9=RU3YAK?IG?W_@(;K3K@>0&+;D)
MJ%,L<O+384@81<)4\PO^H1L"!,E^!7=&:,08&#Y/4O)38TH 1;)UVOS*'^V"
M^'VXS%IX_I:YR[-+=6J\%%<^H>,4@A$B3-.5X3BWF\!VX0*,2ELFU:G15ESY
MA#;2TE]-V@8KX"]@)_[%][Z'RSA,D4H?,?6IT<@/(J&3Y"50D\[I$CA.$8OI
M1*=&7F'=$\Z:]"_$\R1OM?*B(XS3)<0=C#<A.AJ.UB7T*2(CTZEQ)8PEX8[D
ME5"SO?6AA7P4I6Z!M]\ O<D=I#LY)CFJGY!W"N$0\4SXW@Y,P_D3&#X]%HR6
M]'0H%$*0L'@*7I$DSFV/[!Y^0II\4E)F+=#I=LX[BG(H B"AD.0>49O"*&"1
MC\14VE.EL0A"0B3)>Z(:D3T(R\+0'(,TN\E\?SJ$%5<["6LF.4Y*D_3OSX<'
M9*H>FQ&Z2"=M<>KIF4X;G9[9E0O_[H]'=X/1='"'_IJ.'X9WO1G\QVWOH3?J
M#UK37P>#V;3"(9JY$;Q@JVV"CPO#6$=2!$X8))]@37YL=^(;GOXC_OC;KI;C
M^;WM0J@V;'U>%+)..7,CDA4)HWW1N3@[ZUY=PZ'TNMNNU-S* ^T% 62P %(V
MD3*-L;+%]TU7 *FD4S\A\ /P4+FCK<I\/-?C$L!!6N5TP$$>C7$>:+H0CRX+
MZKD6^@^Z(NG5<"#RH!?V#=_?PI4V/N=*$0)77D6%P<-Q7A_E$3>NE]RY7?C!
MM^G2\\,9\%>WAOO7'5BC?O)P\DQ-IP6S8N@81P3+LKCW*YXWU?=']W<$$V "
M*&ETRAV$Y"U.GBQ:R*(T4,8YQ9,:%\;A$JYKTI:C2"&?4"L!<,*3=!2R<=J3
M*W*V4.84PM-)M**Z$!CC".5)D<S3K!F2/^MV+KNG2W,Q,DDG,T/D16F>YY'G
MF@+KNGQR1=DO13LGNAKF>8TH %UTZP+K%KCPC_#),=S(#/>>C_X1?YZR"D4:
MPN4HJAE.^O/JD6. QA>!DF3UY'MKX(=;!!U?H037PFOD<Z//&EA9=!.+,%9=
MNIOX=G9W\0", $SLQ3(<SY\#@.U)6S^P\NBF#'&PDM:3K\!_\0@^ATZC4Q/F
M1$11[DM-.^JDMO%I9G+/J T"V-GE+]TOF';R9E=.#Q)WFBK90-+HD>TBFE82
MWU84/8-R:JE$,5,Q/,@ES3QIPTBUD-CJKNLG8XM\L]"P\!-_ ]&(*JE$22I+
MC*>J=&]W52/HLLXYL <Z%0KX-D8(.923BRRV"W54: 5-]8+W#H3TDL[Q?O52
M: 4]U\O[^_K9&V[,3.](-24,4?-JNJD=_+[G8L/]88?+_B8(O17P.=7$DU4Y
M35663FG4NO0\J2<-[L!+0;0'.7'6/N==N,@]?57PXM34+8>?MXA[:K8F""GU
M$P0OR!JB/_9:N%#&&</MA-%/"9P8946(*.32Y0X?8.9161&2W7&<X#6=212&
M$E#3JRP13DX+IQ0%:'7Q@S"GUSP*X<FMJUY*8]>E1WD";H!8<RWL"$+7L?H@
MM..W_5P+?0!6:\?;H@]2(3D!D0%:0(K<7]%2C<>PD38!\V1O5*$."_-IJ:QR
MJ&M=9UTV)1S4M$1Z+GH&/:4B!E>7('T119R<&&I;<M4ZQ"BT*B\60M82%]U.
MYUQ7^HE098T539.>-Q2%^WQ"W27 B;B&$6$_:[AJOB\@FK)DL*7NDBF%OX;S
M8(0]XV/?VK/[-AC/X^DX_/9#AE3J]3UGO-?W3&?P/X^#T6S:&M^WQD^#26\V
MA D:N<@G>J]]5VN*0QO6X%M!CF]GUTUMT>WJ,D.[4M2Q()U(F4;-;5E27U^(
M2)D7N'?D!GZ8(A;^ZY!4^!$Z+61MS'#L3X'_:IN@]V8?3N]HR90A5H"E/;5"
MJ*CD'ILG/&Y$E0WNO)5A'[XMQTRK#&-"QB=RQ@FN5N+$?<M1W1\!X>$F8AH5
M">.T/,&?6XA,+;8>($(X;=G#9?)&2:T5@R(8J?M!S<Y;X!P6#.&?-!]&/J$R
M#)8:Y@1Q2=K%DSB+$:9Z EZ!NZ$ZJ9*OU:65S5">6B8B?3;U@W \CZ%2M^Y3
M:?3AMQA6U5;;C4AVP0(MS9ND>0)I@29%UQS>0<".AV\N&+RMT;A#;=&,/%E[
M778[[9L3E8$XS*H[#^K(8@H<![UZ US@&PXZQ6&M;-=&BW;T0!A;'WR9]1%*
M!;Q5MRW44<QNBS_R]#QXN8>]&"GUT0(ON!I"AYL_GXWW[D>>ZR5&8/<3M.0:
MJ4$$8=5]!X7Z@D/846/@E4&46F,5, #&(JCZHD[CRX<\7'9?0$VOCPS$(,9"
MJ/HN3^,!#5C\Q>U?RS9?W,ZKOM:CUAFR$0@+9W^9-/KP70PK<0Q5??NG\18]
M,'P7=F'!$_#Q2XVW1F";%+:):?5AG1]>PKY,OV#S#?X0_YWM;,)]_$B!&.+4
M^LJ!!3 11#V/2S0EB#\ NN026+U7.-%9@-$&;5>-Y[D775E]AE 9^HBG.NQ$
M4C(/UR@KJ;AM%3V67+(4[64E!#P15LTW'J@1$OF$N5B"T#81PC2WC/C(RVKQ
MD:V?,C_[KQ./E[SH=*ZOFO)"5@Z9O()MZ:*9YBYB7$;, 1V4>E&3567Z@'X*
M,9,/I.3(H0SS ASFB1<%R%!!TY>;4: 08R^Y\BC'L"A9W'0S\*H5Z!<%6$P-
M!P3,$+]<NE/ADL$$+=RD"*5:##)C(YB<<N34DN6RN!4+Z^0*=6"W:J$RM-1"
M=0M0(XV:<0/B2T$ B(.4$U<H6FVM$)2('\>);85BZTQOX=K_ .L)P!F'A;K
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M&L1(KAY=Y<R=[>&%$=<ZHK.ZGP?*21#^C,HP**6KK8@[YO'ZE,=@)/UA$&R
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MSY]\L+(WJYG7=[P@B42*@Y1(CB#.K/HIHS+Z)&JO>8>RM*C/S"*BO_$1"=1
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M98> ?H"E,,\[8+"<#6H]?\:U^-S--;X ;^$;ZZ5M&J30469:Y?@5=A>(05.
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MWGQ!9SK%WN?89)JE$RQ!4A&>%7V<(0[ CC%_>X@/+# )6+E=<7$;Y$NL6:!
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MIW^*/MJ0_J!A@/?7)ZJ./>8&O-UJDCW5@58:J7H3T(I9=;&2+MO-^H@XD^I
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MY-3I+4'IN-+\6-[GK7$Y0V'Q%QV!@]*=>Y4Z/Y[2>EU23M\O[H\&XDV)C.A
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M!+J9KPF7W:>!NG]I,Y6#;OCP43FX()#C,6RC"ENQ"?^6@Q1D-5.M"0WH.T;
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MB V.^H7?49U?G-:.M^%$QT?;X2O0QCYG:\(.8L=778[Z9%UMB%/#+ J)>F6
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MUO8HGC!WZJ#S)@OIMG<JSKR0>C,?_-E*2K<5O0R[IM:*OK>[R(JF3C'C?C<
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M6)],EO$X"9'37B3AR1:KA\P7\=-#X  W;'AZ\J_XK15\;R-X01B;Y]@*!TT
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MA>8'L<&*3907!;'#'F0S8*N#&-?)"6HFME+:5=_+U2(CWB,95_S2,_DH3XQ
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M?0_O&H,G\+1 *$V?&PDQ;JKN(9;H1 #19(UQ<C4*!Z+%*T[=5J1-=\VK7!)
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M&T0W=T@WR'V]1YR@P":D%%TNL.FLIK35FVDUE=ET%%"7=VV^/C;;40>:4B@
MO6Y+'R?.2=P"7[>"Y*9D/'*^%CM*=QW*E **N)N0)W23\GPW*0=/X'D&U*D$
M=>:FM99X.^<HT02?"+I.#4C3C#N:7*9DR2R',JND%HV?81. CIH?\*CY=R[
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M9<4#3FT:DL8F%5US2IRVQ?Z+ER[/A:[,]]H%D8^,5MD^BK)R6EP*+/,1P-1
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MQU_!_]/[Y;)<$$KV)*NJ7+3X,+FK)2!)+OGK=^8H0.'79=)]O^B38^LU@#'
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MB'QJBH:D8_48:C<YI]C0K>MSOMFNC_#%,YT](>+!-CVCRK/H7(_5?YZR8M"
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M9M('@),O@!L)^\2/QYG17<X<('+7!:]3#.?>-[1T73%H(A=Q#^@L9K>3K]-
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M4?4Z)TCPC!$B/JZS>7A@230, L)]FF4G;N()LG*.M(1XL1<RP1-VIR8ZP/@
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M.)=+.Y?T32+@EPL\%\POB>!<@G,)SB608]_Y7 *]?]1S^6BAT5OF\=DVX60
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MD9,:L3*[C*Z2W3G3[A:?F]%!;2I-:Z-C"!%.;CYIQ<?6@A?K%=GHKE:UW(P
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MJ^[Y:?5X].FLU_M^OO=Q<+8_/5B>COA>['SL'W?V-OOSPR^]Y,O%X70@L%0
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M";6#MKHP/1Q3/]7HESS5OP'3 FQ->AR^;FRTVB;4KV+)LS ?5+,N3#,28U@
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MPN,Q4AJ7P/YWIUU;[>1KV,Q =F,6$ICG4R"2Y+X)"T)2\0@,?%X8I;E>6WO
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MNN6/E^8/OK%%/0.FO\QAB^?RT!?4K!.Y<SJ:P7H05QVEK#R021B%Y2@Z%_I
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M$*UZP93()[3?AA6UN=!7Y'#6;%;GK7]R:F([0.U4CNPW10<^N=?O<.&7+-E
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M6IU&_5_L\7AI/GR>P[8_4Q[Z8N8Y\;7"VY5EQ9+Y-AK/L8[A/!<N4U=FH;(
ML<T1"A09N: CSCP/3.**]#(TBD2!4E/9+(=9@%F<R*)==JY6$7K?J=Y],?I[
M&&)1/ -*HPU#??>QYV7*F5V)5RT8B!2%ZJ(B,\H'(HMN)2-FN4!(J^U&?75]
M281T^G@RT<RS*6TJWLM,05XU/U9*\8+S(2_FXOETEH13>2]M)PHQ R5&[)%G
MDZ,!;7HF!2!Z//.Q%UXB8< .\+B3^2R<S-T(6! VX@32:<DP4Z&F=2F2T*S%
M+[.J,S<!F;#_=[#U_P@9A^34KM>DH?!_&XU:Z__QOZ4)G#.2&QMX\)UUXXDW
MMP4-<XF@L3 G44%#6\]?Z?:$6%+<MJBR+-RO?",80[>G")G(1<:U)#2H]LY(
M-K;J4(A&S,LQ7D>.+*!6S9FDP!TETI_"-H5F#!H_!DP#%3A$AY-FL!PL5!:/
MT0B"2E%RW(X;8,%*$!"E.:!.!NM9U!F*)[:@)1B'AXI"1ZD7*QB_3+@RCO)M
MZ->^P2(HYH;F-%V^829_YEK-,M\-%V44PI+65ZX9%=:]%H6:C>KD#4BDTKF*
M>Z<J>2LH!6]8%AI5<Z;.*I-PBCV3(FK+ 1HS98%QWJR:4<@QQ,$,?@3_/I!U
MN@YDV6ZSL*TG:1OD.RE$8#>&-6M0@C'"*N&H]X0&/ES-GQ0%X1:O4Z?).M!2
M &A,J9PJ#!-P<)NDJA4K!,8S^9^HT'T@T1;*FR.TR#6J2$K-U  2,S(0R:]5
MJV<N*+HH0^607&ELZ AW</ &3^8<-I(_ ))?:39KS9;^O@9'3"W)J5"W,,8@
M_1)U.FU:+$Q1'5(195DIFW9^FC! M5%K+L.!N6P^A_64HBO!T#H3N9'&:N,^
M9(DH^UB&J?^AVMFJ=O:M;RG>PS (,)V5_8C8U*JH*6H4.]BL8F9T8H>['UX'
MJJ2^IBYT$IJ:W5V734-LY"F&#")6[Z0C71GTWV#!W8@QI6OKM9:UTJHU& V_
MWJPU@,YJ&V^0[>@CQZ^0%&&XO(>TP@GGU)4*3I5[9->L,[U=W :0VHUO1IX
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M2$Y1+Y[*"4F'S1333DCFD!MQXA',D+0KO$/PNZ$GTY9AKZHY*T$"FA .=:-
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M4Q[7^CT((6DA8Q^_)&#WJ?%U!H5-\0CH]%K&U\O/0L0YA",Z1AFO4<GW5)J
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MPUIDJY<4D]4F1PI\S2*(2R0!CCUV@:O=<ZT6#!*P7_"HA?A6$9+"3'\("_
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M\OA7#<GU@.35D!=(*@OHNR+W<11/'HR3^XQ&R#9].;JA$Y)#N@9%#8H:%-]
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M1NIM'/A+$E*+)(QA[#^P_[O))N'?_A]02P,$%     @ >3IO4\)F-I3,YP
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MQ"[I'4=Y4GS G+M+ST274"6#IS4H*8.G!O-?# 3KOWN^2/RGN!X0@*<N\U\
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M<AG;<8RX,Y?+SW2K8\,A'B8J".RG X<BG%8;ZDDRF(J^)[C0V+L8\)VDK&4
MIQKMBW*#.$3D@+[.@?FD!%>[2A%.G+E<-'Y%YS"QXMC*C1<[,VM0(U6OQ-6"
M/@.57K:<$<-LQBF [UXK"2-2R<3(9MF0+9!0(\8MS>H:0DE[WS*I^&62+^DT
MW>*%N-,,F#V_J2Q\2K,CM;#3+%RK[1%POIE^>)"-::2*]I.G"L\GF<7$<6#I
MZTKF4UUB05UT +[9BN0\&SL)D;MFW >N^G7%OJ?5IK=*^Z2NI^D'C-GH41@T
M6XL2J4KI>TPHVO([\J.;^@+#(R-[99VAWAB=&7>$TWV^UE@)G3I*0S3;&<54
M<48-73( 5X5-;?G%WSPBA8)AE3/;KB/S05@ GT]3FQCL^N:M:P27V=B\L]:>
M /2-#(^*5QZDBY%V=.)DZFN O,4F%RZ^L3U79_\!X,*JZ,>9?J @GF='GPHL
MZ6'I2&LP9E[-5D\(#1D2%:Q\Y?5PVZRCDQ\?S[)CGNYS@S2K<WQ,G.;D9^?A
M"3-]+WJOSOD)=W/B9NP8<&,$G7(%!%%!\)YW65WFMMFM)KSXP;OJW-%1Z^#]
M%9T9#>Y;<DQ)L3QH_FQ]V;&AXM'+RQUI6B4VWE=3SM+3&_CTY5>&?S_'^#GI
M"#QU%S"M:4[^,"/:N8\1+X\!^4*15KS2\^2NP!!V&(%B>6TP551>5W*&/T7T
M& HZ*LY&U[IX[/I*JFY[#1-':;4R^&P>$)"A%9"Y"5>TSJ0UA]%N">*82S8@
MN[,5K9L'V)>^OJKX63#0HEJA\(A#^G,-D:4M<"RO4@$>/01Y:K:X+_M(RZ=M
MQ;8I!(\ %"=RM]L?5L,JB]SG:IB)!Q.*%#%0ITC33*&_[)^,:.2:<2:>I6BY
M&$%PMTY$WVS,QCI19\J=-#0Q1=Y*<F"3C:E"B3S>J*VF0)]*.AK"8Z\L:+KQ
MQJ4?1V&[!K;J2(S2]U<EF4$IBL- -2E*SZ2G^^&I?KT:/('S!$8RIX&($S.5
MELU\::(H#!T( F($Y/XK8+3/41LT_W82"'CJK] @ <B9X248[/:U-[&.>T\!
MM"7Y'PL?M>BJ@P+)%GB5J40WM:(= 12#)4IVDM9#1$.*<\:W7D3/=O6) &11
M%CX]D17#="^G6480$&-23M*0("+$UW\HB\,B8;U@_IG?J41YGS6.E,R1A9J8
M4G&NMOZ+:CA-C 24 U"LW5E8Z[RKM<IV A&!Q13U=*^ C^0#JKD(I\<8)*(Y
M:VEX1>!E4#K>.LLJIY878+PQR.P+U1JT2ZE!E Y>J PUY%P:.&/#4__P[PQL
MM35].6_@V_:6I6WXT!#1H0[EU[-2QM;A>GPI!E%AT :WH6%IC.3M>,(8^4*9
MLQ /D(1)1BT[VF+[G+)"0>QKTG"EM6FCP!R,W$7CD;Q[MZ5F6TU+G0*7>2*P
M31].9".SB#S&*/%E%N\GV[A\&_]N!DS3XJ%FR1313++Q<>!\/H_ \U<S6UVP
M(.3C5=QW#Q=QO3++3:_R='/RR;5A#;[8=3H+BAUVG=_V[^V%;!L(:5Y6ALV#
M&;[Q)1VF9[YCRY?/9(@!?_PZ[-1Q4U"*92VE++9N]>8B&G%F9E\K,_\:[G<Z
M1] VY=%E_4)F91)Y9>(=&@-F.?$"KXIJ;C'@TSU)&-_D,365'&4:K8?ZRG6I
ML[W#N-]OH:LU8B79*P3J"^Y8%&A <Y''=)Y*N*!-PTK5[35#JI(N$&C"54UP
M@BFGU9OPX%[>W,ZTN\/[5(L,H5-'941=NB&#"*7/ S5XZ^N;KWX"QYB+MVD_
MGVMF&6M:)["R[]9%Q]_+$]H,:2!ZOA&5R%-7X2'/Z-)0J/_TS6#/@\+/EOB7
M'*GO/,;F;I(F8>(:=_CDP%4\Q_ @?W!SK(]6AK;SF&"DSPEF41W3&9-X/>O+
MRIUX@_1=AO7H.K_YH>))DTI4G?_3MT0O12;S(-[A=R3(R^M0?M;00GZX$.YY
MK8&8$)VT.T%3EO,> ' #/2"%]%A+W!JBPT[3S/&&3B>#4T-%L(1F'D??/C*$
MXPUW"1*QL#]3XP"R6G05^1] OD%N7=Y"!2I/TC#XLOACJRZ>N\%V%66,XF-C
M)GFN8<=MZTI+[Z@%J?Z!K6YZ:;7=/;NZIN7\B0F8:+<]F,+I5G$68'QXK%5"
MD ^)#'^5IO^97OTOUZ>,N;4-<6\.H7C@R$"6/$.%W7Y\-(NG1U3 CUS0OI]2
MB9T6(=1D[N)H\I1'@+)#QB >R_S5[L7'G\C"'J+($^U3F2J*PH/PR,"#V6*%
M]QM9I)47.M=<[I*6#);6F+U#6&+R:]V&F>4?8W.#>!DK ^[[=9(T&D&3%VAO
M?Y_.6XE0KR0$#24]J#MM>>W/(R03\*?"P++6E4C7?$5*GCQQ'8'#@YE6-_CY
MY?:^P[/>_UZ;1217UC!;FLB!_?Q *'UF_C;NY%=N8\3HWMV1FJYIJ VUG(;2
M&T VAA!+0LLEPEY>F2W?HX/GYQ45@\DC&G346UFL#/-.P9O*"'\54OMK>^;:
MK+>%F/)0J5M*/4";C"O65G.V+3L)VB%^(@YX@X%T!!#[2VROW-@K75F(FFTP
M,J"&.2)M[#V\[NF8W_[OU6G$W_@I!3\5O$OLF"W>P5MQO^DF0F\I)NV?KGB2
M:N2/LTO\Q67$'$K25<C=1O'0G8TQRH)(B=?'>OFENCUBP8H)83780[&O&K!C
M388C6%PAHM<4@<-3=I#7C$D%5OYNX3XURK%,+@1AA,O+;8GA[V^ZME$S4LXS
MG!")WBB7Y56#$0&SU?N89*0GO> \O 7]J. Y7BEAI_74V5Y"/1$P41!X=OW'
M19'<*G8<9:SM#&':\HS8_"%AED<'DQ$B.H@A21GUWEF.S,<CS^_8H0E'OE.'
M&LMUF/@.#V9>7<=S_2T!^')UH-#(4)]'RBH-E28WR].T^0E]P6*=L3GQZI<6
MVM=R\R:03E'4V-HUI92J<0' _48+?9T11+P#VWNE)&\@QWL4?K5M?L3=?+L3
M'*Q>%&7F"S8^69EQ2*6T]NU*&L-:Z92_'P"X?=(6WO*75F_(4JZO5@I_^O!$
M82/2T8W9%TA9@.U50[%60&)YS9@T_/4Y;(I* )HG7M*=C0D"[6<-),@@7[NM
MS+?AEF/9AG.Q< SOD+WQE\R/&B@^"U&F?\'']<85#NMG]X&+^-59EO!WWWXO
MLT<KX*WU3]PZTD_E'"(C&A&8<D%0:[@T\,35+[--G1YB+40$2[29ISY]06(X
M$LC&C #U.N%\;1"H8.<9&_/:BQ_"NTJ&6?F]MA)T3U,VL(WW;:!.;E[7VDJ>
M"+Z_LBB%DI_R8[ $.1O^Y!] KSZIC/W.H>?LJ@&ANF,;/PN#VE^F@/Q303GM
MS8V2148#^(.:] G:CI<_.# #R<R"^ \J_1Z^_^;14RY<UR/6?(ZT8KJ.Y[Z7
M)C#N_T3BV,)-I\R_PE[X1/1M ,]&.K/?PAQ)O #@=J/-L\X5P5@I-E-H).,,
M1]/0>;#VU35(4HOV8L+V4*_K+CGUS8BUL[6SHX27-50%2PHUD5."Y-.K;\C\
M>U.KM/2U*_Y'M>?SU"\*# "XC&^M#W4=N5S7ZU=2>LK'PCEKR-NTW+'5B>/[
MX*]82+7!\CFVM)8&@;X=RNXN9B/X2<5&HK??I>%R52&5 @.N"H5.^"7F*FWV
MQ6#I8=$!6TX8+F771_R"@3!7[WM88\Y[(%SXHU;N9*S0?8F^W:<*?Q3J9@\7
MOEVD"CVE;W<;)D\DDX0<:2+5V\ZG2DY8:0P,]K"!S+.L$97N! (6/],[B](G
MJG^I+819L[VJ[YXS!1D\3>1_YR04%M@L-N)(1.-/$J,<QKMPGP[HYP8K,-&G
M?=FU\TF>'O"UQJ]_TWEGRG=-#0< (,%!;A7J8Y0=SB0^><KJ;,!TL^%D7,A3
MZZ<?V12Y(D5$-SGN,Q7:-,T8RK$--&L^J7_[DJ$HL1RKZIK>4O2^]KB)G@E'
M2=],$2B(>CZ&U4=9X32GC@V#7-HB*$ T4C3.N)F'1O>X.MA29_]]37:U6JLY
MDH1>[.>&W+&*W(*CN1=]30@\=FW=KY7GOFB,/#BX8WU22:H-"S>>^JJ<@"']
M(O/4J-Z%A>G#:_WE]ZD)\C$L$?M$PFWSQTYE4&AG*D(^CE1/"GNZ \+'H^81
M6M&RG-SO2;[QU<G;%[:'3E=<)DU7M_9>VV8:T$7S+ WYH:O?=EEWP*M50[TH
M>0KB'6^$;8'5[\&4GL2KW'$%;E0 !0"LS]/L;(M*F/'ME<"Q,IR&SBXN:T$B
M-5Z Y2A7TSC6*"PZIG#Z6E,=1!CM($WVEY%&J*CD)(L&B.P[/BL/T\GRA%R>
MX>]"@D0\QMK>(58L-&*DV]+%=()LNNM3L&2CK7PL2B*7YC!5R*C<O+:AC)BU
M;^*%VRJP9%@Y^^A-0:Y>OU\/2=[870HSA^L7+0,.XFT R7'RFVPR:[(M,$AY
M=38%>=8I^97+LCW_.T.;^&2-%RIJ$^@N>,"1#CB@6)XHAL+KJ-2YBGVF1N^%
M?&ECP8@4E[[+]D79;5:I/0%446Z?]6J$B48 N,4E_["S@:4(&')"''2\95"J
M(R.4[_QDZKHC %PF_SHE4('!K]@1I>8O_;$C8F]_]$I-$B4&WS7QLP)=>JPJ
M@6T4'I<4^YG?/)=#4Y.UA=IGI;C-GJW$_0&H85MI7/TD";: O1=ZD*P*/YD;
M7*<-S*S-.QI[I;LP2JC RA7EVJ;S5(5:^T7R?=/=U8B[Y>Y G4/N'"%3/2:!
M1%]H[,9MV<C6!.?LYA_ K";UERGT::Y(\Y<KZW-4_Z+(FY4N87&;)FR9_<#\
M[IGSN*<Q2&X0BVTG$9#]EOWTC$8WW9;$A99*F90L7&R[IBR],-5;](3_$;BJ
MM>B<$_WK(@U[^H[JC6O"L9K<U@3O!D1;:5CD6_2*=9.%+2UE?]#O397&2ZWO
M+G5U:&7.>&9.-U$><3Z46P:W>( 5+,SOI&5,+S_VZL7L%74Y+#R/Y++O2AI.
M\1N^4<F?*;<-T2N%3^Z(<+W0Y(BQSN750[:\JH#/\6ARHG5TX0K=)D7%I?>=
M[R)$:>Z.H+,7J_K <5S]6CZBBZ67\PZ @O]F86NG]U:S_#8]1K%:!O*D\V*'
MQJ(?N5A-H+O0VG)8LQJWLXUE(JN'=!L@@+A"H%W=DFU6_S?DR1E*%UA;(_\M
M%G_XP-XQB-NM@^WFT)'.&ZS*(\M1*LM7*:Z7VXKPS.\J!RQE%7*X)L[_*OVT
M"BFE%$ -2*L, 0'V<BY^'/#=S1VICQ3IM7C1Z/"-0#Z3UX4@^L)HT5Q<#]GF
M=SNJ_8Z0.I&BS!(\/%QH>G7BQ(R1C$: 0)2.FA0@5"+2V6;RN\[^6T^L#)^;
MN[)T_O#=V<Y1DC/!]]A*E&,$X^>"D]S!<8J'K^X]_L5-%- 4"_J1KX0YJ?IY
MI8>BW9P'3$&6.$'_T25N3[>B"5D6>6IB\6>!TXP$F>5Y"#M[(@\A^$/NL@G]
MUO2H^9#7U9+!4ZB6<6^J+%^D4S;VB#T9UC=]X?@+R2E5NU?7%]/1"6.]3=4>
MLX#,QW(<8C']C9M*Q()E'T#F"3_?=1$K,$=?1\@H,E;SF=1TPX*\P[]UX3<>
MC+3:'/3N;-"92M*>/UV2>&V0\U2W;+,E;S8OA&5>J9E=;XNXO6(41;#'X$K8
MO3("!-BGO5B;6Y7S]O3':XK894A)Q(D,)T+-HXLKH2]7RFZ/7QVZ"Z-PWUH-
MK;Y %*AH982-N8,L>MX1TDCD+FCLRD^>1)M#BV-@!MJ=_0M<F@J/J;%4SW[[
M'[N  -NT%\J]=FJKW\=HJ)NYD9ZHK_,GO;S1*(VZM3H*0^YF;+\Z8G<.<0_+
M2_&?3<'-53BJ2Q!I02@3H2_K.ZMYR/EIHV&TPD_NI^\#*!.%]8D"YF$:TQ70
MF#,REP\/9.T]7E_ )H+M[!3H]'G1@RBHBW,Y)5&M.[H-3 <)2+$R1E9^6Y7\
M;D9U60O]ES5\Q-KP%+,/MJ$F'LR@W@.]EQ58JZU&E3/7G+PA)Y+0= J.+N,Q
M_9#M9B]4IZ.3JT0_1089B:7>Y\<C8_-?'QRURTNSM/1O]R]Q,A5.#4W[PAX]
M )JFTE2ZR./'J/3Q'^Z,)U1:R1O"#DB-=I;5L_-[!?.S=T?V]GYU.51!S$5+
M57X;Q]@]&SM;=;27?)F8N11L3_=D)]$7_=N(K4RYK>T2Z^8(8BE#]IE"N?5@
MO0@Q!5/QD[.>8L6?OT*XVER'D$#>,W0,]'+B,:H$R2//RG)4!DH3-#HWJ1#B
MUP-F/@) T5=<1B);F)K+WX,N\-D76Z,2@KI9*V/Y<VWY(> (=Q=[SS4,*6NT
MHLR.<>W [7S+GT7%"G1T2,,2#1;EUE\@5#?,58:/HE-I2YG?P3;R+;1]) 2Q
M6[;[\VG\@F\OE6J:;5MC7F/3-(V$E8T*5Y]&A7YWFA[-U[CE.<@%S8__USA,
M_XKR/P"_W[;U^_^DCO^?0J'_8=3<^HL]ZJ^(RBG;N[H[D/NU)?:0ZYA<9<<'
MHB[E!@EFG50$K&^LZT\53;D[$Z9\KBV3C1JA*IQVC=Y&JJH@,"*&#%C+0 3Q
M3P(FB79PGJ)P8_O2#U]E5<Y@UM%T)MUL)@'QV\()H@+;$&ULQJ>H'#N]>M);
MP0KS@:($I.5[LAVLM+IHMP-QH;_RK;(ON> NOP.44H('"ULW!9NP2X.[6?MC
MA=R('^>A0Q%O?WRC5< 9N*.LR]AY_J4A<+.]T&K'"!?9=.%P:"M4$9M@S9T,
M6.&I:$:$3YR8*_H0P%M6>L"OO2B4GZ" &E5F 1+MOQA5V(]-F9Z1H(UKN5@O
M<R^5]J*=JZ#_A;:VHLRLV'Q4(#=&=2_PJ&TJ@P=0_U_$WS3PO\D%EZWV7^%#
MN>-\:F0 UM]UXR[B)G.35!-EH#-E6%*2%7I,.IX<$2"\Q,;J$M%N=54AB^;!
MGC\ ?U1H;BHS6AWA$_O'9[B71[RN99? SP'N=3)DQ>SCP46*XD$!;H%6G((V
M\;^=]6X^[DIZ6+,E@SC>8.7@FZT3QESU1?O\2&<";?YOR>1^I#>K'A[]+(6#
MM6FDO_E+)'"+#;]!216[^ROYO PK6J+V*CTC>9QF;OOB"ZZAUO6F_UYY(EMG
MD3U'>$$,(A9M/*8<U:+ANTB>-=KWU6T+[[:#B\))V<8$F5&H):8"%>$=U773
MG;[6QQA-ZG>(/0INAEE)M2 (3%%%OZ1 _'PW+>6)&[X!,BRY2 4FN63%C(?P
M8&9F#.*BVIV0OABK@.C#UP]_9'YW1L'T=HYMF%M>US\B^+P&5=C3'\_9_HR\
MBB4]Q0,CBM]M:-])=\GPU:F^"WW*R=+>S$/9F]F1]24T]*=HFU93A*.()D&>
M:Y%7"#R$:)Y'+TP1W^ 1>S"0G5$O=/K(IIREBOC!94SC9:KYQ^EV*Y*ME K>
M(\$@S&/ZQ&5L0V#AD1%%[.#! /[:4JQ):3FYUW:\OZ]: U+.XHQ!;&:Y'>[S
MAQ_U:>Q*.CT.563"VJA#3H*#OI!;UR&2E+V$3=*5%>)H?L[3I4W)01VX'GCU
MV>W&1B%FEK$J1Q'_/!NFJK$J/4-]> 4]Q""XAIK%7>+CI46+SG>S)G/U*Q6R
MAVPD+]BL=ILU<PP9)N;KP:0W6E)>>>_]B>S^ *"<;,%FN=8(DK35\!99O9EY
M#TERBZ%_ )9'V 9XN\F6.E@&;S 9X;1 _5V7'J%%QG\ UFMVC9>&$#Y.<:;3
MI&BL_@6&L/9/$YM*'?I&G>.?U]H#G%6BX@&]<8&*@-/B\I6U0*6Y\HHJ]K,P
MC_NW6H1+0\ZF"=W$E#$D75]Y,A'IDCYV@I:-SR)&K!YA$FW@%$'[CL_6>4.;
M8YEFDU>DWW*(8!1VI]8T.!.2CEAH?@YR'(NA)3X]V?*T-8.BTO(:;>'IFM#J
M8UV$KR7()_#3Q.J*#O5$"%MC\TBD9JK.=TC]>N74.EQ\-M3SO;[(+R;\5.H"
M[5NO:PY;/H:&2I"X:8N*Q_KQVM42W]JH#3%%)I<YK@I%FS,<SS:6G[,UH,F?
M53 H;,1;TDG'V\#Z,.8&H?Z#\@KS?B&/\+>YQJ,'BQK>S@A2RV(O(4&\-KDM
M6?A'J8_ R6\+&J?1PU-"0*1Q&6):2%8XP&U>^YUWA2%_5/V3O6[<$C*-I2;2
MN%E!T"$$<'JLE7,IU)C=Z"EDN9LG7SY=/R#N76_QG!/UCG(=-HB_N-)C:*!F
MG8CX9FS%RY'6.D37 QA?3!<<FC#7O%<4B)U37=L<,6M+<<?OE;>:'5.J@JDB
MK(:XAC]L\_A2F(ZGG>H3D.?+VV/+^10F/^W#)S&43==@[$2@/^)D_S8E9O<D
M%9NX_9M4Q'LD^$9Y<E_,CF*X[-P6\0>E766IRYVY,\PL_':7/+_29?-5W(3#
M:(\*-M5^\*/^9.W*%'4$_K=?7CN<W7#K07S%E5:!N+]!2I%GY>?;G+VQ0"RP
M_.H2O,FM6%K)$,A,_@QA,M/7R15%HG$2'Z*\RKZ*(W@OHH;X&S^UP-X8ZLG/
M-V7N:BW:^)-+\&Y_[X997E3H!]S60_]XU[)>Z'L&OG67TA0N3!"BZU0EA_ T
MDIR,F<P6??J@;MZL4_H>DU]J RD_B_MN$Q"._%HSM?]B[6UY::K'"3L)L<GO
M%;_1%NHXJCAW'IA9=8.UIJB 11*N0_[JR$U;-HC&M^3B$3B,H>WH.58_9;]'
MA((=*._.W&A!QGMS30!%6UI(7*&K!+DH_H0XJ$+J[:-_Q08?4#P1UF2SVO\^
M0*#DXP#XF.S4U]S3?/<]O6:6*1?U!G:(]Y0Y"'# 6.GS<^#.1?+SM?X$?'6Q
M$ZV?"W?(9[YD,RY5,UNW3*.S/X!^0H_K%0,].H^#WO7/+5H,E=I4+VXPT^HZ
M/E\B$;^[UP*YKD]Z>GD7U-5P#PJ:..YA4]__J.(EE_L4LC63"X*:) BRA'">
M*$SY %9R6VXO#=ZR%PCY;T2@H--(UO]*M(;Y9$V7992\N?7-/"*P8<E(W[#_
MDW]";WU<V]DIL[S@XZ4$Z;RV*$.465-32J7;RI)C;@)VA;YIX+>--Y)4<8-I
M?P H+B7.[''%<CNCM"VL;[YR3R>2[DT]"0X W)*UWGV]U>]@7Y\Y.=7S &_2
M @N\D'YO,;=<AB<>45IS*%+C>"L[[\DU&,\YGNY#N! 9X7)S6[H>/M!>RY-H
M9<]X3SB^U92JH#K(MA9YO"G*(I"M?J^2ZG^7FK'R7;VZM9EX9Y_H_F^EB2;Y
MNX_*&DC.\ M7_7N")M\PAM>_P(?>XOO\BSC^'\ /N"C3U'SM/OW5P3!#7E']
MVE YT F-KKK;3P;_V5KTC428*0=-4<J!1]#RT6+Z5]U9IM23RQ+YQCRW,3*L
MP5;@QSZ?@!J>1".Z:(N@E6JLX/J,%^]SS?V+@!01KL'WAWLBCL1OF8>'.0KD
M#P?03*P^&;\1F[,%LE4F\%R-OZ7GS008OZL:]Z)=SWI=MJ,H6T=*^9;W3QPM
M83R1:9\RBXK6!&\KA)V0;<'E%<3-;]\W_^1TNLWR35I(5$4Z=%G)1V=8 F^M
MFAEY.*[]VN\ 6+^+M=2-=CWPY$3>DR]T$B2B"FSU$KD]$-(P>-@5KS^[&3[]
MX%*N\:W@6OW%PN!Y&(59K*'J7?C-8?1NV#)$?L=/84WL3)RY'((R:]YL&[^&
M7A_^\11=G3^:CS![ ETH#6S$V@PBWF_]*0B:)%8,..-E7;LG,[\L86OWO5O1
MUZJ?M81L;=E27R6Z=5L03V[W4-SFO NY2<OQ6C+ F!D,!IL1>_C/8IF?:RP_
MJ*J\'D!>T%T(DY$EUP=]UC[XC-M#Y3/RKU:7DD[(? U.#AH:L%\+!*&[C5=R
M:AB\[+Q U-EM]05>@7>L&I2<*6S/3;(W!F38MWL-5-,G)K/&2E?1X+@V%_GE
M21557MF?/8\&8I[IBYY&#K*4-V6I26:![BY>>%GQ[[A11+S<]77T!KF!C!T@
M)IA^T/#R@7/TY8-695:YL>HFAK1:HB8_1]H=7S< JK(NCEI'&%;_D"V?;K_<
M.)Z$E+Z;6=OE9G%'D>*"@3GY4R%+697[Y/K\9^K(KVM(( D%%';-8-=/M.)H
M\4W#?&IK^%-%2^I)K6V@E9Q8%),!I9->)X3_^F:GLWZV*)W8D6 =>X^Y/EIR
M"BD;WCR]#BFT(CLXFZ2R>IK'ZAW;N4ZQL82PIN\Y')0'NZ>(6Z_74<.;%H=#
MO1X[>6C-_%@:0,&=%DUPF*>R>&4@VK:2%N_MD">X-AU-T8#1U*_$$F.FCU"7
MV>B$.A-_,IY'!R2+S:"XK;'>]!<:.,V/F[(U2=B]IDNN$Z[N8575<S#"FS/M
M &]B3.MZX@):G'' 3_U4 O#3B,I-<;/;"NT=0A;=*Z>_H1_BXE7$'%R^G2<,
MB+TCC"J88_?H:-<881XOO1S-I]D_1[^\Z2FK\>+^$&D]WC2KQ(BV+[J2]@8N
M'K\N'D'!?A.#?7&$2I5VB'9TBK4@7=8TQ #2KH;H\[#!^HYW,,D9WLGQGJ\@
M_^-^[NWAO2IMJ!X)922E5@=XP5_(GHF +E-D!/\^STW\G?208BPE@NV;_&&Q
M^6,Z95365/1>/%%-F*?<^@HW7WWAGPT#71-7!)CZM';[9#[7JA(\K[Z0Q/_;
M )O6/SDMU]_7MX73?TU:>-<_@*'VKC/^*]X=(]0+B\?[B(&I9SJ2F PLGH2&
M>J0=*@K?^T?MZC?(5-$A')+%K.6L-RN!=4O0/B"FDK<SE>;(T6=&R>G-=O.<
M92_?3>!>EEDYC98LZS[KB8Y%>JC6(L&BVL5=%D9A"OEFC0*NVGSGCK23S'-<
M0+YV]KJNWA'!!-#;";\?*V9FM"UY>_X3OX]86B"ZVKKM71.V%"#F[5>.#S[6
M!0#OHI!\KF,*3H^6D)V.%GI[]Q52B+?ZH?)L!=L?P*:<T<B.W!Y'PAB0F)7(
M9!_:(21*JQSAS0#J77X+%F>6T^EFS>3+\+C+5Z95CE,&"K*R@0>"$5=E1>H@
M76Q8]MY(^A"G*B&YS7=P4YRP/!"VLS7 4.!HAR)Q#N0M>/U](L$N!1=JPHD<
MOAZ00:6Y6A^E')A?)P';?1D"0OJ 6@/_!MH=K]^?($T$3<CN+;Z!_>X;R:)S
M;8QEUPA!O]3J*+)W^9W"7O3T'K=9V #'-Z[J4!\J%U5T2=]6K'>H=?!HV,X
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MFX=&*3U@+Y>LFFY.^7PQI!ZM( PAN_W!L&]&EWKV!6@O*H08X0!>P*[:,[:
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MD=MB>3D1%3A6,+77M?TAD&*);=SCV-KE2ERBP(NB*!TO"3^V%M07US^M\ ?
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M>Q,$X;1TH\P4JK*RWZ2),P\X.1T3UV83YA6#M7&?YJ?>UT\_(W#R+I9;\06
MDMWC3M_&'.]56QYQ7O\3!+;_@D#+Y=2+X Q1)Z483<T<94M$%BJUO9ODVJ?I
M]5,HIBQY_#W\9"FGB^7&H)L,ZM8\ B0U0+5:RH;\]ZDS4",_$D<F4H[C&$5
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MDA91<GY66WX@?S$[" MTO3+Q+<//O8B^_FF(U)M@0UE3QULNC2D%LS-/,</
M7OL:5%I152:UT,NU=-?%0WI>U=T>1=<9I%9LA'.>"N[>$CS6Z00;?U#@_ RG
MZQ #1WR&%C D>M1;]%[Q^(^ADO5!ON>< $RK/1A'[P1RF5FA[,@T53VN#E2#
MKW)ROX*TZW+Y<66N.K%]M$I9&P.HA^%B( O\!?@L@U?S @LSSIF8LY4D#UC]
M?JN?,(&60;19M!DZM*FIVWV%CVA3W.8#6S0-7#M_ >!@A4G0$R%BX2%(4^=9
M+R*UD[G*-EBIT#XK-TAY)DLRTZ$]=95R:S=8<*XKAAE;:1'@(RY:!E]463K&
MD@6F#YPLO80F1(E5U\0W;?=2).XS)5XK%/]"^PO@,NJX8EE+O<DR>B,66^Q1
M5J/54QFVBJ?#VG=(6G&:]KH1K^9$X'UQ'Q_#K]"U<J-JN#!VN3W)TRR>RC\-
MUJHC40J^5C.D'0\MS=1?MJ%BO-V M/X^?Z14SMLB?&]I\8W2*^C+F@!%IM_/
M2T55P:?/^O2]&<6L_'MN,X_[W8<@N=.2'D?I@H-.9??]WJE<UFQ_52J.]X,Q
M@T1D%E7?O00#\^Q)*H:YA*EQ% _WWX_SDWV(V^OC\'N*/-Q,V]C@;E4@]<[@
M^T3_K:K#?U7>]ZLSCQW+?.#C.)D- LN,58Q&!IG9Q<9FK?_S5O3VSA126Q?.
MZ&+_\">T:O.; RC1B[TSXN8X6#=]IEWS$*Z#D4VJ,$3')H95_2B._R]@Y><1
MSP, T[XA1-%VZ?TTP,RU"WKYI-.4KZG8I/)IR;G;9!L&FXY2CU6JL-"(GZ!O
MX-AHL/MZ]ZZO.IYC4V5K@$W@A1^ZV&(^I52>IIJ[>?S=H'W<W_+WX,N(#8Q\
MH2R,S5Y#EK?*E:7K9H_]4GM &$9\3-%=C>N;-<MC\2$,N%>B@8)0A1=]!+S[
M"Y#Y"T!S<'6@$ &^2>;E'WT<T4L>MJ;\(\MM=L.)X=HA'#[XL%]YC><U>CFM
M[ JT-*R$'_KQ%V"-KSA">0-8('SY7=.G$KSO\%6$9>EQ5:NC.T(P8-(-5-SK
M1<AYS#(8?OZV(H^K_TC%LIP??IPC\F.[UN:HZXL@[O'C,GCA, /Z9^#UO;OI
M^/KF U9$A4IF &&!0A^,5L1A@6GF#8?7 R;GIU TOEJN^U44SVW*I32.,0+?
MQ(&!E=7Q$JAAU?FQC#IFD!8EZ44[C@$^X8DG<F5X:0;YH9"-3DT/YOE T?]J
M7VY"L/BEHQ"+SH[ ##_/(1;H@B).5%!-WFS(K8;,\B.2V]_5->9CQN;8X?32
M[ TQRM<LX/%VQ*^&E*Q&)^J":,^4R55,J\G7G8)OFX$.]G& <0KBQ> VT8U[
M;T[G6U[BHBFVU]?<C=X=?"9;0?\U><OY'ZG 2LU8/78W]Y2! [(GG4P\.%65
M11AWEXF05?JQT+?#S')OT?II>1YE899RV8#.>&>J3,M;-=^Y9M+N=P48#P-'
M'0S%&/G.[^UTLO=O2+UQH_ZK9SG!+U/2JT:T6/NX)4QQ[8I8OI#;4F?3!>Y\
M1*\TA)/^UVBFJS,>"T8MC;6E3Y6':]=AU"'5[I/65(G=PO=T:?3/7V\/'C4X
M=RF*=U\&GL&)>'#Z]2R0N\M)2H']&T4G_HU5HOK'/I;R.0R<'&L)^ N9N#VH
M8_>$QJ0$[1IX!@\NU7/O&^.%),4[VAO-*2G$*YSUUT6MA&0+Z9THC_P%[*SU
M#%G*#$2-/K.J!T.[Q^AFD!\#?/42"#F/&XKJ($&9?=@\-W6J?_U'4R8);!C<
M*G?.RB><WCO.\>!R<&#1@87?+@VP,OSCK=01QYU$_$X^XGE;Q]N&')U#P'FT
M*I!F\G,N"2\3]T_OQSE6H;=OC'=X<+.G_7CM84>*=>,O4^%NMU3ZIE,'OQ0"
M%X=6\4M[* I;F!X1,VW,B">(@[^G[O"420/,Q_;("?@K$@S&IVA@4[,7:C;\
MDJKC7*=Q>GWT94/DDZ@VSNU4\H6*N>2;F!'- G/?'1?$B1;_&,H76F;)5;'6
MUJYUI[P3/^U#N'WC[NPG7&2[)/&%[;B'D&O82'_U^"@Q2+N*WRP-T"G\N7U\
M\6;_X=X;5S:*%D,PT)YND?D;4":Q8X+]6[_[5-)?P*O]=VF 9=%[.UGU9^_U
MC9F=HZ^WAE,[KU=L0M[^^U5O(\T$4\Z'?!FMOKO.8L$"L\$5IO]\_!>P1[$4
M[!Y3KHD!8L3/#-W<\1>^P2K9+^O\U9_JX+(TXO0<8U:[),1LWG.AX=)]_Q^"
MCC$8\W250.>^/KW4$$-RP4C8*?SUD&KE7$C('UVKHR/94G[>,OT.>*/Z7?5_
MZF/]K^P2'#M7(9><A0Q9;6K!C= J_3YZ?#ZYEV*^G>D,@92E5=32[8V+K/F,
M;KC6<H.3(RSK-8)3!7LRF2Q)9C.UBW6[OV >Q=C7RCGP7=P>'ZO$>?C@G.G/
M2IQB8*11817^SX[66JFJV-G2BQL)CBF9'(T(LQ 44X.L0&>U2%Z#[?Q>+YQ<
MUGB9?G4S-SX+6]BR:QX UM& .C!X/@*GK6L+8+@0U"6VJSWCXVL:?FB@UCM*
M(?*2LT3SF4 /_PN .]=?]1O9@M7/\]RVN6W$)JUCMV#O!J/M^5S(%V-]AE0U
MO=1FD"BW$<I .<=?8+=6-N\*N^84#C=,>J+H(DS#V?MQBH44B>+2^,=HM\O>
MP"NT+4O;BNN\1L.+?1?7LM'D>+A=8P&>W'";F9IK6@0=*>N?IRB"K%DO8&G#
M=\"\:(7>M'.5T&/;MT4+C+/H2G]H^),NE:=#;R*OTAGRF;S.'ETX*J(MW.
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M'$ YOM=KH7>5;)%H'LI8A4)+6U*E+HXZV< ^B?J;EMO1]#(IYQ3R[SKQN&)
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M*9CA"I,3K5::H9J8-7[!N72[YSVGIWC9KN4?\B <H1N X+BY',DJ^.>-)F:
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M-R8;#B%CKY1F.+)[.(6$7RJ_IQ"T)+"5W_U8Q[&N^#?\=TT,BBR0D2@!@E8
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MM9PIS9AO6.+@EF%T05TD$?X#\Q\ ([%E CS"'61&QLIL[8'IB,]31[>(UB
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MA1BQZA!=E:5*,I!S<5NO_+PTA\-\FSJ46FB ,.^ IVT_?4-XQQ89'VMDW=1
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M#SR >,*@J(;6T:_"<B_153\%3HHJC\2&.8_ZH21PZ6:3>1)33T_5B3][*_(
M[S-]-CD?O0&^/8D4SB%($1UG]FMW=""E6B:"MR!"QNUCQ!F.@D=@7M8^;TO
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M\^Z=N)%+$F<5Z@O=?H]_3-0-NO\"/J M>+"P,QC.\=K.'2N7$X8R51S'!8<
M/L2U,N5U:CU6^GH[WD%#Z4+;0I'C_!O@#64O)ZL_2I9Q'RSQ:M)E_:^PTKK@
MG/A HKS_5-;P_\(>_U[\%U!+ P04    " !Y.F]38GFOK+3A  #L @$ %P
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MAN)5<S,-MMY3MIXR252_#/.9?MAW-XD_^2B4U.2,(MF)QMX5XGRXL+8^<EQ
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M8#>F\_@HXH([T'L1?2.>&S%$S1PC#B.MC^,'8-,HS5+=\S3*+^;H^E/"[FS
M''HMZ8M(:@[X#Q%#SV[OW1\'4ANT.V)C02_@1^8GY,7H=.F&U/%BYB65KH*>
M^&I69OC7#KTS>@D(T!0>XE@ZSEI7WU40;BU)A8&P>TJR["G[(F%'J:$5K%@
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M4.!IOBMX)&AQS0JJ2<\=4(_0$'V;OGZH?<!#RMQGC7_+ )%R] &0U&-,35K
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M2T\,G0#_]J>U?R<L2H/C/6?_4(N*NZV"08:D#!_"I+% KAI?BRGN)^"=)<G
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MR_PEL/?<4R9+24C/]/)^_WQ]_Z4>I\QW3"&1L4R(ZLEMNM,+ZUQ?FI)@ZHA
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MK="]/9D)5\70IO,C&BD@J]R'OU@;'-\CR+?[@JG#&5_F&=#:?OO[=TT^K^
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M.U)$WR<?(R<$QL)PL(CEJFTBMXY:9)T<:MQJ*QO.CC;-X^DER_@OU1)NMD=
M6GFG;#7\ O4RY)&Z^H^_VGN^5*')B@GEQ(?51-1*F^Z)OXY5RK"[TC:4=)-I
M>/7BQ2)70L+EB_1\0WU]6]WAEBJ'R"6=*8;V6ZE/&5/)++6]\')3W4BF7-7_
M79I21NDSH/>OG9^6?JI9E'C4*;"5.%V3V,]^!N@Z9%RCTO&&*3!1,^4C2<N"
MA/7T%$%O?1OBTRNXG="4O@ZOW9-MA K"^%CRDQ;9)>NJK3ECKUUBPF)^!.PP
M%:>XY]@7S\(F2ZIEY-7)%:HJ!)G;SUZ*%2]ROF*&33Z0)//'*>B(+80R5312
M!B5MCP?83/Y5X6H(7O>I,Q4>E$AZ]@,? +?*IIS9#PTG)>HN? 2A0XPT3@&U
M%#DQ ]>_I&Y4(DT]GQOV<@XV(-O6'#=KHS[@BP<6S0,%H/8_>;M2]EZ.GI9X
M<K1]B5D)R$<-/;+[GT>0_D=*K[0TU9IB1!;^0#Y;H\5[XBJ>,^C-\:Y24TM0
M/] GX@4KA%4^?O+G"F[7",K_,Z=5@\_ <%DNDC2=,?[?Z1.J'\T\[ @#<F8(
M;U11[YC0WT0"F I9C^G:JB./YJ3H"<HVG(1C=:$!KYA9; -='*I?;H+Y_;^H
MYF!1.6,K2O[W<?R_/,1Z*FW!G\=76^M8O_[R>&W>T0,:/\F%/+VL%>2]8MM&
M$ X$.U*J!CA_6WD?P/:?Q=0L/\X<AV$/=WPE,_]0Z^P\1 2Z?%,*Q?DO<:69
M#2U!DX=CUB_XNK*90L7/C=/\)2<N '^')&8XKV!K]LL2HO=+M"$[" BL[)%O
M/T"GO\K1F#RL"<_QZAH3A54Q&8?WTX>1O]9P=A+*Y7XDUE:9L+\4,:K12YYO
MR&$-5QL-TS07#?J[/>%")=8:>,(\=3)F]8U86KQF%W?;CU5#Z-;^EP&B=F^0
ME+]0HI-I^"&-!SSF0ED_0TN:6]'O,L,?),,9K--@]A2$XYK&X((D"=6DN:U1
M./O?:1M'ZMFP;PF2MU,C:@'BD6;J7I7T@08?"NW+&H! 06!EP7]98*T)CI5Q
MWMMC!\677PW@FLZ@BQ*Z#8O_'J7)W'JY(>P6TGW8\14+_Q=587\[N2 QMR"$
MSPT^I=JY(V.%-*&FJF>HMUBSAH'\DX&S/_!:'R#W* U0^0]KZKW:Z OAD$KH
M0B58[O1A,#C1I. 2+8!U5%7>"T4[3E<T0$6X6N;G'BEE[&K\/Z'3;)B@JVNM
MKHFK3W77__AB@[JD8>-J#3H=QW#A;B%U%0&TUN2:U A0V?H?+1"IHL0] V!$
M:KAWH]**[W :[@<O"FUL8UO:%$)3"!<Z)US)'6M%4FNAO%]**4;>H=,EI"\K
M $=R%8?9+=)?S<ZV5@?@Z,2AR6YJ76+[*([EZSB6FP;)&'08B<8:)CI,'2U=
MS;*SY<E_!26Z":&5G=7'I^=\D[AQ/!.*7WW7D_$5<]B<-PEK[34O0X[G?'6L
M$4A[;<0L^B+YG&UB=NBL[TW8H/9"PY_ \5/8')-+ JHRTR;N=Z,#=]LM746Q
MFFI.PBY#QB]D:?C3P"E8!JX*D3NA+L*6^#!5"$7O(*+SDE*[P,%[6DJ:Z@S7
MDA#-GE(M]9Y_3?$FKZ7Z5Q[[*1Z8S+@0&8JN4."S:KL[KEH?=(=2V]Q$JF?(
MK<\O!02"00:\+MT\<L!X_9YY6FOXU(7XP\2/=S4X:5_Z]_P)&MM:FG\8S,?S
M1C#S5E:+^H#.@M-0URN&[6=V$=9%>]KV;ZJ6Y&**D08.]5UT>=7@<Q5,TB)_
MP>54EC211M+_+@?=TM;HO^I&$=V_&(WX+T:+>K1.^;9 A%0HK":Y*PU0GY+8
M0"_\-EW:=H=4QB%;/7%42VET<*AD]VHGR6=0-Z+^\< -2%8NE0-P?9%8VW8Y
M_=!Y]]#6AQBKF1QCI>$05HPPE(5^T0&,R?72KSB)A7C5)?A#/$ODH>V]1-<$
M \GXC_G6YOW1X5^B? ..D ,1!2]:+1*01[PO,BU_64?E#1=[@K3T?O%II_<4
M0D0@])P-]BLG!4(]7-U6<PB7NCV,L3VUU7GY+$?61*_<K]^9?3*8D*'=):WM
M<">F3';/R]8)A;LJZW-)NE3I!@^29$*%?"DP 6*RQ\>?K]4G>WZVIDYK7Z37
M+Q-!OS,N<EN5/PSKOU^ )N[HR7 %QN:QHWFK.?['[Z9R=]_6=V8@LZW@!U2N
M_?Z10(R/9G&KZ2>+$/H;>N4OG<AI4$%B4#GK5E5MPRGQXI^$G#]7./1NR_P]
MYR_GISX=KFQ'7BP@Q:!3"^Y^$<X(6YTX0H'Y%>H%0?7CYU4JZ0T]@>C4*D#T
MI3#8PS-@)6C\[D)TZ[( @DUO9#@W/_<,,->K+3'D72'G3^_^9&9^'M,HQJ5U
M><5_KJ-O9(._N,0 EK;?LC[,]2"_S01&'RYP,M*Y#GN[<DH[.E+AT\EEJX;G
M9 =P<JF;BOE\]@D2:B,:;):N@FPC(CN.W@BLRF-5Q#F3E=,YS%%25^NGJ<_,
MBSTN?A_[V^J\S17W+T4>U'#9(&<O)IZ)JW+5W/8+(K>VR_&'D+'>%)NY[].G
M^QXDA&O=EY1?><NW[,Y\XQ/.5NL(P?$Q8B69)W1N%<WXRWH&NEXE&YA?.9)I
M!\]1K3%8>1 H 2X&%DP[G,+JNMA[7D$=!3J#17H#AIA(L/['7 )9U*],G_3"
MA5[J%1%/>HKEF$U(1PW<O5\(-($/=3J,-EL[*#C )2AVG8167*8">\0*=9$G
MSC$%J@10YO7UZ\-E*NE"1'N? 9K;Z9V.BV=71_V7)1B65-YL2]F'+E5*AG*.
MYO)457,8,9* D\8>N6V4::^"W1'K.%%.4N9S>2YV9P\1$HE0);T>8=6DY6G'
M,[2CY<N%<\PBUJ2!3=?YJ(P;V>['N!BY7&=D M]12MJ?8%-!A%#!4%+5O"):
M/.]A5G^Q3BXKI)'R5_@/(&%Z0X_7GI(W]E4&3A85!I=3!3PAOS/V%X[LJM8)
M%QCKWRG%M)<W4-NR3C%P2FU>\$O6-PU5,?:'KS^&#3CD*1_^[:"$;J$]F_G)
M@+R7EZU'OE3Q?!5?6]KK$ RD$[BS]HX<"C1QK^'1FO,O-V_5@+-H6[7@>[\R
M^P$I'YP<"M]K'K[>Y"TF1N-;$FYA2R#ZQ-1C3/35O)+_%2W/O;*8POK!&"\L
M9);.7)4G (-,U*-L'7G$7]/P;L1P5M%^&^&XA45N/\,2F]618_[H]2W.X1E0
MSL/R9QI=D]1[%:?(CSL<ORV4GE*6YK!A^EV!-=Z@=<ZB:+*_VU*!6,L!.Y7#
M]YJVYAY/HQ^NVTNM.%-3E"QR]O8C])R9']5F7B7_;4GCHJ&)QM&/ 18:<^>Z
MY]^5 NOB2DTM @;1J[[4-A_$1PSP3.]JN@K*E.,DF+K0PZR:8!M?@1!I-"X2
M36[EPY;K0\.\0+"QZ:X,FDM@BOPW(R>$2*CGA4^TN/PVA(U'98K]\*&?^I<I
MN.<]FO@O0?*KPJS:ZJE:-N$M3ZBT(Y[^]R5X[ML_G6 P5H#MF),8*CMZYF7.
M/Q6F8K0__8!@JIWXFM"=8C!<*>=@/N';_-WV5V[:NP7^ 1Q\J77DW<BQ44*E
MIN90EMGRC"[NEM'E]IAM9@\0G2BK9\\8USSQSD^:X+.\8^B%GB)VJX-7<D@Y
M[R.QKQ"(_DFZ?*:@_@>D"S.#"^/#-':ORD#>":S4.[\D%[.2IR>)&UY9 \[Q
M;++/"Q"-W[$=/1%#+U?@1)>48/XZFC-\(<:,[7#4@RV)H,?,'^I&@6>E'K(B
M"0(%#U4[/*S9DC(X(MC+M%[GOZM,&'9;YK3$<FXU:_^$;)@&H 8\E'!\'C&9
MV/ZB=)5E\][.K3;#I._W=^.[2S+Q2_ZQY6FC<^K+1L0OVB>BU02?XZ<^^$'Z
M[/RT>&VT^Y7BUQ)JM+7-U:?^'\L\<H=UOF5_/%P3CLUP)G=(A:7S>B+>QM?F
MU'B*(^IX@HK 3DKZ&J\"T26Y$-X%)2:Z#(_N@BSW;*3*OZOKIPRM7-UKSDW9
M1 ,--RK8OP3"'TR1Q1N(58:B5\?"(K>;HI3XU<EHM%W9.'ZZD[+ GP$<UH!K
MA/=%%1(9,!)7S.MNS#CV[13-FM[%O6%FW2BFG#+T+B[=0H*#-?L-4H*'JI28
M8(DA7<)!RH2 MD"$EW>%I-8DU-:K'L!MW#LP'TN//QT<>?'4:M5+=TV$M#4]
M+FV[GB.15I_,X4%&LF17:?"Q %!<ON#9^[FWG.^STKW+33YCPP3L]63(*<$?
MK=4"J\Z,'X4B_,0].)R"0L/>!>2(;[J"<)^1F@HQ%8&1S<CIGN+X!;:'<Q7F
MOEW6?A!%>N_UJ," ABN*:1V/]H.+BY4;IJ)B5_B[P'2:O36=-;9F2DW3S8VG
M#-TCG^W&'"*]CT%W"^=&N#.]:T*\.I>R4%<*%E(COG$7C*N@&;H-TU:29))Z
MDA26FYBM%5UJB4?RAUZ#Z1<RZ S>OT<:$(9_Y1C]ZZWZBC?.N[;]T[_62X@:
M]]#VI K9=,NO0D<BH1?1O-6[_FB;+E-% 6D+,8?JQ><:)#0NGDKT/Q[%[HF!
MNKW#E'\8>[]2T7;Z=$Z+I?,,L%K0G_M0/"?J0>*0S#7OEUGA$EVV]?Y]@\1[
MKQ)2[90R6):-;ND;G?SZ&!8T,F,I;;35 $,_-%E!=.*=10D*=&HF%"_[H/6/
M$R&_LRQ=3+?FUD2XN*)I$?IQ8X3]U))B(5^@<OZS(N1EWU;9*2+P9:C/-[U:
M &T> V=W4.AMN5Q[#R?7;J3A[;$29M867FM$<P/_-"EC%_!+G!Y=_#-@TFN9
M<_[:M[6Y6LMT;"V)]_>Y0]*:@;^>R;X(^/T8)Q.:$Q)M;*N'MW\Z3BI19;M^
MA"7$?>FODG<0O!K6;;^@3:2'.>[7WV(W+]\=/UFFV%2H?,TWU-%5>#V6-3GD
M?'O,0@\B^P#H5GY,193[>^;O7ADY*)' ]3::*A+4?]#56$,X@UXHH)DV)HM_
MCY$K5V[?CFFU:E\/[%6QP3.Z%!WS82%+&1!I7S89?_AX\G%L8$.:_%,(W"6Z
M"RGCJP%ZE.Z(C;#-OKJH]VMYW_76>*QE]O9-+V3*RGF^26-OW($?9YQ>1*Y/
MS>B?X:RN-XZ7*CB*(*JS]OIDD^$M#RQCS44:KW[R'15ZDR8$@6<DHG-J1-%Y
M-&+;A8K&U%Y_'3+\P"R2\:?N5$Z#)I.VL&"L8^+\&5"UV]1RAZ6Z]^*),G6^
MB,.\/C[>/*X;TD(5LL.U@_I>NK:UQ5TWK9HC[+!6I(&>C>50%<#%4B$TA^'P
ME+C3(;D#>'CG]-?:4+P7<D2Q>^J?B"Z1^RMGUOI>,G9'0*"#"Z) =\MUMU2B
MID6T<D&?VN\8]PKL+'>[A/]T!T7#7=SM]O9G(4%T:M4E[[HZ'!^)YK.A: M0
MCA%(H13VN 3)TJ_SNM/*./TFO3?=GW)6*M(MRS?X/0_0"TT/I62AH\^.^2F(
M'!C9FK6[;VJY:J"PN"TP[=SRN7EHB%X=@I=+"'Y!2JMP8><"O?A)Y22XVXWD
M,NC+<54_;;=DH#!APY!Z.(+:P%/1:6Z&\D,5]T. (%E!-W5B;"!O1)EJM0V*
M7[Y/:J-IN#UV_1!+0DR'C-#?K\'W.O>_BR!;IOY9M)C=D>NBL-X9S-9Z#9F"
M__:%-.5;C1>][HOSH(P-FPT.LV5+(WRE-U9;>@LD\5,\@@V"6!K/ (^CF'3;
ML;]Z?%,&[2^X_*3VZ(_TZ/]MRVOK5_XSP'Y/6*RNV&&S]IYZ_(TB,$>>-BV;
M^X8NH1X]PV9FG.'7$X6R&40VGHW=%&=($:_YS\8E'+#5!+\]WO_'+9)BK#T]
M'<$!Z7;@'79XW&PDY7=/4M?C_C2XV197X 18R2BSF0YG71_[.@T[-&N,0:^K
M3J]DJ?8*]>5Y(2\23ETRZO2W7YIN;,+86MV'[)CAB_$1'X+/*KXB)EXY:CO)
M0FW0$ <48SNDI.B?N.:/W1+[]((%X5,.'O;W,\>18Y.'O&("7_AU.X?M\V1M
M\CL^CH5P)YF^1J'Z)7Z$)*%P_!)=%$?96PU\F6<L>KD]6>K:*K9Y/GQ5;5;'
MZ"0D?^8NXDT-GKW6'9A<:0SN(M4ZL^&?<I'<I4G?]LO*._M3^!GO0VV5"Q0#
M[F)8/A6S<DW][K+!5;2S&ZT_P9 B=SS:C)/$JG2%C#/#379 (WV^>JPIEI*;
M/<+,'&*U)G"U)O,]KL,%SH50V#W!566&_<5AF7&LW>U!K@T&8;3<:>![]<,S
M_.UJ65N^YH[<81$K9YLZ>4S6<C#D8Q99VN'N<A'?VW*<9'.WXGG#?A?4S2;F
MG?A>UH 0_.C?.NA;]K=PEV/#V+\(Q"1Y?"XFN'&+YHVM>]V43"OK;JE?O']7
M^!&2$9/#3,ZFA/CC[+#.9"U3S;X*\9P*3][P8IJ*-=EB,HVDNO8,GDM,XLX-
M>B&1,4WG6("NSGGS+2M:M:=;5.I.>4*?L&J=Q=)GDV= L5'3D)Z3W79,[?N]
M0>7ZVFEC4M"L\#Y#OOQ0/B.X3%5.8U,#TD5U^:)5A3;O[=]I]SZ="M"E0GRO
M%?EV(**3VT5CWA6GARRB4&V:UC/$K4W>X_>.[Y[,C8/$2BO9T%2/5YN-WA;(
M9(<"% 2V\8W)HSBW?-I/('14]J;"S^A+24 6ZN:BT<Y_;'SX3+A@HQ6W]^<F
MX@V+T_C/SHQDJ[\&L5>P?3]M(GF:)*I@=LZP%R_BB(-*;+*K\D.\$!*(;+ M
M\V+8.U0(X?T)5VI_++&FXAB&8!L+0M"&.)9A^!Q7+TFA0*K! P77BOW[T\&(
M<@7'D*<%MY<;=1,P/37^,\H25[W07\M?VY.]F'/%.?^B->]\],R'(C^_NU%C
MT?F/PI\]PSHM>FPC.,)_[KW0=G_CR)B^VJ -]R1;*[^I6C0Y56K=P*Q7]V/?
M9%UV,<\GFR.R1*U+:B_;1Q9JSP%<9>V]7/45OK-\H"?YT#F^H$BH)^?&-B82
M<&.0=^V:X.YY@2!>5 .K?9+Z/SDT-OA2?>;+*:2I@^=RL]LA#B9+#<N[^VJ#
M^?K6^#LI)D8#H7M7'T3:W9$;G26IP_+<:3X9?LO89$RO=_Q5XS"_FZ% 0Y;G
MN20W.L?32/Z#H&#"6RO2F]YL=[$.E#S]65:\HFIOF@16\#'#3(43EV<3OH58
M[E]+4NP_NLR+? :H9ZAHC8U9Q CQ(S%^GK[5-F)++SW+3=#[0!]Q3;Z.4CX"
M390QP%GRLU%Z[Y2 'OB5LY_,?&5;]#H_ORFBXT((6&)S76&M-B@4KFAQEGPO
M67].QH_$%CR/3GVN2W)FM$=1%FOO4MB7K8@.T:I)Q7R-W8'B3SR)L+1UH>@%
MV6,5MKF9@3EI):V7+<.&O_@6/G091-[+O+]#WE698U^>RM98UIZ_$+1ELJP=
M=QN,$BF)K9FSP7X''DS?R26,/^)!^+[:\97P>%LD]I3/$#>G2!<SQ>VO&BED
MYYV0,5!N:/W'R@&U)"^O:P6#44[S5U@60C=9I3),:7RE*@"?B(G89>(^1=DZ
MJY"/@V/_89!73=K"YO]T%M]__"!MEZ/?8#S*]T$9L&= ;\!_W" V8B)'KP"3
MU$R9KMD!S#;)@_G6VAY#S=TM;.S+Q\:6Q+'VIFL,]WRG4UK6^CE*%B/%?X@>
M5\!H*Y*B!,J@\92EQOK(HRE;ZV37SZ^CIR?P@_4?O&D:_E"RI#L(C&>9"\40
M)!,PIX58P@$K9H$)-V-Z8>]E3LU8W+^-L#\#JD-Z9V.R0LZ^I]:MDR]&+SCT
M\*AFD/>\!=XSJG)&%503,A=I_9)'DH0K@Z;)J(?Y6CB\OY2BY>"-ZFX?OJ6E
MOYU=WB+"3;-?/$P#:>6<7!398KW=Q(C5M#USATJYV[<9>H\T&=W-/[U<_O?3
ML_VU.(=T772J8BNIDJ==R@@J-VN6!XY4!XIIG,]$3K?3X_>^*5);7W;QP2LL
MCA3SGA6>](9Y^,$Z<4;)SO2H#?_8[!!*/45'D_995.F'/I8PFE]&#K663_BI
M/0&+Z>\Y#C-JHRH%O]]*!=G-5@O-U\<T'K]_:L.]>?W7^)V@*ZU3>K)&#7YU
MH]Y;8"OY(B0->FW0R:J\0+PMU,W]#.CZ+(L*Z])*'M671QV$Y11C#U,$GQ-X
M47=\#OX()6]+^7,P[&4J=KG13[_FHW1U4-RL^8(P#EU_6ZBP5)3B*EX7:-!;
M]]JM%2CS\K=SR#P9_:H,3Y#/R+'%J^GWUD_O6&Q1M_+9OSH>U#1!\ HU(_PR
M"ZF.3,%8ZR@>)80W R(L>@5M8^4P=K91AGO>5$QY2D') 2FZE?CX"4W/!UH0
M6\H''S]\U_&Q8;,@;OX?"=[B&(>!\9<%!IY&ZI,$7K5B,G.*=7)KX9W(]%91
MS'U=0?*L\[(5!1.*=P_8?BQZPM&+D[E3I/P"6GME)AG6K-'II:\@(C3"D45>
M:PWV[&6R,QP,534)@TVM8(YD3%"<C >5F5D 2!=_MQ0*;)H4[7['5^KT\K2/
M>6@6\8!Y4>JSC&6D?'V5= =6L]8%Y^O]3'DQ%C2SA%\=0$G=2RZ8R^5J(/MY
MPO=+*>S/0J>YQ4<N&=]J<GKDAOBD!:F^P^!]U=VYR37/::WJU@8X] MDAAAY
MP&K4(-1G4P?ZK<G617D<._JJ0.)G:7T"?62F7WMEL?'=16FZ[!^(D6PA:@M>
MOYMW/=-> 5,JBD/;"<."!(5$WRLH[2E:#JMP]^2"-JEG0S3,/@OL(+<A.=#:
MT($"\<R=$+5T>4QF3?(VV_5S]$%MN3H:K93<,(V;5Y9J[UB!VBSEK,H[K$\D
M+>TQ=0^=*%$I?^^MX\6L;*=+%#P\U+!_P/=P-"V224Z2%YNXNL8/MX^4INR2
MZEG8"(YI'*8]D9!DU?7\[9DSN37)^C;0_CBDML4G@;T+BQ$;?$V_8GROL=Y3
MU_:5AY(EM@8VY(ZP <>LYJ);O*I4QQ&AB#G^PV/T-HOJFK\T88GAXO7A=<@/
M)BQJ^<[7O<HMH^C?\Q5UB.>5@C1^A^XF#0Q]H)DY/P,[RR,^OS\_>Y18">:K
MI;:SUJ7WCE[\L3<TFJ-7-A7_989=4)"><*Y0<>T&!G,P//_46M]8#Z'WT7ZE
M'T%IPQTG1Y?A/\D!9MMN'$EBL7^R;JE['2] W%7L83KB5EQ]8W)W:PE]>L+@
MR$M:.(HDJ,P%R;<PH20DP)6M<+Z/WQ3+D2?<$ZI"Y( $2_0^9'/!$*3;WZ:!
M:>S*S!6GWY)A-F^MJ*Q)KO 699V;E0\W5M:%1!H IH5")=XQ847RA8;ZUMY@
M_LJ]ET6N5>UF="'SC2^!Z%0NO<1:^QU1$AEVR4QUA+NG7ZI$?=(_??R[-<1/
MZ .F(*OL;R@YKHLP!ITI-C#4^.CX7D6GT[-_7R&>Z;(4)-N',.?#UO;W_=YZ
M!$NW!-V],T8C__.M)/Z$C'I>V?^()TYN6!@7+;GB=WVSL!DVB"R:4KE"QSVN
M(SAA(BVP5YFY&QX,LQ$V6-"^:VU>Z-\D0W$B#N6.(>/2WX#(BE[L2F(^ S#H
MZJ%GKQU]W-P=1</MVI7F6_*<B38 F32*-&TA!)X]#)$+;U.]KQ/T:W-T =ER
MFQK+P0E@_!@7,-4X_<GP]5S^A/UQ9JR:@,46OU64[/G'RB9.N)/[-MT&2%WW
MQL*SW)ZCC$/=-J\%<K29Q%V\F7WV)Q,!P'++^F84]H#W# B^^ZL]^7C]-/E\
M!'Y*L;7$*XP,8\TL4I:K.LD="1'+S'?C+>BW8T=/N&MSW_)?EY$.QI])DL%7
M<' PR/@\%,<I5?RDH=)Q!DMB?0!3*^,<ZX<2]NE.CWBQ]-RY[^K66I\C,B.^
MOE'7@!0/IQD3SIBMQ70L^&>LS1QOUL!3O5!;%Z*QM GL9\:P'EJH_DY&1P^S
MGYYF2_7TA0^+CVP29EW"L),VF*/Q<.)>PWV)&H+-(ULC\%(YP^TJU+@ A_L!
M5Z7M3G-840EZ] Q0:JY/$5P:DV&M>O=Z--D6*29L+*S"C5M49,W:P9YWIORP
M[(,!2TB+4[80M0<!)XXL<AE L$3X6U3I)>:-_12&:>1&8EWZKY<_ E06T9TW
MD,&!*6YM8;HLV"23V[(4OF#X^_BM%V4--!G>Q3M/!,*:&RC?+/A:ZWSK%8GU
M0O>C$8?0G 25PB:*.VCY%49F71#<9[ZQDUL*;<2]C+NK$H CK>I(\G$++J(D
M?+:WMFO>Q43\A8(;N<2![@7&,^"O$.?_\A [_)V5O_@!=8.K1A8!;A+F0@E"
M0L&3D2(V4CK9W[T+29\WP( R-/ 0_.269V$A$ /,CT'(^D4-;%A+MT+GK"V;
M<+06JH#LG;7U)*]E<*F]8)@&ZFR*TK;W[]O)EI$J$\U1\/PZB$,$@K]DUKGZ
MD)<9>_61NB_9?8+(&:%Z!XG)MCKJ[+:9CCYU_D0F<OK$&9[ !HT4QK$6F0U-
MYO(56HMP9'-MX"@])K M4>$7^47LOL!=R!& ([4-I+.L5<&-TECV2]I7;*FV
M#)7/Y"%ZW)%*(L-22'.W4R\(S=,SP*&M0Q&V;XFK"<\E82,9'MR-:9D2SU@1
M*=&;]XE@KSG=D.*E;:@UM_Z0OWC4!=$39*S7=5Z<(:YIA.7?_,%<=SC?O4[2
MNN8?=D$Y#YE_PQSJ\#T^P 6A&X1+8&!T$R43PEIV '. >*%#2R)&Z)@[4>+[
MX3BX?%8WEL.UH[#\=%T62GFV/"2Y<^0N(+VW]X06#>VDR23O8-2B,F:XZP:$
M*9Z.::@T4,H4(@":C_3[6,?+%VUCP%H8I=C<>HO9_%&-&'!I24=X(%1Z??K#
MF:]I]\[@\%[%K+[X]0P7.3W5$1#%M,!_ OKZI+6GNJC7C;H;VH$+&5V<__7=
M-Z$537(1X7M!_#9XM<C5HY[;0)8C(1\6._#=K*3:X<[X(J_\\M]-:!+_N0E-
MV(BXDUYK6Z6RN95'-RK_3/.;"SZ<O$I6"'V37)0BE%KK](DB6@.NM#O^Z<EA
M-/U>'IVL6]9ZU4]6J:[:0$(]Z%W2L-V1KAQF23'D P<02X"FQ45[?<1,!?6;
M,64(MU_XO->\,K>,@$F$W>&C Z:KR8W_QMZ8EY-GM1;4U.$+1)$H6B,.;>63
M*3UA^[!B7D=QM*V&7CF!T:!]OB+YS,@?T4FNL-<5C9=4)DT[>-V.1-)1=M+Z
M=RLFA;/6H=.?)QV@TJZ_(0(8L4TDG-]I]==2EZ78:KG8QKLH8B I"[KMH?(F
M]Q_YWZ!R'@*92U6&Y,GZ49R]M1;+*ATEPK*GS,0UF_4PPQ GV(T2R7R0W[13
M]H<QORQ+NTD2:[*3ZME !+0K6O E=$!\O!Z/-7^UE6,NZCN;J6> )9(*<S/H
M=LQ'!+<L7]VS]H7<M+?!8<8=;[+6FE-;VT=RP0Y!P8Z.CJ*:#(*R B_BFA3[
MS5\-]?=*S<JDA(SD0)25Z,[@F%KY!YYB(R"VBD;]SVY;MMKR1*1/C@9Y&QL;
MZQ7M^[KQ.T<I28ENV^RL,)K%9.O;011RF@R/RX+I_W&/'6?+AS4V=?B]?DW0
MDEQ6S3AJES;P:^?&PPQ<3K"=; _;JGNM#ZA8?D@ITDQH;\?>YD]Z79D0/4 $
M=>G!%8U4<NQ,UDW?O(@SZ"32;OHVL_$%2!^$P=P>/)X0KS+9PIG2=4Z^C8GU
M]\U 2#]V"Z>#)Y .I&BTO_T, '@;W?V3'<4<SR1LPR-%F3K(U.;G89V->%IO
M2\I &3H7<'#?\-N\-2E3'[X:"OO-TSHIAO'YD"YF*: 0$-3.B,Q(3!KV(,:>
MZ,+6M9M;0G0VH:/SDILGK7(CX4 P1VWDDG&"_8BW50;3K$U:,2\%^34*^^*.
M%)E]BTLOD02=H05_]=K@B5MY1<^N-5HR]6+MW"&0U=/.DA$8P#5SKS5V4[7$
MT"H<DC@96!OBP"6H;@9.STI&.5,A$SUC3CP.WO0L8[,K6XL9L^<6>5&598G&
M<U9!=Y\6V5QZ\Y6O)#4):ER!,&%S_]ZO1>"(C4 QPWGW###Z^<TH^8&@Z69I
MU*Z\H*$:2F[_AK"&<MW=<]"^C[G+30R7ST-]HFSZCW!,9MVYSD*O/4L/Y-!"
M'6ENP<QGK4J[H_IW<J&>W-Q'@H6N-S*5%7@!R&B#-+EIKKL&;V$F<TE1/L9E
M0-MP&KH-LW= \MPKU,9?!9X_%GBD7 J,I(3G, L[,]^N"J(4JBL[^^]V;&6*
M\\00M9&F&"R63B7!/#9%9'KD.CIZI@2%#D"?]\2IDYZDS5HY395\J/L*G%@U
MCFB6.52\NZ+:M24-J_5W*U+3Q17%DNI@%$7T>%T01==MB1#<;_N()P"'Q+[C
MS=L)<;8 OX+#*5+W%Y2.M>50HE\F<.XL^6UZ+!HO8I*,,L-ESS(1^=*C4I-[
MY"'[HQ?_C;VW#HHKZ/9%AP A00/!/;B[NP0+P8,.[C:X2R 0;'!W=W>WX YA
M\,$]N+L]\IWSU3OWOCIUZMZZ]FZ=/U9-[=V]]N[=NWOMWYI>_5O;D4EOJN@4
MK,/,(C;*+#,(=-0.VVH/0^IN:C^I[R#K:/ <=>G&I;A$E@Q4,!666&+?H#:4
M6V.\^VJ4B-(:X\ZS>_FO8YHI<R[Q\>/W_\'9&MY_>@%HT>207.6 $Y2)[&\2
M]Q1G"L-X\:C!ME$=!3^[<MJQC ;U5*1>#]+[#/_?@]  \*5JY"=O.6*Q^Q0F
M;/I)-8& *PYWI'WS)HU*"8USG.G)+>;BG/7_-2I&., 70"3\O\8;N"YA66G_
MD/ [_QL36F!1Q=0U]'K5TST)>5(]%=G_A<WZ3Y7_5/D/52+^SKUXPW<+<),R
MX1A*$IB!F&K?\RLLH))=WD[1. \E#C*/\%]:XG/[0&1?B/D3%C^2,N!N"DK)
MQQT.7E?MV+>T,$Y*8(8BTK4?'75D6MYPL[G;4['-4^/QD!07;<\PK.'(,;1B
M3\/2LT4!!'E/;A5ETU1J?>8NDQW A6;%T-4JH*L+)5PF&]MC7O22I^HP WJ<
M<26.74YI_56+7GZH3&A0V&"Q_["_GV4?K)S@WVP<!A)J=1T-'9IR=:F]RAP*
M7;@&TZHI<"F6?VARP&\QE13SIY5U9&WR[J(!&B">W4)!E#<@QJ&BHMT,>G-B
MBRV-#=$$4QZ 2A=R]H]!<C+?EO: ''#(\2?9X#4+3%E2RH\"47PI,'6-E#E@
MFK]Y"&&2*WP&P/\2A3G&?8SXO?4%0$S_ M#!N9_B6&VB@=5PROD!^9<D(/^W
MR6:;+&,=_J.C=[VU34#')&7OI_5X5^^E:[*LJ9,\;V'1<R/LZHZ\R9I?FLJJ
M/82^GA^AK3+EZTV*M3V$);PPTRQ/YBR?/^OW_I1TR*2Y4VC,5XZ/C\ SH-CG
M+=9Z 9P*/+80(J.YS#:H"T.Y_63JU>MM5]+>C:"'$3\_%<^INW)!G7L1%)NE
MUV;58&BC$C5.W\/='*RT5EO98'T3_8"X^&N>QU:OLEUEVLF-\]V&WA60"7LM
M3NFBYGY*6?VY+:S0+R5T.Z'AB>01K6FSGG9HROG G&FKI3JD?-1!^N&ZV:!9
MW/7HLKA-#*(MON&VE:)"^'8A5VX7*7J".'X12=;@_4]@+QDUY1N4O*N]+[._
MA9,[WBV.]C]F\5=/"=4Y^NBYWF$Q8.:E.*R^ !I> %N=L!'3-K9.>_72AX7I
M;>%<5&'\B72R:8V"9ZO0K, +Y4;(E2:C[4828Y'SYV9N- *SA"%80N--:&LV
MLJ$X:3AW%11H/D2<?%G0 X)O81-'MB\EC (#J$]SDPK]$SFG#^OO"%WB0)WK
MK-78C><ZA?.$"3%R6QA2/GO0@C/0+;"A0::"/(5?+5ZZ^5Q%,)*PUGXJWUE)
M<U&D*Z<1S 8#*($)N\J/67F?KJMAY*+0HBE*OB<S?&B%1/E%L>/584Z\(_1B
MT]Y/O.=0T5TB&\M/ICS/HVUNVHVXTII3;&JN/GUTG;N0L.).HTJ3J:JEY8>Q
MO4@Y5H:^&\8,Y*1I_?83UOR2V"\*"L2%HUHA_\#[3A&$L*>0[/)<3[WO^ SR
M$0YZS%QQ7'E/!_V>I29.EWIGMUN*REOBH0.5<VO$@;;W<N]<;7!E/RLWDU*-
M]^#>=6H=D@?2B*)+!N,>?_J&G*EENY#U( 452'H\-!J%<AL=S"9R%82B4+[K
M?_#1N2>DG69J2VC%N4@W.EI1K%T]/UH-;Q7DNLB<S2P6G$O<D*WO;)6J:1)_
MDY='=]K>&N'A5+%Z>.K^[!-+DA[FGBIYZ&%6_A;Z5A,K.RQ$7AN3A'MN-B7Q
MZ@:O#3/%8N2^=FY.[]<&9^M!*DC-*J'=G4P4[T.7\_80#JSP)URO9TY;Y986
MSS%GLDZN+%%K(POM@+"TW2>(AVE+8WUCS+?XM9 \A:91W_A[XNE-.(GT,)GF
M?L(C/(,_WA:.]&C[L6WM1R^ H1= YIK[Y47]7"!GJQDW9=:WV&>AMMO[Z^^%
MT_[*^]SJ2!Z,6=-P7-6:N8LCE.LB,N- 4J); ?TY9Z+R-I8D0S^*D):<+$0?
M1'$3RR%\ O,O S<P80;?,^+N!N_#CLZL;&<ZYTYY:3OF/$M'D&^F"L8^F=K6
M#JM^37[H+IUOA%Y%HNCJ:LOLC!CW5D<5F<'I?^?=<JW8ZD&/&C02.VR5!>&1
M3PG%3=0L'H5X!5>CCQKIWPEEQ-'ZZ/G<)9R"6B]\9 KOA=M2P#1%_-VO]AEY
MS/59 .>YY2_XZ;13N5J]/=6[_],YFUSPU"6"WY./B1JG",]H>"XG_+FS/9A>
MQM:6HH0@FRXO[%EU=-$J@[3.F\G[BP[=QLJSQCHZM#0O6-N86 8.=7,J98^S
M5=/6B4@2 D">6I3!?V/'C47J>,69F>VF(#69VYB!PC1+,!.BNOT9;YRWZ_$/
MT']>^M$J>\B,$J(]:"#Y;7E+>'PK"LOM+M7_UU!QYSK#Y N@1C[W.N'\<X;\
M!&W;!/M#*FNK:P.[1D('\8RU &].DF&@G/C7#)GPUJ&?45RG(C8#*%$6PE7U
MG9SUJ[6+/A8$DTX,7JNQYD'#BYVXR_YIFT1%;\TMB!D;IIF8/D?DO(+U 7-5
M7&PAY0Y<XJ 3YX$OOUO.J!+-4*9KM3\P%F*/9^-61_EV?8-)X"$OL$I^[IH3
MFRAZBIA>J:AH^>G2[45?&$-.WTI(W!8-3>- <=;5^=IE/3>Y7W#/;\N]%8U,
MQM9:W8-J)WWT-Q>J3Q?:P5^<;C&T:870.9E5AZ% G$O?K_WY+JSH3P\AT3P<
MH;ZC?&@_'Z@CV83S:"T%^-.,Q+0Q:EO\ ] &B2XBF1/XP ^,.9&>-JFIU<QM
MCY')"K@^C/B\&#-_-^\L5"_U95) =/T/B+JNIJ$UN1R^;%+@0:"FAI_^;1><
MP1V1.:S'3;\6I?_G&AW^9'T<UKL/;:VYU 2!O]V>58N<"5@+?,Q3?SZ0Q.^Z
M+]RY&/$^EJ;]]F)WSM/M-68=C-XSG!]L,U5@3?<E2MS!,IV2G0%YP:(F@\A$
MBP?,R=26HRH0C)[,/7UT]1O)6\[&DU(D\UVMJ6.L:)#[WY/&<!E,2L,[-@H.
MO*F7;#;/(-:Q7$\AT*/XNKVI_\W3CUU;IS+ >6AWAK+)?^A!-Y8RQWVN?[TG
M87"('$!X_6B5-^/T)*YZ2GC]=IFL,V5:TH M$*9ITU4<$I$YE^3\W!8TMBF(
M_>Y3_';F1QL:/ZC8]K>UCM_-2,]S7U)N^E(XP]0@,D[&P*3'^<=@J++1\S,F
M(7/GE\*B!<MKOOD9CE9I9N398A"%\MAVTG#UIQ]=@W<14E5E!XP(P-.%AE0%
MOSG%Z+)9J).%5U884:;#%DGB+CF1&R9,K?LF$49O/V4K\XY((^U6+\0F.,V&
M0'1S#E)F\4P)J9>]J:EMOJ#2>.R[PV4(_;44)HF+')%\H*&E'F#+,83("E;D
M\+=JEX>)&SP6(1)[G/'Y.EEQ9-,F=$X&7S.E!;5F61^,_+$O)*Z@<+!#,K<E
MRPT&'3VJ4X6S<5@094)U7201>7>I<6%A*SS.Y(/Z\3FN&UV1!, )U7AY%Z1.
M5*R/EN_@$Y=,:Q\EU@^.@&K-&GY(P&76PQ45*F1YW)KT=FG> :QPG)^VVU/U
M$B!&T'%&/U C0TX>&+Y=_9NUNY+H;D\&].0>67FUY22W60ZCK,:MG,D,5]08
M5:WRJ&]$*0PE])R>ZV";9* Z+V@Q7%%6>&A*'TA8Z'G,>FQS\%2AFCS64VMJ
MTI@:\:;0HAU\>$C:W!NL<!A&,>W1RACO'Y[=<(8PE.]@C%5)VI,NIQ$-HSK0
M/'>R_G6@+_A>\1OF'KZC6*UVK7MUB%0L@32<66[#;Y?*YHVT9RI([+=(^8^U
M2]*AI.C]H]FX&+A5N$A=6V?: ;L_3ABI?V0U\H$)>$#:*&*R.H$LDM(J%[03
M\CF-=>UO+N2G3XP## *YID!'H$'#=1WNW4H*E)Y*+4"R%RCW"_6'$?8VN[9!
ME#8PE2H>Y7L289OD8B_A#4\=!\B@[]FRMI9W7N]@#U)Z(=R/Z(R,=JN$*2_.
M#9S9RX=V,38X] G,FI'OI@P3Q-PE:_#:UX07ZAQ'U+U\]A ;HZH&]_4J/J?!
M&YYWL&]J8"-$_R[J_%V.A'D!Z 4]?G06T,L=8DR3$8BDW'C_Z5O D EC(S7L
MCXR\RV+K-J6\??R@^?)CO'S>=_U4WV*)7%AQK3T_:N@2GHYG&S@:SOW ,IH<
M2PN+>(^!QVU_!"Y>GT!8MF@)CW/E\T@Z1%4^W5=N\GH#HR'3G4;L^&L7\[*)
MO3WA6R!U@MI[?%I30SL D9SCT28*UXEL9\;PP8BGE:/00:@[8&&A>PU;S[F<
MP*)@AD/*HMPH0E/Y\[DQ:-"=CDU*T:?<WLY-3Y=/M]*\*E76HLRX$3QV,M;-
M$71<@XTG01CV<<F.5=HJ>TINDQ%C]NB(B1E1]F-POBUM@V2?*$$JKJ(#B\QU
M(7-8G;B)X*(.GP3<$'*',5-8V>[V(#F/8.27L=2>1HC%_189S\B*GCB'IL$P
M32CO"Z #O\2MHOL8*;6U5SJXN6/J)\%BH'%L^HH_A=(+ /82@W/GS*2^SV^B
M0.@&.,^8'V&^@ ?;1%C<14@('N\X"^_U*,@L@,H@Q^KHR2+)7FMJDG^V!OW:
M7PX91]"-VYET#I>TJ"=H-6<\IFJN[6N1[;2V&VJJM@;(#&W^1O0."JI'\K8<
MWODLBJD^-]6,*G38Z?AXG>W^ @#"/G=B''YGFCJZ7)0Y/F[;8X*M>4I8D:14
M!2= 8?01Q!2P+&_Z^"1B@.S+M@]?W*/=I2%>F:O\HMT/&?01MO#[BN(&=M;/
M<PPN1[8,Z/MHUBHW9>O^M#W(W*2S;?C8I=DC5E2)1A9T[2E0621ME@]1HUW^
M+)2)N[Q$'HK7L"I?SPAMUT9 /BK& ?C+ILFYRJJ.?WAYBC('M-Y0A,TI1])6
M'5R[<\,_/[.F9QXYW93XG$;JO0"Z:R+%6 >NURVCL9:XCI'?[T(J5O_,J>-
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MT2TUB@PN2*KL---1B@7Q."QK0):3B^XH#!Z=PADJW7ANX8I5!T;"\)84R%,
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MVHE'*$^34E""AYR<G%#XH>^_5Y<QO;,[6^CH_K/P/PO_[RC<C&M=^R'!]C?
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M-ZS( G7VU(F=U"[&:-P!<&]-]S<7[^?*UNQ_;>;#B/P!W",2=\Y5WOE-DB=
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MWR$8XL]U2I^%#R2P&/+X-D^8(=G%%4+G3W3XY@IV.6#:X/_6]9?\$I^!K!>
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MX?AIF2O3M-7+C88*2M9<YMZ7]SDM4-A:.J9MZ6Q;6A*E)2XACAIW4/'1T:O
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MIZ99:VO+ W;*!193K'*>^=0*Q\J; XNOJ(OX3\YBJ_'Z\HTA%E'4-CDY\BR
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M@+_#_R+^A_<_O/\S+PEY_LH__,.?J?\&4$L#!!0    ( 'DZ;U.TP9_))U<
M -R(   7    <&QX+3(P,C$P.3,P>#$P<3 P-RYJ<&?LO 5<5.W6*+X)Z3!
MFD$!*0&E$6$P*)%&0$)0I+M+&$) D9!6I*11 4$:<12E0;I+NCL')OY[D%=]
MSWF]]SOG=[_[/^=^9_QM7,]Z5J^GUMY[!M./^08<OR&K( O@X ( #O@/P P!
MUP B @)"@F-$A(2$Q,1$)&14Y&2DI&1T)T]14C'10YB9Z!D96=CX.%C.GF=E
M9.04Y3I_X:*0D!"$0UQ23. RGZ"0 %8(#C$Q,1DI&2TY.:W &<8S O_P!_,1
M.$&$<Q9?# _G+(![ @?O! [F"P ![3R&<_@!CCXXN'CXQP@(B8A)2$&"DN,
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M]@Q>3AGWX:]15M^.NE>Y%H?OEQ77@'MYC8WC\M(#&X[%$&"3-UOL4UL6)TN
M/Y'4]EP'@\Y[;8G+D<WN.QYAMWMT%% CG\/Z5_7'0C-/+JBN!(G-ZOC&WQ^]
M^Q7VR)< =@EH0=>^IQ>T?./'&Q#(4$1J5LX<FV+ )NHX[,ZA>JI%_\TZ-X$D
ME2MU:_ONL;=J,E3 WUPXDK-('R7T>IXB/]GPG?YK8'"(6)^'U'&\,+Y(R.AP
MV^W[@:#2I?ONV[7PJ#83.^=1ZPQBIPVF$7<A9[R3!@0[QSX(/-0P;2KB<U3V
M-.Y]YUJZ7*7L?=' )KS$Y=SS?,MS,HK9[H]8*"Z%$[[-Z\'9?O&DW,2PF('S
M68;UHZ\J&A7ES%LX,U4ZB3;B6[4,.HD =MG(91^:L*HOUF&:*0U%1N,_W8^Y
M)Y+R(/(ZKQU%5<ZS$0ZX^XE(_"<,>$C%JBSO.;Q6>Z=0IWD]41^:[O-+S"NR
M?@\M\\XKG+L?RAP8;!E?ZWA^<+6148&OA^)L/*QUQ5Y\.R],4:FZ$RDA<!UN
M'C>.=\= J,D^?4^:XUQX/$6I6,A?'=&3-]%2>G/P!DUJ,&(/RCI@3U/)&2@I
MVF!&_#X#)G;$3K2BIZR;/2FXBO9<]^GLC*.;R,UH(]'601KM!8R]>7E;(G=(
M_3*+_5=%PQ[&)%+&%Q!D=&Z_?I+9Q]]?SUC3<]V2D#3@(]". 0K*:;9W$\-[
M1\HLP%$Q.%2Z# ;&DXQCV7,ZK.NF_W3QQZFPEQD/(C]=QEO5LLVL?V3-$<8[
M:/;.R.TKWFG"5/L+.FHH'R./_-Z14,;]>_XDB<>O[!;<.#<(/7F%;8-U5/(E
M*4,EH?82:;B QTP%G*Z%O:KDY#5&-QZ:59&VF;+2"8 ..8<;N5:[UT6^L_B
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M\D\OU'YQ#I#;80,]5IA7_VV.(?W1G1&%V9F_BPD^S%CEAB%( /TUT+\D()7
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MB0>F3[::Q\5&RP9'C=@*&AS>\XAYL=6 ?(J[\MG4-S [DC7?F\/YL9HR!L2
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MJ$*9KZ<@]@]ZAK'K\N;\2>L$*8=A5?5_V*6XRTN'O65](DR+<W8BOME0!B'
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M_ZU<P>'*<*4MQ0T/]22SI8!N*K+<^Q]02P,$%     @ >3IO4[0?YXAE"
MN28  !<   !P;'@M,C R,3 Y,S!X97@S,60Q+FAT;>U:?V_;.!+]*KP4W2:
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MJ+]_N&(8WS9PKUOY=[+<2UXG_P=02P,$%     @ >3IO4T,\E,-X"   (2@
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M& 3A: 17;^'H-IH_M\O/+N?1'U>+1NW5[>F;Y1QZCN?]/IQ[WEETUDR,7#^
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MKXU88TFCN%M*8JS&M69[H \?+CL+<?(S@Z?I5]M/37]R_AB<>UJ9)/@VY!\
M\AE6\1 NT&$?VZ9@W+1-#:)O%3G?24G]_KT"W7OP=Y"[-=S_@K#\Z40+K#T]
MVRH3E/>FN>84NN>G1W.R5WF[#Q1?X[1/8=/F,J4DZF,+\.,ZUES7/*9734']
M;U[\83WTOP+[K,?Q']P]GNW4NV;D>S%OIS_*MH\&,4G>KY2L"_K@/FOG+G1_
MHNT]3?$TUV).^]_?>\AI[EOWGG+VAK:7NR59,:?I4DF*SRTAN9.<MFZ?3-S!
M:%MAFC'?W@<WE\;V%OKX+U!+ P04    " !Y.F]3$1N:8XD%  !T%P  %P
M '!L>"TR,#(Q,#DS,'AE>#,R9#(N:'1M[5C[;]LV$/Y7;BG6IH#U\B-P93=
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M %!+ 0(4 Q0    ( 'DZ;U/!\)QOR X  )V    0              "  0
M  !P;'@M,C R,3 Y,S N>'-D4$L! A0#%     @ >3IO4X;% W?A"@  EH\
M !0              ( !]@X  '!L>"TR,#(Q,#DS,%]C86PN>&UL4$L! A0#
M%     @ >3IO4ZE?NEW6(@  #" " !0              ( !"1H  '!L>"TR
M,#(Q,#DS,%]D968N>&UL4$L! A0#%     @ >3IO4W'R?>^H0@  W7(# !0
M             ( !$3T  '!L>"TR,#(Q,#DS,%]L86(N>&UL4$L! A0#%
M  @ >3IO4UK-6!:@,0  @D$# !0              ( !ZW\  '!L>"TR,#(Q
M,#DS,%]P<F4N>&UL4$L! A0#%     @ >3IO4VB0@R^<C $ _+ 0 !0
M         ( !O;$  '!L>"TR,#(Q,#DS,'@Q,'$N:'1M4$L! A0#%     @
M>3IO4\)F-I3,YP  2O0  !<              ( !BSX" '!L>"TR,#(Q,#DS
M,'@Q,'$P,#4N:G!G4$L! A0#%     @ >3IO4V)YKZRTX0  [ (! !<
M         ( !C"8# '!L>"TR,#(Q,#DS,'@Q,'$P,#8N:G!G4$L! A0#%
M  @ >3IO4[3!G\DG5P  W(@  !<              ( !=0@$ '!L>"TR,#(Q
M,#DS,'@Q,'$P,#<N:G!G4$L! A0#%     @ >3IO4[0?YXAE"   N28  !<
M             ( !T5\$ '!L>"TR,#(Q,#DS,'AE>#,Q9#$N:'1M4$L! A0#
M%     @ >3IO4T,\E,-X"   (2@  !<              ( !:V@$ '!L>"TR
M,#(Q,#DS,'AE>#,Q9#(N:'1M4$L! A0#%     @ >3IO4V\^AT^$!0  6A<
M !<              ( !&'$$ '!L>"TR,#(Q,#DS,'AE>#,R9#$N:'1M4$L!
M A0#%     @ >3IO4Q$;FF.)!0  =!<  !<              ( !T78$ '!L
K>"TR,#(Q,#DS,'AE>#,R9#(N:'1M4$L%!@     -  T :P,  (]\!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
